<tstset trglang="any" setid="test" srclang="any">
<doc sysid="Edinburgh" docid="doc">
<seg id="1">"the present document is a summary of the European public administration (EPAR), in which explains how the Committee for Humanarzs (CHMP) were assessed by the use of the application of the drug."</seg>
<seg id="2">"if you need further information about your disease or their treatment, please read the packaged goods (also part of the EPAR) or contact your doctor or pharmacist."</seg>
<seg id="3">"if you wish to read more information regarding the recommendations of the CHMP, please read the scientific discussion (also part of the EPAR)."</seg>
<seg id="4">"as a 5 mg, 10 mg, 15 mg and 30 pills tablets, than 10 mg, 15 mg and 30 mg of melting tablets (tablets used in mouth), as a solution for insertion (1 mg / ml) and as injure solution (7,5 mg / ml)."</seg>
<seg id="5">"if you are interested in the following criteria, you will find these under" "Tools, Internet Options, Security" "and" "Tools, Internet Options, Security" "and" "Tools, Internet Options, Privacy". ""</seg>
<seg id="6">"abilify the treatment of the drugs which have been used in the past, they have been used in the past."</seg>
<seg id="7">"the injection moulding solution is used for fast control of disasters or behavioral disorders, if the result of the drug use is not possible."</seg>
<seg id="8">"in both diseases, the solution can be used for inserting or melting tablets for patients which are used for tablets."</seg>
<seg id="9">"in patients, the same medication may take other drugs, as well as Amentia should be adjusted to the dose of Abilify."</seg>
<seg id="10">"the signal transmission between brain cells through" neurotransmitter ", i.e. the chemical substances that allow the communication of nerve cells."</seg>
<seg id="11">Aripiprazol is probably more than "partial Agonist" for the recipes for the neurotransmitter Dopamine and 5-hydroxyloyptamin (also serotonin).</seg>
<seg id="12">"this means that Aripiprazol such as 5-hydroxyloyptamin and Dopamine, but in lower measurements as the neurotransmitter has to activate the recipes."</seg>
<seg id="13">"since Dopamine and 5-hydroxyloypsytamin in schizophrenia and bipolar disorder, the activity of the brain is to normalize the activity of the brain, which reduces mental or manic symptoms."</seg>
<seg id="14">"the effectiveness of Abilify, the recovery of symptoms of symptoms, was examined in three studies by up to a year."</seg>
<seg id="15">The effectiveness of injection systems was compared in two studies in 805 patients with schizophrenia or similar disorders that compared to a period of two hours.</seg>
<seg id="16">"in another study, Abilify has been taken over twelve weeks of 347 patients with haloperify, in another study the effectiveness of Abilify and Placebo that occur in another study."</seg>
<seg id="17">"the effectiveness of Abilify Injection hoods was compared to 301 patients with bipolar disorder, which was compared with Lorazepam (a different anti-psychotic) and Placebo over a period of two hours."</seg>
<seg id="18">"in all studies, the change of symptoms of patients using a standard skala for bipolar disorder or the number of patients suffering the treatment."</seg>
<seg id="19">Firm of the Year for Insolvency Administration Schneider Geiwitz & Partner Firm of the Year for Tax Gleiss Lutz</seg>
<seg id="20">"in the two studies using the injection moulding solution, patients, Abilify in cans of 5,25 mg, 9,75 mg or 15 mg, a significant reduction of symptoms over the patient, which was a placebo."</seg>
<seg id="21">"in the application for treatment of bipolar disorder, reduced Abilify in four of five courses studies at four of the five courses studies."</seg>
<seg id="22">"abilify the search interface in English, German, English, French, German, Italian, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese, Spanish, Portuguese,</seg>
<seg id="23">"abilify anotherm injections in 10- or 15-mg cans, also effective as a placebo the symptoms of the symptoms of the symptoms and were similar to Lorazepam."</seg>
<seg id="24">"the most common side effects of Abilify for insertion (observed in 1 to 10 of 100 patients), seductions (inclination), seductions (incineration), fatigue and exhaustion (soaring), fatigue and exhaustion, insomnie (sleeping), fatigue and exhaustion, insomnie (sleeping), fatigue and exhaustion."</seg>
<seg id="25">"the committee of the Humanist agents (CHMP) to the end, that the benefits of Abilify in the treatment of schizophrenia and from medium-difficult times to the treatment of schizophrenia, and in which the manoeuvre had suffered in the treatment of Aripiprazol, to the risks of the risks."</seg>
<seg id="26">"in addition, the Committee on the result that the benefits of injunction in patients with schizophrenia or in patients with manic symptoms in bipolar-I disturbing, when a orale therapy is not suited to the risks."</seg>
<seg id="27">"June 2004, the European Commission to the European Commission of Otsuka Research Europe Ltd. a permit for the incoming of Abilify in the whole European Union."</seg>
<seg id="28">"abilify the treatment of a new manic acid of bipolar-I- error, and for prevention of a new manic interview in patients with Aripiprazol (see section 5.1)."</seg>
<seg id="29">The recommended starting dose for abilify is 10 or 15 mg / day at a reduction dose of 15 mg / day once a daily rate of food.</seg>
<seg id="30">"the effectiveness of a daily dose of 15 mg was not identified, although individual patients can benefit from a higher dose."</seg>
<seg id="31">The recommended starting dose for abilify is 15 mg once daily, regardless of meals as monotherapy or combination therapy (see section 5.1). "</seg>
<seg id="32">The effectiveness of abilify in the treatment of schizophrenia and bipolar-I- error at patients ≥ 65 years.</seg>
<seg id="33">"with regard to the larger sensitivity of these patient, a lower initialdose should be observed when clinical factors are available (see section 4.4)."</seg>
<seg id="34">"when the CYP3A4-inductor from the combination of combination, the Aripiprazol dose is reduced to the recommended dose (see section 4.5)."</seg>
<seg id="35">The occurrence of suizidable behaviour belongs to psychotic disorders and affectious disorders and was found in some cases after the beginning or change of antipsychotic therapy, even with Aripiderzol (see section 4.8). "</seg>
<seg id="36">The results of an epidemiological study showed that there was no risk of patients with bipolar disorder.</seg>
<seg id="37">"Aripiprazol should be applied to patients with known cardiovascular diseases (Myokardinfectomy, overline disorders), zerebrovascular diseases, treatment with blood pressure (including akzelerated and maligne form)."</seg>
<seg id="38">"3 late dyskina.com: in clinical trials, which one year or less favourable, there were several reports across the treatment with Aripiprazol, as well as in the treatment of Aripiprazol."</seg>
<seg id="39">"if in one with abilify the patient signs and symptoms of a late dyskinetry, should reduce the dose to reduce the dose or treatment."</seg>
<seg id="40">"if a patient signs and symptoms are developed to make a mutations, or unclear high fever without an additional clinical manifestation of MNS has to be set to all antipsychotic, including abilify, including abilify."</seg>
<seg id="41">"for example, Aripiprazol at patients with crampfancies in the Anamnese or in states that are used with crampfancies."</seg>
<seg id="42">56 - 99 years) with Aripiprazol in patients with psychotic symptoms associated with Alzheimer's disease had been treated patients who were treated with Aripiprazol in comparison to the placebo.</seg>
<seg id="43">"however, there were, however, in one of these studies, a study with fixed dosage, a significant relationship between the dosage and the guarantee for undesired lasebrovascular events with Aripiprazol treated patients."</seg>
<seg id="44">"hyperglyphemia, in some cases extremely and associated with Ketoazio or hyperosmolarem Koma or death, was treated with atypical antipsychotic acid, including abilify."</seg>
<seg id="45">There are no exact risk factors for hyperglyceremia-related symptoms with abilify and other atypical antipsychotic therapy.</seg>
<seg id="46">Polydipit, polyurie, polyphagie and weakness) are observed and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored. "</seg>
<seg id="47">"in patients with bipolar patients and patients with bipolar disorder, the application of antipsychotherapy, which is known as a side effect, or a unhealthy lifestyle, and could be observed too serious complications."</seg>
<seg id="48">"due to the primary effect of Aripiprazol at the central nervous system, the central nervous system is set to be used when Aripiprazol in combination with alcohol or other centrally effective drug use (see section 4.8)."</seg>
<seg id="49">"the H2 Antagonis Famotidin, a Magensacid-Blocker, reduces the resorpness rate of Aripiprazol, with this effect however, however, is not relevant."</seg>
<seg id="50">"in a clinical study with healthy subjects, a highly effective CYP2D6-Inhibitor (Chinidin) the Auc von Aripiprazol to 107%, while the Cmax."</seg>
<seg id="51">"it is to expect that other highly effective inhibitors from CYP2D6, such as Fluoxetin and Paroxetin, similar effects, and therefore should be similar to crates."</seg>
<seg id="52">"in CYP2D6 'bad' (=" "") Metabolism can result the common application with high-effective Inhibitors from CYP3A4 in higher Plasmakerzol results in comparison to CYP2D6 lightweight Metabolism. "</seg>
<seg id="53">"if you have the joint gift from Ketoconazol or other highly effective CYP3A4 Inhibitors with abilify, the potential benefits of potential risks for patients."</seg>
<seg id="54">"other high-effective Inhibitors from CYP3A4, such as Itraconazol and HIV-prothibitors, such as Itraconazol and HIV-prothibitors, which is similar to similar restrictions."</seg>
<seg id="55">* Use five-year forecasts to assess how the market is predicted to develop.</seg>
<seg id="56">Diltiazem or Escort opram) or CYP2D6 together with abilify.</seg>
<seg id="57">"in clinical trials, cans of 10-30 mg Aripiprazol per day no significant effect on the Metabolism of the substrate of CYP2D6 (LAP2D6), 2C9 (Wareprazol), 2C19 (Wareprazol), 2C19 (Wareprazol)."</seg>
<seg id="58">The patient should be to inform your doctor if they are pregnant or pregnancy during treatment with Aripiprazol.</seg>
<seg id="59">"due to the insufficient data situation for the safety of people, and due to the reproductive concerns of the animal, this drug may not be applied in pregnancy, unless the potential benefit does not affect the potential risk for flawus."</seg>
<seg id="60">"as well as in other antipsychotic symptoms, patients should be noted, dangerous machines, including power vehicles, including power vehicles, until they are sure that Aria prazol is not a negative impact."</seg>
<seg id="61">The following side effects are more frequent (≥ 1 / 100) on the following side effects (*).</seg>
<seg id="62">"the frequency of the side effects are defined by the following criteria: frequently (&gt; 1 / 100, &lt; 1 / 10); occasionally (&gt; 1 / 1,000, &lt; 1 / 100)."</seg>
<seg id="63">"schizophrenia - in a controlled term study of 52 weeks, patients who were treated with Aripiprazol, a total of less induction (25,8%) of EPS including Parkinsonism, Akathons and Dyskinetry, compared with patients who were treated with haloperitis (57,3%)."</seg>
<seg id="64">"in a placebo controlled term study on 26 weeks, the insolvency of EPS 19% in patients with Aripiprazol treatment and 13,1% in patients with Placebo."</seg>
<seg id="65">"in another controlled term-term study on 26 weeks, the insolvency of EPS 14.8% in patients who were treated with Aripiprazol, and 15,1% in patients under Olanzapin therapy."</seg>
<seg id="66">"in a controlled study about 12 weeks, the insolvency of EPS 23,5% in patients with Aripitizol- treatment and 53% in patients with haloperious treatment."</seg>
<seg id="67">"in another study about 12 weeks, the incidence of EPS 26,6% in patients with Aripiprazol Treatment and 17.6% for those under lithium-treatment."</seg>
<seg id="68">In the long-term phase on 26 weeks at a placebo controlled study of EPS 18.2% for patients under Aripitizol- treatment and 15.7% for patients among Aripitizol- treatment and 15.7% for patients under Aripitizol- treatment and 15.7% for patients under Aripitizol- treatment and 15.7%.</seg>
<seg id="69">"a comparison between the patient groups of Aripiprazol and Placebo, with which potentially critical changes of the routinely controlled laboratory parameters, there are no medical differences."</seg>
<seg id="70">"the CPK (Kreatin-Phosphokinase), generally speaking and asymptomatic patients were observed in 3.5% of the Aripiprazol treated patients."</seg>
<seg id="71">"to the side effects that can occur in connection with a antipsychotic therapy, the maligne neuroleptic syndrome, late dyskinaries, and increased mortality in elderly patients, hyperglycemia and diabetes mellitus (see section 4.4)."</seg>
<seg id="72">"in clinical trials and since the market launch, unintentional overdosages with Aripiprazol alone at adult patients with estimated to 1260 mg and without death."</seg>
<seg id="73">"however, there are no information about the effectiveness of a hemalalysis in treatment of a overdose with Aripiprazol. however, it is likely that hemalalysis in treating a overdose of benefit is, da Aripiprazol is a high plasma cutting."</seg>
<seg id="74">"there will be, that the effectiveness of Aripiprazol in schizophrenia and bipolar-I disturbing the combination of a partial agonist effect on Dopamine D2- and serotonin 5HT1a- recipes and a antagonist effect on serotonin 5HT6 receptors."</seg>
<seg id="75">"Aripiprazol showed a high affinity for Dopamine D2- and D3 receptor for the Dopamine D2-, for serotonin 5HT2c- and 5HT7-, for alpha-1-adrenergen and the histamine-H1recipes."</seg>
<seg id="76">"at the gift of Aripiprazol in Dosiding from 0.5 to 30 mg each day of a dosages of 0.5 to 30 mg, a D2 / D3-receptor-Ligatures, a D2 / D3-receptor-Ligations, on Nucleus caudatus and the coup."</seg>
<seg id="77">In three Placebo controlled short-term studies (4 to 6 weeks) at 1.228 biophrined patients with positive or negative symptoms showed Aripiprazol compared to placebo a statistical survey of psychotic symptoms.</seg>
<seg id="78">"in a haloperious-controlled study was in a week 52 of the proportion of the health patients who thought about the study in both groups (Aripiprazol 77% and haloperized 73%)."</seg>
<seg id="79">"the current values from measuring points are defined as secondary research targets, including PANSS and the Montgomery-Asberg- Deployal rates of scale, showed a significant stronger than in haloperious."</seg>
<seg id="80">"in a placebo controlled study over 26 weeks of stabilized patients with chronic schizophrenia showed a significantly higher reduction of the return rate, which was at 34% in the Aripiprazol group and at 57%."</seg>
<seg id="81">"in an Olanzapin-controlled, multinational double blind study in schizophrenia over 26 weeks, the 314 patients had been increased by at least 7% compared to the output value (i.e. a increase of at least 5.7 kg at an average weight of ca."</seg>
<seg id="82">"in two Placebo controlled Monotherapy studies with flexible dosage of 3 weeks, patients with a manganese or mixed lot of bipolar-I, Aripiprazol is one of EUR 3 weeks for reducing symptoms over 3 weeks."</seg>
<seg id="83">"in a placebo controlled Monotherapy study about 3 weeks with fixed dosage with patients with a manic or mixed lot of bipolar-I, Aripiprazol on Placebo no overefficacy."</seg>
<seg id="84">"in two Placement and active-controlled Monotherapy studies on 12 weeks, patients with a manic or mixed lot of a bipolar or mixed hypothesis, Aripiprazol has a negative effects in week 3 and a reduction of effect, which was comparable with lithium or haloperious in week 12."</seg>
<seg id="85">Firm of the Year for Insolvency Administration Schneider Geiwitz & Partner Firm of the Year for Tax Gleiss Lutz</seg>
<seg id="86">"in a placebo controlled study over 6 weeks with patients with a manic or mixed lot of a bipolar-I, with or without psychotic characteristics which would not be found on Lithium- or Valproat-Monotherapy with or without psychotic characteristics that would be found in the monotherapy with lithium or Valproat."</seg>
<seg id="87">"10 In a placebo controlled study on 26 weeks followed by a long time period of a long-time period phase over 74 weeks, the Aripiprazol during a stabilization phase before the prevention phase before the prevention phase."</seg>
<seg id="88">"based on the vitro studies, the enzyme CYP3A4 and CYP2D6 for the Dehydrizol responsible for the Dehydrizol, the N-Dealkyzation is responsible for the N-Dealkyzation."</seg>
<seg id="89">"for example, Eliminationshoring time is approximately 75 hours for Aripiprazol at extensive Metabolism via CYP2D6 and with annulent 146 hours at 'bad' (=" "" ") metabolism over CYP2D6."</seg>
<seg id="90">At Aripiprazol there is no differences in the pharma ocinetics between male and female healthy subjects.</seg>
<seg id="91">An eye-specific evaluation of the pharma-specific evaluation to the pharma's significant differences in the ethnicity or the impact of the room on the pharma ocinetics of Aripiprazol.</seg>
<seg id="92">The big makokinetic characteristics of Aripiprazol and Dehoro-Aripiprazol were similar to patients with severe kidney cancer patients in comparison to young healthy subjects.</seg>
<seg id="93">"a single dose study on subjects with different livelous liver cells (Child-Pugh class A, B and C) showed no significant effect in impairment of the liver function on the respiratory function of the liver function."</seg>
<seg id="94">"based on conventional studies on the conventional studies on the safety spharmakologie, toxicity, reproduction of repeated gift, reproductive use, Genotoxity and the international potential of the preclinical data are no special dangers for humans."</seg>
<seg id="95">Toxikologically significant effects were observed only with Dosities or expositions that have led the maximum dosage or exposition in humans for the clinical application only limited or no importance.</seg>
<seg id="96">"the effects showed a doscope with a doscope (lipofuscin-pigment, and combined heat loss) at the recommended maximum dose. (Auc) at the recommended maximum dose of 60 mg / kg / day (the 10ft of the middle steamer / kg / day (at the recommended maximum dose) at the recommended maximum dose when people)."</seg>
<seg id="97">"furthermore, a choleliac is considered as a result of the precipitation of Sullithozol in the Galle from monkey to repeated clinical dose or from 16- to 81cm the recommended maximum dose when people based on mg / m2)."</seg>
<seg id="98">Firm of the Year for Insolvency Administration Schneider Geiwitz & Partner Firm of the Year for Tax Gleiss Lutz</seg>
<seg id="99">"in case of rabbit, these effects have been observed after surgery that were observed to expositions of the 3- and 11cm of the middle Steady State Auc at the recommended clinical maximum dose."</seg>
<seg id="100">"fill in the form below to send an email directly. if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="101">"15 late dyskina.com: in clinical trials, which one year or less favourable, there were several reports across the treatment with Aripiprazol, as well as in the treatment of Aripiprazol."</seg>
<seg id="102">"there will be, that the effectiveness of Aripiprazol in schizophrenia and bipolar-I disturbing the combination of a partial agonist effect on Dopamine D2- and serotonin 5HT1a- recipes and a antagonist effect on serotonin 5HT6 receptors."</seg>
<seg id="103">"results appear ordered" "by relevance" "or" "by date" "(publication date),"</seg>
<seg id="104">"27 late dyskina.com: in clinical trials, which was a year or less, there were several reports on the treatment of Aripiprazol, as well as in the treatment of Aripiprazol."</seg>
<seg id="105">"there will be, that the effectiveness of Aripiprazol in schizophrenia and bipolar-I disturbing the combination of a partial agonist effect on Dopamine D2- and serotonin 5HT1a- recipes and a antagonist effect on serotonin 5HT6 receptors."</seg>
<seg id="106">"34 In a placebo controlled study on 26 weeks followed by a long-time period of a long-time period phase over 74 weeks, the Aripiprazol during a stabilization phase before the prevention phase before the prevention phase before the prevention phase."</seg>
<seg id="107">"39 late dyskina.com: in clinical trials, which was a year or less, there were several reports across the treatment with Aripiprazol, as well as in the treatment of Aripiprazol."</seg>
<seg id="108">"there will be, that the effectiveness of Aripiprazol in schizophrenia and bipolar-I disturbing the combination of a partial agonist effect on Dopamine D2- and serotonin 5HT1a- recipes and a antagonist effect on serotonin 5HT6 receptors."</seg>
<seg id="109">"46 In a placebo controlled study on 26 weeks followed by a long time period of a long-time period phase over 74 weeks, the Aripiprazol during a stabilization phase before the prevention phase before the prevention phase."</seg>
<seg id="110">The recommended starting dose for Aripiprazol is 10 or 15 mg / day at a reduction dose of 15 mg / day once every day daily from the meals.</seg>
<seg id="111">Patients who are difficulties during the treatment of abilify tablets can take the melt cleanse yourself to abilify tablets (see section 5.2).</seg>
<seg id="112">The occurrence of sucos behaviour belongs to psychotic disorders and affectious disorders in some cases after the beginning or change of antipsychotic therapy, even with Aripiderzol (see section 4.8). "</seg>
<seg id="113">"late dyskina.com: in clinical trials, which one year or less favourable, there were several reports across the treatment with Aripiprazol, as well as in the treatment of Aripiprazol."</seg>
<seg id="114">"clinical manifestation of a MNS are high fever, muscle stimulation, changing levels of consciousness and signs of the lack of consciousness (irregular pulse or blood pressure, speedykarmic, shredness and heart rhythmatism)."</seg>
<seg id="115">"in patients with bipolar patients and patients with bipolar disorder, the application of antipsychotherapy, which is known as a side effect, or a unhealthy lifestyle, and could be observed too serious complications."</seg>
<seg id="116">The patient should not get their doctor if they are pregnant or pregnancy during treatment with Aripiprazol</seg>
<seg id="117">The following side effects are more frequent (≥ 1 / 100) on the placebo.</seg>
<seg id="118">"in two Placebo controlled Monotherapy studies with flexible dosage of 3 weeks, patients with a manganese or mixed lot of bipolar-I, Aripiprazol is one of EUR 3 weeks for reducing symptoms over 3 weeks."</seg>
<seg id="119">"58 In a placebo controlled study over 6 weeks with patients with a manic or mixed lot of a bipolar-I, with or without psychotic characteristics which would not be found on Lithium- or Valproat-Monotherapy with or without psychotic characteristics that would be found in the monotherapy with lithium or Valproat."</seg>
<seg id="120">"in a placebo controlled study over 26 weeks followed by a long time period of a long-time period phase over 74 weeks, the Aripiprazol during a stabilization phase before the prevention phase before the prevention phase."</seg>
<seg id="121">"in rabbit, these effects have been used to dosities that are up to expositions of the 3- and 11cm of the middle Steady State Auc at the recommended clinical trials."</seg>
<seg id="122">Patients who are difficulties during the treatment of abilify tablets can take the melt cleanse yourself to abilify tablets (see section 5.2).</seg>
<seg id="123">"late dyskina.com: in clinical trials, which one year or less favourable, there were several reports across the treatment with Aripiprazol, as well as in the treatment of Aripiprazol."</seg>
<seg id="124">"in a placebo controlled study over 6 weeks, patients with a manganese or mixed lot of a bipolar-I disturbing, with or without psychotic characteristics which would not be found on Lithium- or Valproat-Monotherapy with cancer or valproat-monotherapy with cancer or valproat."</seg>
<seg id="125">Patients who are difficulties during the treatment of abilify tablets can take the melt cleanse yourself to abilify tablets (see section 5.2).</seg>
<seg id="126">"late dyskina.com: in clinical trials, which one year or less favourable, there were several reports across the treatment with Aripiprazol, as well as in the treatment of Aripiprazol."</seg>
<seg id="127">"84 In a placebo controlled study over 6 weeks with patients with a manic or mixed lot of a bipolar-I, with or without psychotic characteristics which would not be found on Lithium- or Valproat-Monotherapy with or without psychotic characteristics that would be found in the monotherapy with lithium or Valproat."</seg>
<seg id="128">200 mg Fruyl-4-hydroxybenzoat (E218) per ml 0.mg-4-hydroxybenzoat (E218) per ml.</seg>
<seg id="129">The recommended starting dose for abilify is 15 mg once daily, regardless of meals as monotherapy or combination therapy (see section 5.1). "</seg>
<seg id="130">"in the prevention of the detergent in patients who have already signed Aripiprazol, the treatment of the same dose may be taken into the same dose."</seg>
<seg id="131">"late dyskina.com: in clinical trials, which one year or less favourable, there were several reports across the treatment with Aripiprazol, as well as in the treatment of Aripiprazol."</seg>
<seg id="132">"hyperglyphemia, in some cases extremely and associated with Ketoazio or hyperosmolarem Koma or death, was treated with atypical antipsychotic acid, including abilify."</seg>
<seg id="133">There are no exact risk factors for hyperglyceremia-related symptoms with abilify and other atypical antipsychotic therapy.</seg>
<seg id="134">"92 In a clinical study with healthy subjects, a highly effective CYP2D6-Inhibitor (Chinidin) the Auc von Aripiprazol to 107%, while the Cmax."</seg>
<seg id="135">Diltiazem or Escort opram) or CYP2D6 together with abilify.</seg>
<seg id="136">"in a controlled study about 12 weeks, the insolvency of EPS 23.5% in patients with Aripiprazol-"</seg>
<seg id="137">"there will be, that the effectiveness of Aripiprazol in schizophrenia and bipolar-I disturbing the combination of a partial agonist effect on Dopamine D2- and serotonin 5HT1a- recipes and a antagonist effect on serotonin 5HT6 receptors."</seg>
<seg id="138">"in an Olanzapin-controlled, multinational double blind study in schizophrenia over 26 weeks, the 314 patients had been increased by at least 7% compared to the output value (i.e. a increase of at least 5.7 kg at an average weight of ca."</seg>
<seg id="139">"97 In a placebo-controlled Monotherapy study over 3 weeks with fixed dosage with patients with a manic or mixed lot of bipolar-I, Aripiprazol on Placebo no overefficacy."</seg>
<seg id="140">"in a relational biodical study, which was compared with 30 mg Aripiprazol in tablet form of 30 mg Aripiprazol in tablet form and the value of the tablets at 122% (N = 30)."</seg>
<seg id="141">"the recommended dose of Sullipizol can be found at the recommended dose of Sullithozol in the Gall of monkey, from 25 to 125 mg / kg / day / day (the 1- up to 33.3 of the middle part) in the recommended clinical dose or from 16- to 81cm of the recommended maximum dose when people based on mg / m2)."</seg>
<seg id="142">"in case of rabbit, these effects have been observed after surgery that were observed to expositions of the 3- and 11cm of the middle Steady State Auc at the recommended clinical maximum dose."</seg>
<seg id="143">"abilify powering solution is used for fast control of Agids and deficiency in patients with schizophrenia or in patients with manoeuvre of bipolar-I disturbing, when a orale therapy is not mounted."</seg>
<seg id="144">"as soon as it is mounted, the treatment should be finished with Aripiprazol injection solution, and with the orbital application of Aripiprazol."</seg>
<seg id="145">"to increase the Resorption and the Variability to minimise a injections in the M. deltoideus or deep into the Gluteus-maximus muscle under circulation of adipous regions."</seg>
<seg id="146">A lower dose of 5.25 mg (0.7 ml) can be given depending on the individual clinical status under consideration of the individual clinical status under consideration of the treatment or acute therapy (see section 4.5).</seg>
<seg id="147">"if a further orale treatment with Aripiprazol can be found, see the summary of the features of the drug by abilify tablets, abilify melting tablets or abilify solution."</seg>
<seg id="148">"there are no investigations to effectiveness of Aripiprazol injection solution for patients with Agiveness and behavioral disorders, which were different than by schizophrenia and manic conclusions of bipolar-I disturbing."</seg>
<seg id="149">"in case of parental therapy with benodiazepines, in addition to Aripiprazol injection solution as necessary, patients should be observed in high seas or a blood pressure (see section 4.5)."</seg>
<seg id="150">Investigations on security and effectiveness of Aripiprazol injection systems are used for patients with alcohol or drug cancer.</seg>
<seg id="151">"Aripiprazol should be applied to patients with known cardiovascular diseases (Myokardinfectomy, overline disorders), zerebrovascular diseases, treatment with blood pressure (including akzelerated and maligne form)."</seg>
<seg id="152">"late dyskina.com: in clinical trials, which one year or less favourable, there were several reports across the treatment with Aripiprazol, as well as in the treatment of Aripiprazol."</seg>
<seg id="153">"clinical manifestation of a MNS are high fever, muscle stimulation, changing levels of consciousness and signs of consciousness (irregular pulse or blood pressure, speedykarmic, shredness and heart rhythmatism)."</seg>
<seg id="154">Polydipit, polyurie, polyphagie and weakness) are observed and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored. "</seg>
<seg id="155">"however, patients with bipolar patients and patients with bipolar disorder, the application of antipsychotherapy, which is known as a side effect, or a unhealthy lifestyle, and could be observed too serious complications."</seg>
<seg id="156">"nevertheless the intensity of the Sedation is larger compared with each of some gift of Aripiprazol, in a study, in the healthy subjects of Aripitizol (15 mg dose) and the same Lorazepam (2 mg dose) intramuscular."</seg>
<seg id="157">"105 Der H2 Antagonis Famotidin, a Magensacid-Blocker, reduces the resorpness rate of Aripiprazol, with this effect however, however, is not relevant."</seg>
<seg id="158">"in CYP2D6 'bad' (=" "" ") Metabolism can result in comparison to CYP2D6 lightweight Metabolism, the common application with highly effective inhibitors from CYP3A4 in higher Plasmakerzol results."</seg>
<seg id="159">"other high-effective Inhibitors from CYP3A4, such as Itraconazol and HIV- protohibitors, such as Itraconazol and HIV- Proteins"</seg>
<seg id="160">* Use five-year forecasts to assess how the market is predicted to develop.</seg>
<seg id="161">"106 Lorazepam (2 mg dose) intramuscular, was the intensity of Sedation greater compared with the after some gift of Aripiprazol."</seg>
<seg id="162">The following side effects appeared in clinical trials associated with Aripiprazol injection packers in clinical trials (≥ 1 / 100) as well as possible medical effects (*) (see section 5.1):</seg>
<seg id="163">"the frequency of the side effects are defined by the following criteria: frequently (≥ 1 / 100, &lt; 1 / 10); occasionally (≥ 1 / 1,000, &lt; 1 / 100)."</seg>
<seg id="164">107 The following side effects are more frequent on (≥ 1 / 100) as under Placebo or in clinical trials with oral Aripiprazol as possible medical treatment (*) (see section 5.1):</seg>
<seg id="165">"in a placebo controlled term study on 26 weeks, the insolvency of EPS 19% in patients with Aripiprazol- Treatment and 13.1% in patients with Placebo."</seg>
<seg id="166">"in another study about 12 weeks, the incidence of EPS 26,6% in patients with Aripiprazol- Treatment and 17.6% for those under lithium-treatment."</seg>
<seg id="167">In the long-term phase on 26 weeks at a placebo controlled study of EPS 18.2% for patients under Aripiprazol treatment and 15.7% for patients among Aripidia patients.</seg>
<seg id="168">"a comparison between the patient groups of Aripiprazol and Placebo, with which potentially critical changes of the routinely controlled laboratory parameters, there are no medical differences."</seg>
<seg id="169">"the CPK (Kreatinphosphokinase), generally speaking and asymptomatic patients were observed in 3.5% of the Aripiprazol treated patients."</seg>
<seg id="170">"to the side effects that can occur in connection with a antipsychotic therapy, the maligne neuroleptic syndrome, late dyskinaries, and increased mortality in elderly patients, hyperglycemia and diabetes mellitus (see section 4.4)."</seg>
<seg id="171">110 and behavioral dysfunction was the Aripiprazol injection moulding solution with statistical significant improvements of Agids / permeats associated with Placebo and was similar to haloperious.</seg>
<seg id="172">"results appear ordered" "by relevance" "or" "by date" "(publication date),"</seg>
<seg id="173">"after the primary 2-hour final point, the Component score with the primary 2-hour end point was 5,8 for Lorazepam and 8,7 for Aripitizol."</seg>
<seg id="174">"facets, which offer an easy way to limit your search,"</seg>
<seg id="175">"results appear ordered" "by relevance" "or" "by date" "(publication date),"</seg>
<seg id="176">"in a haloperious-controlled study was in a week 52 of the proportion of the health patients who thought that in both groups (Aripiprazol 77% (oral) and haloperized 73%)."</seg>
<seg id="177">"the current values from measuring points are defined as secondary research targets, including PANSS and the Montgomery-Asberg-Deployal rates of scale, showed a significant stronger than in haloperious."</seg>
<seg id="178">"in a placebo controlled study over 26 weeks of stabilized patients with chronic schizophrenia (oral) a significantly higher reduction of the return rate, which was at 34% in Aripitizol- (oral) -group and at 57%."</seg>
<seg id="179">"in an Olanzapin-controlled, multinational double blind study at schizophrenia about 26 weeks, the 314 patients had been increased by at least 7% compared to the output value (i.e. a increase of at least 5.7 kg at an average weight of ca."</seg>
<seg id="180">111 In a placebo controlled study over 6 weeks with patients with a manic or mixed lot of a bipolar-I disguised with or without psychotic characteristics which were partially over 2 weeks to Lithium- or Valproat-Monotherapy with cancer or valproat-monotherapy with cancer or valproat.</seg>
<seg id="181">"in a placebo controlled study about 26 weeks followed by a 74-wreck group, Aripiprazol during a stabilization phase before the prevention phase before the prevention phase before the prevention phase."</seg>
<seg id="182">The Aripiprazol Auc is located in the first 2 hours after intramuscular injections 90% bigger the Auc after the same dose as tray; the systematic exposition was similar between the two formulations.</seg>
<seg id="183">"in 2 studies with healthy subjects, the medium time up to the maximum of the maximum of the maximum plasticity in 1 to 3 hours depending on application."</seg>
<seg id="184">"the gift of Aripiprazol injection solution was made of Rites and monkey good tolerances and resulting in no direct toxicity of a destination (Auc), the 15- / 5 times via the maximum humanoid Exposition of 30 mg intramuscular layers."</seg>
<seg id="185">"in studies for reproductive exposition after intravenous application, no security concerns for maternal exposition, the 15- (Rens) and 29 times (rabbit) via the maximum humanoid Exposition of 30 mg."</seg>
<seg id="186">"based on conventional studies with Aripiprazol (oral) for safety spharmakologie, toxicity, reproduction of repeated gift, reproductive use, Genotoxity and to the international potential of the preclinical data no special dangers for humans."</seg>
<seg id="187">Toxikologically significant effects were observed only with Dosities or expositions that have led the maximum dosage or exposition in humans. so that they have been reduced for the clinical application only limited or no importance.</seg>
<seg id="188">"the effects showed a doscope with a doscope (lipofuscin-pigment, and combined heat loss) at the recommended dose (Auc) at the recommended maximum dose of 60 mg / kg / day (the 10-minimum of the middle-position state-Exposition (Auc) at the recommended maximum dose."</seg>
<seg id="189">"furthermore, a cholelithiasis has been found as a result of the extermination of Sullipizol in the Galle from monkey to repeated clinical dose or from 16- to 81-times the recommended maximum dose when people based on mg / m2)."</seg>
<seg id="190">"in rabbit, these effects have been observed after surgery that were observed to expositions of the 3- and 11-end of the middle-state state Auc at the recommended clinical maximum dose."</seg>
<seg id="191">"the Pharmacvigilance system has to ensure that before and during the product will be described, the pharmaceutical covigilance system, as it is described in the version 1.0 of module 1.8.1. of the certifications."</seg>
<seg id="192">"according to the" CHMP Guideline on Risk Management Systems for human use "needs to be submitted by updated risk management plan at the same time with the next Periodic Safety Update Report (PSUR)."</seg>
<seg id="193">"in addition to the risk of risk management, the current security data, denovigilance or measures to risk assessment, within 60 days after an important milestone of the pharmaceutical company or measures to risk inimation, in order to request the EMEA."</seg>
<seg id="194">14 x 1 tablets 28 x 1 tablets 49 x 1 tablets 56 x 1 tablets 98 x 1 tablets</seg>
<seg id="195">EU / 1 / 04 / 276 / 001 14 x 1 tablets EU / 1 / 04 / 276 / 956 x 1 tablets EU / 1 / 04 / 276 / 956 x 1 tablets EU / 1 / 04 / 276 / 005 98 x 1 tablets</seg>
<seg id="196">EU / 1 / 04 / 276 / 006 14 x 1 tablets EU / 1 / 04 / 276 / 956 x 1 tablets EU / 1 / 04 / 276 / 009 1 x 1 tablets EU / 1 / 04 / 276 / 010 98 x 1 tablets</seg>
<seg id="197">EU / 1 / 04 / 276 / 011 14 x 1 tablets EU / 1 / 04 / 276 / 014 56 x 1 tablets EU / 1 / 04 / 276 / 015 98 x 1 tablets</seg>
<seg id="198">EU / 1 / 04 / 276 / 016 14 x 1 tablets EU / 1 / 04 / 276 / 919 56 x 1 tablets EU / 1 / 04 / 276 / 020 98 x 1 tablets</seg>
<seg id="199">"if one of the side effects of side effects you can differ considerably or you are not aware of any side effects, please inform your doctor or pharmacist."</seg>
<seg id="200">"it is applied for treatment of adults who suffer from one disease, which is marked by symptoms as the hearing, See, or fats of things that are not present, missive, unrelated behaviour, unrelated behaviour."</seg>
<seg id="201">"abilify it is used for adults for treatment of a condition, too much less sleep, a much less sleep, a lot of sleep with fast-changing ideas and sometimes powerful friction."</seg>
<seg id="202">"in the case of cardiovascular disease or cases of diabetes, irregular muscle movements, especially in the face of heart and vessels or cases of a heart - or vessels in the face of heart or vessels in the family, perceiver of the brain (transitory attacks / TIA), the normal blood pressure."</seg>
<seg id="203">"if you are aware of the patient's patient (loss of memory or other mentally abilities), you should have an impact on your doctor. if you ever had a impact or a temporary injunction in the brain."</seg>
<seg id="204">"inform your doctor if you are connected to muscle stiffness or stiffness, with a high fever, changing state state or very easy heart rate."</seg>
<seg id="205">Children and adolescents do not apply for children and adolescents in children under 18 years.</seg>
<seg id="206">If you have other medicines or pharmacist if you have other medicines or pharmacist if you have used other medicines / or before going to be used if it is not needed.</seg>
<seg id="207">Medicines for treatment of cardiovascular diseases such as antidepresssiva or herbal medicines which can be applied for treatment of depression and anxiety disorders.</seg>
<seg id="208">"pregnancy and downtime you should be abilify, if you are pregnant, unless you have pregnant with your doctor."</seg>
<seg id="209">"transport and the filling of machines you should do not drive, and no tools or machines use, until you know how do abilify you."</seg>
<seg id="210">Please take this medicine only after returning with your doctor if you are known to suffer from a unreasonable point towards certain circumstances.</seg>
<seg id="211">Please contact your doctor or pharmacist if you have the impression that the effect of abilify is strong or weak.</seg>
<seg id="212">Even if you feel better to change or use the daily dose of abilify not from without your doctor.</seg>
<seg id="213">"if you have taken a larger amount of abilify you should be taken as if you want to use more abilify tablets (or if someone else, some of your abilify tablets), please contact your doctor."</seg>
<seg id="214">"if you have forgotten your dose of abilify if you have forgotten a dose, take a dose if you think it does not have the double dose."</seg>
<seg id="215">"frequent side effects (with more than 1 of 100, less than 1 of 10 treatment) unking movements, headaches, fatigue, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety and blurred vision."</seg>
<seg id="216">"side effects (with more than 1 of 1,000, less than 1 of 100 treatment) Some people can feel digestible, especially if they are made out of one or sitting position, or they can find an accelerated pulse."</seg>
<seg id="217">"please inform your doctor or pharmacist, if one of the side effects you can choose from either side effects or side effects that are not found in this use."</seg>
<seg id="218">"buy abilify and content of the Buy abilify 5 mg tablets are rectangular and blue, with embossing of A-007 and 5 on a page."</seg>
<seg id="219">"inform your doctor if you are connected to muscle stiffness or stiffness, with a high fever, changing state state or very easy heart rate."</seg>
<seg id="220">Even if you feel better to change or use the daily dose of abilify not from without your doctor.</seg>
<seg id="221">"buy abilify and content of the package abilify 10 mg tablets, rectangular and rosafest, with embossing of A-008 and 10 on one side."</seg>
<seg id="222">"inform your doctor if you are connected to muscle stiffness or stiffness, with a high fever, changing state state or very easy heart rate."</seg>
<seg id="223">Even if you feel better to change or use the daily dose of abilify not from without your doctor.</seg>
<seg id="224">"buy abilify and content of the Buy abilify 15 mg tablets are round and yellow, with embossing of A-009 and 15 on one page."</seg>
<seg id="225">"inform your doctor if you are connected to muscle stiffness or stiffness, with a high fever, changing state state or very easy heart rate."</seg>
<seg id="226">Even if you feel better to change or use the daily dose of abilify not from without your doctor.</seg>
<seg id="227">"buy abilify and content of the Pack abilify 30 mg tablets are round and rosafras, with embossed from A-011 and 30 on one side."</seg>
<seg id="228">"171 If you have a patient of the patient's patient (loss of memory, or other other abilities), you should have an impact on your doctor if you ever had an impact or a temporary injunction of the brain."</seg>
<seg id="229">"inform your doctor if you are connected to muscle stiffness or stiffness, with a high fever, changing state state or very easy heart rate."</seg>
<seg id="230">"important information on certain other components of abilify patients who do not have phenylalanin to take, that abilify the abilify Ratio for phenylalanin."</seg>
<seg id="231">Please see immediately after opening the Blisterpackers the tablet with dry hands and put the melt into the right on the tongue.</seg>
<seg id="232">Even if you feel better to change or use the daily dose of abilify not from without your doctor.</seg>
<seg id="233">"if you have taken a larger amount of abilify you should have taken a bigger amount of abilify your doctor (or if someone else, some of your abilify melt cleaners), please contact your doctor as soon as your doctor."</seg>
<seg id="234">"Calciumtrimetasilicate, Croscarmor oxide, microcrystalline Cellulose, Aspartame, Acesulfam-potum, vanilla - aroma (contains Vanillin and ethylvanillin), vineyards, magnesium stearate, iron (III) - OXID (E172)."</seg>
<seg id="235">"buy abilify and content of the Pack Buy abilify 10 mg melt, with embossing" A "over" 640 "on one side and" 10 "on the other."</seg>
<seg id="236">"177 If you have a patient of the patient (loss of memory or other mentally abilities), you should have an impact on your doctor. if you ever had a impact or a temporary injunction in the brain."</seg>
<seg id="237">"inform your doctor if you are connected to muscle stiffness or stiffness, with a high fever, changing state state or very easy heart rate."</seg>
<seg id="238">"Calciumtrimetasilicate, Croscarmor oxide, microcrystalline Cellulose, Aspartame, Acesulfam-potum, vanilla, aroma (III) - hydroxid-OXID x H2O (E172)."</seg>
<seg id="239">"buy abilify and contents of the pack The abilify 15 mg melt-on-brushes are round and yellow, with embossing" A "above" 641 "on a page and" 15 "on the other."</seg>
<seg id="240">"183 If you are aware of the patient's patient (loss of memory or other mentally abilities), you should have an impact on your doctor. if you ever had a impact or a temporary injunction in the brain."</seg>
<seg id="241">"inform your doctor if you are connected to muscle stiffness or stiffness, with a high fever, changing state state or very easy heart rate."</seg>
<seg id="242">"the abilify key and content of the Pack's abilify 30 mg melt, with embossing" A "above" 643 "on one side and" "30" on the other. "</seg>
<seg id="243">"inform your doctor if you are connected to muscle stiffness or stiffness, with a high fever, changing state state or very easy heart rate."</seg>
<seg id="244">"transport and the filling of machines you should do not drive, and no tools or machines use, until you know how do abilify you."</seg>
<seg id="245">190 for information about certain other substances of abilify Yeder ml abilify Solution for inserting 200 mg Fructose and 400 mg Sucrose.</seg>
<seg id="246">"if your doctor told you that you have received an intolerance against certain circumstances, please contact your doctor before you take this medicine."</seg>
<seg id="247">The dose of abilify Solution for insertion must be measured with the gearing measurement or of the 2 ml dripette to be included in the pack.</seg>
<seg id="248">Please contact your doctor or pharmacist if you have the impression that the effect of abilify is strong or weak.</seg>
<seg id="249">"if you have taken a larger amount of abilify if you should be able to take a bigger amount of abilify (or if any other abilify solution), please contact your doctor immediately."</seg>
<seg id="250">"Dinariumedetate, fructose, Glycerol, Milyl-4- hydroxybenzoat (E216), Propyl-4-hydroxybenzoat (E216), sodium hydroxid, Sucrose, gerated water and natural orange flavour with other natural flavors."</seg>
<seg id="251">"buy abilify and content of the pack abilify 1 mg / ml solution for insertion is a clear, colourless to light yellow liquid in bottles with a safe polypropylene capacitor and 50 ml, 150 ml or 480 ml"</seg>
<seg id="252">"abilify anodical solution is used for rapid treatment of stolen unpleasant ointments, which are marked by symptoms such as: the hearing, See or fats of things that are not present, missive, unrelated behaviour, unrelated behaviour."</seg>
<seg id="253">"people with this disease can also be depressed, guilty or anew. overlap high feeling, the feeling of excessive energy to have a much less sleep, too much less sleep with changing ideas and sometimes powerful friction."</seg>
<seg id="254">"inform your doctor if you are connected to muscle stiffness or stiffness, with a high fever, changing state state or very easy heart rate."</seg>
<seg id="255">"for use of abilify with other medicines, please inform your doctor or pharmacist if you have used other medicines / or before use other medicines, even if it is not taken to be used."</seg>
<seg id="256">Medicines for treatment of cardiovascular diseases such as antidepresssiva or herbal medicines which are used for treatment of depression and anxiety disorders.</seg>
<seg id="257">"if you are unsure if you are pregnant, unless you have pregnant with your doctor."</seg>
<seg id="258">Transport and repair of machines you should do not drive and no tools or machines use when you feel at the application of abilify injection moulding solution.</seg>
<seg id="259">"if you have concerns you have more abilify injection moulding solution than you need to believe, please contact your doctor or house."</seg>
<seg id="260">* Use five-year forecasts to assess how the market is predicted to develop.</seg>
<seg id="261">"side effects (with more than 1 of 1,000, less than 1 of 100 treatment) Some people can feel one changes in the mouth or sitting, or a fast pulse, a drying feeling in mouth or a fast pulse, a dry feeling in mouth or themselves."</seg>
<seg id="262">"frequent side effects (with more than 1 of 100, less than 1 of 10 treatment) unking movements, headaches, fatigue, nausea, nausea, nausea, nausea, nausea, nausea and blurred."</seg>
<seg id="263">"if you need further information about your disease or their treatment, please read the packaged goods (also part of the EPAR), or contact your doctor or pharmacist."</seg>
<seg id="264">Abraxane should only be applied only under the supervision of a qualified Onkologists in the application of cytostatika (separation of cells) specialist departments.</seg>
<seg id="265">Patients who occur specific side effects on the blood or the nervous system can be reduced or treatment.</seg>
<seg id="266">"(44-20) 74 18 84 00 E-mail: info @ emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http: / / www.emea.europa.eu - http:</seg>
<seg id="267">"the effectiveness of Abraxane was examined in a major study, in the 460 women with metastatic breast cancer, which was about three quarters."</seg>
<seg id="268">The effect of Abraxane (in allanes or a Monotherapy) was compared with a conventional Paclitaxy remedy (given in combination with other medicines for reduction of side effects).</seg>
<seg id="269">"in the main study 72 (31%) of 229 with Abraxane treated patients to the treatment, compared to 37 (16%) of the 225 patients who received conventional Paclitaxel medication."</seg>
<seg id="270">"however, only the patient who were treated by metastatic breast cancer, there was no difference between the drug use of the disease and survival no difference between the drug."</seg>
<seg id="271">"on the other hand, patients showed that other treatments of their metastatic breast cancer were carried out in relation to these indications that Abraxane is effective as conventional Paclitaxel medication."</seg>
<seg id="272">It should not be applied to patients who have been used in patient or before the treatment of the treatment.</seg>
<seg id="273">"the committee of the Humanist agents (CHMP) was established that Abraxane is the first treatment for patients in which the first treatment does not have more anites, effective as conventional Paclitaxel compounds, and that it must be given to other drugs, to reduce side effects."</seg>
<seg id="274">"in January 2008, the European Commission of the company Abraxis Bioscience Limited is a permit for the incoming of Abraxane throughout the European Union."</seg>
<seg id="275">Abraxane-Monotherapy is responsible for treatment of metastatic diseases for metastatic disease for metastatic disease for metastatic disease.</seg>
<seg id="276">In patients with severe neutrropenie (Neutroscopy) &lt; 0.50 x 109 / l above a period of a week or longer) or severe sensory Neuropathy during the Abraxane therapy should be reduced in the following series: 220 mg / m2.</seg>
<seg id="277">"at sensory Neuropathy degree 3, the treatment is to break up to a pressure on degrees 1 or 2, and at all the cycles must be reduced to the dose."</seg>
<seg id="278">There are currently no sufficient data for the recommended dose of the liver function (see section 4.4 and 5.2).</seg>
<seg id="279">"there were no studies with patients with cancer cells, and there are no sufficient information to the recommended dose of the kidney function (see section 5.2)."</seg>
<seg id="280">"Abraxane is not recommended for use in children under 18 years, due to no adequate data for uncertainty and effectiveness."</seg>
<seg id="281">Abraxane is a Albumin-called Nanoparticles formulation of Paclitaxel which could be much other formulation of Paclitaxel (see section 5.1 and 5.2).</seg>
<seg id="282">"if a allergic reaction should be treated immediately, and the patient may not be treated with Paclitaxel, and the patient may not be treated with Paclitaxel."</seg>
<seg id="283">"in the patients, no new Abraxane treatment unit will be taken back to &gt; 1.5 x 109 / l, and the Thrombozytenants are placed on &gt; 100 x 109 / l."</seg>
<seg id="284">Patients with severe liver function (bilirubin &gt; 5 x ULN or ASL / ALT &gt; 10 x ULN) should not be treated with Abraxane.</seg>
<seg id="285">"during a clear with Abraxane in connection, cardiovascular disease is not unusual, especially in patients with early anesacyclin treatment or cardiovascular disease."</seg>
<seg id="286">"if the patients were treated after the gift of Abraxane, vomiting and diarrhoea, these are treated with the usual antiemetics and constiphic means."</seg>
<seg id="287">"Abraxane should not be used during pregnancy or women in the exploited age, except the treatment of the mother with Paclitaxel is inumined."</seg>
<seg id="288">Women in secluent age should be considered during and up to 1 month after treatment with Abraxane.</seg>
<seg id="289">Male patients who are treated with Abraxane will be treated during and up to six months after treatment.</seg>
<seg id="290">Male patients should be advisable before treatment with Abraxane because of treatment with Abraxane does the possibility of a misery infertility.</seg>
<seg id="291">"Abraxane can cause side effects such as tiredness (very often) and Schwindel (often), which can affect the transport and the ability to serve machines."</seg>
<seg id="292">"the most common and most important precautions of side effects are listed, which were treated with metastasions of Mammakarzinom, which were treated in the pivotal clinical phase III study once every three weeks with 260 mg / m2 Abraxane."</seg>
<seg id="293">Neutropenie was the most important ingredient and doscope (at 79% of patients reported) and was quickly retained and doscope depending on 71% of patients.</seg>
<seg id="294">"(Hb &lt; 10 g / dl) was observed at 46% of the Abraxane treated patients, and was observed in three cases (Hb &lt; 8 g / dl)."</seg>
<seg id="295">Table 1: side effects in connection with the gift of Abraxane as monotherapy at any dose and indications in studies (N = 789).</seg>
<seg id="296">"very often (≥ 1 / 10); often (≥ 1 / 100, &lt; 1 / 10); occasionally (≥ 1 / 1,000, &lt; 1 / 100); rare (≥ 1 / 1,000, &lt; 1 / 1,000); very rare (&lt; 1 / 10,000)."</seg>
<seg id="297">"occasionally: increased blood pressure, weight reduction, increased lump hydrogenase in blood, increased phosphor in blood, increased phosphor in blood, reduced phosphorum in the blood of heart disease:"</seg>
<seg id="298">"pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain"</seg>
<seg id="299">"pain in the breast cancer, weakness of the musculature, genickness, muscular pain, muscle pain, pain in the skeletal musculature, muscular pain, muscular pain, muscles."</seg>
<seg id="300">RuheloWare 1 The frequency of oversensitive realities will be charged based on a standard in connection in a population of 789 patients.</seg>
<seg id="301">"as these events were reported to voluntary basis during the clinical practice, there are no discussion of the actual frequency."</seg>
<seg id="302">Paclitaxel is an antimicrotubuli-active ingredients that promotes circulation of the microtubuli from the tubes of the microtubuli by Heming of their deportees.</seg>
<seg id="303">"this stabilization leads to a hemisphere of the normal dynamic reorganisation of the mikrotubulary network, which is much more important for the vitale intersection and with the erotic cell functions."</seg>
<seg id="304">It is known that Albumin the Transductosis of Plasmaids in the endothelial cells and in the framework of vitro studies was identified that the presence of Albumin the transport of Paclitaxel by the endothelial cells.</seg>
<seg id="305">"it is assumed that this improved transatlantic transport by the gp-60-Albuminescence is produced by the gp-60-Albuminescence in cystone), a paclitaxel accumulation in cysteine) a paclitaxel accumulation in the field of tumors."</seg>
<seg id="306">The use of Abraxane for metastasitic Mammakarma is treated by data of 106 patients in two separate studies and of 454 patients who were treated in a randomised phase III.</seg>
<seg id="307">"in a study, 43 patients were treated with metastasitic Mammakaroma with Abraxane, which was given in the form of an infusion over 30 minutes with a dose of 175 mg / m2."</seg>
<seg id="308">"in the second study, a dose of 300 mg / m2 as infusion over 30 minutes to 63 patients with metastasional Mammakarma."</seg>
<seg id="309">"this multifunctional study was performed in patients with metastatic reaction (N = 225) or in form of Abraxane 260 mg / m2 as a 30-minute Infusion without precondition (N = 229)."</seg>
<seg id="310">"in the study, 64% of patients had an open state (ECOG 1 or 2), 79% had viscerale metastases and 76%."</seg>
<seg id="311">"14% of patients had no chemotherapy, 27% had only a adjuvant chemotherapy, 40% only due to metastatic and 19% due to metastasification and 19%."</seg>
<seg id="312">9 The results for the general contact rate and time to the progress of the disease as well as progression-free survival and survival for patients suffering from the first-line therapy are below.</seg>
<seg id="313">Neurotoxizzed compared to Paclitaxel by improving the improvement of a degree of patients who were able at a time during the therapy of a peripheral new ropathy-degree.</seg>
<seg id="314">Luther Firm of the Year for Pharmaceuticals and Healthcare Hogan Lovells Firm of the Year for Restructuring and Corporate Rescue</seg>
<seg id="315">The Pharmakokinetics of the total-Paclitaxel to 30- and 180-minute Infusions of Abraxane with a dose of 80 to 375 mg / m2 has been determined in clinical studies.</seg>
<seg id="316">The active ingredients (Auc) increased linear from 2653 to 16736 ng.h / ml analogue to a dose of 80 to 300 mg / m2.</seg>
<seg id="317">"in the recommended clinical dose of Abraxane, in the recommended clinical dose of 260 mg / m2, the paclitaxel plasma precipation can be applied to multiple sclerosis."</seg>
<seg id="318">"the medium distribution volume was 632 l / m2; the high distribution volume has a soft-calibrated expediment of paclitanel."</seg>
<seg id="319">"in a study with advanced patients with advanced tumors of 260 mg / m2 Abraxane with the values after a 3-hour injection injector of 175 mg / m2, medium-term paclitaxel compared with the values after a 3-hour injection injector of 175 mg / m2."</seg>
<seg id="320">The Clearance of Paclitaxel was higher than the Abraxane gift higher (43%) as after a non-medium-term Paclitaxel injections and also the distribution volume was at Abraxane higher (53%).</seg>
<seg id="321">"in the published literature about in-vitro studies of human liver microcosine, and two smaller Metabolites (3" -p-hydroxypaclitaxel and 6α -3 -p-Dihydroxypaclitaxel). "</seg>
<seg id="322">After a 30-minute Infusion of 260 mg / m2 Abraxane in patients with metastasions 6α -Hydroxypaclitaxel and 3 "-p-hydroxypaclitaxel and 3" -p-hydroxypaclitaxel and 3 "-p-hydroxypaclitaxel and 3" -p-hydroxypaclitaxel and 3 "-p-hydroxypaclitaxel and 3" -p-hydroxypaclitaxel and 3 "-p-hydroxypaclitaxel and 3" -p-hydroxypaclitaxel and 3 "-p-hydroxypaclitaxel and 3" -p-hydroxypaclitaxel and 3 "-p-hydroxypaclitaxel and 3" -p-hydroxypaclitaxel and 3 "-p-hydroxypaclitaxel and 3" -p-hydroxypaclitaxel and 3 "-p-hydroxypaclitaxel and 3" -p-hydroxypaclitaxel and 3 "-p-hydroxypaclitaxel and 3" -p-hydroxypaclitaxel and 3 "-p-hydroxypaclitaxel and 3" -p-hydroxypaclitaxel and 3 "-p-hydroxypaclitaxel and 3" -p-hydro</seg>
<seg id="323">"in the age of over 75 years, however, only a few data is available, since only 3 patients received this age group at the most important group of this age group."</seg>
<seg id="324">"the chemical and physical stability was tested at 2 ° C - 8 ° C in original box, and protected light through 8 hours."</seg>
<seg id="325">Paclitaxel is a cytotoxic anticular medicine and as well as in other potential toxic substances.</seg>
<seg id="326">"using a sterilen syringe, slowly over a period of at least 1 minute to 20 ml of a 9 mg / ml (0,9%) sodium chlorid-Infusionate solution in a Abraxane stallion bottle."</seg>
<seg id="327">"according to complete condition of the solution, the throughput bottle at least 5 minutes, to guarantee a good basis of the solids."</seg>
<seg id="328">"then the throughput bottle for at least 2 minutes slow and carefully, and carefully, and / or inverted, until a complete resusboard of the powder is done."</seg>
<seg id="329">"if availability or Sinkes are visible, the throughput bottle again have to be washed again in order to achieve a complete resusboard."</seg>
<seg id="330">"for the patients the exact overall dosed volume of the 5-mg / ml package will be calculated and the corresponding amount of rechargeable Abraxane is calculated and the corresponding amount of rechargeable Abraxane is calculated and the corresponding amount of the rechargeable Abraxane is calculated by a empty, sterilen PVC- or non-PVC Infusion bag."</seg>
<seg id="331">"Pharmacvigilance system The owner of the permission of the permission must be presented to ensure that the pharmaceutical covigilance system, as in version 2.0 and in module 1.8.1st of the certifications will be presented and works before and during the medicine."</seg>
<seg id="332">"as a result, the owner of the RMP are accepted as well as in version 4 of the risk management system (RMP) were accepted and in the module 1.8.2 of the certifications of the RMP which are agreed with the CHMP."</seg>
<seg id="333">"in accordance with the CHMP Directive, risk anagementsystems for medicines should be submitted by the following Periodic Safety Update Report (PSUR)."</seg>
<seg id="334">"in addition, an updated RMP can be able to submit a new information which could not affect the current safety device, the pharmaceutical covigilance or risk assessment. • On request of the EMEA region, • On request of the EMEA region"</seg>
<seg id="335">8 hours in the fridge in the water bottle when it is kept in the case to protect the content before light.</seg>
<seg id="336">"Abraxane is used to treat Mammakarzinom, but not successfully, and if you don't have successfully to use acyclin-contained therapies in question."</seg>
<seg id="337">Abraxane can not be applied: • If you are oversensitive (allergic) against Paclitaxel or one of the other components of Abraxane • If you have more sensitive (allergic) of &lt; 1.5 x 109 / l - your doctor will inform you about your doctor.</seg>
<seg id="338">Special mention in the application of Abraxane is required: • If you have a cause kidney-function • If you have to suffer cancer pain - if you suffer from severe liver problems • If you have a heart problems</seg>
<seg id="339">"for use of Abraxane with other medicines, please inform the doctor if you can use other drugs or before recently, even if it could not be used for non-refusal medicines, as this may cause a change effect with Abraxane."</seg>
<seg id="340">Women in secluent age should be considered during and up to 1 month after treatment with Abraxane.</seg>
<seg id="341">"moreover, they should be able to advise you before the treatment of a sperm treatment, as by the Abraxane treatment is the possibility of a permanent infertility."</seg>
<seg id="342">Transport resistance and the filling of machines Abraxane can cause side effects such as tiredness (very often) and digestive (frequently) which can be used on transport and the ability to serve machines.</seg>
<seg id="343">"if you get in the framework of your treatment, other medicines you should advise in terms of driving or to serve machines of your doctor."</seg>
<seg id="344">"22 • The effects on the peripheral nerves (pain and dibance) • pain in one or several joints • pain in one or several joints • pain in one or several joints • pain in the muscles • nausea, diarrhoea, and fatigue."</seg>
<seg id="345">"the frequent side effects (at least 1 of 100 patients) are: • skin care, juene, dry skin, moisturising, muscle pain or abdominal pain"</seg>
<seg id="346">The rare side effects (at least 1 of 10.000 patients reported) are:</seg>
<seg id="347">"please inform your doctor or pharmacist, if one of the side effects you can choose from either side effects or side effects that are not found in this use."</seg>
<seg id="348">"if it is not easy to use, it can be stored in the filter bottle up to 8 hours in the fridge (2 ° C - 8 ° C), when it comes to protect the content before light."</seg>
<seg id="349">"any penetration bottle contains 100 mg Paclitaxel. • The other part is Albuminum, sodium caprylate and N Acetyltryptophan (Ph.Eur.))"</seg>
<seg id="350">The preparation of the preparation and application Paclitaxel is a cytotoxic anticular medicine and as well as in other potential toxic substances.</seg>
<seg id="351">"using a sterilen syringe, slowly slowly over a period of 1 minute to 20 ml of a 9 mg / ml (0,9%) sodium chloride (0,9%) sodium chloride (0,9%) sodium chloride for injections."</seg>
<seg id="352">"the filter bottle for at least 2 minutes, slow down and / or inverted, until a complete resusboard of powder is carried out."</seg>
<seg id="353">"for the patients the exact overall dosed volume of the 5 mg / ml sets, and the corresponding amount of rechargeable Abraxane in a empty, sterilen PVC Infusion bag Type IV injizations."</seg>
<seg id="354">Parenterology should be carried out prior to the application of a view on the particles of particles and discurances when always the solution or the containers.</seg>
<seg id="355">Stability Uncooled electric bottles with Abraxane are designed to protect the content from light to protect the content before light.</seg>
<seg id="356">"thanks to the stability of the recharitable Suspension, the first rectification should be filled in an infusion bag."</seg>
<seg id="357">"the member states must ensure that the owner of the approval is responsible for the incoming of the market launch of medical experts in Dialysis centers and individual business meetings with the following information and materials:"</seg>
<seg id="358">• Training brochure • Summary of the features of the drug using (technical information), labelling and packing operations. • With unambiguous display of the correct application of the product caused by cooling boxes for transport through patients. "</seg>
<seg id="359">"this means that Abseamed a biological drugs is similar to the European Union (EU), and the same function can be used in the European Union (EU)."</seg>
<seg id="360">It is used in patients with normal blood cells that could occur in connection with a blood of genetic complications. if the procedure is not possible and they expect a blood loss of 900 to 1 800 ml.</seg>
<seg id="361">Treatment with Abseamed has to be taken under the supervision of a doctor in treatment of patients with diseases that is displayed in the treatment of disease.</seg>
<seg id="362">Patients with kidney problems and patients who want to make a own blood circulation is Abseamed into a Vene.</seg>
<seg id="363">The injections can also be sent by the patient or family counselling; if they have an appropriate manual instructions.</seg>
<seg id="364">In patients with chronic kidney cancer or patients who receive a chemotherapy should always be seen in the recommended area (between 10 and 12 grams per deciliter at adults or between 9.5 and 11 g / dl in children).</seg>
<seg id="365">The iron values of all patients have to control the treatment to ensure that no iron deficiency should be obtained during the whole treatment.</seg>
<seg id="366">Patients who receive a chemotherapy or in patients with kidney problems can be caused by an Eryy poietindeficiency.</seg>
<seg id="367">Eryeri poietin is also used before operations to increase the number of red blood cells and thus reduces the consequences of a blood losses.</seg>
<seg id="368">"it is produced by a cell that is produced by a cell (DNA), which was developed by epetin alfa."</seg>
<seg id="369">"Abseamed was considered to be used as injections in a vene in the framework of a main study, which can be compared with kidney cancer problems."</seg>
<seg id="370">All at this study participating patients was at least eight weeks long Eprex / Erypo in a Vene injected before they were found on Abseamed or continue to Eprex / Erypo.</seg>
<seg id="371">"in the end of the study, the change of hemmogloomy values between the beginning of the study and the distribution period in the weeks of 25 to 29."</seg>
<seg id="372">"the company put on the results of a study, in which the effects of Eprex / Erypo at 114 Kremer were examined, which were obtained a chemotherapy."</seg>
<seg id="373">"in the study of patients suffering from kidney cancer cells, the hemmogloomy values were observed in the same extent as in those patients who still continue to Eprex / Erypo."</seg>
<seg id="374">"compared to this, the patients who continue to Eprex / Erypo received an increase of 0,063 g / dl of the output of 12,0 g / dl."</seg>
<seg id="375">"the most common-effect of Abseamed is an increase of blood pressure, the occasionally to symptoms of a endogenic acid (brain problems) such as sudden, stechoes of the current headache and confusion."</seg>
<seg id="376">"Abseamed may not be applied to patients, which may possibly be sensitive (allergic) against epetin alfa or another of the other components."</seg>
<seg id="377">"Abseamed as injections under the skin is not recommended for treatment of kidney cancer, as additional studies are required to ensure that this is no allergic reactions."</seg>
<seg id="378">"the Committee on Humanist agents (CHMP) to the end, that for Abseamed according to the regulations of the European Union of proof was that the drug has been a comparable quality of quality, security and privacy profile such as Eprex / Erypo."</seg>
<seg id="379">"the company, the Abseamed, is responsible for medical professionals in all member information information including information on safety of the drug."</seg>
<seg id="380">"in August 2007, the European Commission of Medic medicines Pütter GmbH & Co KG has been a permission for the incoming of Abseamed into the whole European Union."</seg>
<seg id="381">"treatment of anemia and reduction of the Transfusion requirements for adults with solid tumors, maliglass, or multiplem Myelom, which is a chemotherapy and with which the risk of a transgenital status (e.g. kardiovaskulary status, pre-existing anemia at the beginning of the chemotherapy)."</seg>
<seg id="382">"the treatment should only be performed for patients with medium-hard anemia (hemmoglobin [Hb] 10 - 13 g / dl [6,2 - 8,1 mmol / l], no iron deficiency (4 or more units in women; 5 or more units in men)."</seg>
<seg id="383">For reduction of foreign blut can be applied to adults without iron deficiency in adults without iron deficiency.</seg>
<seg id="384">HB 10-13 g / dl) and an expected blood loss of 900-1800 ml is applied to participate in an autologists of blood pressure programme.</seg>
<seg id="385">"the Hämoglobin-target concentration is between 10 and 12 g / dl (6,2 - 7,5 mmol / l), except for pädiaternal patients, for which the hemostomy concentration between 9.5 and 11 g / dl (5,9 - 6,8 mmol / l)."</seg>
<seg id="386">"as a result, the assessment of the individual clinical trials and disease resistance is required by the doctor."</seg>
<seg id="387">An increase of hemmoglobin around more than 2 g / dl (1.25 mmol / l) over a period of four weeks.</seg>
<seg id="388">"due to the variability of patients, occasionally can be observed in a patient individual hemmoglobinaries over or under the hemmoglobinaries."</seg>
<seg id="389">"in view of this hemmoglobinvariability, the Hämoglobin-target concentration was performed by 10 g / dl (6,2 mmol / l) to 12 g / dl (7,5 mmol / l)."</seg>
<seg id="390">"when the hemmogloomy is to exceed more than 2 g / dl (1,25 mmol / l) per month or if the permanent hemmogloomy value 12 g / dl (7,5 mmol / l), is the epetin-alfa dose to reduce 25%."</seg>
<seg id="391">The patients should be monitored to ensure that epoxtin alfa in the lowest possible dose which is required for control of Anemia and Anconmiesympic symptoms.</seg>
<seg id="392">"as a result of clinical results, patients with initial Hb value (&lt; 6 g / dl or &lt; 3,75 mmol / l) may be higher wage treatment. (Hb &gt; 8 g / dl or &gt; 5 mmol / l)."</seg>
<seg id="393">"as a result of clinical results, patients with initial Hb value (&lt; 6,8 g / dl or &lt; 4,25 mmol / l) may be higher wage treatment. (Hb &gt; 6,8 g / dl or &gt; 4,25 mmol / l)."</seg>
<seg id="394">"starting dose 50 sheets / kg three per week by intravenous application, if necessary with an increase of 25 items / kg (three per week), up to the desired destination (this should be done in steps of at least 4 weeks)."</seg>
<seg id="395">"as a result, the assessment of the individual clinical trials and disease resistance is required by the doctor."</seg>
<seg id="396">"in view of this hemmoglobinvariability, the Hämoglobin-target concentration was performed by 10 g / dl (6,2 mmol / l) to 12 g / dl (7,5 mmol / l)."</seg>
<seg id="397">Patients should be monitored to ensure that epetin alfa in the lowest possible dose which is required for control of the anesympympic symptoms.</seg>
<seg id="398">"at least 1 g / dl (0,62 mmol / l) or the reticuloaders of ≥ 40,000 cells / µl compared to the output value, the dose of 150 items / kg three per week or 450 items / kg once per week."</seg>
<seg id="399">"when the hemmoglobinanrose &lt; 1 g / dl (&lt; 0,62 mmol / l) and the reticulocytenant &lt; 40,000 cells / µl compared to the output value, the dose is lifted up to 300 mg / kg three times per week."</seg>
<seg id="400">"if after another 4 treatment weeks, 300 ° / kg three per week of the hemmogloomy value to ≥ 1 g / dl (≥ 0.62 mmol / l) or the reticulocytenant to ≥ 1 g / kg (≥ 0.62 mmol / l), the dose of 300 m / kg three times per week."</seg>
<seg id="401">"on the other hand, the presmography value of &lt; 1 g / dl (&lt; 0,62 mmol / l) or the Reticulocytenant (&lt; 0,62 mmol / l) or the Reticuloaders of the output), an approach to the epigtin-alfa therapy is likely to be broken and the treatment should be broken."</seg>
<seg id="402">"patients with lighter Anemia (Hämatokrit 33 - 39%), which is needed in a dose of 600, / kg body weight twice a week for 3 weeks prior to the operating procedure."</seg>
<seg id="403">"with the Iron Cross, as early as possible - e.g. a few weeks before the beginning of the autologists programme - started to be at the beginning of the beginning of the beginning of the beginning of the beginning of the beginning of the end of the blood-therapy."</seg>
<seg id="404">"6 The recommended Dosage is 600 copies / kg epetin, the once per week on three weeks (day 21, 14 and 7) before the operating procedure and the day of the procedure (day 0)."</seg>
<seg id="405">"data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data. why buy this report? * Get a detailed picture of the Personal Care market; * Pinpoint growth sectors and identify factors driving change; * Understand the competitive environment, the market's major players and leading brands;"</seg>
<seg id="406">"alternatively, the injections at the end of the dialysis can be given via the hose of a fistelnadel, followed by 10 ml isotonical cookey solution to ensure the hose and sufficient injection of the drug."</seg>
<seg id="407">Patients treated under the treatment with any Erythroatactin (Pure Red Cell Aplasia, PRCA), should be no Abseamed or another Erythropotin (see section 4.4 - Eryy blaenie). "</seg>
<seg id="408">"cardiovascular system or percussions within a month before the treatment, instabile Angina pectoris, increased risk for deep Veneto."</seg>
<seg id="409">"in patients who can participate in patients who are responsible for a larger electrification process, the use of epetin alfa in the following pre-mentioned disease, peripheral arteries, peripheral arterial disorder; in patients with short-term heart disease or cerebrovascular diseases."</seg>
<seg id="410">EryStarblastopie (PRCA) Very rare has been written about the occurrence of an anticulous PRCA to monthly - up to years of long treatment with subcutanem Erytoppotin.</seg>
<seg id="411">"in patients with sudden loss of loss, the Reticulosis value (1 - 2 g / dl per month) with increased need of Transfusion, the Reticulozyn (1 - 2 g / dl per month) with increased need of Transfusion, infections or infections, blood loss and infections)."</seg>
<seg id="412">"if the Reticulocytes, under consideration of anemia (i.e. the Reticulocytes" index "), which is not found (&lt; 20,000 / mm3 or &lt; 20,000 / Mikrolite or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Thrombotic or &lt; 0.5%), the Throm</seg>
<seg id="413">The data for immunogenization in subcutaneous use of Abseamed in patients with a risk for an anticinduction PRCA (patients with renal anemia) are not sufficient.</seg>
<seg id="414">8. in patients with chronic kidney cancer should not be exceeded in preparation therapy under the section 4.2 the upper limit of hemmoglobin-target concentration.</seg>
<seg id="415">Clinical studies were observed in clinical trials (ESA) was observed in clinical trials (ESA) with a hemmogloomy - target concentration of over 12 g / dl (7,5 mmol / l).</seg>
<seg id="416">"controlled clinical trials have no significant benefits that has been made on the gift of epoxins, when the hemostasis concentration and avoids the concentration of blood transgressions."</seg>
<seg id="417">"about 1 g / dl (0,62 mmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month."</seg>
<seg id="418">In patients with chronic kidney disease and corneal transplantation should not be exceeded in preparation therapy under the section 4.2 the upper limit of hemmoglobin-target concentration.</seg>
<seg id="419">"according to the time, the treatment of antietin with epetin alfa in adults with kidney cancer, which does not require dialysis, the progress of kidney cancer is not accelerating."</seg>
<seg id="420">"in the chemotherapy of chemotherapy, a 2-week delay between epetin-alfa-offering, and the Erythropotin are taken into account (patients, which may be transformer)."</seg>
<seg id="421">"if the Hb increase is bigger than 2 g / dl (1,25 mmol / l) per month or a Hb value of 13 g / dl (8,1 mmol / l) per month or a Hb-value of 13 g / dl (8,1 mmol / l) must be exceeded by the aim to minimise the risk for possible thrombal cancer (8.6 g / dl and 12 g / dl)."</seg>
<seg id="422">"the decision for the use of recombinable Erygopoetine should be based on a benefit risk under the participation of the patients, which should consider the specific clinical context."</seg>
<seg id="423">"in patients who are examined for a larger electromechanical intervention, if possible, before the epetin-alfa therapy causes the cause of anemia and accordingly."</seg>
<seg id="424">Patients who can withdraw from a larger electromechanical intervention because it should have an appropriate worsenoseprophylaxis, as they have an increased risk of vascular and vascular diseases, especially with an underlying cardiovascular disease. "</seg>
<seg id="425">"in addition, treatment can not be excluded that in treatment with epetin alfa for patients with a starting point of treatment: 13 g / dl an increased risk of postoperative inflammation / vaskulsion events."</seg>
<seg id="426">"in several controlled studies, epetine does not understand that they improve the tumour patients with the disease patients and the risk of tumors."</seg>
<seg id="427">4 months for patients with metastatic breast cancer that was led to chemotherapy of 12 - 14 g / dl (7.5 - 8.7 mmol / l)</seg>
<seg id="428">Epetin alfa together with Ciclosporin applied to the blood flow of Ciclosporin and associated with Ciclosporin and the Ciclosure.</seg>
<seg id="429">"in vitro-investigations at the tumor, no notes on an exchange effect between epetin alfa and G-CSF or GM-CSF or GM-CSF or GM-CSF."</seg>
<seg id="430">"patients, glaucoma patients, glaucoma patients, glaucoma patients, glaucoma patients, glaucoma patients, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, biodiversity, glaucoma patients."</seg>
<seg id="431">The most common problem during treatment with epetin alfa is a dosed of the blood pressure or the reduction of an existing hypertension.</seg>
<seg id="432">(see section 4.4 and Section 4.8 - General) was observed in patients with Eryeri poetines.</seg>
<seg id="433">"regardless of the Erythropotin treatment, it can come from surgical patients with kardiovaskulary diseases, after repeated blood of blood and vascular complications."</seg>
<seg id="434">"the genetically modified, glykogel is identical to the amino acids and the carbohydrate are identical to the endogenous humanoid arthritis that was isolated from the urine patients."</seg>
<seg id="435">It could be shown with the help of cultures of human bone markings that epetin alfa specifically stimulates the Eryamin poese and the Leukopoese.</seg>
<seg id="436">"389 patients with hemisphere (221 multiple Myelome, 144 non-Hodgkin- Lymphology, 23 gynecological tumore, 23 gastrointestinal bacteria, 21 gastrointestinal carcinoma, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal disease."</seg>
<seg id="437">"1895 patients with solids tumors (Luke Mammakarma, 260 Bronchial carcinoma, 174 gastrointestinal tumors, 300 gastrointestinal tumors and 478 others) and 802 patients with hemoplasty."</seg>
<seg id="438">These studies were examined in five large-controlled trials associated with a total of 2833 patients; four of these studies were double blind placebokontocular studies and</seg>
<seg id="439">"in the open study, no difference in the overall survival between the recombinantanpogenic patients and the control patients."</seg>
<seg id="440">"in these studies, in these studies showed themselves with recombinant humanities patients with an anemia due to various common malignant."</seg>
<seg id="441">The overall assessment in the studies could not be explained by differences in the insolvency of Thrombolysis and associated complications with recombinable humanoid therapy.</seg>
<seg id="442">It consists of increased risk for thrombolic events in tumor patients who can be treated with recombinant humanoid artin and a negative impact on the overall survival cannot be excluded.</seg>
<seg id="443">"as far as far as these results appear on the application of recombinant humanistic beliefs, which were treated with chemotherapy with the goal to transfer a hemostomy value under 13 g / dl, as a few patients with these characteristics are included in the overloaded data."</seg>
<seg id="444">Epetin-alfa provisions according to repeated intravenous application has a half-time period of approximately 4 hours in patients with kidney cancer.</seg>
<seg id="445">"after subcutaneous injections, the serum mirror of epetin alfa much lower than the serum mirror that can be achieved after intravenous injections."</seg>
<seg id="446">"there is no Kumulation: the serum mirror shall remain equal, regardless of whether they are 24 hours after the first gift or 24 hours after the last gift."</seg>
<seg id="447">(bone markfibrosis is a well-known combination of chronic kidney cancer in humans and could be caused by a secondary hyperparathyreointolerance or unknown factors.</seg>
<seg id="448">"in a study of hemalalysis, the three years with epetin were treated with epetin in the control group with dialysis."</seg>
<seg id="449">"14 In the experimental studies with annotation of the application in the application of the application in the application of the use of the recommended accommodation, epigtin alfa for a delay of the Ossification and to an increase of flawlessness."</seg>
<seg id="450">"these reports are available on the vitro combination with cells from human tumors, which are based on the clinical situation but of unsafe Signifikanz."</seg>
<seg id="451">"in the framework of outpatient application, the patient's patient can be found at a time of maximum 3 days outside of the cooling device and not over 25 ° C."</seg>
<seg id="452">"the fuel is used with graduation and the filling volume is displayed by a printed label, so that if necessary, the dimension of partial volumes can be possible."</seg>
<seg id="453">Treatment with Abseamed has to be taken under supervision of the treatment in treatment of patients with the above mentioned indications.</seg>
<seg id="454">"21 The recommended dosage amounts to 600 copies / kg Epoetin alfa, once per week on three weeks (day 21, 14 and 7) before the operating procedure and the day of the procedure (day 0)."</seg>
<seg id="455">23 In patients with chronic kidney cancer</seg>
<seg id="456">"about 1 g / dl (0,62 mmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month."</seg>
<seg id="457">"patients, glaucoma patients, glaucoma patients, glaucoma patients, glaucoma patients, glaucoma patients, arteries, arteries, arteries, arteries, arteries, arteries, glaucoma patients, glaucoma patients."</seg>
<seg id="458">(see section 4.4 and Section 4.8 - General) was observed in patients with Eryeri poetines.</seg>
<seg id="459">"389 patients with hemisphere (221 multiple Myelome, 144 non-Hodgkin- Lymphology, 23 gynecological tumore, 23 gastrointestinal bacteria, 21 gastrointestinal carcinoma, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal disease."</seg>
<seg id="460">"29 In the experimental studies with annotation of the application in the application of the application in the application of the use of the recommended accommodation, epigtin alfa decreased to a delay of the Ossification and to an increase of flawlessness."</seg>
<seg id="461">"in the framework of outpatient application, the patient's patient can be found at a time of maximum 3 days outside of the cooling device and not over 25 ° C."</seg>
<seg id="462">"36 The recommended dosage amounts to 600 copies / kg Epoetin alfa, once per week on three weeks (day 21, 14 and 7) before the operating procedure and the day of the procedure (day 0)."</seg>
<seg id="463">38 In patients with chronic kidney cancer</seg>
<seg id="464">"about 1 g / dl (0,62 mmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month."</seg>
<seg id="465">"patients, glaucoma patients, glaucoma patients, glaucoma patients, glaucoma patients, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arterial sclerosis, glaucoma patients."</seg>
<seg id="466">(see section 4.4 and Section 4.8 - General) was observed in patients with Eryeri poetines.</seg>
<seg id="467">"389 patients with hemisphere (221 multiple Myelome, 144 non-Hodgkin- Lymphology, 23 gynecological tumore, 23 gastrointestinal bacteria, 21 gastrointestinal carcinoma, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal disease."</seg>
<seg id="468">"44 In the experimental studies with annotation of the application in the application of the application in the application of the use of the recommended semiconductor body weight, to a delay of the Ossification and to an increase of flawlessness."</seg>
<seg id="469">"in the framework of outpatient application, the patient's patient can be found at a time of maximum 3 days outside of the cooling device and not over 25 ° C."</seg>
<seg id="470">"51 The recommended dosage amounts to 600 copies / kg Epoetin alfa that should be given up to three weeks (day 21, 14 and 7) before the operating procedure and the day of date (day 0)."</seg>
<seg id="471">53 In patients with chronic kidney cancer</seg>
<seg id="472">"about 1 g / dl (0,62 mmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month."</seg>
<seg id="473">"patients, glaucoma patients, glaucoma patients, glaucoma patients, arteries, arteries, arteries, arteries, arteries, glaucoma patients, arteries, glaucoma patients, glaucoma patients."</seg>
<seg id="474">(see section 4.4 and Section 4.8 - General) was observed in patients with Eryeri poetines.</seg>
<seg id="475">"389 patients with hemisphere (221 multiple Myelome, 144 non-Hodgkin- Lymphology, 23 gynecological tumore, 23 gastrointestinal bacteria, 21 gastrointestinal carcinoma, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal disease."</seg>
<seg id="476">"59 In the experimental studies with annotation of the application in the application of the application in the use of the application in humans, epigtin alfa decreased, to a delay of the Ossification and to an increase of flawlessness."</seg>
<seg id="477">"in the framework of outpatient application, the patient's patient can be found at a time of maximum 3 days outside of the cooling device and not over 25 ° C."</seg>
<seg id="478">66 The recommended dosage amounts to 600 items / kg epetin alfa that should be given up to three weeks (day 21, 14 and 7) before the operating procedure and the day of the procedure (day 0). "</seg>
<seg id="479">68 In patients with chronic kidney cancer should not be exceeded in preparation therapy under the section 4.2 the upper limit of hemmoglobin-target concentration.</seg>
<seg id="480">"about 1 g / dl (0,62 mmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month."</seg>
<seg id="481">"patients, glaucoma patients, glaucoma patients, glaucoma patients, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, glaucoma patients"</seg>
<seg id="482">(see section 4.4 and Section 4.8 - General) was observed in patients with Eryeri poetines.</seg>
<seg id="483">"389 patients with hemisphere (221 multiple Myelome, 144 non-Hodgkin- Lymphology, 23 gynecological tumore, 23 gastrointestinal bacteria, 21 gastrointestinal carcinoma, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal disease."</seg>
<seg id="484">"74 In the experimental studies with annotation of the application in the use of the application in the application of the use of the recommended accommodation, epigtin alfa for a delay of the Ossification and to an increase of foul mortality."</seg>
<seg id="485">"in the framework of outpatient application, the patient's patient can be found at a time of maximum 3 days outside of the cooling device and not over 25 ° C."</seg>
<seg id="486">"81 The recommended dosage amounts to 600 copies / kg Epoetin alfa that should be given up to three weeks (day 21, 14 and 7) before the operating procedure and the day of date (day 0)."</seg>
<seg id="487">83 In patients with chronic kidney cancer</seg>
<seg id="488">"about 1 g / dl (0,62 mmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month."</seg>
<seg id="489">"patients, glaucoma patients, glaucoma patients, glaucoma patients, arteries, arteries, arteries, arteries, arteries, arteries, glaucoma patients"</seg>
<seg id="490">(see section 4.4 and Section 4.8 - General) was observed in patients with Eryeri poetines.</seg>
<seg id="491">"389 patients with hemisphere (221 multiple Myelome, 144 non-Hodgkin- Lymphology, 23 gynecological tumore, 23 gastrointestinal bacteria, 21 gastrointestinal carcinoma, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal disease."</seg>
<seg id="492">"89 In the experimental studies with annotation of the application in the application of the application in the application of the use of the recommended accommodation, epigtin alfa for a delay of the Ossification and to an increase of flawlessness."</seg>
<seg id="493">"in the framework of outpatient application, the patient's patient can be found at a time of maximum 3 days outside of the cooling device and not over 25 ° C."</seg>
<seg id="494">96 The recommended dosage amounts to 600 copies / kg Epoetin alfa that should be given up to three weeks (day 21, 14 and 7) before the operating procedure and the day of the procedure (day 0). "</seg>
<seg id="495">98 In patients with chronic kidney cancer should not be exceedged under examination of the hemorglobin-target concentration.</seg>
<seg id="496">"about 1 g / dl (0,62 mmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month."</seg>
<seg id="497">"patients, glaucoma patients, glaucoma patients, glaucoma patients, glaucoma patients, arteries, arteries, arteries, arteries, arteries, arteries, glaucoma patients, arteries, glaucoma patients, glaucoma patients."</seg>
<seg id="498">(see section 4.4 and Section 4.8 - General) was observed in patients with Eryeri poetines.</seg>
<seg id="499">"389 patients with hemisphere (221 multiple Myelome, 144 non-Hodgkin- Lymphology, 23 gynecological tumore, 23 gastrointestinal bacteria, 21 gastrointestinal carcinoma, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal disease."</seg>
<seg id="500">"in the experimental studies with annotation of the application in the application of the application in the application of the use of the recommended accommodation, epigtin alfa decreased to a delay of the Ossification and to an increase of flawlessness."</seg>
<seg id="501">"in the framework of outpatient application, the patient's patient can be found at a time of maximum 3 days outside of the cooling device and not over 25 ° C."</seg>
<seg id="502">111 The recommended dosage amounts to 600 items / kg epetin alfa that should be given up to three weeks (day 21, 14 and 7) before the operating procedure and the day of the procedure (day 0). "</seg>
<seg id="503">113 In patients with chronic kidney cancer should not be exceedged under examination of the hemorglobin-target concentration.</seg>
<seg id="504">"about 1 g / dl (0,62 mmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month."</seg>
<seg id="505">"patients, glaucoma patients, glaucoma patients, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, glaucoma patients"</seg>
<seg id="506">(see section 4.4 and Section 4.8 - General) was observed in patients with Eryeri poetines.</seg>
<seg id="507">"389 patients with hemisphere (221 multiple Myelome, 144 non-Hodgkin- Lymphology, 23 gynecological tumore, 23 gastrointestinal bacteria, 21 gastrointestinal carcinoma, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal disease."</seg>
<seg id="508">"119 In the experimental studies with annotation of the application in the use of the application in the application of the use of the recommended semiconductor body weight, to a delay of the Ossification and to an increase of flawlessness."</seg>
<seg id="509">"in the framework of outpatient application, the patient's patient can be found at a time of maximum 3 days outside of the cooling device and not over 25 ° C."</seg>
<seg id="510">"126 The recommended dosage amounts to 600 copies / kg Epoetin alfa that should be given up to three weeks (day 21, 14 and 7) before the operating procedure and the day of the procedure (day 0)."</seg>
<seg id="511">128 In patients with chronic kidney cancer should not be exceeded in preparation therapy under the section 4.2 the upper limit of hemmoglobin-target concentration.</seg>
<seg id="512">"about 1 g / dl (0,62 mmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month."</seg>
<seg id="513">"patients, glaucoma patients, glaucoma patients, glaucoma patients, glaucoma patients, arteries, arteries, arteries, arteries, glaucoma patients"</seg>
<seg id="514">(see section 4.4 and Section 4.8 - General) was observed in patients with Eryeri poetines.</seg>
<seg id="515">"389 patients with hemisphere (221 multiple Myelome, 144 non-Hodgkin- Lymphology, 23 gynecological tumore, 23 gastrointestinal bacteria, 21 gastrointestinal carcinoma, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal disease."</seg>
<seg id="516">"134 In the experimental studies with annotation of the application in the application of the use of the application in the use of the recommended semiconductor body weight, to a delay of the Ossification and to an increase of flawlessness."</seg>
<seg id="517">"in the framework of outpatient application, the patient's patient can be found at a time of maximum 3 days outside of the cooling device and not over 25 ° C."</seg>
<seg id="518">141 The recommended dosage amounts to 600 copies / kg Epoetin alfa that should be given up to three weeks (day 21, 14 and 7) before the operating procedure and the day of date (day 0). "</seg>
<seg id="519">143 In patients with chronic kidney cancer</seg>
<seg id="520">"about 1 g / dl (0,62 mmol / l) per month and should not exceed 2 g / dl (1,25 mmol / l) per month."</seg>
<seg id="521">"patients, glaucoma patients, glaucoma patients, glaucoma patients, glaucoma patients, arteries, arteries, arteries, glaucoma patients, glaucoma patients, glaucoma patients, glaucoma patients, glaucoma patients."</seg>
<seg id="522">(see section 4.4 and Section 4.8 - General) was observed in patients with Eryeri poetines.</seg>
<seg id="523">"389 patients with hemisphere (221 multiple Myelome, 144 non-Hodgkin- Lymphology, 23 gynecological tumore, 23 gastrointestinal bacteria, 21 gastrointestinal carcinoma, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal bacteria, 21 gastrointestinal disease."</seg>
<seg id="524">"149 In the experimental studies with annotation of the application in the application of the application in the application of the use of the recommended semiconductor body weight, to a delay of the Ossification and to an increase of flawlessness."</seg>
<seg id="525">"in the framework of outpatient application, the patient's patient can be found at a time of maximum 3 days outside of the cooling device and not over 25 ° C."</seg>
<seg id="526">"the owner of the permission of the permission is responsible for the insolvency of the market launch, and according to agreement with the relevant authorities in Dialysis centres and individual business meetings with the following information and materials: • Training brochures in dialysis centres and individual business meetings with the following information and materials."</seg>
<seg id="527">"the owner of the permission of the permission to ensure that this is applied in version 3.0, and in the module 1.8.1st of the approval registration, the pharmaceuticals can be used in the transport and as long as long as in the transport sector."</seg>
<seg id="528">"the owner of the permission of the permission of the Insolvency Administration (RMP) agreed to be agreed, as in version 5 of the certifications of the Risk Management Plans (RMP), as well as in accordance with the CHMP Sharommenen Survey of Risk Management Plans."</seg>
<seg id="529">"a updated RMP should be provided according to the" CHMP Guideline on Risk Management Systems for use in the "" CHMP Guideline on Risk Management Systems for use "simultaneously with the next updated report on the insolvency of the drug using (Periodic Safety Update Report, PSUR)."</seg>
<seg id="530">"in addition, a updated RMP will be submitted on the current safety specifications (Safety Specification), the pharmaceuticals kovigilance or the measures to risk analysis (Safety Specification), the pharmaceutical-vigilance or risk analysis, • after receipt of an important (the pharmaceutical-vigilance or risk analysis)."</seg>
<seg id="531">"• within a month before your treatment, a heart disease or an impact of litina pectoris (for the first time or reinforced breast cancer)"</seg>
<seg id="532">"the disease of the heart (coronare heart disease), the artery of the legs or arms (peripheral arterial disorder), the neck vessels (vascular disease) or the brain (Zerebrovascular diseases)."</seg>
<seg id="533">"during the treatment with Abseamed, it can come back to a light dosed of the blood flow of blood flow."</seg>
<seg id="534">Your physician will be able to control regular blood tests to control the number of blood pressure during the first 8 weeks of treatment.</seg>
<seg id="535">"iron deficiency, resolution of red blood cells (Hämingse), blood loss, vitamin-Bitter or folacid deficiency should be considered, and before the start of therapy with Abseamed."</seg>
<seg id="536">Treatment: untreated clarity: opaque 1 piece 25x18 mm EUR14.40 &lt; &lt; BACK TO CATEGORY tourmaline (indigolite)</seg>
<seg id="537">"if you are interested in EryStarblastopie, he will treat your therapy with Abseamed Cancel and delete it as your Anemia am best."</seg>
<seg id="538">"therefore, Abseamed through injections in a vene (intravenous), if you are treated due to a kidney disease due to a kidney disease."</seg>
<seg id="539">"the risk for problems with the heart or the blood vessels, and the dying person could be increased."</seg>
<seg id="540">"with increased or controllable potassium, your doctor may withdraw your doctor an interruption of treatment with Abseamed into consideration, until the potassium values are reproduced again in the standard."</seg>
<seg id="541">"when you suffer from chronic kidney disease, the doctor, your doctor will ensure that your heads will ensure that your hemmoglobines is a certain value."</seg>
<seg id="542">"according to the time, the treatment of the blood shall be observed by the treatment of blood vessels in adults with chronic kidney cancer (kidney cancer), which is not dialympse of kidney cancer."</seg>
<seg id="543">"a 2 - 3-week delay between epetin-alfa-offering, and the unwanted effect should be taken into consideration for evaluation of Abseamed."</seg>
<seg id="544">"200 your doctor will determine your values of red blood vessels (hemmoglobin), and your Abseamed dose is to adjust the risk of a blood of blood cells."</seg>
<seg id="545">"this risk should be transferred to the treatment with epetin alfa, especially when you have been able to have a risk of risk of patient (adipity) or when you are already registered in the past."</seg>
<seg id="546">"if you are interested, you may think that Abseamed such as a growth factor for aperture and certain circumstances, the tumor is negative."</seg>
<seg id="547">"if you have a larger orthodontic surgery, it should be examined before treatment with Abseamed the cause of your anemia."</seg>
<seg id="548">"if your values of red blood vessels (hemmoglobin) are high, you should not get Abseamed, because an increased risk of blood vessels after surgery."</seg>
<seg id="549">"please inform your doctor or pharmacist if you have taken other drugs, if you have used other drugs, even if it is not needed."</seg>
<seg id="550">"if you take Ciclosporin (means to the oppression of immune system) during your therapy, your doctor will be able to measure certain blood tests to measure the blood flow of Ciclosinto."</seg>
<seg id="551">"laboratory tests have no exchange effect between epetin alfa and G-CSF or GM-CSF. (G-CSF and GM-CSF are the means for construction of the immune system, for example of cancer - chemotherapy or with HIV)."</seg>
<seg id="552">"depending on how your blood pressure (Anemia) can be adapted to the treatment, the dose may be adjusted for about four weeks, until your condition is under control."</seg>
<seg id="553">Your doctor will be able to verify that the medicines is correct and make sure that the medicines is correct and your hemostomy value is not exceed a certain value.</seg>
<seg id="554">"once you are well set, you will receive regular cans of departure between 25 and 50 items / kg twice per week, distributed on two equations."</seg>
<seg id="555">Your doctor will be able to check your doctor as a regular way to check the treatment process and ensure that your hemostomy is not exceed a certain value.</seg>
<seg id="556">"depending on how the anemia can be adapted to the treatment, the dose may be adjusted for about four weeks, until the state is under control."</seg>
<seg id="557">"in order to ensure that the hemostomy does not exceed a certain value, the treatment of regular blood tests."</seg>
<seg id="558">"when it is necessary, the treatment time before surgery can be taken before surgery, a dose of 300 m / kg of 10 in the following days before surgery, on the day of the surgery and other 4 days after surgery."</seg>
<seg id="559">"however, you can also learn how you can learn how you can learn how you can learn abamed yourself under the skin."</seg>
<seg id="560">"heart, heart disease, brain dwellings, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries, arteries patients"</seg>
<seg id="561">"eye-catching and lips (Quincke-ÖKO) and shockable allergic reactions with symptoms such as cribens, Roman, juckreiz, heat, feeling and accelerated pulse, in rare cases."</seg>
<seg id="562">Eryxxblastopie means that no more sufficient red blood cells can be formed in bone mark (see section "Special") with the use of Abseamed is needed.</seg>
<seg id="563">"after repeated blood vessels, it may come up - regardless of the treatment with Abseamed - to a blood of blood vessels"</seg>
<seg id="564">Treatment with Abseamed can be observed with an increased risk for blood probiotics after surgery (postoperative cymbal events).</seg>
<seg id="565">"please inform your doctor or pharmacist, if one of the side effects you can differ considerably or if you are viewing side effects that are not in this use."</seg>
<seg id="566">"when a fuel was taken from the fridge, and room temperature has been reached (up to 25 ° C), it must be used either within 3 days or."</seg>
<seg id="567">Aclasta is used for treating the following diseases: • Osteoporosis (a disease that makes the bone of bone) both of women according to the exchange years as well as men.</seg>
<seg id="568">"• Morbus Paget of the bone, including patients who have recently had a slightly abrasion of the bone, a disease that changed the normal course of the bone consumption."</seg>
<seg id="569">"in addition, patients with Morbus Paget at least 500 mg calzium twice daily for at least 10 days after treatment, patients with hip joints should be obtained before the first infusion of vitamin D (50 000 to 125 000 IE) oral or through injections."</seg>
<seg id="570">"symptoms of paramamol or Ibuprofen (means of inflammation) in the three days after the application of Aclasta can cause symptoms, such as fever, muscle pain, grievesimilar symptoms, joint pain and headaches."</seg>
<seg id="571">"in the treatment of Morbus Paget, Aclasta is only of doctors, the experience in the treatment of these disease."</seg>
<seg id="572">As the active ingredient in Aclasta is the same as in Zometric a part of the data material for Zometa to review by Aclasta.</seg>
<seg id="573">"at the first study, almost 8 000 older women with Osteoporosis, and it was examined the number of spacial and hip sculptures by a period of three years."</seg>
<seg id="574">"the second study published 2 127 men and women with Osteoporosis, the number of groups were examined by a period of up to five years."</seg>
<seg id="575">"in Morbus Paget, Aclasta has been tested in two studies in a total of 357 patients and six months long with Risedronat (another Bisphosphonate)."</seg>
<seg id="576">"main indikator for effectiveness was, whether the percentage of alkaline phosphatase in serum (a enzymm, the bone conducts) in the blood of normal or at least 75% compared to the output."</seg>
<seg id="577">"in the study with older women, the risk of antibiotics have been reduced under Aclasta (without any other Osteoporosemedical) over a period of three years in comparison to the patient under Placebo to 70%."</seg>
<seg id="578">In comparison of all patients among Aclasta (with or without other Osteoporosemedical) with those under Placebo was reduced by 41%.</seg>
<seg id="579">"in the study with men and women with hip resistance, 9% of patients with acetone (92 of 1 065) compared to 13% of patients among the patients among the patients among the patient (139 of 1 062)."</seg>
<seg id="580">Most side effects of Aclasta will come within the first three days after the infusion process and are less frequent.</seg>
<seg id="581">Aclasta may not be applied to patients which may possibly be oversensitive (allergic) against zoledronic acid or other bisphosphonate or other bisphosphonate or other substances.</seg>
<seg id="582">"as for all Bisphosphonation, patients at Aclasta the risk of kidney disease, reactions to the infusion, and Osteonekrose (die of bone tissue) in the jaw."</seg>
<seg id="583">"the manufacturer of Aclasta provides a medical material for doctors, the Aclasta for treatment of Osteoporosis, which contains information such as the medicines, as well as a similar material for patients who should contact the side effects of the drug."</seg>
<seg id="584">"in April 2005, the European Commission of the company Novartis Europharm Limited is a permit for the incoming of Aclasta in the whole European Union."</seg>
<seg id="585">"in addition to a safe and effective use of the drug use, THE DURCH DIE member states are implemented in a safe and effective use of the drug policy."</seg>
<seg id="586">Treatment of Osteoporosis in postmenopausal women and women with an increased risk for groups including patients with a recently erlittable high-traumatic gases.</seg>
<seg id="587">"the patient information provided by calcium and vitamin D, adequate physical activity of calcium and vitamin D, adequate physical activity of calcium and vitamin D, adequate physical activity, of non-smoking and healthy nutrition."</seg>
<seg id="588">Treatment of Osteoporosis</seg>
<seg id="589">For the treatment of postmenoporosis and the Osteoporosis in men will recommended an intravenous infusion of 5 mg Aclasta once annually.</seg>
<seg id="590">Patients with a low-traumatic incture is recommended for patients with low-traumatic incture (see section 5.1).</seg>
<seg id="591">"for the treatment of Morbus Paget, Aclasta is only of doctors, the experience in the treatment of the Morbus Paget."</seg>
<seg id="592">After a treatment of the Morbus Paget with Aclasta was observed in patients who were observed in therapy (see section 5.1).</seg>
<seg id="593">"in addition, it is very advisable to ensure patients with Morbus Paget a sufficient amount of calcium, according to at least 10 days after the gift of Aclasta (see section 4.4)."</seg>
<seg id="594">"in patients with a recently erlitty low-traumatic hip circumference is a initialdose of 50,000 to 125.000, or intramuscular vitamin D before the first Aclasta Infusion."</seg>
<seg id="595">"the frequency of symptoms which occur within the first three days after the delay of Aclasta, can be reduced by a gift of parlaamol or Ibuprog shortly after the application of Aclasta."</seg>
<seg id="596">Patients with kidney compounds (see section 4.4) in patients with a Kreatinin-Clearance &lt; 35 ml / min will not recommended Aclasta as limited clinical experience for this patient.</seg>
<seg id="597">"older patients (≥ 65 years) A Dosisance is not necessary, since the bioavailability, distribution and Elimination of older patient is similar to the younger patients."</seg>
<seg id="598">Children and adolescents Aclasta is not recommended for the application of children and adolescents under 18 years since the data is missing for uncertainty and effectiveness.</seg>
<seg id="599">Aclasta is not recommended for patients with severe kidney cancer (Kreatinin-Clearance (Kreatinin-Clearance &lt; 35 ml / min)</seg>
<seg id="600">A pre-existing Hypokaline emia is based on the treatment of calcium and vitamin D for treating calcium and vitamin D (see section 4.3).</seg>
<seg id="601">Due to the rapid change of the effect of Zoledronic acid in bone construction can develop a temporary injunction in the first 10 days after the infusion of Aclasta (see section 4.8).</seg>
<seg id="602">"in addition, it is very advisable to ensure patients with Morbus Paget a sufficient amount of calcium, according to at least 10 days after the gift of Aclasta (see section 4.2)."</seg>
<seg id="603">"cancer treatment, chemotherapy, treatment with cornerosteroids, bad oral hygiene) should be taken from a application of bisphosphonate a dental examination with appropriate pre-ventilating dental treatment."</seg>
<seg id="604">"for patients who require dental handles, there are no data available if the interruption of treatment with bisphosphonate is reduced to the jaw."</seg>
<seg id="605">"the clinical evaluation through the treated physician should be based on the treatment of a every patient, and on an individual benefit risk assessment."</seg>
<seg id="606">The frequency of symptoms which occur within the first three days after the use of Aclasta can be reduced by a gift of parlaamol or Ibuprofen shortly after the application of Aclasta (see section 4.2).</seg>
<seg id="607">"in comparison to patients, Aclasta had to be increased (1.3%) (51 of 3,862) compared to patients who were received (0.6%) (22 of 3,852)."</seg>
<seg id="608">"in the Osteoporosis studies (PFT, HORIZON - recurrent Fracture Trial (2.6%) and Placebo (2.1%)."</seg>
<seg id="609">"very common (≥ 1 / 10), frequent (≥ 1 / 100, &lt; 1 / 10), opportunity (≥ 1 / 1,000, &lt; 1 / 100), rare (≥ 1 / 1,000, &lt; 1 / 1,000) undesired drug effects are listed in table 1."</seg>
<seg id="610">Kidney-controlled coledronic acid has been developed by kidney function (i.e. an increase of serum-Kreatinins) and in rare cases as an acute kidney cancer.</seg>
<seg id="611">The change of Kreatinin-Clearance (annually are measured) and the occurrence of kidney disease was comparable in a clinical study at Osteoporosis in a clinical study at Osteoporosis.</seg>
<seg id="612">A temporary increase of serum-Kreatinins within 10 days after the gift was observed in 1.8% of with Aclasta patients compared to 0.8% of the associated patients.</seg>
<seg id="613">"based on the evaluation of the laboratory published on the evaluation of the laboratory, the equivalent asymptombstum-values that were below the normal swankers (less than 2,10 mmol / l), compared to 21% of the acetylene in the Morbus-Paget studies."</seg>
<seg id="614">"all patients received sufficient amounts of vitamin D and calcium in the study of postmenopausal Osteoporosis, in the study to avoid clinical trials and in Morbus-Paget studies (see section 4.2)."</seg>
<seg id="615">"in the study to avoid clinical trials, the vitamin D mirror were measured, however, the majority of patients had a initialdose of vitamin D before the delay of Aclasta (see section 4.2)."</seg>
<seg id="616">"&lt; div &gt; c't uplink 14.4: smartwatches, Schnüffel-Add-ons, PS4 Pro, Nintendo Classic Mini &lt; / div &gt;"</seg>
<seg id="617">"Osteonekrosen in the jaw area, especially with Kredionekrosen (primal in the jaw area) reports that were treated with Bisphosphonate, including Zoledronic acid."</seg>
<seg id="618">"many of these patients had signs for local infections including Osteomyelitis, and the majority of the reports refers to Kremiths according to tooth extraction or other dental levels."</seg>
<seg id="619">"7 study with 7.736 patients, Osteonekrose in the jaw area with Aclasta, and with a placebo-treated patients."</seg>
<seg id="620">"in case of overdoscope that leads to a clinically relevant Hypokalzemia, can be reached by the gift of calcium calcium and / or a intravenous infusion of calcium phosphate."</seg>
<seg id="621">"as a result of clinical effectiveness in the treatment of postmenopausal Osteoporosis (7.736 women in age between 65 and 89 years), with either a bone of intraocular pressure - (BMD)."</seg>
<seg id="622">The effects on the morphometrics and corneal transplantation is significantly exceeded by a period of three years and already after a year the frequency of one or several new varieties (see table 2).</seg>
<seg id="623">Aclasta-treated patients from 75 years and older they had been reduced to 60% reduced risk for spine surgery compared with placebo patients (p &lt; 0.001).</seg>
<seg id="624">Matching Problems in the Labour Market: between Skills Shortage and Overeducation</seg>
<seg id="625">The effect on bone density (BMD) Aclasta increased the bone density (BMD) Aclaine compared to all time points (6, 12, 24 and 36 months). "</seg>
<seg id="626">9 increase the bone density of the varnished by 6.7% of the whole grain to 6.0% of the Schenkelhum by 5.9% and distal radius by 3.9%.</seg>
<seg id="627">Osteoporosis (N = 82) or Placebo (N = 70) were treated with Aclasta (N = 82) or Placebo (N = 70) were treated with Aclasta (N = 70).</seg>
<seg id="628">A microscopic patients (µCT) analysis showed an increase of extra bed patients in comparison with Aclasta treatment in comparison to placebo.</seg>
<seg id="629">From 517 to 1.246 patients in the Serum and the Beta-C Telepeptid (b-CTx) in the Serum and the Beta-C Telopeptid (b-CTx) in the Serum and the Beta-C Telopeptid (b-CTx) in the Serum and the Beta-C Telopeptid (b-CTx) in the Serum.</seg>
<seg id="630">Treatment with a annual average 5-mg dose is reduced by 30% compared to the output value and was held at 28% below the starting point of up to 36 months.</seg>
<seg id="631">P1NP was significantly reduced by 61% below the starting point of 12 months and was held at 52% below the starting point of up to 36 months.</seg>
<seg id="632">B-CTx was significantly reduced by 61% below the starting point of 12 months and was held at 55% below the output from up to 36 months.</seg>
<seg id="633">"the vitamin D mirror were measured, but the majority of patients received an initial dose of vitamin D (50,000 to 125.000, oral or intramuscular) 2 weeks prior to Infusion."</seg>
<seg id="634">"the overall performance was at 10% (101 patients) compared with Aclasta treated group, compared with 13% (141 patients) in the placebo group."</seg>
<seg id="635">The effect on the bone density (BMD) In the HORIZON-RFT study increased the Aclasta treatment in comparison to the placebo treatment of BMD at the total of the total of time of time.</seg>
<seg id="636">The Aclasta treatment led over 24 months in comparison to the placebo treatment to an increase of BMD at 5.9% of the total amount and around 4.3% at the Schenkelhas.</seg>
<seg id="637">"results appear ordered" "by relevance" "or" "by date" "(publication date),"</seg>
<seg id="638">The study was not designed to show a reduction of clinical trials in men; the frequency of clinical trials was 7.5% at Aclasta treated men in comparison to 8.6%.</seg>
<seg id="639">"Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems."</seg>
<seg id="640">Clinical effectiveness of treatment at Morbus Paget of the Knobs Aclasta has been examined in patient and patients in the age of 30 years with radiologically approved by the alkaline phosphate the alkaline phosphatase according to 2.6GBP until 3.00s-specific upper normal value at the study).</seg>
<seg id="641">11 The effectiveness of an infusion of 5 mg risedronate compared to 30 mg risedronat once daily during 2 months.</seg>
<seg id="642">"for the combined results, after 6 months, a similar removal of pain strength and pain is observed in comparison to the output value for Aclasta and risedronate."</seg>
<seg id="643">Patients who were killed at the end of the sixth year of the main study as a consultant.</seg>
<seg id="644">"from the 143 with Aclasta and the 107 with risedronat treatment, the therapeutic approach was compared with 71 of the treated patients, compared with 71 of the patient treatment in the middle of 18 months after the application period of 18 months after the application."</seg>
<seg id="645">"a unique and multi-tone 5 and 15 minutes long infusion of 2, 4, 8 and 16 mg coledronic acid in 64 patients received the following two patients received as doscope-independent."</seg>
<seg id="646">"after 24 hours a maximum of 4 hours and &lt; 1% after 24 h, followed by a long-lasting phase very low concentration, not more than 0.1% of the maximum."</seg>
<seg id="647">"due to the long-term objective of the German-speaking territories, it is not possible to take place on the basis of a long-term basis."</seg>
<seg id="648">"the early distribution of phases (α and purposes, with the above mentioned degree of ½ -values) represent the rapid resorption into the bones, and the preaching of the kidneys."</seg>
<seg id="649">"in the first 24 h, 39 ± 16% of the prescribed dosage at Urin, while the rest is bound to bone tissue."</seg>
<seg id="650">The total body Clearance is independent from the dose 5.04 ± 2.5 l / h and remains uninfluenced by gender, age, race or body weight. "</seg>
<seg id="651">"a extension of the infusion time of 5 to 15 minutes, in the end of the infusion, had no effect on the surface under the curve (plasma concentration against time)."</seg>
<seg id="652">"if you have any queries, please log in using your e-mail address and your password.:"</seg>
<seg id="653">"specific patient groups (see section 4.2) The renal Clearance of the Zoledronic acid correlated with the Kreatinin-Clearance, namely 75 ± 33% of Kreatinin-Clearance, and at the 64 ± 29 ml / min (range 22 to 143 ml / min)."</seg>
<seg id="654">This result is that a light (Clr = 50- 80 ml / min) and a moderate kidney function of up to a Kreatinin-Clearance up to 35 ml / min no socket adaption of Zoledronic acid.</seg>
<seg id="655">"as for heavy duty functional interference (Kreatinert Clearance, &lt; 30 ml / min) only limited information, are possible for these population."</seg>
<seg id="656">The highest level of intravenous single dose was caused by mite 10 mg / kg body weight and at Reins 0.6 mg / kg body weight.</seg>
<seg id="657">"in case of studies, individual doses of 1.0 mg / kg (based on the Auc the 6ch of the recommended dose therapeutic exposition), received by a period of 15 minutes, good and without any renal flow."</seg>
<seg id="658">"in a total of 6-minute Infusion 1 mg / kg, measured by 0.6 mg / kg as a 15-minute Infusion 1 mg / kg, used in Intervall of 2- 3 weeks (a cumulative dose, which corresponds to a total of 6-minute infusion in 3-day interval)."</seg>
<seg id="659">"in long term studies with repeated exposure, the maximum of the intended Human-Exposition is sufficient, the maximum of the intended Human-Exposition is sufficient, including the Gastrointestinal tract and the liver, as well as on the intravenous injunctions."</seg>
<seg id="660">"the most common, and in studies with repeated applications was an increase in the metaphysiveness of the long-bone of animals in the growth phase with almost all dosities, one-and, which is reflected in the substance, antiresorptive effect of the substance."</seg>
<seg id="661">"at the same time, a Teratogenic acid at Dosilica was removed from 0.2 mg / kg as an external and inner (visceral) misery and such as the skeleton."</seg>
<seg id="662">"in case of rabbit effects or embryo-fatty effects, although the maternal infections at 0.1 mg / kg due to erlow serum-calum-mirror."</seg>
<seg id="663">"if the medicines may not be used, the user is responsible for the storage time after preparation and the conditions before the application; usually 24 h at 2 ° C up to 8 ° C."</seg>
<seg id="664">Aclasta is used as a pack of package as a package of package.</seg>
<seg id="665">Treatment of Osteoporosis in postmenopausal women and women with an increased risk for groups including patients with a recently erlittable high-traumatic gases.</seg>
<seg id="666">"the patient information provided by calcium and vitamin D, adequate physical activity of calcium and vitamin D, adequate physical activity of calcium and vitamin D, adequate physical activity, of non-smoking and healthy nutrition."</seg>
<seg id="667">"in July 2007, 11 September 2006, on 29 September 2006, in the module 1.8.1 of the registration deadline for the pharmaceutical system in power is and works before and during the product."</seg>
<seg id="668">Risko Management - Plan is obligated to perform the studies and the additional activities to the pharmaceutical project plan (RMP) in module 1.8.2 of the certifications of the RMP-approved versions of the RMP-approved versions of the RMP.</seg>
<seg id="669">"according to the CHMP directives for risk management systems, the overworked RMP together with the next" Periodic Safety Update Report (PSUR). "</seg>
<seg id="670">"• In stock of 60 days, the present statements can influence the present statements for security, the pharmaceutical covigilance plan or activities to minimize risk of risk. • In the requirement of the EMEA. • In order to request the EMEA."</seg>
<seg id="671">"Zoledronic acid is a representative of a Substling class, the Bisphosphonate, and is used for the treatment of Osteoporosis of men and the Morbus Paget."</seg>
<seg id="672">Gender: posts: 15338 NTF & C.O.N.S. Co-Star ®</seg>
<seg id="673">"in Morbus Paget, the bone structure is too fast, and a new bone material is uncontrolled, which makes the bone of the bone as normal."</seg>
<seg id="674">Aclasta affects the bone of osteoporosis as well as a normal bone fractures and thus the bone of bone.</seg>
<seg id="675">"if you have to withdraw your doctor or dental surgery, inform your doctor that you will be treated with Aclasta."</seg>
<seg id="676">"for use of Aclasta with other medicines, please inform your doctor, pharmacist or the nursing staff, if you have to use other medicines / or before going to be used, even if it is not needed."</seg>
<seg id="677">"for your doctor, it is particularly important to know whether you take drugs, of which they are known."</seg>
<seg id="678">"for use of acetylene together with food and drink, you are sure that you have enough liquid before and after the treatment with Aclasta."</seg>
<seg id="679">"Osteoporosis The usual dose is 5 mg once per year, which will receive you from your doctor or the staff."</seg>
<seg id="680">"if you have broken the hip, then recommended the delay from Aclasta two or more weeks after the operating supply of the hip."</seg>
<seg id="681">"Morbus Paget The usual dose is 5 mg, which is used by your doctor or the nursing staff as infusion in a vene."</seg>
<seg id="682">"since Aclasta for a long time, you will be able to make a further dosage only after a year or longer."</seg>
<seg id="683">It is important to follow these instructions to follow the calcium mirrors in your blood in time after the infusion.</seg>
<seg id="684">"in Morbus Paget, Aclasta can be more than a year, and your doctor will inform you if you need a new treatment."</seg>
<seg id="685">"if the delay from Aclasta, you will be immediately sent to your doctor or hospital in conjunction with your doctor or hospital in order to make a new appointment."</seg>
<seg id="686">"before the treatment of therapy with Aclasta, please take the treatment of the treatment with Aclasta, please take your next doctor ttermin and discuss this with your doctor."</seg>
<seg id="687">"side effects in connection with the first infusion, very often on (at more than 30% of patients), are less frequent."</seg>
<seg id="688">"fever, fever or joint pain, muscle or joint pain and headaches, enter into the first three days after the delay from Aclasta."</seg>
<seg id="689">"currently, it is clear that Aclasta these unregular heart rate, but you should report to your doctor when you receive such symptoms when you have a lasta."</seg>
<seg id="690">"physical symptoms due to low calorie - concentration in blood, such as muscle groups, or critical feeling, especially in the area around the mouth."</seg>
<seg id="691">"pain, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, stiffness, and pain."</seg>
<seg id="692">Persistent pain and / or non-healing wines in the mouth or the jaw have been treated with patients who were treated with bisphosphonate because of other diseases.</seg>
<seg id="693">"about allergic reactions, including less cases of atemastness, Nymphenburg and Angioids (such as for example swelling in the face, the tongue or in the Rachen)."</seg>
<seg id="694">"please inform your doctor, pharmacist or the nursing staff, if one of the correct side effects you can choose from either side effects or side effects that are not listed in this use."</seg>
<seg id="695">"if the drugs is not directly used, the user is responsible for the storage time and conditions for the application; usually 24 h at 2 ° C up to 8 ° C."</seg>
<seg id="696">"in patients with a short-term low-traumatic hip resistance is recommended, the Infusion of Aclasta two or more weeks after the operating supply of the hip surface."</seg>
<seg id="697">"before and after the delay of Aclasta, patients must be sufficient with liquid; this is particularly important in patients who receive a diuretic therapy."</seg>
<seg id="698">"due to the rapid change of the effect of Zoledronic acid in bone construction can develop a temporary, sometimes glamorkalzemia, their maximum usually within the first 10 days after the infusion of Aclasta."</seg>
<seg id="699">"in addition, it is very advisable to ensure patients with Morbus Paget a sufficient amount of calcium, according to at least 10 days after the gift of Aclasta for at least 10 days after the gift of Aclasta."</seg>
<seg id="700">"in patients with a recently, low-traumatic hip circumference is recommended for a starting dose of 50,000 to 125.000, or intramuscular vitamin D prior to the infusion of Aclasta."</seg>
<seg id="701">"if you need further information about your disease or their treatment, please read the packaged goods (also part of the EPAR) or contact your doctor or pharmacist."</seg>
<seg id="702">"ACOMPLIA, in addition to a diet and movement for the treatment of adult patients suffering from 30 kg / m ² or later, or even the overstated are (BMI of 27 kg / m ²) and beyond, one or more I"</seg>
<seg id="703">"there were four studies on over 7 000 patients, in which ACOMPLIA was used in comparison to a placebo."</seg>
<seg id="704">"the studies on the setting of the space, however, no unified results, so that the effect of ACOMPLIA on this application area was difficult."</seg>
<seg id="705">"this risk is associated with ACOMPLIA? it is the most common side effects of ACOMPLIA, which were observed during studies (observed) and infections of the upper breathing."</seg>
<seg id="706">"it may also be applied in patients who are not applied to patients with antidepressiva, because it can cause the risk of deportations and among other patients suffering from patients suffering from patients."</seg>
<seg id="707">"caution is commanded at simultaneous application of ACOMPLIA using drug use like Ketoconazol or Itraconazol (drugs against fungal infectomy), Ritonavir (a means to application at HIV- infection), Telivermycin or Clariant mycin (antibiotics)."</seg>
<seg id="708">The Committee on Humanist agents (CHMP) to the end that the effectiveness of ACOMPLIA in regard to the weight reduction in patients with Adidas or overdrive</seg>
<seg id="709">Medicines for patient is applied to health and non-cosmetic reasons (by provision of detention for patients and physicians) and around the Arz</seg>
<seg id="710">"in addition to diet and movement to the treatment of a Adidas (BMI ≥ 30 kg / m ²), one or more important patients (BMI &gt; 27 kg / m ²), which are also one or several risk factors (see section 5.1)."</seg>
<seg id="711">ACOMPLIA is not recommended for use in children and adolescents under 18 years on the reason of the absence of data to effectiveness and intrueness.</seg>
<seg id="712">"La Depressive disorders or voice changes with depressive symptoms were at up to 10%, preferably at up to 1% of patients, the Rimonabant (see section 4.8)."</seg>
<seg id="713">The risk of treatment is not applied to the risk of treatment in the individual case of the risk (see section 4.3 and 4.8).</seg>
<seg id="714">"in addition to patients who are not involved in patients, who are not able to occur in addition to the Adidas - no means of risks, depressive reactions can occur."</seg>
<seg id="715">"as a result, such symptoms occur that it is necessary to make use of such symptoms such as such symptoms."</seg>
<seg id="716">• Election of the effectiveness and intruthfulness of Rimonabant at the treatment of patients over 75 years.</seg>
<seg id="717">Patients with a cardiovascular system (Myokardinfotainment or percuscase) is less than 6 months of studies with Rimonabant.</seg>
<seg id="718">"rifampicin, phenytoin, phenytoin, phenytoin, Johannisene) is assumed that the current gift of potent CYP3A4-inductors the plasma concentration of Rimonabant"</seg>
<seg id="719">"results appear ordered" "by relevance" "or" "by date" "(publication date),"</seg>
<seg id="720">"the following table (table 1) shows the following table (table 1) shows the following table (table 1) shows the following table effects in placebokontological studies in the placebokontocratic studies in patients, which were treated to weight reduction and due to severe metabolic diseases."</seg>
<seg id="721">"if the intoxication statistics was significantly higher than the correlation of the placebo (for undesirable effects (1%) or if they are relevant (for unwanted effects: 1%) or if they were forced to be placed in the review of side effects:"</seg>
<seg id="722">Very frequently (≥ 10%); often (≥ 1, &lt; 10%); occasionally (≥ 0.1, &lt; 1%); rare (≥ 0,01, &lt; 0,1%); "</seg>
<seg id="723">"in an adjustment study, which had been found in a limited number of persons employed by up to 300 mg only slight symptoms were observed."</seg>
<seg id="724">"the patient had a BMI ≥ 30 kg / m ², or BMI &gt; 27 kg / m ² and one at the same time existing Hypertension and / or."</seg>
<seg id="725">"n weight reduction after a year, for ACOMPLIA 20 mg 6.5 kg, related to the output, compared with 1.6 kg of CI95% -5.7% -5,3; -4,4, p &lt; 0.001)."</seg>
<seg id="726">"patients who were treated with ACOMPLIA 20 mg, and 1.2 kg in the Placement group (difference -3,8 kg; CI95% -4,4, -3.3; p &lt; 0.001)."</seg>
<seg id="727">"after 2 years, the difference between ACOMPLIA and Placebo -4,2 kg (CI95% -5.0%; -3,4, p &lt; 0.001). EIM"</seg>
<seg id="728">"9 Weight reduction and additional risk factors in patients with patients without diabetes, in which a mixed population of patients with patients"</seg>
<seg id="729">"at Rimonabant 20 mg, an average amount of triglyceride by 6,9% (output value Triglyceride 1,62 mmol / l) compared to an increase of 5.7%"</seg>
<seg id="730">"in a second study, patients with a Adidas and previously unsuccessful type-2- diabetes (Serenade), the absolute change of HbA1c value (with an output value of 7,9% for both groups) after 6 months -0.8 for Rimonabant 20 mg and 0.3 under Placebo I"</seg>
<seg id="731">The percentage of patients suffering from &lt; 7% compared to 51% in the Rimonabant group and 35% in the placebo group.</seg>
<seg id="732">The difference of the middle weight change between the 20 mg- and the placebo group was at 3.8 kg (CI95% -5.0 (-2,6 p &lt; 0.001). LN</seg>
<seg id="733">"improvement of HbA1c deficiency in patients, the Rimonabant 20 mg had been taken over 50% through direct effects of Rimonabant and about 50% through the weight reduction of Rimonabant and about 50% through the weight reduction."</seg>
<seg id="734">"after 13 days (Cmax = 196 ± 28,1 ng / ml; Ctw = 91,6 ± 14,1 ng / ml; AUC0-24 = 2960 ± 268 ng.g / ml)."</seg>
<seg id="735">"influence of food: he subjects, the Rimonabant, either in the distal state or according to a few of the food, in case of the food, a 67% increased by 48% increased by 48% increased by 48%."</seg>
<seg id="736">Patients with black skin can have a up to 31% less Cmax and a um 43% lower Auc.</seg>
<seg id="737">The most popular spinal analysis (age spectrum 18- 81 years) is estimated that a 75- year old patient is estimated 21% higher Cmax and a bit 27% higher Auc.</seg>
<seg id="738">5.3 preclinical data to the safety of folklore that were not observed in clinical trials that were not observed in clinical trials. however, they were relevant for the clinical application of the clinical application. "</seg>
<seg id="739">"in some, however, not in all cases, the beginning of the contra-related stress as to use with the animals."</seg>
<seg id="740">"Rimonabant was given by a longer period before the Paarung (9 weeks), which were observed by the initials effects of Rimonabant allowed, so no undesirable effects on the fermentation or cyclusdysfunction were observed."</seg>
<seg id="741">The impact of Rimonabant on the pre- and postnatale development was examined at the Races in Dosical from up to 10 mg / kg / day.</seg>
<seg id="742">"in a study to preventive and postnatal development, a exposition with Rimonabant in utero and is no changes in learning behaviour or on memory."</seg>
<seg id="743">Detailed information on this medicine are based on the site of the European Medicines Agency (EMEA) http: / / www.emea.europa.eu / item.</seg>
<seg id="744">"La View of the package of the drug has to be given a name and address of the manufacturer, which are responsible for the release of the implementation."</seg>
<seg id="745">"at the same time, such as deportations or voting changes were received at patients who received ACOMPLIA, reports (see paragraph, WELCHE side effects)."</seg>
<seg id="746">"if you are using a depression (see below) during treatment with ACOMPLIA, please contact your doctor and break the treatment."</seg>
<seg id="747">"digestive, diarrhos, anxiety, juckreiz, overhauled chimney, tendons, tendon, tendon, tendons, grief, grief, grief, grief, grief, grief, grief, grief, grief, grief."</seg>
<seg id="748">"please note your doctor or pharmacist, when one of the side effects you can choose from either side effects or side effects that are not found in this use."</seg>
<seg id="749">"Summary of the EPAR for the public document is a summary of the European public administration (EPAR), in which explains how the Committee of Humanist (CHMP) are assessed by the application of the drug administration (CHMP)."</seg>
<seg id="750">• It can be applied to the treatment of type-2 diabetes. • It can be applied alone (Monotherapy) in patients (especially in important patients). • It can be applied together with another Diabetesmediator (Dualtherapy). • It can be applied together with another Diabetesmediator (Dualtherapy).</seg>
<seg id="751">It can also be applied in metformin patients (especially in important patients) which can be used with metformin alone in the highest possible dose.</seg>
<seg id="752">"in combination with a Sulphylharnine or Insulated the previous dose of Sulzylharnils, except in patients with hypoglycemia (lower blood sugar); here should the dose of Sulphylate infection or the insins can be reduced."</seg>
<seg id="753">"this means that the physical activity can be better than better, and the blood sugar levels should be reduced to reduce type 2 diabetes."</seg>
<seg id="754">"in more than 1 400 patients, the effectiveness of Actos was examined in Tripletherapy; however, patients received a combination of metformin with a Sulphylharnal, in addition to 3.5 years, either Actos or Placebo."</seg>
<seg id="755">"in the studies, the concentration of a substance in blood (glycosyliosis of hemmoglobin, HbA1c), which shows how well the blood sugar is set."</seg>
<seg id="756">Acura led to a decrease of HbA1c value, which means that the blood sugar values for use of 15 mg, 30 mg and 45 mg. "</seg>
<seg id="757">"in the end of the tripletherapy study showed the effect of the additional gift of Actos for existing treatment with metformin and a Sulliylharnate in a reduction of HbA1c values at 0.94%, while the additional gift of Placebo was brought to a decrease of 0.35%."</seg>
<seg id="758">"in a small study, in which the combination of Actos and Insulin at 289 patients, patients, the Actos in addition, patients suffering from 0.69% after 6 months compared with 0.14% compared to the patients who are in addition."</seg>
<seg id="759">"the most common side effects in connection with acettos were tendon dysfunction, infections of upper breathing, weight gain, and hypoetic thesia (reduced sensitivity compared to friction)."</seg>
<seg id="760">"Actos may not be applied to patients who may respond to patients with liver problems, nor in patients with liver problems, herpathogenence or diabetic Ketoazio (high Ketonmirror - acid / cells - in the blood)."</seg>
<seg id="761">"it was decided that Actos in the framework of a monotherapy (with a number of use) as an alternative to the standard treatment with metformin patients, where metformis not displayed."</seg>
<seg id="762">"in October 2000, the European Commission sent the European Commission to companies Takeda Europe R & D Centre Limited in the entire European Union."</seg>
<seg id="763">"these tablets are white to white, round, curved and wear on a side" "15" "and on the other side."</seg>
<seg id="764">Pioglitazon is also shown for the combination with insulin in patients with type 2 diabetes mellitus, their blood sugar with insulin or intoxicity. "</seg>
<seg id="765">The application of Pioglitazon in patients under 18 years are no data available, therefore the application in this age group not recommended. "</seg>
<seg id="766">"in patients treated through the presence of at least a risk of risk factors (e.g. early Herzinfotainment) endangered heart disease, the doctor should start the treatment with the lowest possible dose of dose and the dose."</seg>
<seg id="767">"patients should be observed on signs and symptoms of a heredical, weight loss or oils, especially those with reduced cardiovascular reserve."</seg>
<seg id="768">"patients should be observed on signs and symptoms of a herd, weight loss and oils when Pioguazon in combination with Insulated."</seg>
<seg id="769">A cardiovascular study with Pioglitazon in patients under 75 years with type 2 diabetes mellitus and pre-existing advanced civascular disease was performed.</seg>
<seg id="770">"in this study, the report showed a increase of the reports of carcinogenesis, which is not an increase of mortality in the study."</seg>
<seg id="771">In patients with increased increase of the liver diseases (ALT &gt; 2.5 x upper limit of the standard) or with other signs of a liver disease may not be used.</seg>
<seg id="772">"if the ALT-mirror up to 3 times the upper limit of the standard area are increased, the liver values are as soon as possible."</seg>
<seg id="773">"if a patient symptoms are developed, such as unmistakable dysfunction, such as unmistakable, fatigue, appetite, appetite, appetite, appetite, appetite, appetite, appetite, appetite, appetite, and / or dark Harn, are the liver values."</seg>
<seg id="774">"the decision, whether the treatment of patients with Pioglitazon, should be considered to be determined by the laboratory parameters of clinical assessment."</seg>
<seg id="775">Clinical trials associated with Pioglitazon was identified in clinical trials with Pioglitazon in clinical trials.</seg>
<seg id="776">"as a result of a hemisphere, under the therapy of Pioglitazon a minor reduction of the middle hemmogloomy values (relative reduction in 4%) and the Hämatokrits (relative reduction around 4,1%)."</seg>
<seg id="777">Similar changes were observed in glaucoma (relative reduction of hemmoglobin around 3-4% and the hematocrits around 1-2% and the Hämatokrits (relative reduction of hemmoglobin around 1-2%).</seg>
<seg id="778">"as a consequence of the increased muscle growth of patients, the Pioglitazon as orale two or three or triple combination therapy with a Sulphylharnals or two or three or triple combination therapy, the risk of a doscope dependent hypoglycemia."</seg>
<seg id="779">"after the market launch, under the treatment with Thiazolidindigenous, including Pioglitazon, including Pioglitazon, on a occurrence or a reduction of a diabetic macular dems, with a reduction of the tendon."</seg>
<seg id="780">It is unclear whether it should be aware between the taking of Pioguazon and the occurrence of macular dems are aware of the possibility of a macular dems; an appropriate ophthalmology should be taken into consideration.</seg>
<seg id="781">"with more than 8,100 patients who were treated with a period of up to 3.5 years with more than 8.100 patients who were treated with Pioglitazon."</seg>
<seg id="782">"the insolvency proceedings of 1,9 groups per 100 patient-years have been treated with Pioglitazon treated with Pioglitazon treated with Pioglitazon treated with Pioglitazon treated with Pioglitazon treated with Pioglitazon."</seg>
<seg id="783">"in the proactive study, a study published over 3.5 years in investigation of cardiovascular events, compared to 23 / 905 (5.1%; 1,0 groups per 100 patient-years) of patient who were treated with a comparison to a comparison."</seg>
<seg id="784">"the patient should be aware of a pregnancy, and if a patient does a pregnancy or that, the treatment is absent by the treatment (see section 4.6)."</seg>
<seg id="785">"in the investigation of the exchange of interaction, Pioglitazon has no relevant effects on the respiratory or pharmaceutical industries of Digoxin, Warfarin, phenyoumon and metformin."</seg>
<seg id="786">"the search interface PubPsych offers an easy to use search interface in English,"</seg>
<seg id="787">The current application of Pioglitazon with Gemfibrozil (a Cytochrome P450 2C8- Inhibitor) resulting in an increase in Auc from Pioglitazon around the 3 times.</seg>
<seg id="788">The current application of Pioglitazon with Rifampicin (an Cytochrome P450 2C8-inductor) resulting in a lowering of the Auc from Pioglitazon to 54%.</seg>
<seg id="789">This is the case that under treatment with Pioglitazon which reduces hyperinsulinemia and increased musculine of the mother and thus reducing the availability of the metabolic growth.</seg>
<seg id="790">"very often &gt; 1 / 10; frequently &gt; 1 / 100, &lt; 1 / 10; occasionally &gt; 1 / 1000, &lt; 1 / 100; rare &gt; 1 / 10000, &lt; 1 / 1000,"</seg>
<seg id="791">"this lead to a temporary change of the turkors and the bending radius of the lens, as they are observed in other hypoglycemia."</seg>
<seg id="792">"in clinical trials with Pioglitazon, ALT-Anstiff about the three-round of the standard of the standard of the standard of the standard of the standard of the standard of the standard."</seg>
<seg id="793">"in a Outcome study in patients with pre-existing advanced civascular diseases, the frequency of a severe hereditary disease was the frequency of a severe heritazon around 1.6% higher than among the placebo when Pioglitazon."</seg>
<seg id="794">"since the market launch, however, however, more than Pioglitazon reports, however, however, when Pioglitazon are used in combination with Insulin or in patients with carcinogenesis in the Anamnese."</seg>
<seg id="795">"there was a compound analysis of news intimized events of randomised, controlled, double blind-clinical trials over a period of up to 3.5 years with more than 8.100 patients in the year with cellullitazon treatments and over 7.400 patients."</seg>
<seg id="796">"compared to a period of 3.5 years, the proactive study published on 44 / 905 (5.7%) of patients with Pioglitazon treated patients were treated with a comparison."</seg>
<seg id="797">"in taking a maximum dose of 120 mg / day over four days, then 180 mg / day over seven days."</seg>
<seg id="798">Pioglitazon seems to have an activation of specific core reformers (Peroxisome Proliferator Activated Receptor omnidirectional receptor of liver, fat and skeletal muskeletal cells. "</seg>
<seg id="799">It could be shown that Pioglitazon the Glucosity production in the liver reduces the peripheral equipment in the case of a Insulinaria.</seg>
<seg id="800">A clinical study with Pioglitazon versus Gliclazid as Monotherapy was led to investigate the time to the therapeutic effect (defined as HbA1c ≥ 8.0% after the first 6 treatment).</seg>
<seg id="801">"at the time after two years after the treatment, a blood pressure regulates (defined as HbA1c &lt; 8,0%) by Pioglitazon at 69% of the patients under Gliclazid)."</seg>
<seg id="802">"in a placebokontocratic study on 12 months, patients, their blood sugar despite a few monatiger optimization phase with insulin in insufficient time, Pioguazon or Placebo randomised."</seg>
<seg id="803">Patients under Pioglitazon reduced the middle of HbA1c - value by 0.45% compared to the patients who continue to have been observed; a reduction of the insulin in the Pioglitazon treated group was observed.</seg>
<seg id="804">Clinical trials showed a significant increase in clinical trials in clinical trials at Pioglitazon. a statistical analysis of the Albumin / Kreatinin-Quotiations compared to the output.</seg>
<seg id="805">"the effect of Pioglitazon (Monotherapy with 45 mg / placebo) was tested in a small, on 18 weeks."</seg>
<seg id="806">"in most clinical trials have been observed in most clinical trials, compared to placebo-triglyceride and free fatty acids and an increase of HDL- cholesterol levels, but also significantly higher LDL- cholesterol levels."</seg>
<seg id="807">"in clinical trials over a period of up to two years, Pioglitazon compared to placebo, metformin or Gliclazid the total plasmatriglyceride and the free fatty acids and increased the HDL cholesterol levels."</seg>
<seg id="808">"in comparison to placebo was found under Pioglitazon no statistical analysis of the LDL cholesterol levels, while under metformin and Gliclazid."</seg>
<seg id="809">"in a study of 20 weeks, Pioglitazon is not only the nuts of Triglyceride, but improved beyond the effect on the triglycerid absorption as well as the hepatic triglycerid synthesis."</seg>
<seg id="810">"in the proactive study, a kardiovaskulary Outcome study, 5238 patients with type 2 diabetes mellitus and pre-existing advanced civascular diseases (Pioglitazon or Placebo)."</seg>
<seg id="811">"after oral use, Pioglitazon fast resorated, with the peak concentration of Pioglitazon in plasma, usually 2 hours depending on application."</seg>
<seg id="812">"on this basis corresponds to the contribution of M-IV to effectiveness in about the size of the effectiveness of Pioglitazon, on the relative effectiveness of the M-II minimal."</seg>
<seg id="813">"in Intereconomics studies, Pioglitazon has no relevant effect on the pharma ocinetic or pharmaceutical dynamics of Digoxin, Warfarin, phenyoumon and metformin."</seg>
<seg id="814">The current application of Pioglitazon with Gemfibrozil (a Cytochrome P450 2C8 Inhibitor) or with Rifampicin (see section 4.5).</seg>
<seg id="815">After oral use of radioactive marketed Pioglitazon in humans was found in Fäzes (55%) and to a higher extent in Harn (45%).</seg>
<seg id="816">The medium plasma-Eliminationshoring time of unmodified pioglitazon amounts to the people 5-6 hours and the entire active metabolite is at 16 - 23 hours.</seg>
<seg id="817">The plasma concentration of Pioglitazon and its metabolites are in patients with limited kidney disease in patients with limited kidney disease.</seg>
<seg id="818">"toxic substances used in toxic substances, with mutants, rations, dogs and monkey."</seg>
<seg id="819">This is the case that under treatment with Pioglitazon which reduces hyperinemia and increased insulin resistance to the body. it reduces the availability of metabolic substrate for the fenced growth.</seg>
<seg id="820">In long term studies (up to 2 years) were increased in long term studies (up to 2 years).</seg>
<seg id="821">"in one animal model of the family-friendly polyethylene (FAP), the treatment with two other Thiazolidindices is increased to an increased frequency of collisions."</seg>
<seg id="822">"these tablets are white to white, round, flat and wear on one side the mark" "30" "and on the other side."</seg>
<seg id="823">"the insolvency proceedings of 1,9 groups per 100 patient-years have been treated with Pioglitazon treated with Pioglitazon treated with Pioglitazon treated with Pioglitazon treated with Pioglitazon treated with Pioglitazon."</seg>
<seg id="824">"in the proactive study, a study published over 3.5 years in investigation of cardiovascular events, compared to 23 / 905 (5.1%; 1,0 groups per 100 patient-years) of patient who were treated with a comparison to a comparison."</seg>
<seg id="825">In another study about two years the effects of a combination of metformin with Pioglitazon or Gliclazid.</seg>
<seg id="826">"in clinical trials about 1 year, under Pioglitazon are typical for a statistical process of the Albumin / Kreatinin-Quotiations compared to the output."</seg>
<seg id="827">"in a study of 20 weeks, Pioglitazon is not only the kidney disease of triglyceride, but improved beyond the effect on the Tryglyzerid absorption as well as the hepatic Tryglizerid synthesis."</seg>
<seg id="828">"although the goal is the goal for its primary endocrity, which is a combination of the overall mortality, non-fatal myokardinfaral, cross-case coronation of leg arteries, the results close to that with the taking of Pioglitazon, the results close to the taking of Pioglitazon."</seg>
<seg id="829">"these tablets are white to white, round, flat and wear on one side the mark" 45 "and on the other side."</seg>
<seg id="830">"with more than 6,100 patients who were treated with a period of up to 3.5 years with more than 8.100 patients who were treated with Pioglitazon, which were treated with Pioglitazon, which were identified with Pioglitazon."</seg>
<seg id="831">"in the proactive study, a study published over 3.5 years in investigation of cardiovascular events, compared to 23 / 905 (5.1%; 1,0 groups per 100 patient-years) of patient who were treated with a comparison to a comparison."</seg>
<seg id="832">"in a study of 20 weeks, Pioglitazon is not only the nuts of Triglyceride, but improved beyond the effect on the triglycerid absorption as well as the hepatic triglycerid synthesis."</seg>
<seg id="833">"the application of the drug has to be used in the operation of the drug, and the address of the manufacturer, which is responsible for the release of the application is given."</seg>
<seg id="834">"in September 2005, an additional 6 months ago Periodic Safety Update Report (PSUR) and then annual PSURs will be rich, up to a different decision of the CHMP."</seg>
<seg id="835">It must be updated to the CHMP-Guideline on Risk Management Systems for Medicinal Products for Human Use.</seg>
<seg id="836">If you are interested in type 2 diabetes tablets that support Actos 15 mg tablets for control of your blood sugar levels by making a better understanding of the body's own medicine.</seg>
<seg id="837">"if you have known that you are known under a sugar, please contact your doctor before taking Actos 15mg tablets your doctor."</seg>
<seg id="838">Please inform your doctor or pharmacist if you have any other medicines or to be recently taken if it is not possible to do.</seg>
<seg id="839">"if you need Actos 15 mg tablets in combination with other medicines for treatment of diabetes (such as insect, chlorpropylen, Gliclazid, Toledo), your doctor will reduce the dose of your medicine."</seg>
<seg id="840">"in some patients with long-term type 2 diabetes mellitus and cardiovascular disease, which were treated with Actos and Insulated, developed a hermeation."</seg>
<seg id="841">"in clinical trials, in which Pioglitazon with other orally anti-diabetics or Placebo (active-free tablets) was compared with women (but not in men), the Pioglitazon took a higher number of bone."</seg>
<seg id="842">"if you have created a lot of tablets, or if any other or a child you have taken your medicines, you have to pay immediately with a doctor or pharmacist."</seg>
<seg id="843">"like Actos, and contents of the pack of the pack 15 mg tablets are white to white, round, curved tablets with the mark" 15 "on one side and the" "Actos" on the other side. "</seg>
<seg id="844">"if you are interested in type 2 diabetes, support Actos 30 mg tablets used the control of your blood sugar levels by making a better understanding of the physical body into the body."</seg>
<seg id="845">"if you have known that you are known under a sugar, please contact your doctor before taking Actos 30mg tablets for your doctor."</seg>
<seg id="846">"if you need Actos 30 mg tablets in combination with other medicines for treatment of diabetes (such as insane, chlorpropylen, Gliclazid, Toledo), your doctor will reduce the dose of your medicine."</seg>
<seg id="847">61 Informed you soon as possible to determine your doctor if you are signs of a heredical or rapid weight gain or rasp weight gain (Ödeme).</seg>
<seg id="848">"in clinical trials, in which Pioglitazon with other orally anti-diabetics or Placebo (active-free tablets) was compared with women (but not in men), the Pioglitazon took a higher number of bone."</seg>
<seg id="849">"as Actos, and contents of the pack 30 mg tablets are white to white, round, flat tablets with the mark" 30 "on one side and the" "Actos" on the other side. "</seg>
<seg id="850">If you are interested in type 2 diabetes tablets that support Acura 45 mg tablets that can lead to your blood sugar levels by making a better understanding of the body's own medicine.</seg>
<seg id="851">"if you have known that you are known under a sugar, please contact your doctor before taking Actos 45mg tablets your doctor."</seg>
<seg id="852">"if you need Actos 45 mg tablets in combination with other medicines for treatment of diabetes (such as insect, chlorpropylen, Gliclazid, Toledo), your doctor, whether you need to reduce the dose of your medicine."</seg>
<seg id="853">"66 in some patients with long-term type 2 diabetes mellitus and cardiovascular disease, which were treated with Actos and Insulated, developed a herpes."</seg>
<seg id="854">"as soon as possible your doctor, if you determine the signs of a hermeation, such as an unusual short-term or rapid weight gain (Ödeme)."</seg>
<seg id="855">"in clinical trials, in which Pioglitazon with other orally anti-diabetics or Placebo (active-free tablets) was compared with women (but not in men), the Pioglitazon took a higher number of bone."</seg>
<seg id="856">67. if one of the side effects you can differ considerably or you are not aware of any side effects that are not in this product information, please inform your doctor or pharmacist. "</seg>
<seg id="857">"like Actos, and contents of the pack of the pack 45 mg tablets are white to white, round, flat tablets with the mark" 45 "on one side and the" "Actos" on the other side. "</seg>
<seg id="858">"the present document is a summary of the European public administration (EPAR), in which explains how the Committee for Humanitarian Aid (CHMP) are assessed by the use of the application of the drug."</seg>
<seg id="859">"if you need further information about your medical condition or treatment of your disease, please read the package (also part of the EPAR) or contact a doctor or pharmacist."</seg>
<seg id="860">"if you wish to read more information about the recommendations of the CHMP, please read the scientific discussion (which also part of the EPAR is part of the EPAR)."</seg>
<seg id="861">Actraphane 10: solitary Insulin 20% Actraphane 20% Actraphane 40% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50%</seg>
<seg id="862">Actraphane is normally used once or twice daily when a rapid initiation effect together with a longer lasting effect.</seg>
<seg id="863">"(44-20) 74 18 84 00 fax (44-20) 74 18 86 68 E-mail: mail @ emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int.</seg>
<seg id="864">Actraphane was added to a total of 294 patients with type-1 diabetes.</seg>
<seg id="865">"in the study, the concentration of a substance (glycosyliosis of hemmoglobin (HbA1c), which shows how well the blood sugar is set."</seg>
<seg id="866">Actraphan brought up to one of the HbA1c Spiegels which were seen that the blood sugar is similar to strong as with another humaninsulin.</seg>
<seg id="867">Actraphane should not be applied to patients which may be oversensitive (allergic) to human insulin (rDNA) or one of the other components.</seg>
<seg id="868">"in addition, the cans of Actraphors may be adapted when it comes together with a number of other drugs."</seg>
<seg id="869">"the Committee for Humanist agents (CHMP) to the end, that the benefits of Actraphane at the treatment of diabetes compared to the risks."</seg>
<seg id="870">"in October 2002, the European Commission of the company Novo Nordisk A / S are a permit for the incoming from Actraphane in the whole European Union."</seg>
<seg id="871">"mixed colours are usually once or twice daily, if a quick initials effect together with a longer lasting effect."</seg>
<seg id="872">The injunction must be at least 6 seconds under the skin to ensure that the entire dose is injected.</seg>
<seg id="873">"patients, their blood sugar is considerably improved, for example by a Intensimilitia therapy can be improved, the hypoglyphemia may be changed, and should be advised to be advised."</seg>
<seg id="874">"each change in strength to strength, brand (manufacturers), Insulated type (fast-effective, biphonic, long-effective amino acid), type of the insect (animal species) and / or manufacturing method (through recombinant DNS), and / or manufacturing method (through recombinant DNS) and / or manufacturing method (through recombinant DNS), can cause a change of dosage."</seg>
<seg id="875">"if the change is needed to Actraphane when the patient is required, this can be necessary at the first dosage or in the first weeks or months after the application."</seg>
<seg id="876">"some patients, when hypoglycemia reactions after a change of animal on human beings, reported that the early warning symptoms of a hypoglykemia was less pronounced or different than with her previous springs."</seg>
<seg id="877">"before travel, which should be taken over several times, the patient should be applied to the advice of his doctor, as such journeys can be applied to other times, or to be taken to other times."</seg>
<seg id="878">"the doctor must take advantage of the treatment of therapy in therapy, and his patients always ask for others of them."</seg>
<seg id="879">"4, Hypoglykemia, as well as hyperglycemia, which can occur in a non-controlled diabetestherapy, increase the risk of misery and fertility in utero."</seg>
<seg id="880">Heavy hypoglycography can lead to consciousness and / or crampfancies.</seg>
<seg id="881">Disorders of the nervous system occasionally - Peripherical Neuropathy In a rapid expansion of blood sugar can be associated with complaints that are treated as a akurine new ropathy.</seg>
<seg id="882">5 A Intensification of the insect therapy with an abnormative improvement of the blood sugar setting may be associated with a temporary reduction of the diabetic retinopathy.</seg>
<seg id="883">Disorders of the skin and sublimes occasionally - Lidauystrophies An injections can change a Lidauystrophies when the injection moulding within the injection moulding.</seg>
<seg id="884">"general disorders and complaints regarding the discomfort of the injections of the injections of the injuncement of the injustice (Roman, swellation, juckreiz, pain and hemmatom to the injections)."</seg>
<seg id="885">"disorders of the immune system occasionally - Urtikaria, Extract, gastrointestinal diseases, juices, shredness, gastrointestinal infections, respiratory diseases, low blood pressure and Ohrid / consciousness."</seg>
<seg id="886">A Hypoglykemia can be able to develop: • Leipoglycemia can be treated by the orosis of gluten or sugar foods.</seg>
<seg id="887">"Diabetical should therefore always be obtrusion, sweets, chekse or allergic fruit juice. • Refined hypoglyceration of Gluccal or subcutaneous injection of Glucals (0.5 to 1.0 mg) by a preset help section or by Glucose, the intravenous through the doctor."</seg>
<seg id="888">The effect begins within a half hour that is reached within 2 to 8 hours and the entire operating duration is up to 24 hours.</seg>
<seg id="889">Resorption The Resorptionate profile is based on the product to a mix of Insuline products with faster or delay resorption.</seg>
<seg id="890">A series of column (hydrolyse-) places on the humaninsulinopathy were not actively involved; none of the split metabolites is actively involved.</seg>
<seg id="891">"based on conventional studies on the conventional studies on the safety spharmakology, toxicity of repeated gift, genotoxity, to the carcinogenic potential and reproductionxizations, allow the preclinical data no special dangers for humans."</seg>
<seg id="892">It is recommended - after the Actraphan exit bottle from the fridge was removed from the fridge - the temperature of the insins on room temperature (not over 25 ° C).</seg>
<seg id="893">"some patients, when hypoglycemia reactions after a change of animal on human beings, reported that the early warning symptoms of a hypoglykemia was less pronounced or different than with her previous springs."</seg>
<seg id="894">"the doctor must take advantage of the treatment of therapy in therapy, and his patients always ask for others of them."</seg>
<seg id="895">"12 Then Hypoglykemia as well as hyperglycemia, which can occur in a non-controlled diabetestherapy, increase the risk of misery and fertility in utero."</seg>
<seg id="896">"13 An Intensification of the insect therapy with an abnormative improvement of the blood sugar, however, with a temporary reduction of the diabetic retinopathy."</seg>
<seg id="897">The terminale half-time period (t ½) is therefore a measure of Resorption than a measure of Elimination by the plasma (Insulin has a t ½ of only a few minutes).</seg>
<seg id="898">It is recommended - after the Actraphan exit bottle from the fridge was removed from the fridge - the temperature of the insins on room temperature (not over 25 ° C).</seg>
<seg id="899">"some patients, when hypoglycemia reactions after a change of animal on human beings, reported that the early warning symptoms of a hypoglykemia was less pronounced or different than with her previous springs."</seg>
<seg id="900">"20 And Hypoglykemia, as well as hyperglycemia, which can occur in a non-controlled diabetestherapy, increase the risk of misinterpretations and fruit tod in utero."</seg>
<seg id="901">21 An Intensification of Insulating therapy with an abnormative improvement of the blood sugar setting may be associated with a temporary reduction of the diabetic retinopathy.</seg>
<seg id="902">"disorders of the immune system occasionally - Urtikaria, Extract, gastrointestinal diseases, juices, shredness, gastrointestinal infections, respiratory diseases, low blood pressure and Ohrid / consciousness."</seg>
<seg id="903">Patents can only be used together with products that are compatible with them and a safe and effective function of the patents.</seg>
<seg id="904">It is recommended - after Actraphane Pensions from the refrigerator was removed from the fridge - the temperature of the insins on room temperature (not over 25 ° C).</seg>
<seg id="905">"some patients, when hypoglycemia reactions after a change of animal on human beings, reported that the early warning symptoms of a hypoglykemia was less pronounced or different than with her previous springs."</seg>
<seg id="906">"28 Then Hypoglykemia, as well as hyperglycemia, which can occur in a non-controlled diabetestherapy, increase the risk of misery and fertility in utero."</seg>
<seg id="907">29 An Intensification of Insulating therapy with an abnormative improvement of the blood sugar setting may be associated with a temporary reduction of the diabetic retinopathy.</seg>
<seg id="908">"some patients, when hypoglycemia reactions after a change of animal on human beings, reported that the early warning symptoms of a hypoglykemia was less pronounced or different than with her previous springs."</seg>
<seg id="909">"36 Then Hypoglykemia, as well as hyperglycemia, which can occur in a non-controlled diabetestherapy, increase the risk of misinterpretations and fruit tod in utero."</seg>
<seg id="910">"37 The Intensification of the Insulinology with an abnormative improvement of the blood sugar, however, however, with a temporary reduction of the diabetic retinopathy."</seg>
<seg id="911">"44 And Hypoglykemia, as well as Hyperglycemia, which can occur in a non-controlled diabetestherapy, increase the risk of misery and fertility in utero."</seg>
<seg id="912">45 A Intensification of the insect therapy with an abnormative improvement of the blood sugar setting may be associated with a temporary reduction of the diabetic retinopathy.</seg>
<seg id="913">"some patients, when hypoglycemia reactions after a change of animal on human beings, reported that the early warning symptoms of a hypoglykemia was less pronounced or different than with her previous springs."</seg>
<seg id="914">"52 And Hypoglykemia, as well as hyperglycemia, which can occur in a non-controlled diabetestherapy, increase the risk of misinterpretations and fruit tod in utero."</seg>
<seg id="915">53 An Intensification of Insulating therapy with an abnormative improvement of the blood sugar setting may be associated with a temporary reduction of the diabetic retinopathy.</seg>
<seg id="916">The injectors must be prepared before the injections that the socket wrenches on zero and a insulating plate at the top of the injusnadel appears.</seg>
<seg id="917">"59 patients, whose blood sugar is significantly improved, for example by a Intensimilitia therapy can be improved, the hypoglyphemia may be changed, and should be advised to be advised."</seg>
<seg id="918">Both hypoglycemia as well as hyperglycemia that can occur in a non-controlled diabetestherapy. the risk of misinterpretations and fruit tod in utero.</seg>
<seg id="919">A Intensification of Insulating therapy with an abnormative improvement of the blood sugar setting may be associated with a temporary reduction of the diabetic retinopathy.</seg>
<seg id="920">"disorders of the immune system occasionally - Urtikaria, Extract, gastrointestinal diseases, juices, shredness, gastrointestinal infections, respiratory diseases, low blood pressure and Ohrid / consciousness."</seg>
<seg id="921">"only together with products are used only together with products, which are compatible with them and a safe and effective function of the finished pens."</seg>
<seg id="922">"it is recommended - after Actraphane Novounce from the fridge, the temperature of the insins on room temperature (not over 25 ° C)."</seg>
<seg id="923">"67 patients, whose blood sugar is considerably improved, for example by a Intensimilitia therapy can be improved, the hypoglyphemia may be changed, and should be advised to be advised."</seg>
<seg id="924">"75 patients, whose blood sugar is significantly improved, for example by a Intensimilitia therapy can be improved, the hypoglyphemia may be changed, and should be advised to be advised."</seg>
<seg id="925">"83 patients, whose blood sugar is significantly improved, for example by a Intensimilitia therapy can be improved, the hypoglyphemia may be changed, and should be advised to be advised."</seg>
<seg id="926">"91 patients, whose blood sugar is significantly improved, for example by a Intensimilitia therapy can be improved, the hypoglyphemia may be changed, and should be advised to be advised."</seg>
<seg id="927">"99 patients, whose blood sugar is significantly improved, for example by a Intensimilitia therapy can be improved, the hypoglyphemia may be changed, and should be advised to be advised."</seg>
<seg id="928">"each change in strength to strength, brand (manufacturers), Insulated type (fast-effective, biphonic, long-effective amino acid etc.), type of the insins (animal species, human insulin or insananon) and / or manufacturing method (through recombinant DNS), and / or manufacturing method (through recombinant DNS) and / or manufacturing method (through recombinant DNS), can cause a change of dosage."</seg>
<seg id="929">"it is recommended - after Actraphane Innodes of the fridge was taken from the fridge, the temperature of the insins on room temperature (not over 25 ° C)."</seg>
<seg id="930">It is recommended - after Actraphane FlexPen from the fridge was removed from the fridge - the temperature of the insins on room temperature (not over 25 ° C).</seg>
<seg id="931">"the application of the drug has to be used in the operation of the drug, and the address of the manufacturer, which is responsible for the release of the application is given."</seg>
<seg id="932">"if you give your telephone number, we will also gladly call you back."</seg>
<seg id="933">Subcutaneous use Pencil Patents are used for the application with insulated ducers from Novo Nordisk and used to use Actraphane 10 Penalty can only be used by a person</seg>
<seg id="934">"in the refrigerator (2 ° C - 8 ° C) Not available in the fridge, to protect the content from light to protect the content. not in the fridge, or over 30 ° C."</seg>
<seg id="935">Subcutaneous use Pencil Patents are provided for the application with insulated ducts of Novo Nordisk by means of the manual workstations and Actraphane 20 Pensions may be used only from a person</seg>
<seg id="936">Subcutaneous use Pencil Patents are provided for the application with insulated ducers from Novo Nordisk by the manual of the instructions of Actraphane 30 Penalty can only be used by a person</seg>
<seg id="937">Subcutaneous use Pencil Patents are provided for the application with insulated ducts of Novo Nordisk by means of the manual workstations and Actraphane 40 Pensions may be used only from a person</seg>
<seg id="938">Subcutaneous use Pencil Patents are used for the application with insulated ducers from Novo Nora. the manual of the manual workouts of Actraphane 50 Pensions may be used only from a person</seg>
<seg id="939">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="940">"if you give your telephone number, we will also gladly call you back."</seg>
<seg id="941">"using Actraphane 20 Novoût, Novoasis injection packers are provided in NovoFine injection moulding. Actraphane 20 NovoLet may be used only from a person."</seg>
<seg id="942">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="943">"using Actraphane 40 Novoût, Novoasis injection hoods are provided in NovoFine injection moulding. Actraphane 40 NovoLet may be used only from a person."</seg>
<seg id="944">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="945">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="946">"this means that about half hour after you have applied your blood sugar, and that the effect of approximately 24 hours."</seg>
<seg id="947">"if you are allergic (oversensitive) to this insulated product, metacresol or one of the rest of components (see section 7 other information)."</seg>
<seg id="948">"consider the symptoms of a allergigie, if you feel first signs of a hypoglycemia (symptoms of a subordination)."</seg>
<seg id="949">"if your doctor may use a change from a Insulinart or brand to another, possibly the dose may be adjusted through your doctor."</seg>
<seg id="950">► overcheck using the label whether it is to modify the right type of type ► Desinating the rubber-embran with a medical Tuber.</seg>
<seg id="951">"if this doesn't be completely unlocked, if you get the throughput bottle to your pharmacy? if it is not correct, or non-frameworks (see 6 How is Actraphane?) ► If it is not correct, it is not smooth and tracked."</seg>
<seg id="952">Use the injection technology that has your doctor or your Diabetesberaterin recommended ► Read the injection of at least 6 seconds long under your skin to ensure that the complete dose is injected.</seg>
<seg id="953">"the warning signs of a subcontraction can occur and can be occur: kills, cold bacon, headache, heart rate, heart rate, heart rate, heart muscle, nervous system, nervous system, nervous system, confusion, concentrations of concentrations."</seg>
<seg id="954">"tell your friends, friends and narrow working classes that they have to bring you in case of consciousness in the stable side of consciousness and immediately a doctor."</seg>
<seg id="955">"you may not be able to eat or drink, because you may be able to drink or drink. ► When a heavy undercarriage may not be treated, it may lead to death or even to death."</seg>
<seg id="956">You can change the consciousness faster if you give the hormone gluten-agon from a person who is familiar with his gift.</seg>
<seg id="957">"this can happen: • If you eat too much insect in injected • If you eat too little eat or meal, • If you are too little to eat or meal."</seg>
<seg id="958">"amplified harms, Durst, appetite, appetite, appetite, appetite, dry skin, mouth dry and fruity (according to Aceton) riechender."</seg>
<seg id="959">"• You have an insangible base • repeated injizations of less fat in than you need • an infection or fever • more food than usual, less physical movement than usual."</seg>
<seg id="960">"if you give up a injections at the same point, it can be seen at this point of the lower fat tissue (Lipatropphy) or to (Lipohypertropical)."</seg>
<seg id="961">"if you are aware of any of your skin on the injections, please report your doctor or your diabetesthesia, for these reactions can influence your doctor or the recording of your medication."</seg>
<seg id="962">"if you are looking for a doctor upon the symptoms of allergies on other parts of the body, or if you have suddenly feel good and you will feel good and you will feel safe and you have the impression of heart to you."</seg>
<seg id="963">You may possibly have a very rare allergic reaction to Actraphane or its components (a so-called systemic reaction).</seg>
<seg id="964">"if one of the side effects of side effects you can differ significantly or you are able to notice your doctor, please inform your doctor, your diabetesberacin or your pharmacist."</seg>
<seg id="965">What Actraphane 30 contains - The active ingredient is characterized by recombinant DNS technology.</seg>
<seg id="966">"like Actraphane, and contents of the pack The injection suspension will be delivered as a trübe, white, wetsors and packaging with 1 or 5 stats bottles each 10 ml or a meal supply with 5 stats bottles per 10 ml."</seg>
<seg id="967">Use the injection technology that has your doctor or your Diabetesberaterin recommended ► Read the injection of at least 6 seconds long under your skin to ensure that the complete dose is injected.</seg>
<seg id="968">"it is recommended - after being taken from the fridge, the temperature of the stair bottle on room temperature is able to leave the insect in accordance with the manual for the first use."</seg>
<seg id="969">"like Actraphane, and contents of the pack The injection suspension will be delivered as a trübe, white, wetsors and packaging with 1 or 5 stats bottles each 10 ml or a meal supply with 5 stats bottles per 10 ml."</seg>
<seg id="970">► Check out by the label whether it is the right-type of type ► overcheck the Penalty Patents including the rubber-bens (Stoppers).</seg>
<seg id="971">"if any damage is visible, or a gap between the rubber and white band of the label is visible."</seg>
<seg id="972">"for further information, please refer to the instructions of your Insulininfiltrating system. ► Desins you take the rubber-embran with a medical Tuber. ► Use always for every injection packet to avoid any injection moulding."</seg>
<seg id="973">► Rates and conditions (see 6 How is Actraphors'); when it is not correct, it is not correct. "</seg>
<seg id="974">"if you are treated with Actraphane 10 Pensions, and another Insulin in Penalty Patties, you should use two insulin systems, each one for each insinart."</seg>
<seg id="975">"before you can use the patrone into the insulated system, move them at least 20 times between the positions a and b on and from (see picture), so that the glass stands from one end of the patrone to the other."</seg>
<seg id="976">Use the injection technique to remove your doctor or your Diabetesberaterin recommended for the injection of at least 6 seconds.</seg>
<seg id="977">Please enter your e-mail address and your password.:</seg>
<seg id="978">"• You have an insangible base • repeated injizations of less fat in than you need • an infection or fever • more food than usual, less physical movement than usual."</seg>
<seg id="979">"if one of the side effects of side effects you can differ significantly or you are able to notice your doctor, please inform your doctor, your diabetesberacin or your pharmacist."</seg>
<seg id="980">It is recommended - after they are removed from the fridge - the temperature of the Penalty Patrone to room temperature is able to leave the insect in accordance with the manual for the first use.</seg>
<seg id="981">185 Send the patents always in the case if you don't use it to protect them from light.</seg>
<seg id="982">What Actraphane 10 contains - The active ingredient is characterized by recombinant DNS technology.</seg>
<seg id="983">"like Actraphane, and contents of the Pack The injection suspension will be delivered as trübe, white, wetsors and packing boxes with 1, 5 or 10 patents to each 3 ml."</seg>
<seg id="984">"for further information, please refer to the instructions of your Insulininfiltrating system. ► Desins you take the rubber-embran with a medical Tuber. ► Use always for every injection packet to avoid any injection moulding."</seg>
<seg id="985">"if you are treated with Actraphane 20 Pensions and other forms in Penalty Patties, you should use two insulin systems, each one for each insinart."</seg>
<seg id="986">"189 Sight You have to bring your friends, friends and tight working, that they will bring you in the case of consciousness in the stable side of consciousness and immediately a doctor."</seg>
<seg id="987">"if one of the side effects of side effects you can differ significantly or you are able to notice your doctor, please inform your doctor, your diabetesberacin or your pharmacist."</seg>
<seg id="988">"191 reserves the patents always in the case if you don't use it to protect them from light."</seg>
<seg id="989">What Actraphane 20 contains - The active ingredient is characterized by recombinant DNS technology.</seg>
<seg id="990">"like Actraphane, and contents of the Pack The injection suspension will be delivered as trübe, white, wetsors and packing boxes with 1, 5 or 10 patents to each 3 ml."</seg>
<seg id="991">"for further information, please refer to the instructions of your Insulininfiltrating system. ► Desins you take the rubber-embran with a medical Tuber. ► Use always for every injection packet to avoid any injection moulding."</seg>
<seg id="992">"if you are treated with Actraphane 30 Pensions, and another Insulin in Penalty Patties, you should use two insulin systems, each one for each insinart."</seg>
<seg id="993">"195 Sages you have your friends, friends and narrow working sessions that they will bring you in the case of consciousness in the stable side of consciousness and immediately a doctor."</seg>
<seg id="994">"if one of the side effects of side effects you can differ significantly or you are able to notice your doctor, please inform your doctor, your diabetesberacin or your pharmacist."</seg>
<seg id="995">"to protect the Patents are always in the case if you don't use it to protect them from light."</seg>
<seg id="996">Manufacturer's manufacturer can be printed on the mower of the box and on the label to be identified:</seg>
<seg id="997">"in case of the second and third position of the character sets W5, S6, P5, K7 or ZF, the manufacturer Novo Nordisk A / S, Novo Allé, DK- 2880 Bagsvatd, Denmark"</seg>
<seg id="998">"in case of the second and third position of the time, the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F-28002 Chartres, France."</seg>
<seg id="999">"for further information, please see the instructions of your insul ininfiltrating system. ► Desins you take the rubber-embran with a medical Tuber. ► Use always for every injection packet to avoid any injection moulding."</seg>
<seg id="1000">"if you are treated with Actraphane 40 Pensions and other forms in Penalty Patties, you should use two insulin systems, each one for each insinart."</seg>
<seg id="1001">"201 Sages you have your own friends, friends and narrow working sessions that they will bring you in case of consciousness in the stable side of consciousness and immediately a doctor."</seg>
<seg id="1002">"if one of the side effects of side effects you can differ significantly or you are able to notice your doctor, please inform your doctor, your diabetesberacin or your pharmacist."</seg>
<seg id="1003">203 inhabitants are always in the case if you don't use it to protect them from light.</seg>
<seg id="1004">What Actraphane 40 contains - The active substance is characterized by recombinant DNS technology.</seg>
<seg id="1005">"for further information, please see the instructions of your insul ininfiltrating system. ► Desins you take the rubber-embran with a medical Tuber. ► Use always for every injection packet to avoid any injection moulding."</seg>
<seg id="1006">"if you are treated with Actraphane 50 Pensions and other forms in Penalty Patties, you should use two insulin systems, each one for each insinart."</seg>
<seg id="1007">"before you can use the Pencil patrone into the insulin system, move them at least 20 times between the positions a and b on and from (see picture), so that the glass stands from one end of the patrone to the other."</seg>
<seg id="1008">"207 Sages you give your friends, friends and narrow working sessions that they have to bring you in the case of consciousness, and immediately a doctor."</seg>
<seg id="1009">"if one of the side effects of side effects you can differ significantly or you are able to notice your doctor, please inform your doctor, your diabetesberacin or your pharmacist."</seg>
<seg id="1010">209 requests the patents always in the case if you don't use it to protect them from light.</seg>
<seg id="1011">What Actraphane 50 contains - The active ingredient is characterized by recombinant DNS technology.</seg>
<seg id="1012">"oral antidiabetics (for insertion), Monoclutamine, Angiotsalicylate, Angiotsalicylate, thyroid, orangomatimetics, growth shormon, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1013">► overcheck using the label whether it is to avoid the right Insul integer type ► Benches you always use for every injection packet to avoid any contamination.</seg>
<seg id="1014">"in this case it is not correct, but it is not correct but it is not correct. if it is not correct, the danger of the insulin should be damaged or countersunk) (see 6 How is Actraphane?) ► If it is not correct and tracked it is not properly and tracked."</seg>
<seg id="1015">"the warning signs of a subcontraction can occur and can be occur: kills, cold bacon, headache, heart rate, heart rate, heart rate, heart muscle, nervous system, nervous system, nervous system, confusion, concentrations of concentrations."</seg>
<seg id="1016">"214 If one of the side effects of side effects you can differ considerably or you are not aware of any side effects, please inform your doctor, your diabetesberacin or your pharmacist."</seg>
<seg id="1017">"in use of the Novobilis finished pens and such that are used in the fridge, or as replacement, are not found in the fridge."</seg>
<seg id="1018">"it is recommended - after being taken from the fridge, the temperature of the Novoût has been removed from the fridge."</seg>
<seg id="1019">"let's Play Watch Dogs Deutsch Part 48 German Walkthrough Gameplay Review [PS4, Xbox One, PC]"</seg>
<seg id="1020">"like Actraphane, and contents of the Pack The injection suspension will be delivered as a trübe, white, wetsors and packaging with 5 or 10 working pens each 3 ml."</seg>
<seg id="1021">"prior to any injections, check whether even at least 12 units can be used in the Patrone, that is a uniform mixture."</seg>
<seg id="1022">"to avoid the injections of air to avoid, and a correct dosage: • Hold you Actraphane 10 NovoLet with the injunction"</seg>
<seg id="1023">"if air inflatable are available, these are top in the Patrone (Figure C) • During the injunction in the direction of the pipes (Figure C) • During the injunction in direction of the pipes (Figure C) • During the injunction"</seg>
<seg id="1024">• Setting the seal again to the finished parts that the digit 0 compared to the dosing brand (Figure E).</seg>
<seg id="1025">"if not, turn the seal, up to the print head. • Hail your Actraphane 10 NovoLet's horizontal."</seg>
<seg id="1026">"if the pressure switch is not free after the outside, the scale can be switched off from the injection packet • The scale on the seal is 0, 2, 4, 6, 8, 10, 16, 16, 16 and 18 units."</seg>
<seg id="1027">"the print head stands at the outside, while you set up the push button • The scale under the print head shows 20, 40 and 60 units."</seg>
<seg id="1028">"if you have a false dose, you can see the number on the push button you can see the highest number, which you can set on the print button • Adding the two numbers to set the correct dosage. if you have a false dose, turn the right number of units."</seg>
<seg id="1029">"if you have a dose of more than 78 units, you do not have a dose of more than 78 units, take the following steps by:"</seg>
<seg id="1030">Take a look at the push button and set it back to the 0 of the dosing brand.</seg>
<seg id="1031">"if the injection process is caused by the injections on the print head. • Make up the print head after injection, up to the injections of the skin."</seg>
<seg id="1032">"if not, turn the seal, up to the print head of the print head, then you will be described as you described in the use of the print head."</seg>
<seg id="1033">It is not exactly right. you can't set any dose that is higher than the number of in the patrone. you can use the residual quantities of scale as much insane.</seg>
<seg id="1034">"oral antidiabetics (for insertion), Monoclutamine, Angiotsalicylate, Angiotsalicylate, thyroid, orangomatimetics, growth shormon, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1035">"224 If one of the side effects you can differ considerably or you are able to notice your doctor, please inform your doctor, your diabetesberacin or your pharmacist."</seg>
<seg id="1036">"226 in each injection • Overfill, whether even at least 12 units are available in the Patrone, that is a uniform mixture."</seg>
<seg id="1037">"to avoid the injections of air to avoid, and a correct dosage: • Hold you Actraphane 20 Novoût with the injection of 20 Novoût, a few times with the finger slightly against the Patrone."</seg>
<seg id="1038">"if air inflatable are available, these are top in the patrone (Figure C) • During the injunction in the direction of the pipes (Figure C) • During the injunction in direction of the pipes (Figure C) • During the injunction"</seg>
<seg id="1039">"if not, turn the seal, up to the print head. • Hail your Actraphane 20 NovoLet's horizontal."</seg>
<seg id="1040">"oral antidiabetics (for insertion), Monoclutamine, Angiotsalicylate, Angiotsalicylate, thyroid, orangomatimetics, growth shormon, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1041">"234 If one of the side effects of side effects you can differ considerably or you are not aware of any side effects, please inform your doctor, your diabetesberacin or your pharmacist."</seg>
<seg id="1042">"236 In each of any injections, check whether at least 12 units can be used in the Patrone, that is a uniform mixture."</seg>
<seg id="1043">"to avoid the injections of air to avoid, and a correct dosage: • Hold you Actraphane 30 Novoût with the injection of 30 Novoût, a few times with the finger slightly against the Patrone."</seg>
<seg id="1044">"if air inflatable are available, these are top in the Patrone (Figure C) • During the injunction in the direction of the pipes (Figure C) • During the injunction in direction of the pipes (Figure C) • During the injunction"</seg>
<seg id="1045">"if not, turn the seal, up to the print head. • Hail your Actraphane 30 NovoLet's horizontal."</seg>
<seg id="1046">"oral antidiabetics (for insertion), Monoclutamine, Angiotsalicylate, Angiotsalicylate, thyroid, orangomatimetics, growth shormon, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1047">"244 If one of the side effects of side effects you can differ considerably or you are not aware of any side effects, please inform your doctor, your diabetesberacin or your pharmacist."</seg>
<seg id="1048">"if any injectors, check whether or at least 12 units have been used in the Patrone, that is a uniform mixture."</seg>
<seg id="1049">"to avoid the injections of air to prevent the injections of air to avoid, and a correct dosage: • Hold you Actraphane 40 Novoût with the injection of 40 Novoût, a few times with the finger slightly against the Patrone."</seg>
<seg id="1050">"if air inflatable are available, these are top in the Patrone (Figure C) • During the injunction in the direction of the pipes (Figure C) • During the injunction in direction of the pipes (Figure C) • During the injunction"</seg>
<seg id="1051">"if not, turn the seal, up to the print head. • Hail your Actraphane 40 NovoLet's horizontal."</seg>
<seg id="1052">"oral antidiabetics (for insertion), Monoclutamine, Angiotsalicylate, Angiotsalicylate, thyroid, orangomatimetics, growth shormon, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1053">"254 If one of the side effects you can choose from either side effects or side effects, please inform your doctor, your diabetesberacin or your pharmacist."</seg>
<seg id="1054">"it is recommended - after being taken from the fridge, the temperature of the Novoût has been removed from the fridge."</seg>
<seg id="1055">"256 for each of any injections, check whether even at least 12 units are available in the Patrone, that is a uniform mixture."</seg>
<seg id="1056">"to avoid the injections of air to avoid the injection of air to avoid, and a correct dosage: • Hold you Actraphane 50 Novoût with the injunction in the top of the monastery, a few times with the finger slightly against the Patrone."</seg>
<seg id="1057">"if air inflatable are available, these are top in the Patrone (Figure C) • During the injunction in the direction of the pipes (Figure C) • During the injunction in direction of the pipes (Figure C) • During the injunction"</seg>
<seg id="1058">"if not, turn the seal, up to the print head. • Hail your Actraphane 50 NovoLet's horizontal."</seg>
<seg id="1059">"oral antidiabetics (for insertion), Monoclutamine, Angiotsalicylate, Angiotsalicylate, thyroid, orangomatimetics, growth shormon, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1060">"in the insaninfusionic effects, if the Innobility has been damaged, it has been damaged or broken it is not correct, the danger of the amount of insect?) ► If it is not correct, or non-fraction (see 6 How is Actraphane?) ► If it is not correct, it is not smooth and tracked."</seg>
<seg id="1061">"the warning signs of a subcontraction can occur and can be occur: kills, cold bacon, headache, heart rate, heart rate, heart rate, heart muscle, nervous system, nervous system, nervous system, confusion, concentrations of concentrations."</seg>
<seg id="1062">264. if one of the side effects you can differ considerably or you are not aware of any side effects that are not in this product information, please inform your doctor, your diabetesberacin or your pharmacist. "</seg>
<seg id="1063">"in use, the Innodes finished pens and such that can be used in the fridge or as a replacement, not in the fridge."</seg>
<seg id="1064">"it is recommended - after he removed from the fridge - the temperature of the Innodes finished goods on room temperature, before the insect is used for the first use for the first use."</seg>
<seg id="1065">Let's Play Watch Dogs Deutsch Part 48 German Walkthrough Gameplay Review [PS4, Xbox One, PC] "</seg>
<seg id="1066">"like Actraphane, and contents of the Pack The injection suspension will be delivered as a trübe, white, wetsors and packing boxes with 1, 5 or 10 finished pens to each 3 ml."</seg>
<seg id="1067">"the movement must be repeated, up to the liquid up to the liquid. • In the Resustice you will lead you all the following steps of injections without delay."</seg>
<seg id="1068">"• Desinating the rubber-embran with a medical turous • Use the injector of a NovoFine S injection moulding, remove the injections of a NovoFine S injection moulding and the inner injection nozzle and the inner injector cap."</seg>
<seg id="1069">• account the number of units on zero. • In the number of units you have to turn the amount of units to zero if you need to adjust the dose of injectors in the watchstrap (Figure 2).</seg>
<seg id="1070">Do not use the residual load of the scale?</seg>
<seg id="1071">Make the injure technology that allow you to send your doctor • Get the dose by clicking the print head.</seg>
<seg id="1072">The socket wrench is on zero back and listen to the injector • The injections must remain at least 6 seconds.</seg>
<seg id="1073">"medical personnel, family, as well as other members have to be able to avoid general precauditions to the removal and disposal of the injunctions to avoid unhindered Stiche with the injection moulding."</seg>
<seg id="1074">"oral antidiabetics (for insertion), Monoclutamine, Angiotsalicylate, Angiotsalicylate, thyroid, orangomatimetics, growth shormon, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1075">"when the FlexPen has been damaged, it has been damaged or broken it is not correct, the risk of the insulin should be damaged or non-fry (see 6 How is Actraphane?) ► If it is not correct, it is not smooth and tracked."</seg>
<seg id="1076">"if you are aware of any of your skin on the injections, please report your doctor or your diabetesthesia, for these reactions can influence your doctor or the recording of your medication."</seg>
<seg id="1077">"274 If one of the side effects of side effects you can differ considerably or you are not aware of any side effects, please inform your doctor, your diabetesberacin or your pharmacist."</seg>
<seg id="1078">* Use five-year forecasts to assess how the market is predicted to develop.</seg>
<seg id="1079">It is recommended - after he was removed from the fridge - the temperature of the FlexPen finished goods on room temperature is able to leave the insect in accordance with the manual for the first use.</seg>
<seg id="1080">Specify the seal of your FlexPen Cabinets since FlexPen is not used in use to protect the insulin in front of light.</seg>
<seg id="1081">"like Actraphane, and contents of the Pack The injection suspension will be delivered as a trübe, white, wetsors and packing boxes with 1, 5 or 10 finished pens to each 3 ml."</seg>
<seg id="1082">Manufacturer's manufacturer can be printed on the mower of the box and on the label to be identified:</seg>
<seg id="1083">"the manufacturer Novo Nordisk A / S, P5, P5, K7 or ZF appears, the manufacturer Novo Norma Production SAS, 45, Avenue d'Orléans, F- 28002 Chartres, France."</seg>
<seg id="1084">"B Beaches to the finished parts between the positions 1 and 2, and then, so that the glass stands from one end of the patrone to the other."</seg>
<seg id="1085">"move the manufacturing of at least 10 times between the positions 1 and 2 and from, until the liquid, white and trübe appears."</seg>
<seg id="1086">"if you want to reduce the risk of unapproved antistiche, set the inner hedge again to the injections, after you have taken it once."</seg>
<seg id="1087">"279 G Hail the FlexPen with the injection molds to top and move a few times with the finger slightly against the patrone, so that the air bladder can collect from the patrone."</seg>
<seg id="1088">"the dose may be corrected to the top as well according to the below, by using the Dosisms into the corresponding direction, up to the correct dose compared to the mark of the display."</seg>
<seg id="1089">"the present document is a summary of the European public administration (EPAR), in which explains how the Committee for Humanarzs (CHMP) were assessed by the use of the application of the drug."</seg>
<seg id="1090">"the patient is produced in Actigid, Insulin human (rDNA), with the procedure of the so-called" recombinant technology ":"</seg>
<seg id="1091">Deprecated: function ereg _ replace () is deprecated in / www / htdocs / w00cec0c / webEdition / we / include / we _ modules / object / we _ listview _ multiobject.class.php on line 296</seg>
<seg id="1092">Actigid may not be used in patients who could possibly be oversensitive compared to insulin (rDNA) or one of the other components.</seg>
<seg id="1093">"in addition, the cans may be adapted to the cans of Accelid may be adjusted when it comes together with a number of other drugs, which can affect the blood sugar."</seg>
<seg id="1094">"in October 2002, the European Commission of the company Novo Nordisk A / S are a permit for the incoming of Accelid in the whole European Union."</seg>
<seg id="1095">"if two types of insulin can be mixed, first, the amount of the fast-active substance into the amount, then the amount of the long-term effects."</seg>
<seg id="1096">"3 If the change is required for Acasid when patient is required, this can be necessary at the first dosage or in the first weeks or months after the application."</seg>
<seg id="1097">"before travel, which should be taken over several times, the patient should be applied to the advice of his doctor, as such journeys can be applied to other times, or to be taken to other times."</seg>
<seg id="1098">"5 General diseases and complaints lodged to the injections of the injections of the injections of the injunction in the injustice (Roman, swellation, juckreiz, pain and hemmatom to the injections)."</seg>
<seg id="1099">"Diabetical should therefore always be obtrusion, sweets, chekse or allergic fruit juice. • Refined hypoglyceration of Gluccal or subcutaneous injection of Glucals (0.5 to 1.0 mg) by a preset help section or by Glucose, the intravenous through the doctor."</seg>
<seg id="1100">A previous attempt in an intensive station for treatment of hyperglycemia (blood sugar 4.4 - 6,1 mmol / l) the mortality of 42% reduced (8% compared to 4.7%).</seg>
<seg id="1101">The effect begins within a half hour that is reached within 1.5 to 3.5 hours and the entire operating time is about 7 to 8 hours.</seg>
<seg id="1102">Children and adolescents have been examined in a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and youth (in age between 13 and 17 years).</seg>
<seg id="1103">"data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data. why buy this report?"</seg>
<seg id="1104">"infusion systems with acetylid in concentrations 0,05 m / ml - 1,0 + / ml insulin in the infusion fluid cream, 5% D-Glucose and 10% D-Glucose-100 mmol / l potassium chloride are stable at room temperature 24 hours long."</seg>
<seg id="1105">"11 If the change is required for Acasid when patient is required, this can be necessary at the first dosage or in the first weeks or months after the application."</seg>
<seg id="1106">"before travel, which should be taken over several times, the patient should be applied to the advice of his doctor, as such journeys can be applied to other times, or to be taken to other times."</seg>
<seg id="1107">"13 General Surgery and complaints lodged to the injections of the injections of the injections of the injuncement of the injunction in the injustice (Roman, swellation, juckreiz, pain and hemmatom to the injections)."</seg>
<seg id="1108">"Diabetical should therefore always be obtrusion, sweets, chekse or allergic fruit juice. • Refined hypoglyceration of Gluccal or subcutaneous injection of Glucals (0.5 to 1.0 mg) by a preset help section or by Glucose, the intravenous through the doctor."</seg>
<seg id="1109">Children and adolescents have been examined in a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and youth (in age between 13 and 17 years).</seg>
<seg id="1110">The intravenous use of acetylid made from different pens or patents should be found in situations which are available in which no water bottles are available.</seg>
<seg id="1111">"if the change is required for acetylene in patients a dose may be required, this can be necessary at the first dosage or in the first weeks or months after the application."</seg>
<seg id="1112">"21 disorders of the skin and the sublimes-occasionally - Lidauystrophies to the injection point, a Lidauystrophies is to change the insertion within the injector area."</seg>
<seg id="1113">Children and adolescents have been examined in a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and youth (in age between 13 and 17 years).</seg>
<seg id="1114">"29 disorders of the skin and the lower-eye-occasionally - Lidauystrophies An injection point, a Lidauystrophies is to change the insertion within the injector area."</seg>
<seg id="1115">"disorders of the immune system occasionally - Urtikaria, Extract, gastrointestinal diseases, juices, shredness, gastrointestinal infections, respiratory diseases, low blood pressure and Ohrid / consciousness."</seg>
<seg id="1116">Children and adolescents have been examined in a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and youth (in age between 13 and 17 years).</seg>
<seg id="1117">"disorders of the immune system occasionally - Urtikaria, Extract, gastrointestinal diseases, juices, shredness, gastrointestinal infections, respiratory diseases, low blood pressure and Ohrid / consciousness."</seg>
<seg id="1118">"38 A precarious attempt in an intensive station to the treatment of hyperglycemia (blood sugar 4,4 - 6,1 mmol / l) the mortality of 42% reduced (8% compared to 4,6%)."</seg>
<seg id="1119">"disorders of the immune system occasionally - Urtikaria, Extract, gastrointestinal diseases, juices, shredness, gastrointestinal infections, respiratory diseases, low blood pressure and Ohrid / consciousness."</seg>
<seg id="1120">46 A non-diabetic attempt in an intensive station for treatment of hyperglycemia (blood sugar 4.4 - 6,1 mmol / l) the mortality of 42% reduced (8% compared to 4.7%).</seg>
<seg id="1121">"if you give your telephone number, we will also gladly call you back."</seg>
<seg id="1122">Subcutaneous use Pencil Patents are used for use with Novo NorderInsuline systems for use with Novo NorderInsuline systems for use of a person can be used only from a person</seg>
<seg id="1123">"if you give your telephone number, we will also gladly call you back."</seg>
<seg id="1124">"let's Play Watch Dogs Deutsch Part 48 German Walkthrough Gameplay Review [PS4, Xbox One, PC]"</seg>
<seg id="1125">"if you give your telephone number, we will also gladly call you back."</seg>
<seg id="1126">Subcutaneous use for use with Accelid Innod Innodes NovoFine S injectors and Packagings (acetid Innodes only) can be used only from a person</seg>
<seg id="1127">This means that about half hour after you have applied your blood sugar and that the effect of approximately 8 hours.</seg>
<seg id="1128">► Check out by the label whether it is to recover the right type of type. ► Desinfy the rubber-embran with a medical Tuber.</seg>
<seg id="1129">"if this doesn't be completely unlocked, if you get the throughput bottle to your pharmacy? if it is not correct, or non-frameworks (see 6 How is Actid to keep it?) ► If it is not clear like water and colourless."</seg>
<seg id="1130">Use the injection technology that has your doctor or your Diabetesberaterin recommended ► Read the injection of at least 6 seconds long under your skin to ensure that the complete dose is injected.</seg>
<seg id="1131">"83 Sages you have your own friends, friends and narrow working sessions that they have to bring you in the case of consciousness in the stable side of consciousness and immediately a doctor."</seg>
<seg id="1132">You may possibly have a very rare allergic reaction to acetone or its components (a so-called systemic reaction).</seg>
<seg id="1133">"the injure solution is supplied as a clear, colourless, aqueous solution in packaging with 1 or 5 stats bottles each 10 ml or a bows with 5 stats bottles per 10 ml."</seg>
<seg id="1134">"89 Sight you have your friends, friends and narrow working sessions that they have to bring you in the case of consciousness, and immediately a doctor."</seg>
<seg id="1135">► overcheck using the label whether it is the right-type of type ► overcheck the patents including the rubber-bens (Stoppers).</seg>
<seg id="1136">It is the danger of the insult or the device that has been damaged or broken it; it is the danger of the outflow of Insulin ► if it is not correct as water as it is not correct as water and colourless.</seg>
<seg id="1137">"if you are treated with Accelid Pencil, and another Insulated in Penalty Patties, you should use two insulin systems, each one for each insinart."</seg>
<seg id="1138">Use the injection technique to remove your doctor or your Diabetesberaterin recommended for the injection of at least 6 seconds.</seg>
<seg id="1139">"• Falls to the second and third place of charter name the character combination W5, S6, P5, K7 or ZF, is the manufacturer Novo Nordisk A / S, Novo Allé, DK-2880 Bagsvatd, Denmark"</seg>
<seg id="1140">"• Falls to the second and third place of the character set H7 or T6, the manufacturer Novo Nordisk Production SAS, 45, Avenue d" Orléans, F- 28002 Chartres, France. "</seg>
<seg id="1141">"oral antidiabetics (for insertion), Monoclutamine, Angiotsalicylate, Angiotsalicylate, thyroid, orangomatimetics, growth shormon, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1142">► Check out by the label whether it is to avoid the right-inttype type. ► Benches always suitable for every injection packet to avoid any injection moulding.</seg>
<seg id="1143">"in this case it is not correct, but it is not correct as water as it is not correct. it is the danger of the outflow of Insulin ► if it is not correct as water and colourless.) ► If it does not be clear like water and colourless."</seg>
<seg id="1144">"this can happen: • If you have to eat a lot of vitamins in injections • If you eat too little eat or meal, if you can eat more than anything else."</seg>
<seg id="1145">Let the seal of your Novofold has always been set to protect it if he is not in use to protect him.</seg>
<seg id="1146">"• Desinating the rubber-embran with a medical turous • Use the injections of a NovoFine injection, to avoid any injection packet. • remove the injections of a Novoasis injection."</seg>
<seg id="1147">"to avoid the injections of air to prevent the injections of air to avoid, and a correct dosage: • Hold you Accelid Novoût with the injector spring after top of the monastery, a few times with the finger slightly against the Patrone."</seg>
<seg id="1148">"if air inflatable are available, these are able to hold a click in direction of the pipes (Figure B) • During the injunction in direction of the pipes (Figure C) • During the injunction in direction of the injection moulding."</seg>
<seg id="1149">• Setting the seal again to the finished parts that the digit 0 compared to the metering mark (Figure D).</seg>
<seg id="1150">"the pressure on the pressure is not free to move the insulator (0, 2, 4, 6, 8, 10, 12, 16, 16, 16 and 18 units)."</seg>
<seg id="1151">"the print head stands for the outside, while you set up the push button • The scale under the print head (print head lamp) shows 20, 40 and 60 units."</seg>
<seg id="1152">"• If you have the highest number, you can see the highest number, you can see the two numbers to get the correct dosage."</seg>
<seg id="1153">"turn left, until the print head down below, and you will feel a resistance, and put it back again that the 0 of the dosing stamp."</seg>
<seg id="1154">"take advantage of the injections on the print head, • Make up the print head back to the injection head after injections, until the injections of the skin has been removed."</seg>
<seg id="1155">"you can use the residual amount of the number in the patrone, but you can use the residual load of skala, but you can not use the residual load of skala, but you can not use it to stop your dose or simply."</seg>
<seg id="1156">"oral antidiabetics (for insertion), Monoclutamine, Angiotsalicylate, Angiotsalicylate, thyroid, orangomatimetics, growth shormon, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1157">"in this case it is not correct, but it is not correct as water as it is not correct. it consists of the danger of the insulin in ► if it is not correct as water and colourless.) ► If it does not have clear such as water and colourless."</seg>
<seg id="1158">Let the seal of your innodes finished pens is always set when he is not in use to protect him.</seg>
<seg id="1159">• Desinating the rubber-embran with a medical tuberth. • remove the injections of a NovoFine S injection. • remove the injections of a NovoFine S injection.</seg>
<seg id="1160">"the socket wrench is on zero back and listen to the injector • The injection packet needs to make sure that you will not block the dose of at least 6 seconds, if you want to push the socket controller during the injections."</seg>
<seg id="1161">"oral antidiabetics (for insertion), Monoclutamine, Angiotsalicylate, Angiotsalicylate, thyroid, orangomatimetics, growth shormon, Danazol, Octreotid or Lanreotid."</seg>
<seg id="1162">121 ► If there is not correct correctly. (see 6 How is Actid to keep it?) ► If it does not know how water and colourless.</seg>
<seg id="1163">"if one of the side effects of side effects you can differ significantly or you are able to notice your doctor, please inform your doctor, your diabetesberacin or your pharmacist."</seg>
<seg id="1164">Leave the seal of your FlexPen Cabinets since it is not used to protect it from light.</seg>
<seg id="1165">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="1166">The dose may be corrected to the top as well according to the appropriate dose into the corresponding direction according to the correct dosage.</seg>
<seg id="1167">Adenuric is used in patients who have already used signs of Kristallablations. including arthritis (pain and inflammation in the joints) or Gichtknotes ("stones" i.e. larger amount of crystal deposits that can lead to joint and bone damage).</seg>
<seg id="1168">"when the harness can be adjusted for two to four weeks, the dose may be increased at once a daily rate of 120 mg."</seg>
<seg id="1169">"during the first treatment of treatment, it is recommended that patients were at least during the first six months under treatment with Adenuric nor other medicines."</seg>
<seg id="1170">The medicine is not recommended for children and in patients who had an organist since it was not examined for these groups.</seg>
<seg id="1171">"in the first study, the effectiveness of several Adenuric-Dosidies (once a daily 80, 120 and 240 mg) is compared with a placebo (once a daily 80, 120 and 240 mg)."</seg>
<seg id="1172">"in the second study, two dosages of Adenuric (once a daily 80 and 120 mg) is compared to 762 patients each year."</seg>
<seg id="1173">"in both studies, Allophyinol in a dose of once daily 300 mg per day; patients with kidney problems only 100 mg per day."</seg>
<seg id="1174">The main indikator for the effectiveness was the number of patients who was in the blood of the blood in the blood of the last three measurements under 6 mg / dl.</seg>
<seg id="1175">"in the first study 48% (126 of 262) of patients who took the Adenuric in a dose of once daily 80 mg, and 65% (175 of 269) of patients who had once a daily rate of 120 mg in the blood of 6 mg / dl."</seg>
<seg id="1176">"in comparison, this was 22% (60 of 268) of the patients under Alloidinol and in no one of 134 patients with Placebo."</seg>
<seg id="1177">"the most common side effects of Adenuric (observed in 1 to 10 of 100 patients) are headaches, diarrheed, nausea and the normal liver values."</seg>
<seg id="1178">"in particular in patients with heart, there is also an increased risk of certain side effects that affect the heart and the blood vessels."</seg>
<seg id="1179">"the Committee on Humanist agents (CHMP) to the end, that Adenuric at the end, that Adenuric at the end of the hardening of the hardening of the blood, but also a higher risk of side effects in connection with the heart and blood vessels."</seg>
<seg id="1180">Treatment of chronic hyperuricemia in disorders that have already been used to uratablations (including one of the cancer history known or currently no arthritis) and / or a gichtarthritis.</seg>
<seg id="1181">"when the serrated hardening unit after 2-4 weeks, still &gt; 6 mg / dl (357 µMol / l), it can be taken into account with ADENURIC 120 mg 1 x daily."</seg>
<seg id="1182">"in patients with severe kidney types, the effectiveness and safety is not fully investigated (Kreatinert Clearance &lt; 30 ml / min, see section 5.2)."</seg>
<seg id="1183">"children and adolescents in children and adolescents are not recommended for children and adolescents, will not be recommended."</seg>
<seg id="1184">"if there is no experiences yet, the application of the uxostat in this patient is not recommended (see section 5.1)."</seg>
<seg id="1185">Cardiovascular disease in patients with ischal cardiovascular disease or decriminalised Herbs shall not be recommended (see section 4.8).</seg>
<seg id="1186">"as with other harness, it can be used during the treatment of the treatment of the treatment of serum."</seg>
<seg id="1187">"in rare cases the absolute concentration of Xanthin and treatment, Lesch- Nyhan Syndrome), the absolute concentration of Xanthin in rare cases, in rare cases, that it comes to a deposits in urinary tract."</seg>
<seg id="1188">Liver diseases of the clinical trials of the phase 3 have been observed in the clinical trials of the liver oil equivalent (3.5%).</seg>
<seg id="1189">"it is recommended to be recommended before the beginning of the February uxobiotic treatment, and in further course of the clinic and a liver function (see section 5.1)."</seg>
<seg id="1190">"Theophyllin Zwas, however, the XO-Hemisphere has been carried out in an increase of the Theophyllinnik, but it is well known that the XO-Hemisphere can lead to an increase of Theophyllins (a Hematization of Theophyllin) was also known for other XO-Hemmer."</seg>
<seg id="1191">"(Cmax 28%, Auc 41% and t1 / 2 26%)."</seg>
<seg id="1192">"in clinical trials, the application of Naproxen or other NSAR / Cox-2 mixtures not in connection with a clinically significant events."</seg>
<seg id="1193">"Colchicin / Indometacin / Hydrochlorthiazid / Warlock, can be used together with Colchicin or indometacin or indometacin or indometacin."</seg>
<seg id="1194">"in a study with subjects of 120 mg ADENURIC 1 x daily a medium 22%, increase in Auc from Desipramine, a CYP2D6 substrate, which is possible for a possible moderate rate of bitipramine, a CYP2D6-enzymm in vivo."</seg>
<seg id="1195">"Antazida It could be shown that the current extraction of an Antazidans, the magnesium hydroxid and aluminum hydroxid, that contains no significant change of the Cmax to 32%, but no significant change of the Auc."</seg>
<seg id="1196">Pregnancy data via a very limited number of exponents are not allowed on side effects of the pregnancy or health of the fetus / Neurology.</seg>
<seg id="1197">"animal experimental studies are not on direct or indirect impact on pregnancy, embryonic / oale development or birth (see section 5.3)."</seg>
<seg id="1198">"in case of a vehicle, the ADENURIC their performance does not affect the performance of a vehicle."</seg>
<seg id="1199">"results appear ordered" "by relevance" "or" "by date" "(publication date),"</seg>
<seg id="1200">In these patients the risk of risk factors were an arteriosklerotic disease and / or a myokardinfarches.</seg>
<seg id="1201">"common (≥ 1 / 100 to &lt; 1 / 10), opportunity (≥ 1 / 1,000 to &lt; 1 / 100) and rare (≥ 1 / 1,000 to &lt; 1 / 1,000) side effects that could be used in the treatment groups with 80 mg / 120 mg."</seg>
<seg id="1202">* * In the clinical trials they were treated with Colchicin. * * In the clinical studies have no serious skin or heavy oversensitivity.</seg>
<seg id="1203">"7 open long-term extension studies in the open long extension studies, 906 patients up to 1 year long, 322 patients up to 3 years long, 57 patients up to 3 years long and 53 patients up to 4 years."</seg>
<seg id="1204">"during the long-term studies, treatment studies were similar to which studies were similar to studies of phase 3 reports (see table 1)."</seg>
<seg id="1205">"the following treatment were found in all Feb.oint- treatment groups in all, uxoint- treatment groups (up to 4 years with an exposition time of &gt; 1.900 patient years)."</seg>
<seg id="1206">The following treatments were found in the Pivotal Studies of Phase 3 for these cans either or with a higher frequency of frequency:</seg>
<seg id="1207">"diabetes, hyperlipidystie, sleep disorders, hypnosis, body, skin care, skin care, skin care, skin care, skin care, damage in the blood, decline of the lymphocytenant, decline of the lymphocycloning, decrease of the number of white blood cells."</seg>
<seg id="1208">"in the framework of the action of the Purinmetabolic, the final product of the Purinmetabolic and arises in the framework of the reactionary hypoxanthin → Xanthin → uric acid."</seg>
<seg id="1209">"he is a real, not working in vitro-selective Inhibitor of XO (NP-SIXO) with a Ki value for the vitro-Hemet, which is below the nanomolonal area."</seg>
<seg id="1210">"results appear ordered" "by relevance" "or" "by date" "(publication date),"</seg>
<seg id="1211">"in each study of the percentage of patients, in each study of the percentage of patients, in which the last three month of particular serum production processes &lt; 6.0 mg / dl (357 µMol / l)."</seg>
<seg id="1212">"a daily (n = 134), ADENURIC 120 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 134), ADENURIC 240 mg 1 x daily (n = 134), ADENURIC 240 mg 1 x daily (n = 10), ADENURIC 240 mg 1 x daily (n = 10), ADENURIC 240 mg 1 x daily (n = 10), ADENURIC 240 mg 1 x daily (n = 10), ADENURIC 240 mg 1 x daily (n = 10), ADENURIC 240 mg 1 x daily (n = 10)."</seg>
<seg id="1213">The APEX study showed a significant increase in accordance with the reduction of serumharness than 6 mg / dl (357 µMol / l) (see table 2 and Figure 1) as well as with ADENURIC 120 mg 1 x daily (n = 258) / 100 mg (n = 10).</seg>
<seg id="1214">"the FACT study showed a significant increase in regard to the permanent employment of serum, at 6 mg / dl (357 µMol / l), 1 x daily as well as with ADENURIC 120 mg 1 x daily against the treatment with the conventional dose Alloidinol 300 mg."</seg>
<seg id="1215">Patients with serum cancer &gt; 1.5 and ≤ 2.0 mg / dl) or 300 mg 1 x daily (n = 509).</seg>
<seg id="1216">"the reduction of serumhardening of seregels on &lt; 6.0 mg / dl (357 µMol / l) was found in the doctor in week 2, and permanently over the whole treatment."</seg>
<seg id="1217">"509 patients received the Allophyinol 300 mg 1 x daily; 10 patients with serumatic inths &gt; 1.5 and &lt; 2.0 mg / dl per 100 mg 1 x daily."</seg>
<seg id="1218">Primary endpoint endpoint in the subgroup of patients with kidney functionalities The APEX study examines the effectiveness of 40 patients with kidney compounds (i.e. h h).</seg>
<seg id="1219">"with ADENURIC, the primary cut point at 44% (80 mg 1 x daily), 45% (120 mg 1 x daily) and 60% (240 mg 1 x daily) and 60% (240 mg 1 x daily)."</seg>
<seg id="1220">"there was no evidence of significant differences in the process of the process of the process of Serumharness function (58% in the group with normal kidney function and 55% in the group with severe kidney dysfunction)."</seg>
<seg id="1221">Primal endpoint endpoint in the subgroup of patients with serum hardening concentrate ≥ 10 mg / dl Etwa 40% of patients (APEXT and FACT study) had to be found (Baseline).</seg>
<seg id="1222">"in two years, the review of the open extension of the open extension of the phase 3 showed that the permanent reduction of serum increases in the months 16-24 a treatment of the patients in the months 16-24 a treatment of the patients in the months 16-24 a treatment of the patients in the months 16-24."</seg>
<seg id="1223">"this was with a reduction of the moulding tools, which was in 54% of the patients a complete waste of the dust-notes to the month 24."</seg>
<seg id="1224">Increased TSH- values (&gt; 5.5 µIE / ml) were observed in patients who were observed that a long-term treatment with several uxostat (5.0%) and also in the open long-term extension studies (see section 4.4).</seg>
<seg id="1225">"for healthy subjects, the maximum plasma concentration (Cmax) and the surface under the plasma concentration time curve (Auc) of the plasma cutting time-curve (Auc) of several mg up to 120 mg × 120 mg."</seg>
<seg id="1226">"for cans between 120 mg and 300 mg is observed in the Auc, the larger than the doscope."</seg>
<seg id="1227">After taking care or multiple sclerosis of 80 and 120 mg 1 x daily is the Cmax approximately 2.8-3.9 µg / ml and 5.0-5.8 µg / ml.</seg>
<seg id="1228">"however, there was no evidence of significant change in the processor of serum intraocular lenses, unless this was tested (multiple cans of 80 mg)."</seg>
<seg id="1229">Distribution This databook provides an overview of the key vendors operating in this market.</seg>
<seg id="1230">"as a result, the plasma cutting height is about 99.2% (primary binding on Albumin) and is reached over the concentrations width, which is achieved by 80 and 120 mg."</seg>
<seg id="1231">"in vitro studies at humanoid liver, CYP1C8 or CYP2C8 or CYP2C8 or CYP2C9, CYP2C8 or CYP2C9 or CYP2C9 or CYP2C9, CYP2C8 or CYP2C9 or CYP2C9."</seg>
<seg id="1232">"after taking a 80 mg dose of 14C-marketed, uxostat (3%), acetylated metabolites and their conjugate (13%), as well as other unwell-known metabolites (13%)."</seg>
<seg id="1233">"in addition to the insurrection above the Urin, also approximately 45% of the dose in the chair as unmodified, uxostat (12%), whose well-known metabolites and their conjugate (25%), as well as additional unwell-known metabolites (7%)."</seg>
<seg id="1234">"if you have any queries, please log in using your e-mail address and your password.:"</seg>
<seg id="1235">The middle of total-Auc from Febiostat around approx. 1.8 m / ml in the group with normal kidney function on 13.2 g / ml in the group with severe kidney dysfunction.</seg>
<seg id="1236">"the Cmax and Auc Disorders in patients with lighter (Chilean Pugh-Classification A) or medium-hard (Child-Pugh-classification B), the Cmax and Auc from Febiostat and its metabolites are not significantly compared to subjects with normal liver function."</seg>
<seg id="1237">Age It had no significant changes in terms on the Auc of Febiostat or its metabolites after taking multiple patients in comparison to the younger subjects.</seg>
<seg id="1238">"carcinogenesis, nuts, impairment of the fertilation of the Fertilization of the Fertilization of the Fertilizers and carcinoma) only in connection with Xanthin stones are found in connection with Xanthin stones."</seg>
<seg id="1239">These findings are considered as a result of a specialized Purintoxication and urinexhaustion and for the clinical application as not relevant.</seg>
<seg id="1240">"it was noted that Sostat in oral cans of up to 48 mg / kg / day no effect on the Fertilization and reproductive performance of male and female Rites."</seg>
<seg id="1241">"in high cans that about 4,3 times the humanistic exposition, joined together with a reduction of performance and a development delay in the descendants of Rites."</seg>
<seg id="1242">Teratological studies of portable assimiles with expositions which is about the 4,3 seconds and with tragic rabbits with expositions which was about the 13-minute of the humanist exposition.</seg>
<seg id="1243">"Colchicin / Indometacin / Hydrochlorthiazid / Warlock, can be used together with Colchicin or indometacin or indometacin or indometacin."</seg>
<seg id="1244">* * In the clinical trials they were treated with Colchicin. * * In the clinical studies have no serious skin or heavy oversensitivity.</seg>
<seg id="1245">"21 open long-term extension studies in the open long extension studies, 906 patients up to 1 year long, 322 patients up to 3 years long, 57 patients up to 3 years long and 53 patients up to 4 years."</seg>
<seg id="1246">"in each study of the percentage of patients, in each study of the percentage of patients, in which the last three month of particular serum production processes &lt; 6.0 mg / dl (357 µMol / l)."</seg>
<seg id="1247">"in two years, the review of the open extension of the open extension of the phase 3 showed that the permanent reduction of serum increases in the months 16-24 a treatment of the patients in the months 16-24 a treatment of the patients in the months 16-24 a treatment of the patients in the months 16-24."</seg>
<seg id="1248">"26 as unaltered, uxostat (3%), acetylated metabolites and their conjugate (13%), as well as additional unwell-known metabolites (13%)."</seg>
<seg id="1249">"liver function does not contain multiple sclerosis of 80 mg ADENURIC in patients with lighter (Chilean Pugh-Classification A) or medium-hard (Child-Pugh-classification B), the Cmax and Auc from Febiostat and its metabolites are not significantly compared to subjects with normal liver function."</seg>
<seg id="1250">"carcinogenesis, nuts, impairment of the fertilation of the Fertilization of the Fertilization of the Fertilizers and carcinoma) only in connection with Xanthin stones are found in connection with Xanthin stones."</seg>
<seg id="1251">"the owner of the permission of the permission to make sure that a pharmaceutical convigilance system such as in version 2.0 Module 1.8.1 of certifications is described, ready for use before the drugs is brought to the transport."</seg>
<seg id="1252">A updated RMP is used according to the CHMP Guideline to risk management systems for human resources with the next Periodic Safety update Report Report (PSUR).</seg>
<seg id="1253">"in addition, an update of the RMP is necessary to provide an impact on safety information, the pharmaceutical covigilance or activities for risk inimetry. • within 60 days after receiving an important basis (pharmaceutical covigilance or risk assessment) • on request of the EMEA region."</seg>
<seg id="1254">"in some people, the uric acid in blood and can achieve concentrations that urate uric acid is insoluble."</seg>
<seg id="1255">"if you keep the harness concentment through the 1 x daily use of ADENURIC low, the crystal can be avoided and on this way with the time a minute of the complaints."</seg>
<seg id="1256">"ADENURIC may not be taken to be taken, • If you are oversensitive (allergic) against the active compounds, uxostat or one of the other components of ADENURIC."</seg>
<seg id="1257">"before you have to start your doctor before taking care of this drug, if you have a heart rate or the Lesch-Nyhan-Syndroms (a rare congenital disease, which is in the blood of the blood)."</seg>
<seg id="1258">"if you have a givature of severe pain, pressure-sensitivity, tubes, heat and body hair, wait until you start with the treatment with ADENURIC."</seg>
<seg id="1259">"that must not be in any case, but also with you, especially during the first treatment weeks or - monate, occur if you take ADENURIC."</seg>
<seg id="1260">Your doctor will be sent to you in need of any other medicines to treat a giver or to treat the associated symptoms (such as pain and ligaments).</seg>
<seg id="1261">"please inform your doctor or pharmacist if you have taken other drugs, if you have used other drugs, even if it is not needed."</seg>
<seg id="1262">"it is particularly important that you take your doctor or pharmacist, if you are able to take care of your doctor or pharmacist (for treatment of cancer) • Theophyllin (for treatment of asthma) • Warlin (for treatment of asthma) • Warning in (for treatment of asthma)."</seg>
<seg id="1263">There were no studies to the effects of ADENURIC on transport and the ability to serve machines.</seg>
<seg id="1264">"please take ADENURIC, so that you have known to your doctor if you have known that you have been able to suffer from a uncertainty of specific forms."</seg>
<seg id="1265">• tablets must be taken on the back of the Blisterpackers are printed so that you may have to be taken if you have taken a tray with or without food. • The tablets must be repaired and can be taken with or without food.</seg>
<seg id="1266">"if you have taken a overdose, please contact your doctor or to the staff of the nearest hospitals."</seg>
<seg id="1267">"if you have forgotten your approval from ADENURIC, you get this faster, unless the next taking is shortly before."</seg>
<seg id="1268">"when using ADENURIC, you can leave your harness concentment again and your complaints can be screwed, because the new Uratstones are formed in your joints and the environment as well as their environment."</seg>
<seg id="1269">Common side effects (more than 1 of 100 treatment):</seg>
<seg id="1270">"some side effects (more than 1 of 10,000 treatment, but less than 1 of 1,000 treatment): • weakness • nervous system • Duration"</seg>
<seg id="1271">"please inform your doctor or pharmacist, if one of the side effects you can choose from either side effects or side effects that are not found in this use."</seg>
<seg id="1272">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="1273">"for this purpose we would like to hear your opinion, wishes and acquaintances via e-mail. to do so, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="1274">"you will find these under" "Tools, Internet Options, Security" "and" "Tools, Internet Options, Security" "and" "Tools, Internet Options, Privacy". ""</seg>
<seg id="1275">ADROVANCE is used for treatment of Osteoporosis (a disease that is used in case of menopause) with women according to Menopause) in which a risk for a low vitamin D mirror.</seg>
<seg id="1276">"the patient must take the tray with a full glass of water (no mineral water) at least 30 minutes before food, drinking or inserts other drugs (including Antazida, Calcium- and Vitamins."</seg>
<seg id="1277">"in order to avoid a rich of the spades, the patient may take up to the first food intake of the day, the early 30 minutes after taking the tablet."</seg>
<seg id="1278">"since Alendronat and vitamin D3 are already separated from each other, in the European Union, the company shares data from previous studies and the published literature."</seg>
<seg id="1279">Firm of the Year for Insolvency Administration Schneider Geiwitz & Partner Firm of the Year for Tax Gleiss Lutz</seg>
<seg id="1280">"after a 15-wreck treatment, the percentage of patients with lower vitamin D mirror were treated by the patients who had been treated with ADROVANCE, low (11%)."</seg>
<seg id="1281">The company also used data from the location which are used in ADROVANCE uses the dose is exactly the dose that is required for reduction of a bone loss.</seg>
<seg id="1282">"the most common side effects (observed in 1 to 10 of 100 patients) are headaches, pain of movement, diarrhoe (diarrhoea), flatulence, diarrhoe (diarrhos), flatulence, diarrhoe (diarrhoea), cast iron, diarrhoe (saw blade)."</seg>
<seg id="1283">"in patients with etwaering oversensitivity (allergies) against Alendronat, vitamin D3 or one of the other components may be applied to ADROVANCE."</seg>
<seg id="1284">Patients with hypocalcemia (low calcium) or patients who are not at least 30 minutes long.</seg>
<seg id="1285">"in 2007, the European Commission to Merck Sharp & Dohme Ltd. a permit for the execution of ADROVANCE in the whole European Union."</seg>
<seg id="1286">"capsule, white to a white tablets, marked with the switch of a bowl on the one side and" 710 "on the other side."</seg>
<seg id="1287">ADROVANCE is only available with water (not with mineral water) at least 30 minutes before the first food, beverage or inserts of drugs (including Antazida, Calcium- and Vitamins) for the day. "</seg>
<seg id="1288">"the following notes are precisely to follow the risk for infophageants and associated side effects (see section 4.4):"</seg>
<seg id="1289">• ADROVANCE shall be put into the mouth with a full glass of water (at least 200 ml).</seg>
<seg id="1290">"as pyloroplastics, active gastrointestinal disorders, or surgical interventions at the upper Gastrointestinal function, only under particular be given (see section 4.3)."</seg>
<seg id="1291">"data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data. why buy this report? * Get a detailed picture of the Personal Care market; * Pinpoint growth sectors and identify factors driving change; * Understand the competitive environment, the market's major players and leading brands;"</seg>
<seg id="1292">"the doctor should be attentive to all the signs and symptoms that are committed to the potential of sympathetic reactions, and the patients should be observed in the occurrence of sympathetic medicine, and the patients should be observed during the occurrence of the symptoms of symptoms of symptoms and medical treatment (see section 4.8)."</seg>
<seg id="1293">3 The risk of infophageal side effects seems to be increased in patients who are not correct and / or it after the occurrence of symptoms that take on a ösophageal Irritation.</seg>
<seg id="1294">It is very important that all the dosing activities of patients will be transferred and from the patient (see section 4.2).</seg>
<seg id="1295">"while in large proportion of clinical trials with Alendronat no increased risk has been found, rare (after market launch), including some serious and complications, reports (see section 4.8)."</seg>
<seg id="1296">"Osteonekrose des Kiefers, usually in connection with a tooth extraction and / or a local infection (including Osteomyelitis), was created with Kremiths, the therapy of intravenous bisphosphonate."</seg>
<seg id="1297">"there are no data available to indicate whether the removal of a bisphosphonatology of patients, the risk of a Osteonekrose of Kiefers."</seg>
<seg id="1298">The clinical assessment of the treatment of the treatment of the treatment for therapy planning for each patients on the basis of an individual benefit-risk assessment.</seg>
<seg id="1299">Patients should know that they have a dose of ADROVANCE the tablet on the next morning after they have seen them.</seg>
<seg id="1300">"they should take no two tablets on the same day, but the taking of a tablet per week like originally planned on the designated weekday."</seg>
<seg id="1301">"other diseases, the mineral oil change (such as vitamin D deficiency and hypoparathyreoidal), should be treated in the beginning of the therapy with ADROVANCE."</seg>
<seg id="1302">"Alendronat Food and drinks (including mineral water), calcium supplements, Antazida and some orale medicines can be taken at the same time when they be taken at the same time."</seg>
<seg id="1303">Therefore we have to wait for patients after taking Alendronat at least 30 minutes before they take other drugs (see Abbreviations 4.2 and 5.2).</seg>
<seg id="1304">"although specific intercultural studies were not carried out, Alendronat in clinical studies together with a variety of common drug use."</seg>
<seg id="1305">ADROVANCE is only available for use in postmenopausal women and is therefore no longer available during pregnancy.</seg>
<seg id="1306">Animal studies using Alendronat does not notice any notice in terms of pregnancy, the embryonic / oale or postnatal development. "</seg>
<seg id="1307">"Osteonekrose of the Kiefers was reported in patients under Bisphosphonate, and most reports are from credentists, but also at Osteoporoseposepotatius."</seg>
<seg id="1308">"nevertheless, the Serum-Calcians to &lt; 8,0 mg / dl (2,0 mmol / l) and the Serum- phosphate up to ≤ 2.0 mg / dl (0,65 mmol / l) in both treatment groups with similar frequency."</seg>
<seg id="1309">"Alendronat Insequence of an oral overdose may contain hypocalcemia, hypophosphatemia and side effects on the upper Gastroscopy, Sodburn, Ösophthalmology, Gastritis or Ulcera."</seg>
<seg id="1310">Colecalciferol (vitamin D3) Vitamin D3 will be produced in the skin through UV light via the conversion of 7-Dehytail pipes to vitamin D3.</seg>
<seg id="1311">"the main effect of 1,25-Dihydroxy.dll D3 is the increase of the calcium ions of calcium and phosphate, as well as the regulation of serum-calcium and phosphate, the renal failure of calcium and phosphate, the bone of bone and bone."</seg>
<seg id="1312">"in severe cases, a lack of secondary hyperparathyreoidal, hypophosphatemia, weakness of proximal muscle muscles and Osteomalazie and so on a further increased risk for stoves and osteoporosis."</seg>
<seg id="1313">"this small cavity at the spine of the spine is used for a normal, young population, or not the bone density as part of pathological liver."</seg>
<seg id="1314">The patients received ADROVANCE in the lower thickness (70 mg / 2.800) (n = 350) or Fendronat) 70 mg once per week (n = 332); other vitamin D supplements have been undermined.</seg>
<seg id="1315">"after 15-week treatment, the medium Serum mirror is significantly higher (26%) in the group under ADROVANCE (70 mg / 2.800,) (56 nmol / l [23 nmol / l [18.2 ng / ml])."</seg>
<seg id="1316">Share this: print & PDF Email Facebook Twitter Tumblr More Google LinkedIn Pinterest Pocket</seg>
<seg id="1317">Studies with Alendronat The therapeutic effect of Alendronat once per week 70 mg (n = 519) and Alendronat 10 mg daily (n = 370) was obtained in a single-year-Multicular study on postmenoporosis.</seg>
<seg id="1318">"the effects of alendronate on bone mass and groups in postmenopausal women were examined in two phase III studies in two phase III studies in two phase III studies (n = 944), as well as in the Frazier curve - study (FIT: n = 6.459)."</seg>
<seg id="1319">"in the phase III studies, the middle part of the BMD with Alendronat 10 mg / day in relation to placebo after 3 years 8,8% of the spine, 5,9% at the spine, 5,9% at the Trochanter."</seg>
<seg id="1320">"in comparison to the placebo group, a reduction of 48% (Alendronat 3.2% compared to placebo 6.2%) in the proportion of patient who reaches a or more clutties."</seg>
<seg id="1321">"in the two-year-extension of these studies, the BMD of spine and Trochanter continue to continue; also the BMD of the Feminification and the whole body was executed."</seg>
<seg id="1322">"in two years, Alendronat daily (5 mg daily over 2 years and then 10 mg per day) has been taken over 2 years and then 10 mg daily (1 or 2 years):"</seg>
<seg id="1323">In this study the daily gift of Alendronat the occurrence of at least a new spine around 47% (Alendronat 7.9% compared to placebo 15.0%).</seg>
<seg id="1324">Resorption at a intravenous reference dose was added to a intravenous bioavailability of women 0.64% for cans between 5 and 70 mg for cans and two hours prior to a standardized breakfast.</seg>
<seg id="1325">The bichrist was taken according to approximately 0.46% and 0.39% when Alendronat one or half an hour before a standardized breakfast.</seg>
<seg id="1326">"in Osteoporoshi, Alendron was effective when it was taken at least 30 minutes before the first meal or drinking of the day."</seg>
<seg id="1327">"for healthy subjects, the gift of orphaned Prednison (20 mg three times per day) to none of five days) to none of the oral bioavailability of alendronat (increase in the area of 20% to 44%)."</seg>
<seg id="1328">"9 distribution of studies at Rarities have seen that Alendronat is distributed by an intravenous gift of 1 mg / kg in Weichtower, but then rapidly in the bone is distributed or with the urine."</seg>
<seg id="1329">Intravenous painting of a single dose of 14C-Alendronat were approximately 50% of the radioactive substance within 72 hours with the urine and little or no radioactivity was found in the fenced.</seg>
<seg id="1330">After intraveneer gift of a single dose of 10 mg was the renal Clearance of 71 ml / min and the systemic Clearance is not 200 ml / min.</seg>
<seg id="1331">"Alendronat is not affected by the acid or basical transport system of the nest, and therefore not accepted that it is influenced by the people of other drugs through this transport systems."</seg>
<seg id="1332">Resorption In healthy adults and two hours prior to the gift of ADROVANCE according to the gift of ADROVANCE according to the gift of ADROVANCE according to the gift of ADROVANCE according to the gift of ADROVANCE after the gift of a meal (AUC0-120 h) for vitamin D3 296.4 ng • h / ml (without consideration endogener vitamin-D3-mirror).</seg>
<seg id="1333">"the maximum concentration in serum (Cmax) of vitamin D3 was 5,9 ng / ml and the mediantime to the maximum serum concentration (Tmax) 12 hours."</seg>
<seg id="1334">Biotransore vitamin D3 will be placed in the liver quickly to 25-hydroxy.dll D3 hydroxy.dll and then in the Niere to 1.25 dihydroxy.dll D3, the biologically active form, metabolized. "</seg>
<seg id="1335">"at the same time, the radioactive decay of vitamin D3 in healthy subjects was reduced to 48 hours 2.4%, in the barrels of 4 days 4,9%."</seg>
<seg id="1336">"characteristica in patients preclinical studies have shown that the proportion of alendronat which is not included in bones, quickly over the urine."</seg>
<seg id="1337">"although there is no clinical data to suggest that the renal Elimination of Alendronat like in the animal try to be reduced in patients with limited kidney function."</seg>
<seg id="1338">"therefore, patients with limited kidney function a somewhat higher circulation of alendronat in bone (see section 4.2)."</seg>
<seg id="1339">"Alendronat non-clinical data based on conventional studies on the basis of conventional studies for security-harmakologie, for chronic toxicity, for chronic toxicity, there are no special dangers for humans."</seg>
<seg id="1340">Studies at Rites showed that the gift of Alendronat an airstrikes with the occurrence of Dystokie in the mother who went on a hypocalcemia.</seg>
<seg id="1341">"microcrystalline cellulose (E 460) Lactose Mittelketrical triglyceride Gelate Croscarmic Triglyceride Gelate Croscarmic vinegar (Ph.Eur.) (E 321) thickness, modified (corn) aluminium natumsilicate (E 554)"</seg>
<seg id="1342">(1 Etui with 4 tablets), 4 (1 Etui with 4 tablets), 4 (3 Etuis with 4 tablets), 12 (3 Etuis with 4 tablets) or 40 (10 Etuis with 4 tablets) or 40 (10 Etuis with 4 tablets). "</seg>
<seg id="1343">EU / 1 / 06 / 364 / 001 - 2 tablets EU / 1 / 06 / 364 / 002 - 6 tablets EU / 1 / 06 / 364 / 004 - 5 tablets EU / 1 / 06 / 364 / 005 - 40 tablets</seg>
<seg id="1344">"you will find these under" "Tools, Internet Options, Security" "and" "Tools, Internet Options, Security" "and" "Tools, Internet Options, Privacy". ""</seg>
<seg id="1345">"13 • The patients should not be taken from ADROVANCE at least 30 minutes. • ADROVANCE shall not be taken before the sleep or before the first end of the day."</seg>
<seg id="1346">The risk of antiophageal side effects seems to be increased in patients who are not correct and / or it after the occurrence of symptoms that take on a ösophageal Irritation.</seg>
<seg id="1347">"while in large proportion of clinical trials with Alendronat no increased risk has been found, rare (after market launch), including some serious and complications, reports (see section 4.8)."</seg>
<seg id="1348">18 Colecalciferol (vitamin D3) Vitamin D3 will be produced in the skin through UV light via the conversion of 7-Dehytail pipes to vitamin D3.</seg>
<seg id="1349">The patients received ADROVANCE in the lower thickness (70 mg / 2.800) (n = 350) or Fendronat) 70 mg once per week (n = 332); other vitamin D supplements have been undermined.</seg>
<seg id="1350">"vitamin D3 (the amount of vitamin D3 in the higher dose of ADROVANCE) once per week, was shown in a 24-wreck study with 619 postmenopausal women with Osteoporosis."</seg>
<seg id="1351">"after 24-week treatment, the medium Serum mirror is significantly higher in the 5.600-I.E.-Vitamin-D3 Group (69 nmol / l [27,6 ng / ml]) as in the 2.800-I.E.-Vitamin-D3-group (64 nmol / l [25,5 ng / ml])."</seg>
<seg id="1352">There were no statistical analysis difference between the treatment of patients with hypercalciurie at the end of the 24-wreck.</seg>
<seg id="1353">"3.1% at the entire cap in the group with 70 mg per week, or in which with 10 mg daily."</seg>
<seg id="1354">In this study the daily gift of Alendronat the occurrence of at least a new spine around 47% (Alendronat 7.9% compared to placebo 15.0%).</seg>
<seg id="1355">"the bioavailability took information on approximately 0,46% and 0.39%, when Alendronat one or half an hour before a standardized breakfast."</seg>
<seg id="1356">"distribution of studies at Rarities have seen that Alendronat is distributed by an intravenous gift of 1 mg / kg in Weichtower, but then rapidly into the bone is distributed or with the urine."</seg>
<seg id="1357">Resorption In healthy diaries (women and men) was born after the gift of ADROVANCE (70 mg / 5.600) after the gift of ADROVANCE (70 mg / 5.600) after the gift of ADROVANCE (70 mg / 5.600).</seg>
<seg id="1358">"the maximum concentration in serum (Cmax) of vitamin D3 was 12,2 ng / ml and the mediantime to the maximum serum concentration (Tmax) 10.6 hours."</seg>
<seg id="1359">Smaller quantities are stored in fat and muscle tissue and are stored there as vitamin D3 to be stored in the circulation.</seg>
<seg id="1360">"21 vitamin D3 will be able to set up to 25-hydroxy.dll hydroxy.dll and then in the nest to 1.25 dihydroxy.dll D3, the biologically active form, metabolized."</seg>
<seg id="1361">"there were no evidence on a saturation of the recording of the blood flow, up to 35 mg / kg of animals in animals."</seg>
<seg id="1362">(1 Etui with 4 tablets), 4 (1 Etui with 4 tablets), 4 (1 Etui with 4 tablets), 12 (3 Etuis with 4 tablets) or 40 (10 Etuis with 4 tablets) tablets. "</seg>
<seg id="1363">"Pharmacovigilance-system The owner of the permission of the permission of the owner shall be ready to make sure that a pharmaceutical cogilance system as in version 2 Module 1.8.1 of certifications are described, as in version 2 module, and so long as it is in the transport of the transport."</seg>
<seg id="1364">Risk management plan is obligated to provide studies and further development of the pharmaceutical plan that are described in the risk management plan (RMP) and its corresponding updates to version 1 module 1.8.2 of application documents.</seg>
<seg id="1365">A updated RMP is in accordance with the CHMP Guideline to risk management systems for human resources with the next Periodic Saftey Update Report (PSUR).</seg>
<seg id="1366">"additionally, an update of the RMP is necessary to provide a impact on the security code, pharmaceutical covigilance or activities for risk inimitation."</seg>
<seg id="1367">Take advantage of a ADROVANCE tablet after the end and before using the first food and drinking of any other medicines by clicking the tray with a full glass of water (not covered with mineral water).</seg>
<seg id="1368">"if you have any questions, please contact your doctor or pharmacist."</seg>
<seg id="1369">"at least, the eggs are no female hormones, Östrogen, more, that help to get the skeleton of women healthy."</seg>
<seg id="1370">"the brilliance, usually at the hip, the spine or the towel, and can not only be pain, but also significant problems like geugte attitude (" wiwenbud ") and a loss of movement."</seg>
<seg id="1371">ADROVANCE prevents not only the loss of bone mass but also contributes to the bone loss.</seg>
<seg id="1372">"(3) If your doctor found it possible to sit at least 30 minutes, (4) if your doctor found that your calcium is in the blood."</seg>
<seg id="1373">"40 • If you have problems when you have problems with the digestion or digestive levels, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation-treatment, • If you have a chemotherapy or radiation-treatment, • If you have a chemotherapy or radiation-treatment, • If you have a chemotherapy or radiation-treatment, • If you have a chemotherapy or radiation-treatment, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation-treatment, • If you have a chemotherapy or radiation-treatment, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation-treatment, • If you have a chemotherapy or radiation-treatment, • If you have a chemotherapy or radiation-treatment, • If you have a chemotherapy or radiation-treatment, • If you have a chemotherapy or radiation-treatment, • If you have a chemotherapy or radiation-treatment, • If you have a chemotherapy or radiation-treatment, • If you have a chemotherapy or radiation</seg>
<seg id="1374">These complaints can occur in particular if the patients who take the ADROVANCE tablet not with a full glass of water.</seg>
<seg id="1375">"in case of ADROVANCE with other medicines, Calciummies, Antazida and some other medicines may take the effectiveness of ADROVANCE for simultaneous use."</seg>
<seg id="1376">"special medicines or food additives can be found in the ADROVANCE, vitamin D in the body, including artificial fats, mineral oils, ornaments, ornaments, orrhodium and Colestipol."</seg>
<seg id="1377">"please inform your doctor or pharmacist if you have taken other drugs, if you have used other drugs, even if it is not taken to be used."</seg>
<seg id="1378">Please take this medicine only after returning with your doctor if you are known to suffer from a unreasonable point towards certain circumstances.</seg>
<seg id="1379">"please follow the Hindu 2), 3), 4) and 5) to facilitate the transport of the ADROVANCE tablet to facilitate the transport of the request (Ösophagus - the tube that connects your mouth with the stomach."</seg>
<seg id="1380">• Available with coffee or tea. • Not available with coffee or tea. • Not with juice or milk. • Not with juice or milk. • Not with juice or milk.</seg>
<seg id="1381">"(3) Lever you do not stay - stay completely, (in sitting or sitting) - at least 30 minutes long after taking the tablet."</seg>
<seg id="1382">"(5) If you have difficulties or pain in the patient, pain behind the breast is, newly formed or wording the sodburn, set ADROVANCE from and seek your doctor."</seg>
<seg id="1383">(6) Warning from your ADROVANCE tablet at least 30 minutes before you can take your first food, drinks or other drugs such as Antazida (magicides medication), Calcium- or Vitaminda. "</seg>
<seg id="1384">"if you have created a lot of tablets to be taken, drink a full glass of milk and please contact your doctor."</seg>
<seg id="1385">"if you have a tablet on the next morning, you only have a tablet on the next morning after you have noticed your meetings."</seg>
<seg id="1386">"often you can cause pain and pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain</seg>
<seg id="1387">"occasionally: • nausea, vomiting, and infections and infections (Ösophagus - the tube that connects your mouth with your stomach) or the magnets, • black or teerved chair, • skin care; Juckreiz; straight skin."</seg>
<seg id="1388">"after market launch, the following side effects were reported by the following side effects (frequency, not known): • (torque) Schwindel, • Internal problems, • hair loss, • hair loss, • hair loss, • hair loss, • hair loss, • hair problems (Osteonekrose) in combination with delay and infections, • swelling on hands or legs."</seg>
<seg id="1389">43 Dabei is helpful if you knew what complaints you had started and how long they thought about it.</seg>
<seg id="1390">"the other components of microcrystalline cellulose (E 460), Lactose, medium-acid triglyceride, joints, Croscarmsearate (Ph.Eur.) (E 321), strength, modified (corn), and aluminium natumsilicate (E 554)."</seg>
<seg id="1391">The tablets are available in Etui with 4 tablets (1 Etui with 4 tablets) • 4 tablets (1 Etuis with 4 tablets in aluminium-blisterpackers) • 5 tablets (3 Etuis with 4 tablets in aluminium-blisterpackers) • 40 tablets (10 Etuis with 4 tablets) in aluminium-blisterpackers) • 40 tablets (10 Etuis with 4 tablets) in aluminium-blisterpackers) • 40 tablets (10 Etuis with 4 tablets) in aluminium-blisterpackers.</seg>
<seg id="1392">"at least, the eggs are no female hormones, Östrogen, more, that help to get the skeleton of women healthy."</seg>
<seg id="1393">"48 • If you have allergies any allergic, if you have problems when you have problems when you have problems when you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation-treatment, • If you have a chemotherapy or radiation-treatment, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy or radiation therapy, • If you have a chemotherapy</seg>
<seg id="1394">"in case of ADROVANCE with other medicines, Calciummies, Antazida and some other medicines may take the effectiveness of ADROVANCE for simultaneous use."</seg>
<seg id="1395">• Available with coffee or tea. • Not available with coffee or tea. • Not with juice or milk. • Not with juice or milk. • Not with juice or milk.</seg>
<seg id="1396">"3) Lever you do not go - stay completely, (in sitting or sitting) - at least 30 minutes long after taking the tablet."</seg>
<seg id="1397">"5) If you have difficulties or pain in the patient, pain behind the breast is to occur behind the breast of breast, newly formed or wording the Sodburn, set ADROVANCE from and seek your doctor."</seg>
<seg id="1398">6) Warning from your ADROVANCE tablet at least 30 minutes before you can take your first food, drinks or other drugs such as Antazida (magicides medication), Calcium- or Vitaminda. "</seg>
<seg id="1399">"• (rotation) Schwindel, • joint sellings, • hair loss, • hair loss, • hair loss, • hair loss, • hair problems (Osteonekrose) in combination with delay and infections, often after the pulling of teeth, • swelling on hands or legs."</seg>
<seg id="1400">"tablets are available as rectangular, white to a white tablets, marked with the switch of a bone on the other side and" 270 "on the other side."</seg>
<seg id="1401">"Advagraf, adult patients received a kidney or liver transplant to prevent bone loss due to the immune system."</seg>
<seg id="1402">"since Tacrolimus and Prograf / Prograft has been used in the EU, the company has been committed to the results of the following studies using Prograf / Prograft as well as data from the published literature."</seg>
<seg id="1403">"furthermore, the results of a clinical study of 668 patients with kidney transplantation has been compared with kidney transplantation."</seg>
<seg id="1404">"the main indices of the effectiveness was the number of patients suffering from one year (by example, for example, how often a new organist or a recovery of dialysis was necessary)."</seg>
<seg id="1405">"in addition, the shortfall of further studies in 119 patients with kidney transplant and 129 patients with liver transplantation and 129 patients with liver transplant."</seg>
<seg id="1406">"the symptoms of blood cells (hypersensitivity), kidney cancer, increase blood sugar levels (hypersensitivity), hypertension (hypersensitivity), hypertension (hypertension), hypertension (insomnie)."</seg>
<seg id="1407">For patients with etwaering oversensitivity (allergies) against Tacrolimus, macro-antibiotics (such as Erygomycin) or another of the other ingredients may be used. "</seg>
<seg id="1408">Patients and doctors have to be careful if other (especially some vegetable) medicines at the same time as the Advagraf dose or the dose of the same medication must be adjusted accordingly.</seg>
<seg id="1409">"hard disks, the ardized Yellow-orange Gelatinekapites, printed in red ink on the light yellow capsule with" "647" "; they contain white powder."</seg>
<seg id="1410">Only medical treatment with the immunological therapy and treatment of Transplantationspatization are familiar to this medication or changes in immunological therapy.</seg>
<seg id="1411">"due to previous relevant differences between the systemic Exposition of Tacrolimus, this can lead to transcription or to an increased risk of side effects, including lower or overdose."</seg>
<seg id="1412">Patients should always be retained the same Tacrolimus formulation and the appropriate daily dosage; circulation of formulation or the regime should only be carried out under the transplantation of a transplantation (see Sections 4.4 and 4.8).</seg>
<seg id="1413">"in consequence of an alternative formulation, a therapeutic drug monitoring has to be carried out to ensure that the systemic Exposition of Tacrolimus remains."</seg>
<seg id="1414">The dosage of Advagraf should be the first line on the clinical assessment of separation and stimulation in individual cases and on blood cells.</seg>
<seg id="1415">"after conversion of Prograf on Advagraf, the Tacrolimus Talks should be controlled before the conversion and over two weeks."</seg>
<seg id="1416">"at the day 4, systemic exposition, measured as a valley mirror, with both formulations both in kidney and transplant patients."</seg>
<seg id="1417">Careful and repeated controls of the Tacrolimus Talks are recommended during the first two weeks after transplantation under Advagraf.</seg>
<seg id="1418">"as Tacrolimus is a substance with low Clearance, a adaptation of the Advantraf-Dosisschemas several days until the Steady State is reached."</seg>
<seg id="1419">"if the patient's state in the first postoperative phase, the Tacrolimus treatment of intravenous (Prograf 5 mg / ml concentrates at the production of an infusion solution), with a dose of ca."</seg>
<seg id="1420">"in the application of the application of transcription function, the immune system must not be used; consistent, therefore a maximum duration of the oral therapy is not specified."</seg>
<seg id="1421">Dosage recommendations - kidney transplantation was to begin with 0,20 - 0.30 mg / kg / day as a daily gift on the morning.</seg>
<seg id="1422">"if you want to report this message, please log in using your e-mail address and your password.:"</seg>
<seg id="1423">Risk recommendations - liver transplant prophylaxis of Transplantation was to begin with 0,10 - 0.20 mg / kg / day as a daily gift on the morning.</seg>
<seg id="1424">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="1425">Kidney and liver transplant is a circulation of other immune disorders. it has to begin the treatment with kidney and liver transplantation in kidney and liver transplantation.</seg>
<seg id="1426">Heart transplant to adult patients who are on Advagraf is a orale initialdose of 0.15 mg / kg / day daily once in the morning.</seg>
<seg id="1427">Other Transplantation has no clinical experience with Advagraf in lung -, pankee and darmtransplant patients in an oral Initial dose of 0.3 mg / kg / day and at a oral Initial dose of 0.3 mg / kg / day.</seg>
<seg id="1428">"patients with limited liver function, patients with limited liver function can be necessary in patients with severe liver functions in patients with severe liver function dysfunction."</seg>
<seg id="1429">Patients with limited kidney function As the kidney function does not require influence on the pharma ocinetic of Tacrolimus can be carried out that a dose is not necessary.</seg>
<seg id="1430">"due to the nephrotoxical Potentials of Tacrolimus, however, a careful control of the kidney function (including a regular determination of the serpentine seal, a calculation of the Kreatininction and an monitoring of urinary volume)."</seg>
<seg id="1431">Conversion of Ciclosporin on Advagraf In the conversion of a Ciclosmus based on a Tacrolimus-based therapy is caution (see Sections 4.4 and 4.5).</seg>
<seg id="1432">Recommendations for Talks in the full blut The dose should be taken into first line on the clinical assessment of separation and compatibility of full blut-Tacrolimus-Talrolimus-Talrolimus-Talsi controls.</seg>
<seg id="1433">"in the first two weeks after transplantation, during the first two weeks after Transplantation, followed the first two weeks after transplantation."</seg>
<seg id="1434">"the blood flow mirror of Tacrolimus should also be controlled by Prograf on Advagraf, Dosisadaption, changes of immunological therapy or at the same application of substances which could be controlled by the Tacrolimus and full circulation of substances which could be controlled (see section 4.5)."</seg>
<seg id="1435">"as Adagraf is a medicine with a low Clearance, the dose of several days need until the Steady State."</seg>
<seg id="1436">"the data in clinical trials, that a successful treatment in most cases is possible if the valley mirror in the blood 20 ng / ml did not exceed."</seg>
<seg id="1437">"in the clinical practice of the Talrolimus in the first time after liver transplant in the first time after liver transplant, usually in the area of 5 - 20 ng / ml and warm patients at 10 - 20 ng / ml."</seg>
<seg id="1438">"during the following treatment of liver, kidney and cardiovascular diseases were not used in the area of 5 - 15 ng / ml."</seg>
<seg id="1439">"this has led to serious unwanted events, including Transplantation or other side effects that can occur in the result of Tacrolimus subor or overexposition."</seg>
<seg id="1440">Patients should always be retained the same Tacrolimus formulation and the appropriate daily dosage; circulation of formulation or the regime should only be carried out under the transplantation of a transplantation (see Section4.2 and 4.8).</seg>
<seg id="1441">"5 For the treatment of adult patients with transplantation, compared to other immune disorders, are yet no clinical data for the retarded formulation of formagraf."</seg>
<seg id="1442">For prophylaxis of Transplantation with adult heart transplantation and transplantation are still no clinical data for the retardized formulation formagraf.</seg>
<seg id="1443">Due to the potential dangers of the Tacrolim mirror in blood and one of the clinical effect of Tacrolimus can be included in the blood and the weakening of the clinical effect of Tacrolimus is included in the blood and other plant healing during a treatment with Advagraf (see section 4.5).</seg>
<seg id="1444">In patients with Diarrhö is a particularly careful monitoring of the Tacrolimuscular concentrations in the blood as the Tacrolimus-blood cells can be used in such circumstances.</seg>
<seg id="1445">In rare cases a cardiomyopathie was used as cardiomyopathy.</seg>
<seg id="1446">"further factors affecting the risk of such diseases are already existing heart, a treatment with correlation, hypertension, kidney or liver function dysfunction, infections, fluid overload and oils."</seg>
<seg id="1447">"as in other immunotherapy, the effect of sunlight or UV light is due to the possible risk of risk or UV light due to the possible risk of risk due to the possible risk or use of a sunscreen by means of a high protective factor."</seg>
<seg id="1448">"if patients, the Tacrolim, symptoms for PRES such as headaches, alterations of consciousness, lack of consciousness should be a radiological examination (e.g.."</seg>
<seg id="1449">"for patients with the rare HEREDITÄFER Galactose-intolerance, Lactose deficiency or Glucose-Galactose-malnutrition."</seg>
<seg id="1450">"the current application of drug use or herbal treatments that are known as Hemmer or inductors of CYP3A4, can increase the metabolism of Tacrolimus."</seg>
<seg id="1451">"it is advisable to change the Tacroligraphy, to monitor the CYP3A metabolism, to monitor the CYP3A metabolism."</seg>
<seg id="1452">"a strongly pronounced exchange effect was developed with Antimyotika as Ketoconazol, Fluconazol, Itraconazol and preventazol as well as well as with the Macromedia antibiotics."</seg>
<seg id="1453">"respiratory studies, that the increase of the blood pressure is mainly from the increased bioavailability of Tacrolimus, due to the hemisphere of the gastrointestinal tract, resulting from the hemisphere of the gastrointestinal function."</seg>
<seg id="1454">"highly dosically Prednisolon or methylprednisolon, how to increase the concentration of Tacrolimus, can increase the concentration of Tacrolimus in blood."</seg>
<seg id="1455">Effect of Tacrolimus is known as CYP3A4-Hemmer. therefore the current application of Tacrolimus is known as CYP3A4-Hemmer.</seg>
<seg id="1456">"in this case, Tacrolimus the Clearance of Sterilization, and that the Hormonexposition can increase action, is particularly appreciated."</seg>
<seg id="1457">"the results of the animal are shown that the Tacrolimus are potential to reduce the Clearance of Nobarbital and phenazon, and its half-time period."</seg>
<seg id="1458">The results of a small number of investigations on Transplantationspatiers provide no indication that under Tacrolimus compared to other immune disorders.</seg>
<seg id="1459">"in utero Exposition, recommends a monitoring of the new patient to the harmful effects of Tacrolimus (especially in terms of its use)."</seg>
<seg id="1460">There is the risk of a spring (&lt; week 37) and a hypercardial of Neurology (Inzionale 8 of 111 Neubuch).</seg>
<seg id="1461">The real-effective profile of immunolicva can often occur due to the land disease of the patient and the affected treatment with a multitude of other drugs.</seg>
<seg id="1462">"following the side effects after their frequency are listed: very frequently (≥ 1 / 10, ≤ 1 / 10), occasionally (≥ 1 / 100, ≤ 1 / 100), rare (≥ 1 / 1,000, ≤ 1 / 1,000), rare (≤ 1 / 10,000, ≤ 1 / 1,000), rare (frequency on the available data is not abable)."</seg>
<seg id="1463">"hemical disorders of the heart disease, carcinogenic and cardiovascular diseases, myocardiopathy, myocardiac disease, superipherals in EKG, abomes in EKG, abide heart and pulse rate"</seg>
<seg id="1464">"symptoms of diarrholism and worsenation, anomation, pain, pain, pain, pain, pain, pain, pain, pain, pain, and worms of stomach cancer."</seg>
<seg id="1465">"infections and parasites as well as other high-effective immunosva is treated in patients who are treated with Tacrolimus, the Anaesthesia (viral, bacterial, mykotic, protozoale)."</seg>
<seg id="1466">Cases of BK-virus-associated Nephropathy and JC-virus-associated Diagnosis (PML) were reported in patients under immunotherapy therapy including therapy with Advagraf.</seg>
<seg id="1467">"for more information, please log in using your e-mail address and your password.:"</seg>
<seg id="1468">"due to its high molecular weight, its low water-soluble and high conduction of blood cells and plasma can be assumed that the Tacrolimus does not dialysis."</seg>
<seg id="1469">The effects of the attacks on the molecular level is the effects of Tacrolimus by his Binding to a cytosolial protein (FKBP12) which is responsible for the connection of the connection in the cell.</seg>
<seg id="1470">This leads to a calciumatious hemispheres of signal transductive due to the T cell cell and prevents the transcription of a certain number of Lymphokin-Ges.</seg>
<seg id="1471">"Tacrolimus, the activation of the T cells and the T-helper cells of the B cells, the formation of Lymphokinen (such as interleukin-2, interleukin-3 and interferon) as well as the expression of the interleukin-2 recipes."</seg>
<seg id="1472">12 unapproved loss provisions within the first 24 weeks in the Advagraf Group (N = 237) 32.6% and in the Prograf Group (N = 234) 29.3%.</seg>
<seg id="1473">"the patients-survival rates after 12 months over 89,2% for Advantraf and 90.8% for Prograf; in the Advagraf arm, 25 (14 women, 11 men) and in the Prograf arm 24 (5 women, 19 men) deaths."</seg>
<seg id="1474">Kidney transplantation The effectiveness and safety of Advagraf and Prograf was compared to combination with Mycophenolatmofetil (MMF) and cornerstones at 667 de novo kidney transplantation.</seg>
<seg id="1475">"the patient survival rates after 12 months over 96,9% for Advantraf and 97,5% for Prograf; in the Advagraf arm, 10 (3 women, 7 men) and in the Prograf arm 8 (3 women, 5 men) deaths."</seg>
<seg id="1476">"the effectiveness and security of Prograf, Ciclosporin and Advagraf, each in combination with basilimab-antiquinduction, MMF and cornerstones, at 638 de novo kidney transplantation compared to 638 de novo kidney transplantation."</seg>
<seg id="1477">"(N = 214), 15,1% in the Advantraf Group (N = 214), 15,1% in the Ciceberg group (N = 212) and 17.0% in the Ciclosporin-group (N = 212)."</seg>
<seg id="1478">"the difference was -3.0% (Advantraf- Ciclosporin) (95.7%, 4.0%]) for Advantraf vs Ciclosporin and -1,9% (Prograf-Ciclosporin) (95.7%, 5.7%]) for Prograf vs Ciclosporin."</seg>
<seg id="1479">"the Advantraf-arm, 3 (Men), in Prograf arm 10 (3 women, 7 men) and in Ciclosporin-arms 6 (3 women, 3 men) deaths."</seg>
<seg id="1480">"the results of the primary immunologram with Tacrolimus, in the form of twice every day in the form of corneal transplantations in the form of twice daily due to Pankee, lung and intestinal inflammation."</seg>
<seg id="1481">"175 periods of transplant patients, in 475 patients who had taken a Pankreastranquitoes, and in 630 cases are used as a priorient immunity."</seg>
<seg id="1482">"in total, the security profile of orological Prograf in these research studies have been applied in the major studies in which Prograf in liver, kidney and cardiovascular disease was applied to the primary immune immune system."</seg>
<seg id="1483">"results appear ordered" "by relevance" "or" "by date" "(publication date),"</seg>
<seg id="1484">"in the first year after the Transplantation, the bronchitis obliteral syndrome, was less often to observe (2,86% versus 8,57%)."</seg>
<seg id="1485">"the survival rate after a year was 80.8% in the Tacrolimus- and 83% in the Ciclosporin-group (Treede et al., 3rd ICI San Diego, USA, 2004; Abstract 22)."</seg>
<seg id="1486">"compared with Tacrolimus, patients came into 21,7% of cases in the emergence of a bronchitis Oblessans compared to 38,0% of Ciclosporin (p = 0,025)."</seg>
<seg id="1487">"the number of cases in which of Ciclosure in the Tacrolimus had to be significantly (n = 13), was significantly greater (p = 0,02), was significantly higher (p = 2) (Keenan et al., Ann Thoracic Surg 1995; 60: 580)."</seg>
<seg id="1488">"the number of cases where there was no acute transcription rate, after 6 months (57,7% versus 33.8%) and after 1 year (50% versus 33.3%) and after 1 year (50% versus 33.3%) and after 1 year (50% versus 33.3%) and after 1 year (50% versus 33.3%) and after 1 year (50% versus 33.3%)."</seg>
<seg id="1489">"in a study, the frequency of a bronchitis obliteral-literary syndroms are significantly lower."</seg>
<seg id="1490">Pankreastransplantation An multidisciplinary study with orological Prograf was performed at 205 patients who performed at the same time of a randomized method and kidney transplant (n = 102) or Ciclosporin (n = 102).</seg>
<seg id="1491">The orally initialdose (by protocol) of Tacrolimus was 0.2 mg / kg / kg / day and has been moved to the sea level of 8 to 15 ng / ml on 5.</seg>
<seg id="1492">"after 10 years, the clinical results of a cornerstone study associated with orological Prograf became the priorization of corneal transplantation (65 only intestine, 75 liver and intestines and 25 multivisal transcendations) under Tacrolimus and Prednisone of 75% to 1 year, 5% after 5 years and 42% after 10 years."</seg>
<seg id="1493">"methods for the early detection of epstein-barr (EBV) and CMV infections, bone markings, additional gift of the interleukin-2-Antagonists (Abu-Elmagd et al., Ann (g 2001; 234: 404)."</seg>
<seg id="1494">Factors such as a low hemmatocritation and low protein concentration that can lead to an increase of unisonoids; or by treatment with correlation of the metastoids should be responsible for the transplantation.</seg>
<seg id="1495">"on the other hand, the Tacrolimus is almost completely metabolized, with the disappearance mainly on the Galle."</seg>
<seg id="1496">"in the ratio 1: 1 (mg: mg), the systemic Exposition of Tacrolimus (once every day), the systemic Exposition of Tacrolimus (AUC0-24) was found in the ratio of 10% lower than in Prograf."</seg>
<seg id="1497">"in the first two weeks after transplantation, during the first two weeks after Transplantation, followed the first two weeks after transplantation."</seg>
<seg id="1498">"21 For the treatment of adult patients with transplantation, compared to other immune disorders, there are no clinical data for the retardized formulation formagraf."</seg>
<seg id="1499">"further factors affecting the risk of such diseases are already existing heart, a treatment with correlation, hypertension, kidney or liver function dysfunction, infections, fluid overload and oils."</seg>
<seg id="1500">"28 unapproved disinfection within the first 24 weeks in the Advagraf Group (N = 237) 32,6% and in the Prograf Group (N = 234) 29,3%."</seg>
<seg id="1501">"the effectiveness and security of Prograf, Ciclosporin and Advagraf, each in combination with basilimab-antiquinduction, MMF and cornerstones, at 638 de novo kidney transplantation compared to 638 de novo kidney transplantation."</seg>
<seg id="1502">"hard disks, boardial condured-orange juice, printed in red ink on the grilled red capacitor with" 5 mg "and the ornaments capsule with" "a 687" "they contain white powder."</seg>
<seg id="1503">"in the first two weeks after transplantation, during the first two weeks after Transplantation, followed the first two weeks after transplantation."</seg>
<seg id="1504">"37 For the treatment of adult patients with transplantation, compared to other immune disorders, there are no clinical data for the retardized formulation formagraf."</seg>
<seg id="1505">"further factors affecting the risk of such diseases are already existing heart, a treatment with correlation, hypertension, kidney or liver function dysfunction, infections, fluid overload and oils."</seg>
<seg id="1506">"in the first 24 weeks in the Advagraf Group (N = 237) 32,6% and in the Prograf Group (N = 234) 29,3%."</seg>
<seg id="1507">"the effectiveness and security of Prograf, Ciclosporin and Advagraf, each in combination with basilimab-antiquinduction, MMF and cornerstones, at 638 de novo kidney transplantation compared to 638 de novo kidney transplantation."</seg>
<seg id="1508">"in a total of 34 patients from Ciclosure in the Tacrolimus, during only 6 Tacrolimus patients, a other therapy required (Bechstein et al., Transplantation 2004; 77: 1221)."</seg>
<seg id="1509">"after 10 years, the clinical results of a cornerstone study associated with orological Prograf became the priorization of corneal transplantation (65 only intestine, 75 liver and intestines and 25 multivisal transcendations) under Tacrolimus and Prednisone of 75% to 1 year, 5% after 5 years and 42% after 10 years."</seg>
<seg id="1510">"on the other hand, the Tacrolimus is almost completely metabolized, with the disappearance mainly on the Galle."</seg>
<seg id="1511">Risk management plan is obligated to be accepted as well as in version 3.2 of the risk management plan (RMP) have been accepted as well as in version 3.2 of the risk management plan (RMP).</seg>
<seg id="1512">"in accordance with the CHMP guidance line to the risk of risk management systems for drug use, the updated RMP simultaneously must be submitted by the next four different security report (Periodic Safety Update report, PSUR)."</seg>
<seg id="1513">"perhaps you will receive Advagraf also to treat a reduction of your liver, kidney or heart transplantats or another."</seg>
<seg id="1514">"if you have other medicines or pharmacist, you can take other medicines or pharmacist if you have to take other medicines or to be recently used if it is not possible to use other medicines or medicinal herb supplements."</seg>
<seg id="1515">"Amilorid, Triamteren or Spironolacton), certain pain relief (so-called non-astrology antiphlogistika as Ibuprofen), antioagulthood or medicines for treatment of diabetes mellitus."</seg>
<seg id="1516">Pregnancy and downtime If a pregnancy is planned or already exists, ask you before taking your doctor or pharmacist to advice. "</seg>
<seg id="1517">Transport and the filling of machines you may not be able to use the tax of a vehicle or tools if you want to see if you want to make use of Advagraf.</seg>
<seg id="1518">Important information on certain other components of Advantraf Please take the Advantraf only after returning with your doctor if you have known under a incompatibility of certain statutes.</seg>
<seg id="1519">"make sure you are always the same Tacrolimus medicines if you want to solve your recipe, unless your physician has expressly agreed to add a change of the Tacrolimus medicines."</seg>
<seg id="1520">"if you receive a medicine, the appearance of your skin or the dosing instructions, please contact us as soon as possible with your treatments doctor or pharmacist, that ensures that you get the correct medication."</seg>
<seg id="1521">"in this case, your doctor can determine the correct dose and of time to time, he has to determine the blood tests."</seg>
<seg id="1522">"if you have taken a larger amount of Advancraf, you should have to have a larger amount of Advantraf. if you have created a larger amount of Advancraf, you are looking for your doctor or the emergency department of the closest hospitals."</seg>
<seg id="1523">"if you have forgotten the supplements of Advagraf If you have forgotten the capsules, please take this time at the same day as early as early as possible."</seg>
<seg id="1524">"if you have to leave the dose of Advagraf Cancel reply to the treatment with Advagraf, the risk of a separation of your transcendations."</seg>
<seg id="1525">"they are printed with a" "647" "and their oranges are filled with" "647" "and their oranges underlined with" "647" "and their oranges are filled with white powder."</seg>
<seg id="1526">"results appear ordered" "by relevance" "or" "by date" "(publication date),"</seg>
<seg id="1527">"Advagraf 5 mg hard disks, plardized, the grilled top with a" "687" "and their oranges are filled with" "a 687" "and their oranges are filled with" "a 687" "and their oranges are filled with white powder."</seg>
<seg id="1528">"sorry, there is no translation for this news-article."</seg>
<seg id="1529">Slovenská republika Astellas Pharma s.r.o., Cala ač ná zlogika Galváná 15 / C SK- 821 04 Bratislava 2 Tel: + 421 2 4444 2157 "</seg>
<seg id="1530">"Advate shall be used for treatment and prevention of blood vessels in patients with Hammophilie A (one by the lack of factor VIII ary, alleged blood flow interference)."</seg>
<seg id="1531">The dosage and frequency of the application can be applied to the treatment of blood cells or to prevent blood sugar at surgical procedures.</seg>
<seg id="1532">"patients with Hammophilie A suffer from a factor VIII, lack of blood pressure, such as blood vessels in the joints, muscles or inner organs."</seg>
<seg id="1533">"Octocog alfa is not made of human plasma, but according to a method that is called" recombinant DNA technology. "</seg>
<seg id="1534">"it is produced by a cell that is produced by a cell (DNA), which was applied to the formation of the human Gerinnacle factor VIII."</seg>
<seg id="1535">"Advate is one of the other in the European Union called recombinate, similar to which the medicines has no proteins in proteins or animal origin."</seg>
<seg id="1536">"in three additional studies in patients with severe damage to medium Hammophilie A, among a study with 53 children under six years, the application of the drug has been examined."</seg>
<seg id="1537">"in the main study, the effectiveness of Advances in the prevention of blood vessels in 86% of 510 new blood vessels were awarded with" excellent "or with" good "." "</seg>
<seg id="1538">"the most common side effects of disate (observed in 1 to 10 of 100 patients) are didel, headaches, pyrexie (fever) and the formation of antibodies against factor VIII."</seg>
<seg id="1539">"it may not be applied to patients, which may possibly be oversensitive (allergic) against the human brain factor VIII, mouse, or Hamsteroid or another of the other components."</seg>
<seg id="1540">"in March 2004, the European Commission to the European Commission of Baxter AG is a permit for the insolvency of Advances in the whole European Union."</seg>
<seg id="1541">Dosage The dosage and duration of the Substitutions after the severity of the factor VIII; after the place and the extent of blood and the clinical condition of patients.</seg>
<seg id="1542">"in the following hemorrhagical events, the factor of VIII activity will not be found under the indicated plasma bars (in% of the standard or in order / dl)."</seg>
<seg id="1543">Injection all 12-24 hours (8-24 hours at patients under 6 years) for 3-4 days or longer repeat until the pain and the acute impairment are eliminated.</seg>
<seg id="1544">Injections all 8-24 hours (6-12 hours at patients under 6 years) repeat until the risk for patients preached.</seg>
<seg id="1545">"during the treatment of treatment, the determination of injunctions and frequency of injections is an appropriate determination of the factor VIII."</seg>
<seg id="1546">"individual patients can be achieved in their reaction to factor VIII, different in vivo recovery, and different half-value times."</seg>
<seg id="1547">"3 Prophylaxis of the long term prophylaxis of blood vessels in patients with severe hammophilie A, cans between 20 and 40 copies of factor VIII per kg body weight in distance from 2-3 days."</seg>
<seg id="1548">"if the expected factor of VIII plasma systems can't be achieved, or if the blood has not be carried out with a reasonable dose, a test is carried out to obtain an Inhibitor."</seg>
<seg id="1549">"in patients with high Inhibitorisation, it is possible that the factor VII therapy is not effective, so that other therapeutic actions must have to do."</seg>
<seg id="1550">"at the same time, a maximum injection rate of 10 ml / min should not be exceeded."</seg>
<seg id="1551">The formation of neutral antibodies (Inhibitors) against factor VIII is a well known cure for treatment of patients with Hammophilie A.</seg>
<seg id="1552">This Inhibitors are always opposed to prokoagultural activity of factor VIII (B.E.) per ml plasma with modified Bethesda Assay are quantified.</seg>
<seg id="1553">The risk of inhibitors to develop correlated with the extent of exposition towards factor VIII. the risk within the first 20 exhibits at the largest is and of genetic and other factors.</seg>
<seg id="1554">"for pre-treated patients (PTP) with more than 100 exposition and anamnesia-known Inhibitordevelopment was observed, according to a recombinant factor VIII-product to another, the resignation of (low tightly) Inhibitors."</seg>
<seg id="1555">Due to the rare beauty of the Hammophilie A with women are no experiences on the application of factor VIII during pregnancy and downtime.</seg>
<seg id="1556">"in the same number of patients, ADRs were inhibitors against factor VIII (5 patients) that had a higher risk to education of inhibitors, headaches (5 patients), fever, and Schwindel (each patients)."</seg>
<seg id="1557">"very often (≥ 1 / 10), often (≥ 1 / 100 to &lt; 1 / 10), occasionally (≥ 1 / 1,000 to &lt; 1 / 100), rare (≥ 1 / 1,000 to &lt; 1 / 1,000), very rare &lt; 1 / 10,000), very rare &lt; 1 / 10,000), very rare &lt; 1 / 10,000), not known (frequency based on the available dates)."</seg>
<seg id="1558">A) The percentage of patients was calculated using the amount of individual patients (234) calculations.</seg>
<seg id="1559">The blood pressure was taken during the whole time and both the factor VIII- mirrors in plasma and the Clearance Rate were sufficient.</seg>
<seg id="1560">Clinical trials with ADVATE to 145 children and adults 2 with diagnosed hard to medium Hämophilie A (FVIII ≤ 2%) and previous exposition towards factor VIII- concentrates (≥ 150 days) showed a low inhibitortiter (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1561">"in addition, the 53 pädiaternal patients with a age of 6 years and diagnosed hard to medium Hammophilie A (FVIII ≤ 2%) after previous exposition towards factor VIII- concentrates (≥ 50 days)."</seg>
<seg id="1562">"in case of non-treated patients of a current clinical study, 5 of 25 (20%) with ADVATE (20%) were treated with ADVATE (20%)."</seg>
<seg id="1563">The immunologation of patients on traces of conical protectomy has been analyzed by the investigation of the antibodies against these proteins, laboratory parameters and associated side effects. "</seg>
<seg id="1564">"a patient showed both a statistical model of the anti-Cho-cell protein, otherwise, however, no signs or symptoms occur on a allergic reaction or a oversensitivity."</seg>
<seg id="1565">"in four patients the occurrence of Urtikaria, Pruritus, skin, and increased number of eosinophiles Granulozyed with several repeated product expositions in the framework of the study."</seg>
<seg id="1566">"7 How to the other intravenous products was reported at ADVATE, including anodized type, including anodical / annicottoider reactions (frequency not known)."</seg>
<seg id="1567">Activated factor VIII is used as a cofactor for activated factor IX and accelerates the formation of activated factor X from factor X.</seg>
<seg id="1568">All pharma studies with ADVATE were performed at pre-treated patients with severe or medium Hammophilie A (base value of factor VIII-activity ≤ 2%).</seg>
<seg id="1569">The most important result from a cross-Over study with ADVATE in 100 previously treated patients or &gt; 10 years and are listed in the bottom of the table.</seg>
<seg id="1570">"table 3: drivers of supplier power in the country in question, 2008-2019 (US dollars)"</seg>
<seg id="1571">"non-clinical data based on the studies of security-harmakologie, to acute, repeated and local toxicity, show no special risk for humans."</seg>
<seg id="1572">Each individual packet consists of a diameter bottle with 5 ml solution (both glass type I with chlorobutyl-rubber sponge) and one device to recitation (BAXJECT II).</seg>
<seg id="1573">"if the product still can be used in the fridge, both filter bottles with ADVATE powder and solvents from the refrigerator to be found in room temperature (between 15 and 25 ° C)."</seg>
<seg id="1574">A significant increase of pulsfrequency can be increased by slow or time-determination of the injections usually again (see Sections 4.4 and 4.8).</seg>
<seg id="1575">"14 Prophylaxis of the long term prophylaxis of blood vessels in patients with severe hammophilie A, cans between 20 and 40 copies of factor VIII per kg body weight in distance from 2-3 days."</seg>
<seg id="1576">Due to the rare beauty of the Hammophilie A with women are no experiences on the application of factor VIII during pregnancy and downtime.</seg>
<seg id="1577">"children (aged 1 month - 2 years), children (in age of 1 month - 2 years), young children (in age of 12-16 years), adults (over 16 years), adults (over 16 years)"</seg>
<seg id="1578">Clinical trials with ADVATE to 145 children and adults 4 with diagnosed hard to medium Hämophilie A (FVIII ≤ 2%) and previous exposition towards factor VIII- concentrates (≥ 150 days) showed a low inhibitortiter (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1579">"18 As with other intravenous products was reported at ADVATE, including anodized type, including anodical / annicottoider reactions (frequency not known)."</seg>
<seg id="1580">"table 3: drivers of supplier power in the country in question, 2008-2019 (US dollars)"</seg>
<seg id="1581">"non-clinical data based on the studies of security-harmakologie, to acute, repeated and local toxicity, show no special risk for humans."</seg>
<seg id="1582">"25 Prophylaxis of the long term prophylaxis of blood vessels in patients with severe hammophilie A, cans between 20 and 40 copies of factor VIII per kg body weight in distance from 2-3 days."</seg>
<seg id="1583">"children (aged 1 month - 2 years), children (in age of 1 month - 2 years), young children (in age of 12-16 years), adults (over 16 years), adults (over 16 years)"</seg>
<seg id="1584">Clinical trials with ADVATE at 145 children and adults 6 with diagnosed hard to medium Hämophilie A (FVIII ≤ 2%) and previous exposition towards factor VIII- concentrates (≥ 150 days) showed a low inhibitortiter (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1585">"29 How to use other intravenous products, the allergic types of allergic reactions are not known to the allergic reactions (frequency, etc.)."</seg>
<seg id="1586">"non-clinical data based on the studies of security-harmakologie, to acute, repeated and local toxicity, show no special risk for humans."</seg>
<seg id="1587">"36 Prophylaxis of the long term prophylaxis of blood vessels in patients with severe hammophilie A, cans between 20 and 40 copies of factor VIII per kg body weight in distance from 2-3 days."</seg>
<seg id="1588">"young children (aged 1 month - 2 years), children (in age of 1 month - 2 years), young children (in age of 12-16 years), adults (over 16 years), adults (over 16 years)"</seg>
<seg id="1589">Clinical trials with ADVATE at 145 children and adults 8 with diagnosed hard to medium Hämophilie A (FVIII ≤ 2%) and previous exposition towards factor VIII- concentrates (≥ 150 days) showed a low inhibitortiter (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1590">"40 As with other intravenous products was reported in ADVATE, including anodized type, including anodical / annicottoider reactions (frequency not known)."</seg>
<seg id="1591">"non-clinical data based on the studies of security-harmakologie, to acute, repeated and local toxicity, show no special risk for humans."</seg>
<seg id="1592">"47 prophylaxis for long term prophylaxis of blood vessels in patients with severe hammophilie A, cans between 20 and 40 copies of factor VIII per kg body weight in distance from 2-3 days."</seg>
<seg id="1593">"children (aged 1 month - 2 years), children (in age of 1 month - 2 years), young children (in age of 12-16 years), adults (over 16 years), adults (over 16 years)"</seg>
<seg id="1594">Clinical trials with ADVATE at 145 children and adults 10 with diagnosed hard to medium Hämophilie A (FVIII ≤ 2%) and previous exposition towards factor VIII- concentrates (≥ 150 days) showed a low inhibitortiter (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1595">"51 As with other intravenous products was reported by ADVATE, including anodized type, including anodical / annicottoider reactions (frequency not known)."</seg>
<seg id="1596">"non-clinical data based on the studies of security-harmakologie, to acute, repeated and local toxicity, show no special risk for humans."</seg>
<seg id="1597">58 prophylaxis for long-term prophylaxis of blood vessels in patients with severe hammophilie A shall be given between 20 and 40.</seg>
<seg id="1598">"11 Neudorf (in the age of 0-1 month), small children (in age of 1 month - 2 years), young children (in age of 12-16 years), adults (over 16 years), adults (over 16 years)"</seg>
<seg id="1599">Clinical trials with ADVATE to 145 children and adults 12 with diagnosed hard to medium Hämophilie A (FVIII ≤ 2%) and previous exposition towards factor VIII- concentrates (≥ 150 days) showed a low inhibitortiter (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1600">"62 As with other intravenous products was reported by ADVATE, including anodized type, including anodical / annicottoider reactions (frequency not known)."</seg>
<seg id="1601">"non-clinical data based on the studies of security-harmakologie, to acute, repeated and local toxicity, show no special risk for humans."</seg>
<seg id="1602">"Pharmacvigilance-system The application owner has to ensure that a pharmaceutical convigilance system, such as in the section 1.1 of the capital of 1.8.1, in which the product is used during the entire time, in which the product is on the market is in power."</seg>
<seg id="1603">"as in the CHMP Directive, the risk management plan for Human-drugs will be submitted at the same time with the next Periodic Safety Update Report (PSUR)."</seg>
<seg id="1604">"• If a new information contained, the influence on the valid security shines, the pharmaceutical covigilance plan or measures to risk reduction, • within 60 days after an important event (in terms of the pharmaceuticals, or in order to risk reduction)"</seg>
<seg id="1605">1 filter bottle with ADVATE 500 i.E Octocog alfa, 1 throughput bottle with 5 ml sterilized water for injectors purposes, 1 BAXJECT II-Medical product. "</seg>
<seg id="1606">1 filter bottle with ADVATE 1000 i.E Octocog alfa, 1 throughput bottle with 5 ml sterilized water for injectors purposes, 1 BAXJECT II-Medical product "</seg>
<seg id="1607">Special thanks to the application of ADVATE is necessary you should inform your doctor if you have recently developed by factor VIII products, especially if you have developed inhibitors. "</seg>
<seg id="1608">"these symptoms may be able to close the signs of an angible drawing, which can vary in the following symptoms: extreme Schwindel, consciousness-loss and extreme respiratory diseases."</seg>
<seg id="1609">"if you have other medicines, please inform your doctor if you take other medicines or before recently, even if it is not necessary."</seg>
<seg id="1610">"your doctor will calculate your dose of ADVATE (in international units or etc), depending on your physical activity and your body weight, and whether it is used for prevention or treatment of blood."</seg>
<seg id="1611">"patients, factor factor VIII-Inhibitors may develop in your plasma with ADVATE, it could not be achieved by the development of factor VIII- to the development of factor VIII-."</seg>
<seg id="1612">"in conjunction with operations, catheter infectomy, lower number of red blood cells and joints, extended blood pressure after the removal of a Draft, and postoperative hemisphome."</seg>
<seg id="1613">"rare side effects Since the introduction of the drug has been developed over heavy, potential life-threatening reactions (Anaesthesie) and other allergic reactions (see above)."</seg>
<seg id="1614">Inform your doctor if one of the correct side effects you can differ considerably or if you are aware of the side effects that are not listed in this package.</seg>
<seg id="1615">Portugal Baxter Médico Farmacêutica LDA Sintra Business Park Zona Industrial da Abrunheira, Edifício 10 P-2710-089 Sintra Tel: + 351 21 925 25 00 "</seg>
<seg id="1616">"• The BAXJECT II are not used when its sterile barrier and resignation date. • The BAXJECT II is not used when its sterile barrier is broken, its packaging is damaged or signs of a manipulation, as in the symbol."</seg>
<seg id="1617">"important notice: • Not specified, before you have received the special training of your doctor or your nurse."</seg>
<seg id="1618">The solution should be slowly associated with an infusion of the patient and 10 ml per minute.</seg>
<seg id="1619">"106 In case of blood pressure, the factor of blood circulation should not be used in the appropriate time period (in% or in order / ml)."</seg>
<seg id="1620">"these symptoms may be able to close the signs of an angible drawing, which can vary in the following symptoms: extreme Schwindel, consciousness-loss and extreme respiratory diseases."</seg>
<seg id="1621">"patients, factor factor VIII-Inhibitors may develop in your plasma with ADVATE, it could not be achieved by the development of factor VIII- to the development of factor VIII-."</seg>
<seg id="1622">"physical side effects Juckreiz, amplify, irritating, migration, migration, migration, migration, migration, disinfants, abdominal throat, abdominal throat, abdominal cord, abdominal cord, disinfectful, snorkeling, disinfectful, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, body,</seg>
<seg id="1623">"116 In case of blood pressure, the factor of blood circulation should not be used in the appropriate time period (in% or in order / ml)."</seg>
<seg id="1624">"these symptoms may be able to close the signs of an angible drawing, which can vary in the following symptoms: extreme Schwindel, consciousness-loss and extreme respiratory diseases."</seg>
<seg id="1625">"patients, factor factor VIII-Inhibitors may develop in your plasma with ADVATE, it could not be achieved by the development of factor VIII- to the development of factor VIII-."</seg>
<seg id="1626">"126 In case of blood pressure, the factor of blood circulation should not be used in the appropriate time period (in% or in order / ml)."</seg>
<seg id="1627">"these symptoms may be able to close the signs of an angible drawing, which can vary in the following symptoms: extreme Schwindel, consciousness-loss and extreme respiratory diseases."</seg>
<seg id="1628">"patients, factor factor VIII-Inhibitors may develop in your plasma with ADVATE, it could not be achieved by the development of factor VIII- to the development of factor VIII-."</seg>
<seg id="1629">"136 In case of blood pressure, the factor of blood circulation should not be used in the appropriate time period (in% or in order / ml)."</seg>
<seg id="1630">"these symptoms may be able to close the signs of an angible drawing, which can vary in the following symptoms: extreme Schwindel, consciousness-loss and extreme respiratory diseases."</seg>
<seg id="1631">"patients, factor factor VIII-Inhibitors may develop in your plasma with ADVATE, it could not be achieved by the development of factor VIII- to the development of factor VIII-."</seg>
<seg id="1632">"146 In the case of blood circulation should not be used in the appropriate time period, not under the indicated plasma values (in% or in order / ml)."</seg>
<seg id="1633">"these symptoms may be able to close the signs of an angible drawing, which can vary in the following symptoms: extreme Schwindel, consciousness-loss and extreme respiratory diseases."</seg>
<seg id="1634">"patients, factor factor VIII-Inhibitors may develop in your plasma with ADVATE, it could not be achieved by the development of factor VIII- to the development of factor VIII-."</seg>
<seg id="1635">"physical side effects Juckreiz, amplify, irritating, migration, migration, migration, migration, migration, disinfants, abdominal throat, abdominal throat, abdominal cord, abdominal cord, disinfectful, snorkeling, disinfectful, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, snorkeling, body,</seg>
<seg id="1636">"rare side effects Since the introduction of the drug has been developed over heavy, potential life-threatening reactions (Anaesthesie) and other allergic reactions (see above)."</seg>
<seg id="1637">"156 In case of blood pressure, the factor of blood circulation should not be used in the appropriate time period (in% or in order / ml)."</seg>
<seg id="1638">"based on the first registered data, the CHMP will continue to continue to continue as positive as positive, but in consideration that the safety profile of the following reasons can be monitored:"</seg>
<seg id="1639">"therefore the CHMP on the basis of the safety standards of ADVATE, which is required by PSURs all 6 months, we decided that the registration owner of the PSURs is needed in 5 years."</seg>
<seg id="1640">"in December 2008, Genevx molecular Limited was officially founded in the Committee of Humanist (CHMP) officially declared that the company is responsible for the Inherin to the treatment of Li-Fraumeni cancer."</seg>
<seg id="1641">"normally, the chest is the chest, the brain, the bone or the crossover (tissue, the other structures in the body produces)."</seg>
<seg id="1642">This is a type of virus that has changed genetically modified that there is a gene in the cells of the body.</seg>
<seg id="1643">"at the virus in Adexin is a" Adenovirus "," that has been changed, that there was no copies of themselves, and therefore no infections in humans. "</seg>
<seg id="1644">"" "I would like to be reminded by SMS, if SexyJuani is on-line."</seg>
<seg id="1645">"the p53 protein, which is formed from the non-defect in the human body, normally to be damaged DNA and to kill the cells when the DNA is not reproduced."</seg>
<seg id="1646">"with Li-Fraumeni cancer, the p53 protein is not correct, and the cancer cells can continue to grow and share."</seg>
<seg id="1647">"the company put data from a study with a patient before the Li-Fraumeni cancer in the area of subconstruction, in the bone and the brain."</seg>
<seg id="1648">"after the CHMP answers the answers to him, were still some questions."</seg>
<seg id="1649">"based on the testing of the initial telephone documents, the CHMP was sent to 120 a list of questions that sent to the company."</seg>
<seg id="1650">"according to the CHMP, it was not sufficient for the injection of Advexin in Li-Fraumeni tumors of the patient."</seg>
<seg id="1651">"the Committee had concerns concerns about the processing of the drug using in the body, the type of the drug, as well as the safety of the drug."</seg>
<seg id="1652">"in addition, the company is not sufficient to be able to be able to be able to reliable, and that there is neither for the environment nor the environment for people who come into small contact with the patient."</seg>
<seg id="1653">"the company continued the CHMP not of which the return consequences for patients, that currently at clinical trials or" Compassionate Use "programs can participate in clinical trials or" Compassionate Use "programs."</seg>
<seg id="1654">"in case of active substances, the tablets thus set that the tablets are thus set that one of the effective components immediately and the other slowly over some hours."</seg>
<seg id="1655">"aerobze is used to treat the symptoms of seasonal allergiic Rhinitis (hypocrisy, through a allergic against pollen infections) in patients with nasenlithosis (thin nose)."</seg>
<seg id="1656">"for adults and young children from 12 years, the recommended dose of aeronze twice a tablet that should be taken by a glass of water with or without food."</seg>
<seg id="1657">"the duration of the treatment should be as possible as possible as possible, as soon as the symptoms, above all the swelling of the nodes."</seg>
<seg id="1658">A treatment of more than 10 days is not recommended because the effects of the drug can be carried out using the nose.</seg>
<seg id="1659">"the main test dimensions were the changes of the heavy duty of the hypocrisy symptoms, which were treated by the patients before the treatment and during the 15-day treatment."</seg>
<seg id="1660">"during the study the patients had their symptoms all 12 hours in a diary, and with a standard skala, how hard the symptoms were in the last 12 hours."</seg>
<seg id="1661">"with regard of all hypocriss symptoms, except the consension of the nose does the patients, the aerosze took the patients, the aerospace symptoms over 40.0% compared with 35,9% compared to the patients who had pseudoephedrine alone."</seg>
<seg id="1662">"when only the swelling of the noodds was considered, the patients under aerosze a lens of 37.4% compared to 26.7% compared to 26.7% compared to 26.7% compared to the patients suffering."</seg>
<seg id="1663">"the most common side effects of aerosze (observed in 1 to 10 of 100 patients) are the most common side effects (Ruhelogens), respiratory, headaches, fatigue, Insomnie (sleep), sleep disorders, insomnia (sleep disorders), sleep disorders and nervous."</seg>
<seg id="1664">"for patients which may possibly be oversensitive (allergic) against Desloratadin, pseudoephedrine or a other substances that are not applied to allergies (a different medicines for treating allergies)."</seg>
<seg id="1665">"at the same time, aerobics may also be used in patients who are applied to a ENGWINKELGLAUCOM (increased risk of thyroid), heart disease or vessels (overflow of thyroid), or a risk of thyroid (hypersensitivity), or a risk of moromagonal attack."</seg>
<seg id="1666">"on 30 July 2007, the European Commission approved the European Commission to the company SP Europe."</seg>
<seg id="1667">"the tray can be taken with a glass of water, but it can be used in the whole process (i.e. without them to broken, or break down)."</seg>
<seg id="1668">Aerospace should be applied due to the absence of data for uncertainty and effectiveness (see section 5.1) not for children under 12 years.</seg>
<seg id="1669">The duration of the application is as possible as soon as possible and should not be treated by symptoms of symptoms.</seg>
<seg id="1670">"it is recommended to limit the application duration of 10 days, because at long term use the activity of pseudoephedrine with the time."</seg>
<seg id="1671">"after the fall of the swelling of the velling in the upper breathing, the treatment with Desloratadin as a monotherapy."</seg>
<seg id="1672">"as aerosze pseudoephedrine, the medicines also can be used in patients who are treated with a universal oxidase (Mao) -Hemmer, or within 2 weeks after the treatment of such therapy."</seg>
<seg id="1673">"this is based on the alphamimetical activity in combined application of pseudoephedrine, Pergoospitin, Pergoid, Lisurid, Lisurid, Erotic or nasal (phenyl propanolamine, ephedrine, Oxymetazolin, Napedrin, Oxymetazolin, Napier etc.)."</seg>
<seg id="1674">The safety and effectiveness of these combinators were not tested and the data is not tested and the data is not tested in order to comply with appropriate recommendations for the dosage.</seg>
<seg id="1675">"the safety and effectiveness of aerospace, patients with kidney or liver functions are not tested and the data is not tested and the data is not made out of appropriate recommendations for dosage."</seg>
<seg id="1676">Patients need to be informed that the treatment at the occurrence of a hypertension or a speedykarst or the palaces of neurological symptoms (such as headaches or a reduction of headaches) must be made.</seg>
<seg id="1677">Patients with cardiology • patients with cardiology • patients with myokardinfarches in Anamnese, diabetes mellitus, bladder inflammation or bronchoselmus in Anamnese. "</seg>
<seg id="1678">"at least 48 hours before the execution of matureal tests, as anti-histaminika is to prevent positive reactions to indications for future actions or in their extent."</seg>
<seg id="1679">"in the framework of clinical trials with Desloratadin, where Erygomycin or Ketoconazol is used, however, however, there were no evidence to depreciation or changes of the plasma concentration of Desloratadin."</seg>
<seg id="1680">"in the results of the psychomotor tests, there were no significant differences between the units with Deslorate and associated with Placebo treated patients."</seg>
<seg id="1681">"for the metabolism of Desloratadin, enzymes was not identified, that the exchange of other drugs cannot be excluded."</seg>
<seg id="1682">"Desloratulates in-vivo CYP3A4, and in-vitro studies have shown that the medicine CYP2D6 are not inhibited and neither a substrate nor a inhibitor of the P glycol."</seg>
<seg id="1683">"the uncertainty of the application of aerosze during pregnancy is not sufficient, experience from a large number of persons, however, does not increase the frequency of mischief in comparison to the frequency of normal population."</seg>
<seg id="1684">"since the reproductive studies of animals are not always used on humans, and on the reason of the vasokonic properties of pseudoephedrine should not be applied in pregnancy."</seg>
<seg id="1685">"however, patients should be discussed in very rare cases, that it can lead to an impairment of transport or the ability to serve machines."</seg>
<seg id="1686">"symptoms may vary between one ZNS depression (seduced, pharmacies, compression attention, cyanose, Koma, cardiovascular disease) and a ZNS stimulation."</seg>
<seg id="1687">"pain pain, anxiety, muscle, muscle and increased muscle tension, heart disease, respiration, irritation, irritation, irritation, irritation, irritation, pinnitus, pathology and hypertension or hypotonie."</seg>
<seg id="1688">"a ZNS Stimulation is particularly unlikely, as Atropin-typical symptoms (mouth dry, Pupillenstarre and - Dilatation, Hauts and gastrointestinal symptoms)."</seg>
<seg id="1689">"these complete set of proinflammatory cytokines such as IL-4, IL-6, IL-8, IL-8 and IL-13 from human Mastles / Basophiles, as well as the hemisphere of the expression of the Adult cells."</seg>
<seg id="1690">"in a single dose study with adults showed Desloratadin 5 mg no influence on standard measuring sizes of the flood, including the reduction of subjective throat or the tasks that are connected with the fats."</seg>
<seg id="1691">In controlled clinical trials was found in the recommended Dosage of 5 mg daily in the recommended Dosage of 5 mg daily.</seg>
<seg id="1692">"the orale application of pseudoephedrine in the recommended Dosage can be found in the recommended Dosage, such as an increase of blood pressure, a tykarmic or manifestations of a ZNS base."</seg>
<seg id="1693">It took 1.248 patients in age between 12 and 78 years with seasonal allergies and 414 patients.</seg>
<seg id="1694">"in both studies, the histaminantagonistic effectiveness of aerospace tablets, determined by the overall function of the symptoms (except in a monotherapy with pseudoephedrine), significantly higher than among a monotherapy with pseudoephedrine treatment."</seg>
<seg id="1695">The effectiveness of aerospace tablets are significantly higher than among a monotherapy with Desloratans via the 2-wreck treatment.</seg>
<seg id="1696">The effectiveness of aerospace tablets showed no significant differences in terms of gender, age or ethnical patient groups, no significant differences. "</seg>
<seg id="1697">"in the framework of a single dose study, Desloratadin is Desloratadin within 30 minutes after the delay in plasma."</seg>
<seg id="1698">"after the peroral application of aerospace and healthy subjects over 14 days, the flow rate of Desloratadin, 3-Hydroxydesloratadin and pseudoephedrine is 10."</seg>
<seg id="1699">"in the framework of a big makokinetic multi-study study, which was carried out with the formulation as a tablet to healthy adults."</seg>
<seg id="1700">"a components of interactivity study shows that the exposition (Cmax and Auc) of pseudoephedrine, according to the number of pseudoephedrine biosis was the exposition after the gift of an aerospace case."</seg>
<seg id="1701">"based on conventional studies on the conventional studies of the safety spharmakology, for toxicity and reproductionxizations, the preclinical data with Desloratadin are not special dangers for humans."</seg>
<seg id="1702">"the combination of no larger toxicity than their individual components, and the observed effects were included in the context with the ingredient of pseudoephedrine."</seg>
<seg id="1703">The combination of Loratadin / pseudoephedrine in a dosage of up to 150 mg / kg / day and an rabbits in a dosage of up to 120 mg / kg / day.</seg>
<seg id="1704">"March 2007 and in module 1.8.1 of certifications, the pharmaceutical covigilance system and works before and while the product is on the market."</seg>
<seg id="1705">"antihistaminika to prevent the allergic symptoms by making them that histamine, a body's own substance, its effect."</seg>
<seg id="1706">"aerobze tablets are symptoms that occur in connection with seasonal allergies (hypocrisp), such as Niesen, current or juckling nose, or juckling eyes at the same time of the nose."</seg>
<seg id="1707">20 The specific circumstances may be particularly sensitive compared to the mucous drugs pseudoephedrine which is included in this medicine.</seg>
<seg id="1708">"with the liver, thin layers of magnets, a bladder, a bladder, or the supply of the stomach, bronchoscoping, bronchoscoping, bronchospassive or the supply of the liver, a prostate or problems with the liver, the kidneys, or the bladder."</seg>
<seg id="1709">Inform your doctor if you have been diagnosed in the application of aerobze the following symptoms or disease: • Bluthoenes • heart surgery • heart disease and headaches or a reduction of existing headaches.</seg>
<seg id="1710">"if you have other medicines or pharmacist, you can take other medicines or pharmacist if you take other medicines or before going to be used if it is not necessary."</seg>
<seg id="1711">Transport and the use of machines for use in the recommended Dosage is not so that aerobze leads to Benommenities or the attention.</seg>
<seg id="1712">"if you have taken a larger amount of aerospace, you should have to be taken by your doctor or pharmacist, if you should have a larger amount of aerospace."</seg>
<seg id="1713">"if you have forgotten your medicine by aerobze, if you have forgotten a dose of time, get the application so soon as possible and contact the next dose."</seg>
<seg id="1714">"please inform your doctor or pharmacist, if one of the side effects you can choose from either side effects or side effects that are not found in this use."</seg>
<seg id="1715">"disease, disease, disease, disease, disease, appetite, appetite, appetite, appetite, fatigue, headache, sleep disorders, nervous system, nervous system, nervous system, nervous system, nervous system, nervous system, nervous system, nervous system, nervous system."</seg>
<seg id="1716">"pain, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety, anxiety,</seg>
<seg id="1717">"after the market launch of Desloratadin was very rare about cases of severe allergic reactions (breathing, pipes, nuts, nuts and swelling) or skin."</seg>
<seg id="1718">"about cases of cardiovascular disease, heart pain, abdominal pain, diarrative, diarrative, diarrative, diarrative, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarrhoea, diarratives,</seg>
<seg id="1719">"it is a 5 mg-tray, 5 mg- Lyophilix (solenoid), 2.5 mg- and 5 mg-melting tablets (tablets that can be used in mouth), 0.5 mg / ml-Sirup and as 0.5 mg / ml solution."</seg>
<seg id="1720">"for children in age from a to five years, the dose is 1.25 mg each daily, which was placed in the form of 2.5 ml syrup."</seg>
<seg id="1721">"for children in the age of six to eleven years, the dose is 2.5 mg each daily, either in the form of 5 ml Sirup."</seg>
<seg id="1722">Aerius was examined in eight studies with about 4 800 adults and adolescents with allergic rhinitis (including four studies in seasonal allergies and two studies in patients who also had asthma).</seg>
<seg id="1723">"the effectiveness was measured by the change of symptoms (Juckreiz, number and size of the squares, impairment of the sleeping, and the performance of the days) before and after the weekly purchase."</seg>
<seg id="1724">"there were other studies in order to make sense that the body of the Sirup, the solution to take and melt the melt into the same way as the tablets and the use of children is uncomfortable."</seg>
<seg id="1725">"in case of allergic rhinitis, when the results of all studies were taken, the two-week treatment with 5 mg Aerius were taken up to an average reduction of the symptoms of the symptoms of 12 to 26% compared to the patient who received a placebo."</seg>
<seg id="1726">"in the two studies at Urtikaria, the removal of the symptoms of the symptoms of the symptoms of symptoms of Aerius 58 and 67% compared with 40 and 33% compared with the placebo treated patients."</seg>
<seg id="1727">Aerius may not be applied to patients which may possibly be oversensitive (allergic) against Desloratadin, Loratadin or another of the other components. "</seg>
<seg id="1728">"in January 2001, the European Commission of SP Europe is a permit for the incoming of Aerius in the whole European Union."</seg>
<seg id="1729">"a tablet once daily, with one or without a meal, to treat the symptoms of allergic rhinitis (including intermittent and any allergic.) and Urtikaria (see below 3.1)."</seg>
<seg id="1730">There are restricted experience from clinical trials to the effectiveness of Desloratadin in adolescents from 12 to 17 years (see Sections 4.8 and 5.1).</seg>
<seg id="1731">The treatment of intermedically allergiical Rhinitis (occurrence of symptoms for less than 4 days per week or less than 4 weeks) should be completed according to the procedure of the symptoms.</seg>
<seg id="1732">Treatment of symptoms occur 4 or more days per week and more than 4 weeks) can be recommended for patients during the allergy time.</seg>
<seg id="1733">There are currently no product reviews. register Login Format: 1 × 50 ′ Science + Knowledge HD 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 31 next</seg>
<seg id="1734">"in a clinically-print study, caused by Aerius and alcohol the powerful effect of alcohol cannot be strengthened (see section 5.1)."</seg>
<seg id="1735">"however, patients should consider that it can lead in very rare cases that can lead to an impairment of traffic or the ability to serve machines."</seg>
<seg id="1736">Clinical trials in various indications including allergic rhinitis and chronic diseases were treated in the recommended dose of 5 mg daily 3% more side effects in patients with arerius.</seg>
<seg id="1737">"the most common side effects of side effects on the most common side effects, the more common than in Placebo was impecologically (1.2%), mouth dry (0.8%) and headaches (0.6%)."</seg>
<seg id="1738">"in a clinical study with 578 youth patients from 12 to 17 years, the most common side effects of the headache, which was treated by 5.8% of patients who were treated with Desloratadin."</seg>
<seg id="1739">"in a multi-dose study, at the up to 45 mg Desloratadin (Neunparalleled clinical dose) were obtained."</seg>
<seg id="1740">"this includes both sides of propulammatorical cytokines such as IL-4, IL-6, IL-8, IL-8, IL-8, IL-8, IL-8, IL-8, IL-8, IL-8, IL-8, IL-8, IL-8, IL-8, IL-8, IL-8, IL-8, IL-8, IL-8, IL-8, IL-8 and IL-13."</seg>
<seg id="1741">"in the framework of a clinical study with multiple sclerosis, in a dosage of up to 20 mg daily in a dosage of up to 20 mg daily in a dosage of up to 20 mg daily in a dosage of up to 20 mg daily."</seg>
<seg id="1742">"in a clinically-physiologic study, in the Desloratadin in a dosage of 45 mg daily (the Neunfold of the clinical dose) showed no extension of the Qtc intervalls."</seg>
<seg id="1743">"in a single dose- study with adults showed Desloratadin 5 mg no influence on standard measuring sizes of the flood, including the reduction of subjective throat or the tasks that are connected with which are associated with them."</seg>
<seg id="1744">"in patients with allergic rhinitis, Aerius affect the symptoms of symptoms such as Niesen, Nasensedition, and Juckreiz of nose, Juckreiz, Trension, and Roman, and Juckreiz at the palate."</seg>
<seg id="1745">"in addition to the established classification in seasonal and perennial, allergic rhinitis can be divided into account by the duration of the symptoms."</seg>
<seg id="1746">Interchangeable rhinitis is defined as a result of symptoms for less than 4 days per week or less than 4 weeks.</seg>
<seg id="1747">"as a result of the symptoms of the symptoms, the symptoms are defined as a result of the symptoms of 4 or more days per week and more than 4 weeks."</seg>
<seg id="1748">"at the same time, Aerius are shown at the quality of quality of quality in Rhino-industrialist."</seg>
<seg id="1749">"the chronic idiopathic Urtikaria has been examined for further forms of Urtikaria, since the underlying pathophysiology of the pathology is similar to the different forms of different forms and chronic patients."</seg>
<seg id="1750">"as the historian infantry, as the historian factor in all urarious disorders, is expected that Deslorattained except for other forms of the Urtikaria. this is confirmed by the recommendations of clinical guidelines."</seg>
<seg id="1751">"in two Placebo controlled trials over 6 weeks in patients with chronic diseases, Aerius effect is effective in the improvement of pruritus and the Herabytes of size and number of squares at the end of the first time interval."</seg>
<seg id="1752">"as in other studies with anti-histopathic Urtikaria, the minority of the patients who do not depend on anti-histopathics from the study."</seg>
<seg id="1753">A improvement of the juckness to more than 50% of the treated patients were observed in 55% of with Desloratan patients in comparison to 19% of the treated patients.</seg>
<seg id="1754">"the treatment with Aerius reduced the disturbance of the sleep and the wax, such as a 4-points of scale in the evaluation of these variables."</seg>
<seg id="1755">"in a pharma-study study, which was comparable to patients with the general seasonal sular rhinitis population, was comparable to 4% of patients a higher concentration of Deslorate."</seg>
<seg id="1756">There are no limit points for a clinically relevant Kumulation after the daily use of Desloratadin (5 20 mg) over 14 days before.</seg>
<seg id="1757">"for the metastal of Desloratadin, enzymes has not been identified, that the exchange of other drugs cannot be excluded."</seg>
<seg id="1758">Desloratulates in-vivo not CYP3A4 and in-vitro studies have shown that the medicine CYP2D6 is not inhibited and neither a substrate nor a inhibitor of the P glycol.</seg>
<seg id="1759">"in a single dosed study with Desloratadin in a dosage of 7,5 mg, meals (oversary, calorienrich breakfast) does not apply to the availability of Desloratadin."</seg>
<seg id="1760">"with Desloratadin and Loratan increased clinical studies, with a comparable degree of Desloratadin, no qualitative or quantitative differences in the toxicity of Deslorate and of Loratadin."</seg>
<seg id="1761">"based on conventional studies on the conventional studies on the safety spharmakology, toxicity of repeated gift, genotoxity and reproductive data with Desloratadin no special dangers for humans."</seg>
<seg id="1762">"color-coloured film (contains Lactose-monohydrate, Hypromative, titanium dioxide, Indigoculat (E 132)), colourless film (contains Hypromative, Macrogol 400), carbide wax, warm wax."</seg>
<seg id="1763">"Aerius can be taken independently from the meals, to reduce the symptoms of allergic sinitis (including intermitage and any allergic.) and Urtikaria (see under section 5.1)."</seg>
<seg id="1764">"the doctor should be aware that most cases of Rhinitis in children under 2 years caused by an infection (see section 4.4), and that no data could support the treatment of a infectic Rhinitis with Aerius."</seg>
<seg id="1765">"in addition to the exclusion of upper breathing, or anatomical anomalies should be a role in diagnosing the anamese, physical investigations and other laboratory tests."</seg>
<seg id="1766">About 6% of the adults and children between 2 and 11 years metabolise Desloratadin and learn a higher substrate load (see below 5.2).</seg>
<seg id="1767">"the safety of Aerius Sirup with children between 2 and 11 years, the serious metabolic is identical with children, the normal metabolic."</seg>
<seg id="1768">This drug contains Saccharosis and sorbitol; therefore patients should not take patients with any problems of a fructose-intolerance or a Saccharase-Isomaltzation of this medicine.</seg>
<seg id="1769">There are currently no product reviews. please enter a valid e-mail address and your password.:</seg>
<seg id="1770">"in a clinically-print study, compared to simultaneous use of Aerius tablets and alcohol the powerful effect of alcohol cannot be strengthened (see section 5.1)."</seg>
<seg id="1771">The total amount of side effects in children between 2 and 11 years was similar to the Aerius Sirup group similar to the placebo group.</seg>
<seg id="1772">"in clinical trials with adults and adolescents in various indications, including allergic rhinitis and chronic pain, were treated in the recommended dose 3% more side effects in patients with arerius."</seg>
<seg id="1773">"in a multi-dose study on adults and adolescents, at the up to 45 mg Desloratadin (Neunchy clinical dose) were obtained."</seg>
<seg id="1774">Children in the age between 1 and 11 years that came to a daily Desloratadindose of 1,25 mg (in age between 1 and 5 years) or 2.5 mg (in age between 6 and 11 years).</seg>
<seg id="1775">"because the course of allergies are allergic / chronic pain, and the profile of Desloratadin in adults and children are similar to the children of Desloratadin in adults."</seg>
<seg id="1776">"in the framework of a clinical study with multiple sclerosis of adults and adolescents, in the Desloratadin in a dosage of up to 20 mg daily in a dosage of up to 20 mg daily in a dosage of up to 20 mg daily."</seg>
<seg id="1777">For adults and adolescents in a dosage of 45 mg daily (the Neunfold of clinical dose) has been applied to adults in a dosage of 45 mg daily (the Neunfold of clinical dose) showed no extension of the Qtc intervalls.</seg>
<seg id="1778">In controlled clinical trials was found in the recommended Dosage of 5 mg daily for adults and adolescents.</seg>
<seg id="1779">"in a single daily dose of 7,5 mg the Aerius tablets used to adults and adolescents in clinical trials, no impairment of psychomotors."</seg>
<seg id="1780">"in clinically-clinical studies of adults, it came to increase the risk of alcohol nor a reduction of alcohol-inducing power."</seg>
<seg id="1781">"with adult and youthful patients with allergic tablets, Aerius tablets have been effective in the lens of symptoms such as Niesen, Nasensedition and Juckreiz of the nose, Juckreiz, Trentric, and Roman, and Juckreiz at the palate."</seg>
<seg id="1782">"at the same time, Aerius tablets are shown at the quality of quality of quality in Rhino-industrialist."</seg>
<seg id="1783">"in two Placebo controlled trials over 6 weeks in patients with chronic diseases, Aerius effect is effective in the improvement of pruritus and the Herabytes of size and number of squares at the end of the first time interval."</seg>
<seg id="1784">"the distribution of this limited implants was comparable to adults (6%) and children between 2 and 11 years (6%) and in both popularities bigger in Black (18% adults, 16% children) as well as Caucasions (2% adults, 3% children)."</seg>
<seg id="1785">Similar to makokinetic parameters were observed in a Brazilian real-dose study with the Sirupformulation of children between 2 and 11 years with allergic reactions in children between 2 and 11 years with allergic reactions.</seg>
<seg id="1786">"the load (Auc) by Desloratadin was about 3 to 6 hours, approximately 6mal higher and the Cmax approximately 3 to 4times higher than about 120 hours."</seg>
<seg id="1787">There are no responsibility for a clinically relevant operating environment after once-day application of Desloratadin (5 20 mg) over 14 days in adults and adolescents.</seg>
<seg id="1788">"12 In different individual dose studies showed that AUC and Cmax values from Desloratadin patients were comparable to the recommended dose, with those of adults, the Desloratadin-Sirup in a dosage of 5 mg."</seg>
<seg id="1789">"the metastal of Desloratadin are not identified, however, that the exchange of other drugs cannot be excluded."</seg>
<seg id="1790">"Aerius Sirup is offered in Type-III-Braunged bottles with a safe polypropylene frame with 30, 50, 60, 100, 120, 150, 225, 150 and 300 ml."</seg>
<seg id="1791">"equipped with a rigid, transparent polystyrene measuring spoon, kalibriert with 2.5 ml and 5 ml (only for the 150 ml bottle)."</seg>
<seg id="1792">"a dose of Aerius Lyophiliana to take a daily daily in the mouth, to avoid the symptoms of allergic rhinitis (including intermitage and any allergic.) and Urtikaria (see under section 5.1)."</seg>
<seg id="1793">"immediately before the application, the Blister carefully open and the dose of the Lyophilisats can be removed without them."</seg>
<seg id="1794">There are no translations available. please enter a valid e-mail address and your password.:</seg>
<seg id="1795">"with clinical trials in various indications, including allergic rhinitis and chronic pain, were treated in the recommended dose of 5 mg daily 3% more side effects in patients with Aerius tablets."</seg>
<seg id="1796">"in a multi-dose study, at the up to 45 mg Desloratadin (Neunparalleled clinical dose) were observed."</seg>
<seg id="1797">"in two single dose studies, Aerius Lyophilisat for inserting well; this was documented by clinical laboratory results, medical investigations, Vitalps and EKG-Intervalldata."</seg>
<seg id="1798">"in the framework of a clinical study with multiple sclerosis, in a dosage of up to 20 mg daily in a dosage of up to 20 mg daily in a dosage of up to 20 mg daily in a dosage of up to 20 mg daily."</seg>
<seg id="1799">"in a clinically-clinical study, in the Desloratadin study, which was applied in a dosage of 45 mg daily (the Neunfold of clinical dose) has been applied to an dosage of the Qtc intervalls."</seg>
<seg id="1800">In controlled clinical trials was found in the recommended Dosage of 5 mg daily in the recommended Dosage of 5 mg daily.</seg>
<seg id="1801">"in a 17 single dose study with adults showed Desloratadin 5 mg no influence on standard - measuring sizes of the flood, including the reduction of subjective throat or the tasks that are connected with the fats."</seg>
<seg id="1802">"in patients with allergic's symptoms, Aerius tablets have been effective in patients with allergies of symptoms such as Niesen, Nasensedition and Juckreiz of nose, Juckreiz, Trension, and Roman, and Juckreiz at the palate."</seg>
<seg id="1803">"at the same time, Aerius are shown at the quality of quality of quality in Rhino-industrialist."</seg>
<seg id="1804">18 In a Pharmakokinetic study that was comparable to patients with the general seasonal sular rhinitis -population was comparable to 4% of patients a higher concentration of Desloratadin.</seg>
<seg id="1805">Food has no significant impact on Auc and Cerius Lyophiliana to take care during food Tmax from Desloratadin from 2.5 to 4 hours and Tmax from 3-OH-Desloratadin from 4 to 6 hours.</seg>
<seg id="1806">Gelene Mannitol Aspartame (E 951) Polacrylin-potum colourant opatint Red (E 464) and Hypromative (E 464)) Aroma Tights-FRUTTI water free Citronutriic acid</seg>
<seg id="1807">"a Aerius 2.5 mg melt in the mouth with allergic acid once daily in the mouth, to prevent the symptoms of allergic rhinitis (including intermitage and any allergic.) and Urtikaria (see below 3.1)."</seg>
<seg id="1808">"two Aerius 2.5 mg melt a daily daily in the mouth, to prevent the symptoms of allergic rhinitis (including intermitage and any allergic.) and Urtikaria (see below 3.1)."</seg>
<seg id="1809">There are restricted experience from clinical trials to the effectiveness of Desloratadin in adolescents from 12 to 17 years (see Sections 4.8 and 5.1)</seg>
<seg id="1810">"immediately before the application, the Blister is carefully open and the dose of melting can be removed without damaging them."</seg>
<seg id="1811">The efficacy of Aerius 2.5 mg melt in the treatment of children under 6 years.</seg>
<seg id="1812">The total amount of side effects between the Desloratadine Sirup- and the Placebo group was given and did not significantly significantly from the adult patients.</seg>
<seg id="1813">"in the recommended dose, Aerius melt melt into the Aerius 5 mg conventional tablets-formulation and Aerius 5 mg Lyophilisat for inserting the formulations of Deslorate."</seg>
<seg id="1814">"in the framework of a clinical study with multiple sclerosis, which was applied in a dosage of up to 20 mg daily in a dosage of up to 20 mg daily in a dosage of up to 20 mg daily."</seg>
<seg id="1815">"in a single dose study with adults showed Desloratadin 5 mg no influence on standard - measuring sizes of the flood, including the reduction of subjective throat or the tasks that are connected with the fats."</seg>
<seg id="1816">"the distribution of this bad patient was comparable to adult (6%) and pädiatology between 2 and 11 years (6%), and under the Black (adults 18%, children 16%), the safety profile of these patients was not far from the general population."</seg>
<seg id="1817">"in single dose cross-section studies of Aerius melt quality with Aerius 5 mg conventional tablets or Aerius 5 mg Lyophilisat for inserting the formulations of biosis."</seg>
<seg id="1818">Aerius 2.5 mg tablets have been examined in combination with the dose of clinical studies in children with the Dosage groups with children from 6 to 11 years in children from 6 to 11 years.</seg>
<seg id="1819">Food has no significant impact on Auc and Cerius Lyophiliana to take care during food Tmax from Desloratadin from 2.5 to 4 hours and Tmax from 3-OH- Desloratadin from 4 to 6 hours.</seg>
<seg id="1820">The overall analysis of preclinical and clinical irritation tests for the melt-efficient risk for local Irritations.</seg>
<seg id="1821">Microcrystalline cellulose glylate thickness of carboxymium acrylate protein oxide (Ph.Eur.) Crombvidon (Ph.Eur.) Crombvidon chloride (Ph.Eur.) Crombvidon Aspartame (E951) Aroma Tights FRUTTI</seg>
<seg id="1822">"the cold forming film consists of polyvinylchloride (PVC), of laminated on a related polyamide (OPA) film, detecting laminated on a polyvinylchloride (PVC) film."</seg>
<seg id="1823">"a Aerius 5 mg melt cleaners once daily in the mouth, to prevent the symptoms of allergic rhinitis (including intermitage and any allergic.) and Urtikaria (see below 3.1)."</seg>
<seg id="1824">"in the recommended dose, Aerius 5 mg melt in the Aerius 5 mg conventional tablets-formulation and Aerius 5 mg Lyophilisat for inserting the formulations of Deslorate."</seg>
<seg id="1825">"in the framework of a clinical study with multiple sclerosis, in a dosage of up to 20 mg daily in a dosage of up to 20 mg daily in a dosage of up to 20 mg daily in a dosage of up to 20 mg daily."</seg>
<seg id="1826">"in a 30 single dose study with adults showed Desloratadin 5 mg no influence on standard - measuring sizes of the flood, including the reduction of subjective throat or the tasks that are connected with the fats."</seg>
<seg id="1827">"in patients with allergic's symptoms, Aerius tablets have been effective in patients with allergies of symptoms such as Niesen, Nasensedition and Juckreiz of nose, Juckreiz, Trension, and Roman, and Juckreiz at the palate."</seg>
<seg id="1828">"in single dose cross-section studies of Aerius 5 mg melting tablets with Aerius 5 mg conventional tablets or Aerius 5 mg Lyophilisat for inserting the formulations of biosis."</seg>
<seg id="1829">The overall analysis of preclinical and clinical irritation tests for the melt-efficient risk for local Irritations.</seg>
<seg id="1830">"the security of Desloratadin in children between 2 and 11 years, the serious metabolic is identical with children, the normal metabolic."</seg>
<seg id="1831">"this medicine contains Sorbitol; therefore, patients with any problems of a fructment intolerance, Glucose-Galactose-absorption of this drug may not take this medicine."</seg>
<seg id="1832">The total amount of side effects in children between 2 and 11 years was similar to the Desloratadin group.</seg>
<seg id="1833">"in case of small kinks between 6 and 23 months, the most common side effects that was reported by the more common side effects, diarrhoe (3.7%), fever (2.3%) and sleep (2.3%)."</seg>
<seg id="1834">"in an additional study, in an additional study of 2.5 mg Desloratadin solution to take no side effects of patients in age between 6 and 11 years."</seg>
<seg id="1835">"in the recommended dose, the plasma concentration was comparable to Desloratadin (see below 5.2) in the children and adult population."</seg>
<seg id="1836">In controlled clinical trials was found in the recommended Dosage of 5 mg daily for adults and adolescents.</seg>
<seg id="1837">"in addition to the established classification in seasonal and perennial, allergic rhinitis in dependence on the duration of the symptoms are also found in intering allergic rhinitis and"</seg>
<seg id="1838">"at the same time, Aerius tablets are shown at the quality of quality of quality in Rhino-industrialist."</seg>
<seg id="1839">"the distribution of this limited implants was comparable to adults (6%) and children between 2 and 11 years (6%) and in both popularities bigger in Black (18% adults, 16% children) as well as Caucasions (2% adults, 3% children)."</seg>
<seg id="1840">"as Aerius solution to take the same concentration of Deslorat.dll, there was no bio-quivalence study, it is necessary to expect that it is necessary to expect the Sirup and tablets."</seg>
<seg id="1841">"in different individual dose studies showed that AUC and Cmax values from Desloratadin patients were comparable to the recommended cans with those of adults, the Desloratadin-Sirup in a dosage of 5 mg."</seg>
<seg id="1842">"sorbitol, Propylenglysis, Sucralose E 955, hydrite citrate 2 H2O, natural and artificial flavours (Bubble-GUM), water-free Citronensic acid, sodium edetate (Ph.Eur.), gerated water."</seg>
<seg id="1843">"Aerius solution for insertion is equipped with 30, 50, 60, 100, 120, 150, 225, 150, 225, 150, 225, 150, 225, 150, 225, 150, 225, 150, 225, 150, 225, 150, 150, 225, 150, 150, 225, 150, 150 and 300 ml in type III Braungglass bottles with a multi-sided polyethylene."</seg>
<seg id="1844">All package sizes except the 150 ml package size are offered with a measurement range of 2.5 ml and 5 ml.</seg>
<seg id="1845">The 150 ml package size is a measuring spoon or a application tool for mounting with scalability of 2.5 ml and 5 ml.</seg>
<seg id="1846">"then on the extension of the approval, the authorisation of the approval is regularly updated to regularly updated reports about the insolvency of a drug using all two years, except it will be done from the CHMP."</seg>
<seg id="1847">"you will find these under" "Tools, Internet Options, Security" "and" "Tools, Internet Options, Privacy". ""</seg>
<seg id="1848">"you will find these under" "Tools, Internet Options, Security" "and" "Tools, Internet Options, Privacy". ""</seg>
<seg id="1849">Sirup 30 ml with 1 measurement spoon 100 ml with 1 measurement spoons 150 ml with 1 measuring spoons 150 ml with 1 measuring spoons 150 ml with 1 measuring spoons of 150 ml with 1 measurement technique</seg>
<seg id="1850">30 ml with 1 measurement spoon 100 ml with 1 measurement spoons 150 ml with 1 measuring spoons 150 ml with 1 measuring spoons 150 ml with 1 measuring spoons 150 ml with 1 measuring spoons 150 ml with 1 measurement spoons</seg>
<seg id="1851">You can paste it in any place on your page where you want to add the vat of 19%. shipping to a german destination is 7 euros. [...]</seg>
<seg id="1852">Home › Products › Products Request Product Your purchase price! 9013-FX3.04</seg>
<seg id="1853">Solution for inserting 30 ml with 1 measurement spoon 100 ml with 1 measurement spoons 150 ml with 1 measurement of 150 ml with 1 measuring spoons 150 ml with 1 measuring spoons of 150 ml with 1 measurement technique</seg>
<seg id="1854">Pregnancy and downtime questions you have your doctor or pharmacist to advice your doctor or pharmacist to advice.</seg>
<seg id="1855">Transport and use of machines for use in the recommended dosage is not so that Aerius is used to use or the attention.</seg>
<seg id="1856">"if you have told by your doctor said that you have an intolerance against certain sugar, ask your doctor before you take this medicine."</seg>
<seg id="1857">"for the treatment of treatment, your physician will find the kind of allergic rhinitis, under which you suffer, and will allow you to take it as long you take Aerius."</seg>
<seg id="1858">"if your allergic rhinitis intermitment is (the symptoms less often than 4 days per week, or less than 4 weeks), your doctor will recommend you a treatment scheme that is dependent on your previous symptoms."</seg>
<seg id="1859">"if your allergic rhinitis may occur (the symptoms of 4 or more days per week occur, and more than 4 weeks), your doctor may recommend a longer lasting treatment."</seg>
<seg id="1860">"if you have forgotten your dose if you have forgotten your dose in time, take it as soon as possible, and follow the normal treatment plan."</seg>
<seg id="1861">"71 To market launch of Aerius was very rare about cases of severe allergic reactions (difficulties during breathing, pipes, nuts, nuts and swelling) and skin."</seg>
<seg id="1862">"about cases of cardiovascular disease, heart pain, abdominal pain, diarrative, diarrative, diarrative, diarrative, diarrative, diarrative, diarrative, diarrative, diarrative, diarrative, liver, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarratives, diarrho</seg>
<seg id="1863">"this paper investigates the impact of non-take-up for two hypothetical scenarios, namely increasing and decreasing the base amount of social assistance in Germany by €100 per month. IAB-Discussion Paper 20 / 2015"</seg>
<seg id="1864">"you can select the most suitable payment method: credit card, bank transfer, check, PayPal etc."</seg>
<seg id="1865">"Aerius Sirup is displayed in the age between 1 and 11 years, adolescents (12 years and older) and adults, older people included."</seg>
<seg id="1866">"important information on certain other components of Aerius you should not take Aerius Sirup, if you are allergic to the colourant E 110 allergic."</seg>
<seg id="1867">"if you wish your doctor, you will have an incompatibility to some sugar species, please contact your doctor before you take this medicine."</seg>
<seg id="1868">"when the Sirup is a application syringe, you can use this form to take the corresponding amount of Sirup to take the corresponding amount of Sirup."</seg>
<seg id="1869">"for the treatment of treatment, your physician will find the kind of allergiic Rhinitis, under which you suffer, and will allow you to take it as long you have to take Aerius Sirup."</seg>
<seg id="1870">"however, with children under 2 years ago, fever and sleeping symptoms of common side effects, during adults, mouth, mouth and headaches often more often than with Placebo."</seg>
<seg id="1871">"after the market launch of Aerius was very rare about cases of severe allergic reactions (difficulties during breathing, pipes, nuts, nuts and swelling) and skin."</seg>
<seg id="1872">"77 Aerius Sirup is available in bottle with a safe seal with 30, 50, 60, 100, 120, 150, 150 and 300 ml."</seg>
<seg id="1873">"Aerius Lyophiliana to take the symptoms of allergic rhinitis (through a allergies of allergies, such as hypocrisy or house dust-dust-allergies)."</seg>
<seg id="1874">"in case of Aerius Lyophilisat for inserting together with food and drinks, Aerius Lyophilido not need to take water or any other liquid."</seg>
<seg id="1875">"for the treatment of treatment, your physician will find the kind of allergic rhinitis, under which you suffer, and will allow you to take it as long you can take Aerius Lyophilii."</seg>
<seg id="1876">"81 If you have forgotten your dose of Aerius Lyophilix to have forgotten your dose in time, take it as soon as possible, and follow the normal treatment plan."</seg>
<seg id="1877">"after the market launch of Aerius was very rare about cases of severe allergic reactions (difficulties during breathing, pipes, nuts, nuts and swelling) and skin."</seg>
<seg id="1878">"(users Viewing this Forum: 0) 1,506 194 Tauchschein?"</seg>
<seg id="1879">Aerius melt cleaners improved the symptoms of allergies to allergic cancer (through a allergies of allergies or house dust).</seg>
<seg id="1880">"when taking Aerius melt cleaning together with food and beverage, Aerius melt cleaners need not be taken with water or other liquid."</seg>
<seg id="1881">"for the treatment of treatment, your physician will determine the type of allergiic Rhinitis."</seg>
<seg id="1882">86 If you have forgotten your dose if you have forgotten your dose if you have forgotten your dose is possible to take it as soon as possible and follow the normal treatment plan.</seg>
<seg id="1883">"Aerius melting is individually packed in Blisterpackets with 5, 6, 10, 12, 15, 18, 20, 50, 90, 90 and 100 cans of melt."</seg>
<seg id="1884">"when taking Aerius melt cleaning together with food and beverage, Aerius melt cleaners need not be taken with water or other liquid."</seg>
<seg id="1885">"if you have forgotten your dose if you have forgotten your dose in time, take it as soon as possible, and follow the normal treatment plan."</seg>
<seg id="1886">"after the market launch of Aerius was very rare about cases of severe allergic reactions (difficulties during breathing, pipes, nuts, nuts and swelling) and skin."</seg>
<seg id="1887">"sorry, there is no translation for this news-article."</seg>
<seg id="1888">"if the solution is placed on the solution for insertion with scalability, you can be able to take it in order to take the appropriate quantity to take the appropriate solution."</seg>
<seg id="1889">"for the treatment of treatment, your physician will find the kind of allergic rhinitis, under which you suffer, and will allow you to take it as long you take Aerius solution to take it."</seg>
<seg id="1890">"however, with children under 2 years diarrhos, fever and sleep disorders during adults, adults, mouth and headaches often more often than with Placebo."</seg>
<seg id="1891">"97 Aerius solution for insertion is available in bottle with a safe seal with 30, 50, 60, 100, 120, 150, 225, 150 and 300 ml."</seg>
<seg id="1892">The 150 ml package size is a measuring spoon or a application syringe for mounting with scalability of 2.5 ml- and 5 ml cans.</seg>
<seg id="1893">"June 2008, Novartis Vaccines and Diagnostics S.r.l. to the Committee for Humanitarian Aid (CHMP) officially declared that the company will bring his request to the insolvency of Aflunov to the preventive H5N1 Influenza at adults and older people."</seg>
<seg id="1894">Aflunov should be caused by adults and older people to protect against flu that are caused by the trunk (type) H5N1 of the Influenza-A virus.</seg>
<seg id="1895">"this is a special type of vaccine which may cause a trunk of the Grippevirus, which may cause a future panic cause."</seg>
<seg id="1896">"a Grippepandey breaks out when a new trunk of the Grippevirus may be caused by man to man, because the people still have no immune system (no protection) against it."</seg>
<seg id="1897">"according to the vaccination of the vaccine detects the immune system, the immune system is used in the vaccine of the Grippevirus as" physical impunity "and forms of antibodies."</seg>
<seg id="1898">This is the immune system later in the position to form a contact with a Grippevirus.</seg>
<seg id="1899">"then the membrane cover of the virus is used with the" surface coating "(proteins on the membrane surface, the human body as physical body as physical body.), cleansed, and an integral part of the vaccine."</seg>
<seg id="1900">An inspection of some of the studies showed that the study is not done according to the "good clinical practice" (GCP).</seg>
<seg id="1901">"in this way, the scope of the clinical data base for the evaluation of the vaccine does not affect the requirements of the vaccination of the EMEA for preventive vaccine."</seg>
<seg id="1902">"should you need to participate in a clinical examination and further information about your treatment, please contact your doctor doctor."</seg>
<seg id="1903">"if you wish to read more information regarding the recommendations of the CHMP, please read the scientific discussion (also part of the EPAR)."</seg>
<seg id="1904">"in combination with other antiviral medicines for treatment of adults and children over four years, which is caused by human immunovirus from type 1 (HIV-1) which is caused by the humanesynthesis (AIDS)."</seg>
<seg id="1905">"for patients who do not swallow the capsules, Agenerals can be taken as a solution that can not be taken together with Ritonavir, since the safety of this combination was not examined."</seg>
<seg id="1906">"Awarase should only be considered, when the physician has been tested, which has been developed, and the likelihood of the patient has taken the virus to the medicines."</seg>
<seg id="1907">The recommended dose for patients over twelve years is 600 mg twice daily that can be taken together with twice daily 100 mg of Ritonavir and other antiviral drug.</seg>
<seg id="1908">"for children between four and twelve years and in patients with a body weight of less than 50 kg, the recommended dose of Awarase after the body weight."</seg>
<seg id="1909">"in combination with other antiviral drug use the HIV amount of blood, and keeps them on a low level."</seg>
<seg id="1910">"they are not too heal, however, however, the cause of immune system, and thus the development of the immune system, and the development of AIDS associated infections and disorders."</seg>
<seg id="1911">"Awarase was examined in combination with other antiviral cancer, but without Ritonavir, in two main studies with 736 HIV-inths."</seg>
<seg id="1912">"that with low temperature, Ritonavir amplifiers Awarase was taken in 206 adults that had previously been modified with other prototypes."</seg>
<seg id="1913">"the general indices for the effectiveness was the proportion of patients with non-proven concentrations of HIV in blood (Viruslast) or the change of the Viruslast after treatment."</seg>
<seg id="1914">"in the studies with patients who had no prototyped to 48 weeks under Awarase more patients had a Viruslast under 400 copies / ml as under Placebo, but Awarase was less effective than indinavir."</seg>
<seg id="1915">"for children reduced Awarase, the Viruslast, however, however, of the children who were treated with protesters, only very few on the treatment."</seg>
<seg id="1916">"in the study with adults that were treated with Protonavir reinforced drugs Awarase the Viruslast after 16-week treatment, as well as other protruined treatment:"</seg>
<seg id="1917">"in the patients with HIV, which was opposed to four other prototypes together with Ritonavir, it came under Awarase together with Ritonavir to four weeks as in the patients who were able to continue their previous prototypes."</seg>
<seg id="1918">"the most common side effects of Awarase (observed in more than 1 of 10 patients) are headaches, diarrhö (flow), Flatulence (nausea), break, skin and fatigue (fatigue)."</seg>
<seg id="1919">"2 / 3 Agenerase may not be applied to patients, which may possibly be oversensitive (allergic) against Amstraavir or another of the other components."</seg>
<seg id="1920">Awarase may also be applied to patients who are used for treatment of depression) or medicines which are as well as Agenerase inhibitors and in high concentrations in blood health.</seg>
<seg id="1921">"as in other medicines, patients, Awarase, the risk of a Lidauystrophies (changes in distribution of the body), a Osteonekrose (changes in the distribution of the body), a Osteonekrose (symptoms of bone tissue) or a immune system (symptoms of infection that are caused by a relaxing immune system)."</seg>
<seg id="1922">"the Committee for Humanist agents (CHMP) to the end, that the benefits of Awarase used in combination with other antiretroviral drug use in combination with other antiretroviral cancer and children over four years."</seg>
<seg id="1923">"Awarase will be taken in the rule together with the cervionic amplifier Ritonavir, but the Committee confirmed that the benefit of Awarase in combination with Ritonavir in patients who had no protested in combination with Ritonavir patients who had no protested."</seg>
<seg id="1924">"Awarase was originally found under" "extraordinary circumstances" "since the time of the permission from scientific reasons only limited information."</seg>
<seg id="1925">"in October 2000, the European Commission has launched the European Commission on the company of Glaxo Group Limited, an approval for the incoming of Awarase in the whole European Union."</seg>
<seg id="1926">Awarase is displayed in combination with other antiretroviral medicines for treatment of HIV-1- inseparating adults and children from 4 years.</seg>
<seg id="1927">"for usually, Awarase capsules for the most common values of Amnesty avir together with low dose of Ritonavir, (see Secur 4.2 and 4.5)."</seg>
<seg id="1928">The use of Amstraavir should be carried out under consideration of the individual viral resistance of the patient and treatment of the patients (see section 5.1).</seg>
<seg id="1929">The bioavailability of Amberavir is a solution to take advantage of 14% lower than by Amstraavir as capsule; therefore Awarase capsules and solution to one milligram per milligram (see section 5.2).</seg>
<seg id="1930">The recommended dose for Awarase capsules is 600 mg Amstraavir twice daily together with 100 mg of Ritonavir twice daily in combination with other antiretroviral cancer.</seg>
<seg id="1931">"2 If Awarase capsules is used without the amplification process by Ritonavir (Boostats), have to be applied to Awarase (1200 mg twice daily)."</seg>
<seg id="1932">The recommended dose for Awarase capsules is 20 mg Amstraavir / kg body weight twice daily in combination with other antiretroviral drug use up to a daily dose of 2400 mg Amstraavir that should not be exceeded (see section 5.1).</seg>
<seg id="1933">"the pharyninetics, effectiveness and security of Awarase in combination with low cans of Ritonavir or other protesters were not examined for children."</seg>
<seg id="1934">Awarase is not recommended for use in children under 4 years because of the absence of data for uncertainty and effectiveness (see section 5.2).</seg>
<seg id="1935">"based on clinical pharmacokinetic data, the dose of Agenerase capsules was reduced to 450 mg twice daily and in patients with severe liver function dysfunction to 300 mg twice daily."</seg>
<seg id="1936">The current application should be carried out in patients with easier or reduced liver function with caution in patients with severe liver function.</seg>
<seg id="1937">"Agenerase cannot be given at the same time, the low therapeutic breadth of the Cytochrome P450-Isoenzyms 3A4 (CYP3A4)."</seg>
<seg id="1938">"herbal Supplements, the Johannisiere (Hypericum perforatum) must be applied, must be applied due to the risk of the risk of Amberavir during the taking of Amstraavir, (see section 4.5)."</seg>
<seg id="1939">Patients should have to develop that Agenerase or any other antiretroviral therapy does not develop a healing of HIV infection or other complications of HIV infection.</seg>
<seg id="1940">The current antiviral therapy including treatment with Agenerase prevents the risk of a transfer of HIV on other through sexual contact or contamination with blood.</seg>
<seg id="1941">"usually, Awarase capsules together with low cans of Ritonavir and in combination with other antiretroviral drug use (see section 4.2)."</seg>
<seg id="1942">Patients who are treated to chronic hepatitis B or C.</seg>
<seg id="1943">"for the case of premature ejaculation treatment of hepatitis B or C, please read the information about this medicine."</seg>
<seg id="1944">"patients with pre-reduced liver function including a chronic-active hepatitis, a higher frequency of liver function can be monitored under an antiretroviral combination skin and should be monitored according to clinical practice."</seg>
<seg id="1945">"the current application of Agenerase and Ritonavir with fluticason or other glucaviorrhoids, which is not recommended unless the possible benefit of the risk of systemic therapy of the effects including Morbus Cushing and soup of the outflow function (see section 4.5)."</seg>
<seg id="1946">The HMG-CoA-Reinductase-Hemmer Lovastatin and Simvastatin strongly from CYP3A4 is not recommended for the increased risk of myopathies including rhabdomyolysen.</seg>
<seg id="1947">"4 For some of the medicines that cause severe or food effects, such as Carbamazepin, phenytoin, tricyclos, phenytoin, tricycasiva and Warfarin (under monitoring of the active ingredient)."</seg>
<seg id="1948">"in patients who take this medicine at the same time, Awarase due to reduced plasticides of Amstraavir less effective (see section 4.5)."</seg>
<seg id="1949">"due to the possibility of metabolic exchange with Amstraavir, the effectiveness of hormonal tissue can be changed, however, the information does not be sufficient to estimate the kind of exchange effects."</seg>
<seg id="1950">"if methadon is given at the same time, the patient should be monitored at the opiatinths of the disease, particularly if the low dose of Ritonavir was used."</seg>
<seg id="1951">"due to the possible risk of a toxicity due to the possible risk of toxicity, the Agenerase solution can be applied in children under a age of four years in children under a age of four years, and should be applied to certain other patient groups."</seg>
<seg id="1952">Awarase should be set up to duration, if a skin supplement is accompanied by systemic or allergic symptoms (see section 4.8). "</seg>
<seg id="1953">"patients suffering from diabetes mellitus, hyperglycemia, or a exazerbation of an existing diabetes mellitus."</seg>
<seg id="1954">Many of patients had other diseases whose therapy medicines were necessary to be brought with the development of a diabetes mellitus or a hyperglycemia.</seg>
<seg id="1955">"B. higher age, and with drug-dependent factors such as a longer-lasting antiretroviral treatment and associated disorders, associated."</seg>
<seg id="1956">"in hammophilen patients (type A and B) who were treated with protesters, are opinions about a increase of blood, including spontaneous hemalysts and hemmargins."</seg>
<seg id="1957">"with HIV-inducing patients with severe immunity, at the time of the introduction of an antiretroviral infections (ART) is developing an anti-inflated reaction to asymptomatic or inhibital infections, which leads to severe clinical trials or reduction of symptoms."</seg>
<seg id="1958">"although a multifactorization (including application of cortilesions, alcohol consumption, severe immune diseases, higher body-mass index), was reported by Osteonekrose in particular in patients with advanced HIV illness and / or long-term application of antiretroviral infections (ART)."</seg>
<seg id="1959">"CYP3A4-Substrate with a low therapeutic breadth of the Cytochrome P450-Isoenzyms 3A4 (CYP3A4)."</seg>
<seg id="1960">CYP2D6-substrate with a low therapeutic width Awarase with Ritonavir may not be linked together with drugs.</seg>
<seg id="1961">"it was shown that Rifampicin a 82% reduction of the Auc from Amstraavir, which can lead to a virological failure and to an resistance development."</seg>
<seg id="1962">"in combination with Ritonavir in combination with Ritonavir in combination with Ritonavir, very often undesired effects on the liver."</seg>
<seg id="1963">JOHANNISKRAUT (Hypericum perforatum) The Serum mirror of Amstraavir can be reduced by the current application of herbal supplement with Johannisite (hypericum perforatum).</seg>
<seg id="1964">"when a patient has already Johannisite, the Amstraavian mirror and when it is possible to check the Viruslast and to check the Johannisring."</seg>
<seg id="1965">A dose example for one of the drugs is not necessary if the caviavir together with Amstraavir) (see also Efavirenz below).</seg>
<seg id="1966">"508% increased, for Cmax on 30% lower when Ritonavir (100 mg twice daily) in combination with Amstraavir capsules (600 mg twice daily)."</seg>
<seg id="1967">"in clinical trials, Dosilica of 600 mg Amstraavir twice daily and Ritonavir 100 mg twice daily, the effectiveness and uncertainty of this treatment."</seg>
<seg id="1968">52% lower in combination with Kaletra (400 mg twice daily) in combination with Kaletra (400 mg per day) in combination with Kaletra (400 mg Lopar avir twice daily).</seg>
<seg id="1969">"the Cmin-values from Amstraavir (600 mg twice daily) with Kaletra (600 mg twice daily) with Kaletra (400 mg twice daily), about 40 to 50% lower than when Amstraavir (600 mg twice daily) in combination with 100 mg of Ritonavir twice daily."</seg>
<seg id="1970">"a dosing recommended for the current reduction of Amberavir and Kaletra can not be given, however, however, it is not known to the efficacy of this combination."</seg>
<seg id="1971">"in combination with Didanosine, however, however, due to diocosine in combination with Didanosine, however, due to the antaine component of didanosin and Awarase at least one hour apart (see Antazida below)."</seg>
<seg id="1972">"therefore, the gift of Efavirence in combination with Amstraavir (600 mg twice daily) and Ritonavir (100 mg twice daily) and Ritonavir (100 mg twice daily)."</seg>
<seg id="1973">The treatment with Efaviation in combination with Amstraavir and Saquinavir is not recommended because the Exposition of both Proteins were low.</seg>
<seg id="1974">The effect of Nevirapin to other prototypes and existing data may make sure that Nevirapin the serum concentration of Amstraavir may be obtained.</seg>
<seg id="1975">If this drug should be used to be used as Delavirdin because of the reduced or possibly subtle plasticides are less effective.</seg>
<seg id="1976">"if these drugs are applied to be used, a thorough clinical and virological supervision shall be seen as a precise positioning of the combination of Amstraavir and Ritonavir on Delavirdin."</seg>
<seg id="1977">"the current gift of Amberavir and Rifabutin made up to a increase of the plasma concentration (Auc) of Rifabutin at 193%, and thus to a increase of with Rifabutin."</seg>
<seg id="1978">"when it is necessary, Rifabutin together with Awarase, is recommended to reduce the dosage of Rifabutin at least the half of the recommended dose, although no clinical data could be done."</seg>
<seg id="1979">Pharmakokinetic studies with Awarase in combination with Erythromycin were not carried out in combination with Erythromycin which could be increased in the case of premature ejaculation.</seg>
<seg id="1980">"the current application of twice daily 700 mg of Fetoconazole once a increase of Cetoconazol in plasma around 25% and the Auc (0-year) on the value, which was observed after 200 mg Ketoconazole once daily without equal use of ramprenavir with Ritonavir."</seg>
<seg id="1981">"other medicines which are listed below are listed below, including Substrate, Hemmer or inductors of CYP3A4, if they can be applied together with Awarase, possibly too."</seg>
<seg id="1982">"patients should therefore be connected to toxic reactions, which are monitored by these drug reactions when they are used in combination with Awarase."</seg>
<seg id="1983">"based on the data of other prototypes, it is advisable that Antazida does not be taken at the same time as Awarase."</seg>
<seg id="1984">"the current application of anticulsiva, which are known as enzyme (phenytoin, phenobarbital, Carbamazepin),"</seg>
<seg id="1985">"the Serum concentrations of Calciumkanizers like Amlodipin, diltiazem, diodipin, diodidipin, Niesdipin, Nixdipin, Diodidipin, Dixazem, Diodidipin, Diapamil can be increased 10 by Amstraavir, which may be increased, and preventing the activity and toxicity of these drugs."</seg>
<seg id="1986">"(see section 4.4) strengthen the current side effects of hypotension, tendinants and priapism (see section 4.4)."</seg>
<seg id="1987">"in a clinical study, in the Ritonavir 100 mg capsules twice a day with 50 µg Fluticasonprosis at intranassol (4 times daily) over 7 days."</seg>
<seg id="1988">"as a result, the uniform gift of Awarase with Ritonavir together with these Glucavitikoids are not recommended unless the possible benefit of the risk of systemic therapy of the effects (see section 4.4)."</seg>
<seg id="1989">"HMG-CoA-Reduction tase inhibitors such as Lovastatin and Simvastatin, whose result was strongly used by CYP3A4."</seg>
<seg id="1990">This HMG-CoA-Reinductase-Hemmbers can lead to myopathie including a Rhabdomyolysis, the combined application of these medicine is not recommended. "</seg>
<seg id="1991">"a frequent exchange of therapeutic concentrations up to stabilization of the mirrors, since the plasma concentration of Cymbporin, Rapamycin and Tacrolimus can be increased (see section 4.4)."</seg>
<seg id="1992">"therefore, Awarase cannot be applied together with oral defects (see section 4.3), while at the same application of Agenerase with parental Midazolam."</seg>
<seg id="1993">Data for simultaneous use of parental Midazolam with other prototypes of Midazolam around the 3- to 4-hour.</seg>
<seg id="1994">"if methadon together with Amberavir, the patient should be monitored on the opiatinths of the disease, especially if they are still under a low dose of Ritonavir."</seg>
<seg id="1995">"due to its small amounts of historical applications, no recommendation can be given no recommendation as the Amstraavid's dose is possible when Amstraavir at the same time with methadon at the same time."</seg>
<seg id="1996">"at the same gift of Warfarin or other oral antioagulthood together with Awarase, a reinforced control of the INR (International Normalisation) is recommended for the possibility of a debug or gain of antibacterial effect (see section 4.4)."</seg>
<seg id="1997">"the effect of an additional delay of Ritonavir on hormonal defects, therefore, as well as alternative methods to be recommended."</seg>
<seg id="1998">A careful control of the therapeutic effects and side effects of tricycysts (for example Desipramine and Nortryptilin) is recommended for the same gift of Awarase (see section 4.4).</seg>
<seg id="1999">This drug may be applied during pregnancy during pregnancy only after careful consideration of the possible risks to the possible risks for the fetus.</seg>
<seg id="2000">"in the milk, Amstraavir-related substances, however, it is not known that Amstraavir is not known to people in the mother's milk."</seg>
<seg id="2001">"at the end of the standpoint of Amberavir, a reduction of 12 body weight loss was reduced compared to the end of the present time."</seg>
<seg id="2002">"the other development of the presence, including fertilting and reproductive capacity, was not impaired by the delay of Amberavir to the mother's mother."</seg>
<seg id="2003">"for adults and children from 4 years, adults and children from 4 years in controlled clinical trials in combination with different antiretroviral cancer."</seg>
<seg id="2004">"most of the Awarase treatment associated with side effects were light up to moderate, early on, and led to the treatment of treatment."</seg>
<seg id="2005">"in many of these events this events is not dissolved, whether they are in connection with Agenerase or another at the same time to HIV therapy medicines, or whether they are a result of the land disease."</seg>
<seg id="2006">"most of the bottom side effects are made from two clinical trials (PROAB3001, PROAB3006) which were not treated twice daily."</seg>
<seg id="2007">"(degree 2 to 4), which were identified as in connection with the study programme, and at more than 1% of patients, as well as under the treatment, laboratory changes (degrees 3 to 4) are listed below."</seg>
<seg id="2008">"the antiretroviral combination skin has been associated with HIV patients, including a loss of peripherals and visceral fat tissue, hypertropical fish of breasts and dorsovikine fat."</seg>
<seg id="2009">"under 113 anti-viral non-treated people who were treated with Lamivudin / Zidovudin in combination with Lamivudin / Zidovudin on a medium duration of 36 weeks, only a case (Stiernes) (&lt; 1%)."</seg>
<seg id="2010">"in the study PROAB 3006, were treated with 241 NRTI- pretreated patients with 241 patients under Indinavir 7 cases (11%) in comparison to 27 cases (11%) at 241 patients under Indinavir, in combination with various NRTIs over a medium duration of 56 weeks (p &lt; 0.001)."</seg>
<seg id="2011">"in two weeks, the treatment of skin types are usually slightly asymmetrical, with or without Juckreiz, and came to the rule during the second treatment week and had to be broken into two weeks without the treatment with Amstraavir."</seg>
<seg id="2012">"cases of Osteonekrose in particular in patients with general known risk analysis, advanced HIV illness or long-term use of antiretroviral infections (ART)."</seg>
<seg id="2013">"with HIV-inpatient patients with severe immunity, at the time of the introduction of an antiretroviral infections (ART) is developing an anti-inflated reaction to asymptomatic or inhibital infections (see section 4.4)."</seg>
<seg id="2014">"with PI pre-treated patients, 600 mg Awarase twice daily together with low-treatment Ritonavir (degree 3 to 4) and laboratory changes (degree 3 to 4) and laboratory changes (degree 3 to 4) and laboratory changes (degree 3 to 4) and laboratory changes (degree 3 to 4) and laboratory changes (degree 3 to 4) and laboratory changes (degree 3 to 4) and laboratory changes (degree 3 to 4) and laboratory changes (degree 3 to 4) and laboratory changes (degree 3 to 4) and laboratory changes (degrees 3 and 4)."</seg>
<seg id="2015">In case of overdosation is the patient to observe the signs of an intoxication (see section 4.8) if necessary, are necessary measures. "</seg>
<seg id="2016">Amstraavir binds to the active Centre of HIV-1-protector and prevents the procedure of the viral Gagging and Gag-pol- Polyproteinated levels with the result of a formation of a formation not infectiously virus particles.</seg>
<seg id="2017">The antiviral activity of Amstraavir in vitro against HIV-1 IIIB was examined both in acute and chronic lymphocytic cell lines (MT-4, CEM-CCRF, H9) as well. "</seg>
<seg id="2018">"50%, Hemmconcentration (IC50) of Amstraavir is located in the area of 0,012 to 0,08 µm with acute cells and amounts 0.41 µm with chronic diseases."</seg>
<seg id="2019">The connection between the activity of Amstraavir against HIV-1 in vitro and the Heming of HIV-1 replication in humans is not defined.</seg>
<seg id="2020">"in the treatment of antiretroviral patients with the currently approved riamprenavir / Ritonavir-Dosiders have been observed - like at other Ritonavir-Dosiders - like at other Ritonavir-Dosims, which were only rarely observed."</seg>
<seg id="2021">"for sixteen years of 434 antiretroviral-treated patients, the 700mg of Famprenavir with 100mg Ritonavir twice daily in the study of ESS100732, a virological failure up to 48 on, with 14 insulation genotype can be examined."</seg>
<seg id="2022">A genotype analysis of the insulating analysis of the Isolate of 13 of 14 children who had a virological failure within the 59 which was formed with protrusted patients which were similar to adults.</seg>
<seg id="2023">"L10F / I / V, V11I, I13V, V32I, I50V, I50V, I50V, I50V, I45E, I84V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I113V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90V, L90</seg>
<seg id="2024">The APV30003 and its extension APV30005 and its extension APV30005 (700 mg of Famprenavir / 100 mg of Ritonavir twice daily: n = 107) with protocols of patients with virological Versailles.</seg>
<seg id="2025">"on genotypes of the analysis of the analysis of Amberavir / Ritonavir, Ritonavir or Famprenavir / Ritonavir, patients with protesters-resistant insulation."</seg>
<seg id="2026">"the current (July 2006) ANRS-AC-11 series is defined as the presence of the mutations V32I + 147a / V, L33V, M36A / C / S / S / M / S / S / S, I62V and L90M, as well as a reduced probability of a virological response (resistance)."</seg>
<seg id="2027">"the conclusions are subject to alterations of certain mutations or mutations, can be recommended by additional data, and it is recommended to withdraw the current interacting systems to analysis the results of resistance tests."</seg>
<seg id="2028">"results appear ordered" "by relevance" "or" "by date" "(publication date),"</seg>
<seg id="2029">Firm of the Year for Insolvency Administration Schneider Geiwitz & Partner Firm of the Year for Tax Gleiss Lutz</seg>
<seg id="2030">"each of these four with a reduced sensitivity against Amberavir associated genetic patterns creates a certain cross-war against Ritonavir, the sensitivity against Indinavir, the sensitivity against Indinavir, caviavir and Saquinavir."</seg>
<seg id="2031">"there are currently data about the cross-border between Amstraavir and other protocols for all 4 Famprenavir resistance, either alone or in combination with other mutations."</seg>
<seg id="2032">"at the basis of feit twenty antiviral / Ritonavir (three of 25 Isolate), Darinavir / Ritonavir (three of 24 Isolate), Darinavir / Ritonavir (three of 24 Isolate), Saquavir / Ritonavir (three of 24 Isolate), Saquavir / Ritonavir (4 of 24 Isolate)."</seg>
<seg id="2033">"on the other hand, Amstraavir his activity against some other prototypes were observed against the number and the type of resistance mutations in the insulation."</seg>
<seg id="2034">It is recommended to maintain a variety of mutations in the limits of a variety of mutations in limits which can affect the following treatment.</seg>
<seg id="2035">"the cover of Awarase in combination with Ritonavir 100 mg twice daily, based on the study PRO30017, a randomised study, in which with PI treatment (100 mg twice daily) and Nucleosidanaloga (NRTI) or a standard therapy (standard of care, SOC) with a PI, a randomized Ritonavir."</seg>
<seg id="2036">ISO-8859-1 (Western Europe) iso-8859-2 (Western Europe) iso-8859-2 (Central Europe)</seg>
<seg id="2037">"the primary analysis, the non-underline of APV / Ritonavir in terms of the output value (AAUCMB) in terms of the output value (AAUCMB) in terms of the output value (AAUCMB) in the analysis of the output value (AAUCMB) in the analysis of the output value (AAUCMB) in the analysis of the output value (AAUCMB) in the plasma after 16 weeks, at a non-lower risk of 0.4 log10 copies / ml."</seg>
<seg id="2038">"the result of unbent Awarase is based on two hypothetical scenarios, with a total of 288 HIV-based children in the age of 2 to 18 years, by which 152 with PI were treated."</seg>
<seg id="2039">"in the studies, Awarase solution for insertion and capsules in Dosification of 15 mg / kg three daily, 20 mg / kg twice daily, 20 mg / kg twice daily, 20 mg / kg twice daily, with the number of patients 20 mg / kg twice daily."</seg>
<seg id="2040">The majority of the patients had been given at least one (78%) or two (42%) or two (42%).</seg>
<seg id="2041">"after 48 weeks, about 25% of the study found a plasma-HIV-1-RNA concentration &lt; 10,000 copies / ml and 9% &lt; 400 copies / ml at a median increase of the CD4 cell number of 26 cells / mm ³ (n = 74) compared to the output value."</seg>
<seg id="2042">19 Basically on this data should be examined in the therapy optimization with PI treatment with PI treatment of "undefined" Awarase. "</seg>
<seg id="2043">"after oral countermeasures, the middle duration (TMax) up to maximum serum concentration of Amstraavir about 1 to 2 hours for the capsule and about 0.5 to 1 hour for the solution."</seg>
<seg id="2044">"508% increased, for Cmax on 30%, when Ritonavir (100 mg twice daily) together with Amstraavir (600 mg twice daily)."</seg>
<seg id="2045">"there is no effect on the concentration of Amstraavir, but no effect on the concentration of Amstraavir 12 hours after dosage (C12)."</seg>
<seg id="2046">"therefore, the minimal concentration in the Steady State (Cmin, ss) of the food intake is influenced by the food intake the extent and the rate of Resorption."</seg>
<seg id="2047">"the distribution volume is about 430 mm (6 l / kg by a body weight of 70 kg), and can be used on a large distribution volume, as well as a high level of penetration of the blood circulation in tissue."</seg>
<seg id="2048">"these changes leads to a decrease in the total concentration of the active ingredient in plasma, whereby the amount of unborn Amstraavir, which is likely to remain unchanged."</seg>
<seg id="2049">"during the absolute concentration of unstable Amberavir, fluctuating the percentage of the free active stock of the free active stock during the dosing interval during the dosing interval during the dosing interval of the Cmax, ss up to Cmin."</seg>
<seg id="2050">"therefore, drugs, the CYP3A4 or substrate of CYP3A4 or a substrate of CYP3A4, with caution (see Sections 4.3, 4.4 and 4.5)."</seg>
<seg id="2051">"the gift of Awarase capsules, either 20 mg / kg twice, or 15 mg / kg three times, leads to a similar daily Amstraavir exposition as for adults with a dosage of 1200 mg twice daily."</seg>
<seg id="2052">Amstraavir is made of the solution 14% less biophthalates than consists of the capsules; therefore Awarase solution and Awarase capsules not found on a millimetres.</seg>
<seg id="2053">"this is the renal Clearance of Ritonavir, therefore, the effect of a kidney function based on the Elimination of Amberavir and Ritonavir."</seg>
<seg id="2054">"this treatment Schata lead to Amstraavir-plasticized, who are comparable to a dose of 1200 mg Amstraavir twice daily without the current delay of Ritonavir."</seg>
<seg id="2055">"in long term studies in the proceedings with Amnesty and Rites at the male animals, the use of male animals, or 3,8- (Ratte) or 3,8- (Ratte) or 3,8- (Ratte) or 3,8- (Ratte) of the exposition on humans, according to twice a gift of 1200 mg Amstraavir, said."</seg>
<seg id="2056">The 21 underlying mechanism for the origin of hepatonic Adenome and carcinoma has not been involved and the relevance of these observed effects for people is unclear.</seg>
<seg id="2057">The assumption of full take-up tends to exaggerate the simulated increase in caseloads and fiscal costs of a social policy reform.</seg>
<seg id="2058">"in a standard batteries from In-vivo- and in-vitro-Genotoxation tests, the bacterial test tests (Ames test), the bacterial test of romphom test (Ames test), the bacterial test of rocket and chromosomes."</seg>
<seg id="2059">"these liver toxic substances can be monitored in clinical life through measurement, ALT and the activity of alkaline phosphatase."</seg>
<seg id="2060">"in clinical trials, there was no significant increase in clinical trials nor no significant liver cells in patients, nor during the treatment of Awarase nor after the end of the treatment."</seg>
<seg id="2061">"studies on toxicity, which were treated from a age of 4 days, both were treated as well as with Amnesty and treated them a high mortality."</seg>
<seg id="2062">"however, a number of minor changes including thymuselongation, were observed, however, a number of minor changes including thymuselongation and minor skeletal changes, which are treated to a delayed development."</seg>
<seg id="2063">"24 If the generals are used without the amplification of Ritonavir (Boostats), have to be applied to Awarase (1200 mg twice daily)."</seg>
<seg id="2064">The recommended dose for Awarase capsules is 20 mg Amstraavir / kg body weight twice daily in combination with other antiretroviral drug use up to a daily dose of 2400 mg Amstraavir that should not be exceeded (see section 5.1).</seg>
<seg id="2065">"the current application should be carried out in patients with low or lighter liver function with caution, in patients with severe liver function."</seg>
<seg id="2066">"26 For some medicines that cause serious or life-effects side effects, such as Carbamazepin, phenytoin, tricycasics, phenytoin, tricycasiva and Warfarin (under monitoring of the active ingredient)."</seg>
<seg id="2067">Awarase should be set up to duration 27 when a skin supplement of systemic or allergic symptoms (see section 4.8).</seg>
<seg id="2068">"a increased risk for a Lidauystrophies, with individual factors, such as higher age, and with drug-dependent factors, such as a longer-lasting antiviral treatment and associated disorders."</seg>
<seg id="2069">"it was shown that Rifampicin a 82% reduction of the Auc from Amstraavir, which can lead to a virological failure and to an resistance development."</seg>
<seg id="2070">"508% increased, for Cmax on 30% lower when Ritonavir (100 mg twice daily) in combination with Amstraavir capsules (600 mg twice daily)."</seg>
<seg id="2071">"the Cmin-values from Amstraavir (600 mg twice daily) with Kaletra (600 mg twice daily) with Kaletra (400 mg twice daily), about 40 to 50% lower than when Amstraavir (600 mg twice daily) in combination with 100 mg of Ritonavir twice daily."</seg>
<seg id="2072">"a dosing recommended for the current reduction of Amberavir and Kaletra can not be given, however, however, it is not known to the efficacy of this combination."</seg>
<seg id="2073">The treatment with Efaviation in combination with Amstraavir and Saquinavir is not recommended because the Exposition of both Proteins were low.</seg>
<seg id="2074">"if these drugs are applied to be used, a thorough clinical and virological supervision shall be seen as a precise positioning of the combination of Amstraavir and Ritonavir on Delavirdin."</seg>
<seg id="2075">"when it is necessary, Rifabutin together with Awarase, is recommended to reduce the dosage of Rifabutin at least at least half of the recommended dose."</seg>
<seg id="2076">"the Serum concentrations of Calciumkanizers like Amlodipin, diltiazem, diodized, dipping pin, diodidipin, diodidipin, diodidipin, diodidipin, diaphragm, which may be increased by Amstraavir, allowing the activity and toxicity of these drugs."</seg>
<seg id="2077">"in a clinical study, in the Ritonavir 100 mg capsules twice a day with 50 µg Fluticasonprosis at intranassol (4 times daily) over 7 days."</seg>
<seg id="2078">"at the same gift of Warfarin or other oral antioagulthood together with Awarase, a reinforced control of the INR (International Normalisation) is recommended for the possibility of a debug or gain of antibacterial effect (see section 4.4)."</seg>
<seg id="2079">1 / 35 (0.035 mg × ethinyl stradiol plus 1.0 mg Norethindron) resulted in a removal of the Auc and Cmin from Amstraavir to 22%.</seg>
<seg id="2080">This drug may only be applied during pregnancy during pregnancy only after careful consideration of the possible risks of the possible risks to the fades.</seg>
<seg id="2081">"at the end of the standpoint of Amberavir, a reduction of body weight in the Uterus until the end of the standpoint of Amberavir was retained during the present time."</seg>
<seg id="2082">"for adults and children from 4 years, adults and children from 4 years in controlled clinical trials in combination with different antiretroviral cancer."</seg>
<seg id="2083">In case of overdosation is the patient to observe the signs of an intoxication (see section 4.8) if necessary, are necessary measures. "</seg>
<seg id="2084">The antiviral activity of Amstraavir in vitro against HIV-1 IIIB was examined both in akut and chronic lymphocytic cell lines (MT-4, CEM-CCRF, H9) as well as peripheral blood lymphocytes. "</seg>
<seg id="2085">"50%, Hemmconcentration (IC50) of Amstraavir is located in the area of 0,012 to 0,08 µm with acute cells (1 µm = 0.50 µg / ml)."</seg>
<seg id="2086">"on the other hand, Amstraavir his activity against some other prototypes were observed against the number and the type of resistance mutations in the insulation."</seg>
<seg id="2087">"based on these data, we should be examined in therapy optimization with PI pre-treated confidentiality."</seg>
<seg id="2088">"during the absolute concentration of unstable Amberavir, fluctuating the percentage of the free active stock of the free active stock during the dosing interval during the dosing interval during the operation of Cmax, ss to Cmin, ss.."</seg>
<seg id="2089">"therefore, drugs, the CYP3A4 or substrate of CYP3A4 or a substrate of CYP3A4, with caution (see Sections 4.3, 4.4 and 4.5)."</seg>
<seg id="2090">"this is the renal Clearance of Ritonavir, therefore, therefore, the effect of a kidney function based on the Elimination of Amberavir and Ritonavir."</seg>
<seg id="2091">"in long term studies in the proceedings with Amnesty and Rites at the male animals, the use of male animals, or 3,8- (Ratte) or 3,8- (Ratte) or 3,8- (Ratte) or 3,8- (Ratte) of the exposition on humans according to two days."</seg>
<seg id="2092">The underlying mechanism for the emergence of hepatulary Adenome and carcinoma has not been involved and the relevance of these observed effects for people is unclear.</seg>
<seg id="2093">The assumption of full take-up tends to exaggerate the simulated increase in caseloads and fiscal costs of a social policy reform.</seg>
<seg id="2094">"in a standard batteries from In-vivo- and in-vitro-Genotoxation tests, the bacterial test tests (Ames test), the bacterial test of romphom test (Ames test), micro-Lymphom test."</seg>
<seg id="2095">"studies on toxicity, which were treated from a age of 4 days, both were treated as well as with Amnesty and treated them a high mortality."</seg>
<seg id="2096">"these results allow that the metaphysics are not fully equipped, so that Amstraavir or other critical components of the formulation (z."</seg>
<seg id="2097">Awarase solution for insertion is used in combination with other antiretroviral cancer treatment for treating HIV-1-inseparating adults and children from 4 years.</seg>
<seg id="2098">"the benefit of with Ritonavir" toosterter "Agenerals solution, nor does not take any of the treated patients with PI patients."</seg>
<seg id="2099">The bioavailability of Amberavir is a solution to take advantage of 14% lower than by Amstraavir as capsule; therefore Awarase capsules and solution to one milligram per milligram (see section 5.2).</seg>
<seg id="2100">"the patients should consider once they are able to swallow the capsules, using the solution of the solution (see section 4.4)."</seg>
<seg id="2101">The recommended dose for Awarase solution is 17 mg (1.1 ml) Amstraavir / kg body weight times daily in combination with other antiretroviral drug use up to a daily dose of 2800 mg Amstraavir that should not be exceeded (see section 5.1).</seg>
<seg id="2102">"in addition, there is no obligation recommended for the current application of Awarase solution to take-up and low dosing system, this combination can be avoided at this patient."</seg>
<seg id="2103">"although a delay for Amphenavir is not necessary for necessary, is a application of Agenerase solution for insertion in patients with kidney cancer (see section 4.3)."</seg>
<seg id="2104">"due to the potential risk of a toxic reaction as a result of the high Propylenglycolgeological is Agenerase solution for small children and children under 4 years, with limited liver function or liver transplantation and patients with kidney cancer."</seg>
<seg id="2105">This medicine can lead to an authorisation of the metabolition of this medicine and possibly serious side effects such as heart rhythmatism (z.</seg>
<seg id="2106">Patients should have to develop that Agenerase or any other antiretroviral therapy does not develop a healing of HIV infection or other complications of HIV infection.</seg>
<seg id="2107">The current antiviral therapy including treatment with Agenerase prevents the risk of a transfer of HIV on other through sexual contact or contamination with blood.</seg>
<seg id="2108">"for some medicines that cause serious or life-effects side effects, such as Carbamazepin, phenytoin, tricycasiva and Warfarin (under monitoring of the active ingredient), methods for determination of the active ingredient is available."</seg>
<seg id="2109">Awarase should be set up to duration when a skin can be accompanied by systemic or allergic symptoms (see section 4.8).</seg>
<seg id="2110">"a increased risk for a Lidauystrophies, with individual factors, such as higher age, and drug use of 49 dependent factors such as a longer-lasting antiretroviral treatment and associated disorders."</seg>
<seg id="2111">"in hammophilen patients (type A and B) who were treated with protesters, are opinions about a increase of blood, including spontaneous hemalysts and hemmargins."</seg>
<seg id="2112">"it was shown that Rifampicin a 82% reduction of the Auc from Amstraavir, which can lead to a virological failure and to an resistance development."</seg>
<seg id="2113">"508% increased, for Cmax on 30% lower when Ritonavir (100 mg twice daily) in combination with Amstraavir capsules (600 mg twice daily)."</seg>
<seg id="2114">(see section 4.4) will strengthen the current side effects of hypotension, tendons and priapism (see section 4.4). "</seg>
<seg id="2115">On the basis of the data to 54 other CYP3A4-Inhibitors will be significantly higher Plasmaisoning by Midazolam.</seg>
<seg id="2116">The potential risk for humans is not known as well. Awarase solution to take due to possible toxic reactions of the fetus can not be applied during pregnancy (see section 4.3).</seg>
<seg id="2117">"in the milk, Amstraavir-related substances, however, it is not known that Amstraavir is not known to people in the mother's milk."</seg>
<seg id="2118">"at the end of the standpoint of Amberavir, a reduction of 55 body weight loss was retained during the present time."</seg>
<seg id="2119">"for adults and children from 4 years, adults and children from 4 years in controlled clinical trials in combination with different antiretroviral cancer."</seg>
<seg id="2120">"in many of these events this events is not dissolved, whether they are in connection with Agenerase or another at the same time to HIV therapy medicines, or whether they are a result of the land disease."</seg>
<seg id="2121">"in the treatment of antiretroviral patients with the currently approved riamprenavir / Ritonavir-Dosiders have been observed - like at other Ritonavir-Dosiders - like at other Ritonavir-Dosims, which were only rarely observed."</seg>
<seg id="2122">The early stages of a versagulation of 60 therapy is recommended to maintain a variety of mutations in the limits which can lead to the following treatment.</seg>
<seg id="2123">62 Basically on this data should be examined in the therapy optimization with PI treatment with PI pre-treated. Awarase into consideration.</seg>
<seg id="2124">"the distribution volume is about 430 mm (6 l / kg by a body weight of 70 kg), and can be adjusted to a large number of penetration of the blood circulation in the tissue."</seg>
<seg id="2125">The underlying mechanism for the disease of hepatonic Adenome and carcinoma has not been involved and the relevance of these observed effects for people is unclear.</seg>
<seg id="2126">"however, a number of minor changes including thymuselongation, were observed, however, a number of minor changes including thymuselongation and minor skeletal changes, which are treated to a delayed development."</seg>
<seg id="2127">"if you have any questions, please contact your doctor or pharmacist."</seg>
<seg id="2128">"if you are aware of other people, even if these are the same symptoms such as you did. if one of the side effects you do not hesitate to contact side effects, please inform your doctor or pharmacist."</seg>
<seg id="2129">"your doctor will normally indicate, Awarase capsules together with low cans Ritonavir, to strengthen the effect of Awarase."</seg>
<seg id="2130">The use of Awarase is based on your doctor for you continuous the individual viral resistance test and your treatment history.</seg>
<seg id="2131">"inform your doctor if you suffer from one of the above mentioned disorders, or any of the above mentioned medicines."</seg>
<seg id="2132">"if your doctor recommended that you can take Awarase capsules along with low cans of Ritonavir, make sure you have to read before the beginning of the treatment of the use of Ritonavir carefully."</seg>
<seg id="2133">There are no sufficient information in order to recommend the application of Awarase capsules along with Ritonavir for active ingredients in children aged 4 to 12 years or general in patients under 50 kg of body weight.</seg>
<seg id="2134">"therefore, it is important that you start the section" "In case of Awarase with other medicines, before you start with taking Awarase."</seg>
<seg id="2135">Possibly need to control additional factor VIII to control the blood vessels.</seg>
<seg id="2136">"if you have specific medicines which may lead to serious side effects such as Carbamazepin, phenytoycin, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine,"</seg>
<seg id="2137">"there is recommended that HIV positive women have their children under no circumstances, to avoid a transfer of HIV."</seg>
<seg id="2138">Transport and the filling of machines have no studies to influence the influence of Awarase on driving conditions or the ability to serve machines.</seg>
<seg id="2139">Please take this medicine only after returning with your doctor if you are known to suffer from a unreasonable point towards certain circumstances.</seg>
<seg id="2140">"Didanosin), it is advisable that you can take this more than one hour before or after Awarase, otherwise the effects of Awarase."</seg>
<seg id="2141">Dosage of Awarase capsules is 600 mg twice daily together with 100 mg of Ritonavir twice daily in combination with other antiretroviral cancer.</seg>
<seg id="2142">"if your doctor decides that taking the Ritonavir for you not, you will have to take higher cans (1200 mg Amstraavir twice daily)."</seg>
<seg id="2143">"85 Damit Agenerals one as possible as possible as possible as possible, it is very important that you do not have the entire daily dose that take you to your doctor."</seg>
<seg id="2144">If you have taken a larger amount of Awarase you should have to be taken up when you have taken more than the written dosage of Awarase you should be able to contact your doctor or pharmacist contact.</seg>
<seg id="2145">"if you have forgotten the taking of Awarase you have forgotten it, if you think it will remember, and set the taking as before."</seg>
<seg id="2146">"for treating a HIV infection, it is not always possible to say if possible side effects due to Agenerase, by other medicines which can be taken into the same time or by the HIV disease itself."</seg>
<seg id="2147">"headaches, muscle pain, disease, disease, aperture, aperture, aperture, aperture, aperture of skin, or juckreiz) - occasionally, the skin can be severe nature and you shall break the skin of this drug."</seg>
<seg id="2148">"the lack of depression, depression, sleep disorders, appetizing movements, uncomfortable or excessive stomach, soft chairs, increase of certain liver milk, disinfectants, increase of a enzymes of pancree. Amylase"</seg>
<seg id="2149">"increased blood values for sugar or cholesterol in (a certain BLUETT), blood values of a metabolic named Bilirubin swelling of the face, the lips and the tongue (Angioöp."</seg>
<seg id="2150">"this may be fat loss of legs, arms, and in the face, a fat increases on the stomach and in other inner organs, breast cancer and fat burning in the neck (" Stiernes ")."</seg>
<seg id="2151">"please inform your doctor or pharmacist, if one of the side effects you can choose from either side effects or side effects that are not found in this use."</seg>
<seg id="2152">"therefore, it is important that you start the section" "In case of Awarase with other medicines, before you start with taking Awarase."</seg>
<seg id="2153">"in some patients, a antiretroviral combination can be treated as a Osteonekrose (Abdie of bone tissue due to insufficient complications due to insufficient blood supply of the bone)."</seg>
<seg id="2154">"Didanosin), it is advisable that you can take this more than one hour before or after Awarase, otherwise the effects of Awarase."</seg>
<seg id="2155">"94 Damit Agenerals one as possible as possible as possible as possible, it is very important that you use the entire daily dose that take you to your doctor."</seg>
<seg id="2156">"if you have forgotten the taking of Awarase, If you have forgotten the taking of Awarase you take it as soon as you think, and set the taking as before."</seg>
<seg id="2157">"headaches, muscle pain, disease, disease, aperture, aperture, aperture, aperture, aperture of skin, or juckreiz) - occasionally, the skin can be severe nature and you shall break the skin of this drug."</seg>
<seg id="2158">"please inform your doctor or pharmacist, if one of the side effects you can choose from either side effects or side effects that are not found in this use."</seg>
<seg id="2159">Dosage of Awarase capsules is 600 mg twice daily together with 100 mg of Ritonavir twice daily in combination with other antiretroviral cancer.</seg>
<seg id="2160">It is very important that you do not have the entire daily dose that take you to your doctor.</seg>
<seg id="2161">"if you have larger quantities of Awarase, when you should have taken more than the dosage dose of Awarase you should be taken immediately with your doctor or pharmacist contact."</seg>
<seg id="2162">"the benefit of with Ritonavir" toosterter "Agenerals solution, nor does not take care of depreciation patients with protested patients."</seg>
<seg id="2163">"for the use low dose of Ritonavir (usually applied to the effects of the use of Awarase capsules), together with Agenerase solution can be added together with Agenerase solution."</seg>
<seg id="2164">"Ritonavir solution for insertion), or additionally soylenglyas during the taking of Awarase solution (see also Agenerase cannot be taken)."</seg>
<seg id="2165">Your doctor will take you to side effects on side effects associated with the Propylenglycolcolcontent of the Agenerase solution for insertion in connection, especially if you have a kidney or liver disease. "</seg>
<seg id="2166">"111 If you have specific medicines which may lead to serious side effects such as Carbamazepin, phenytoycin, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine, tricycine,"</seg>
<seg id="2167">Ritonavir solution for inserting) or additional Propylenglysis included during the taking of Awarase (see Awarase cannot be taken).</seg>
<seg id="2168">"important information on certain other components of Agenerase solution to the insertion, the Propylenglysis, which can lead to side effects."</seg>
<seg id="2169">"Propylenglysis can cause a number of side effects including crampfancies, obommenities, heart rasen and the reduction of red blood cells (see also Awarase cannot be taken away)"</seg>
<seg id="2170">"if you have forgotten the taking of Awarase you have forgotten it, if you think it will remember, and set the taking as before."</seg>
<seg id="2171">"headaches, muscle pain, disease, disease, aperture, aperture, aperture, aperture, aperture of skin, or juckreiz) - occasionally, the skin can be severe nature and you shall break the skin of this drug."</seg>
<seg id="2172">"this may be fat loss of legs, arms, and in the face, a fat increases on the stomach and in other inner organs, breast cancer and fat burning in the neck (" Stiernes ")."</seg>
<seg id="2173">"the other components of Propylenglysis, Tocofersolan (TPGS), Tocofersolan (TPGS), Tocofersolan (TPGS), Tocofersolan (TPGS), Tocofersolan (TPGS), Tocofersolan (TPGS), toidulfam-potassium, sodium citrine, sodium-hydrate, dried water."</seg>
<seg id="2174">"the applicability and the duration of the treatment with algae in the genital area is Aldara to a maximum of 16 weeks per week. • In addition to a maximum of 16 weeks per week, it is suitable during one or two four weeks of treatment, with four weeks break between the treatment unit, three weeks per week."</seg>
<seg id="2175">The cream is in front of the sleeping surfaces on the affected skin surfaces that they have enough long (about eight hours) on the skin before they washed them.</seg>
<seg id="2176">"in all studies, Aldara was compared to the same fluid, but without the active substance). • Aldara was tested in four main studies at 923 patients with Warning in the genital area of 16 weeks."</seg>
<seg id="2177">• Aldara was examined in 724 patients with small basal cell carcinations in two studies in which patients were treated six weeks and Aldara or the placebo either daily or fifty times per week.</seg>
<seg id="2178">• Aldara was tested in two studies based on a total of 505 patients with acute keratants.</seg>
<seg id="2179">"• The results of the two studies in Basal cell carcinogenous patients, however, only 3% to 18% compared with Aldara treated patients, but only 3% to 18% compared with Aldara treated patients in comparison to 0% up to 3% in the placebo group."</seg>
<seg id="2180">The most common side effects of Aldara (observed in more than 1 of 10 patients) are reactions to the use of cream (pain or juckreiz).</seg>
<seg id="2181">"on the face or on the head of immune diseases (AKs) in the face or on the head of immune diseases, when the size or number of lence the effectiveness and / or the acceptance of a crative treatment options and other topical treatment options can be found or less suitable."</seg>
<seg id="2182">"Monday, Wednesday and Friday or Tuesday, Thursday and Saturday) prior to the cubettings and 6 to 10 hours long on the skin."</seg>
<seg id="2183">The treatment with Imiquimod-cream is so long to take up to all the visible feigners in the genital or Peripherals of the genital area or to a maximum of 16 weeks per treatment.</seg>
<seg id="2184">An interruption in the above treatment should be observed when intensive local inflammation can occur (see section 4.4) or if in the treatment area is observed.</seg>
<seg id="2185">"if the Follow-up examination 4 to 8 weeks after the second treatment, the treated spoils are only incomplete, should a other therapy should be started (see section 4.4)."</seg>
<seg id="2186">"when a dose is lifted up, soled the patient to wear the cream, once he / she will notice and then put it with the usual treatment plan."</seg>
<seg id="2187">Imiquimod-cream is divided into a thin layer.</seg>
<seg id="2188">"in this regard, patients undertake a reduction between the benefit of a treatment with Imiquimod and with a possible balance of their autoimmune diseases."</seg>
<seg id="2189">"in this regard, patients undertake a reduction between the benefit of a treatment with Imiquimod and a possible immune system or Graft-versus-Host- reaction risk."</seg>
<seg id="2190">"in other studies, there were no daily preparation in other studies, two cases have observed two cases of hard disks, and a case with one to the transgression-determination."</seg>
<seg id="2191">"in a application of Imiquimal cream in higher than the recommended dose, a increased risk for heavy local guides (see section 4.2.) In rare cases, the treatment is needed and / or to a temporary physical injury."</seg>
<seg id="2192">"in cases where such reactions are carried out at the output of the urges, some women are difficulties at the output of the urine, which are necessary for an emergency stop and treatment of affected area."</seg>
<seg id="2193">"the use of Imiquimod-cream is directly used in the connection to a treatment with other treatment for treatment of treatment for treatment of treatment in the genital and Peripherals, no clinical experience."</seg>
<seg id="2194">"limited to a higher rate of barrels with HIV-positive patients, Imiquimod-cream has been shown in this patient."</seg>
<seg id="2195">"the treatment of the Basal cell carcinoma with Imiquimod within 1 cm around the eye, the nose, the lips or the hair was not examined."</seg>
<seg id="2196">"local government actions are often, but the intensity of these reactions are generally employed in general during therapy or the reactions to the treatment with Imiquimod cream."</seg>
<seg id="2197">"when it comes to complaints of patients or due to the severity of local residents, can be made a treatment of several days."</seg>
<seg id="2198">The clinical outcome of therapy can be assessed according to the regeneration of the treated skin for 12 weeks after the treatment of treatment.</seg>
<seg id="2199">"there are no data about the long-term heating rates of more than 36 months after treatment, should be drawn up to two fizial basal cell carcinations."</seg>
<seg id="2200">"in patients with rezidification and pre-treated BCCs are no clinical experience, therefore the application should not be recommended."</seg>
<seg id="2201">Data from an open clinical study indicate that in large tumors (&gt; 7.25 cm2) a lower probability of the response to the Imiquimod therapy.</seg>
<seg id="2202">"Imiquimod was not used for treatment for treating keratants, inside the nose or ears or ears on the lights."</seg>
<seg id="2203">"there are only very limited data via the application of Imiquimod for the treatment of allergies in anatomical places, outside of the facial and head."</seg>
<seg id="2204">The available data about the akincic keratosis on the underpoor and hands support the effectiveness of this application that is not recommended for such use.</seg>
<seg id="2205">"local Hauts are often used, but these reactions are usually carried out in the course of therapy to the intensity, or go after the therapy of therapy with Imiquimod-cream."</seg>
<seg id="2206">"if the local residents have to cause patients with patients, or very strong, the treatment for some days are subject to some days."</seg>
<seg id="2207">"in the case of an open clinical study, patients with more than 8 AK- Läsions are reduced less full working rate as patients with less than 8 lence."</seg>
<seg id="2208">"due to the immunointal properties, Imiquimal cream with caution in patients who receive a immunotherapy treatment (see 4.4)."</seg>
<seg id="2209">"there are no direct or indirect polar effects on the pregnancy, embryonic / fötale development, empiries or the postnatal development (see 5.3)."</seg>
<seg id="2210">"although neither after a multi-dimensional application quantification of serum mirror (&gt; 5ng / ml), no recommendation can be given to the application during the standtime."</seg>
<seg id="2211">"the most common mites and as probably or may possibly be found with the application of Imiquimod-cream in connection with a three weeks, local reactions at the place of the treatment of feigners (33.7% of the patient treatment)."</seg>
<seg id="2212">"the most frequently reported, as probably or may may be associated with the application of the Imiquimod cream in connection side effects on application site with a frequency of 28,1%."</seg>
<seg id="2213">The study of 185 with Imiquimal-cream-treated basaliom patients from a placebo controlled clinical study of phase III.</seg>
<seg id="2214">"the most common, as probably or may may be associated with the application of the Imiquimal cream in connection effect in these studies have a reaction of application place (22% of with Imiquimal treated patients)."</seg>
<seg id="2215">Side effects that were listed below the placebokontocratic clinical studies of Phase III with Imiquimal-cream treatment.</seg>
<seg id="2216">"according to the test plan, the clinical signs shows that it is often used in these placebo controlled clinical trials associated with Imiquimod-cream, including Eryy (61%), Exkoriation / Abbreviations (23%) and ÖKO (14%) (see section 4.4)."</seg>
<seg id="2217">"according to the test plan, this according to the clinical signs that it shows that this studies with five times a weekly treatment with Imiquimod-cream is very often to heavy duty (13%), and to severe cooperations and cabbage (19%)."</seg>
<seg id="2218">Clinical trials in clinical trials for the treatment of Imiquimod for treatment of acute keratosis was taken with a frequency of 0.4% (5 / 1214) on the treatment area or in the surrounding area.</seg>
<seg id="2219">"when the content of about 16 mg Imiquimod, what the content of about 16 bag is corresponds to the content of about 16 bags, could cause cancer, headaches, myalom and fever."</seg>
<seg id="2220">"the clinically severe side effect, which after several orbit cans of &gt; 200 mg was placed in hypotonie, which according to oraler or intravenous fluid levels."</seg>
<seg id="2221">"in a Brazilian application, according to the topical application of Imiquimod-oriented concentrations of the Alphainterferons and other cytokine."</seg>
<seg id="2222">"in 3 operating systems, the effectiveness of relevant phase 3 will be shown that the effectiveness in relation to a complete loss of barrels at a Imiquimod-treatment over 16 weeks of a placebo treatment."</seg>
<seg id="2223">"in 60% of the total of 119 with Imiquimod-patient treatment, which was complete; this was one of 20% of the 105 with placebo. this was the case at 20% of the 105 with placebo."</seg>
<seg id="2224">A complete separation could be achieved by 23% of 157 with Imiquimod-treated male patients (95% CI):</seg>
<seg id="2225">"the effectiveness of Imiquimod in five weeks application per week over 6 weeks, was examined in two double blind, placebo controlled clinical studies."</seg>
<seg id="2226">The target values were histologically confirmed by single primary basal cell carcinoma with a minimum size of 0.5 cm2 and a maximum diameter of 2 cm.</seg>
<seg id="2227">"according to four years, data could show that approximately 79.3% [95% CI (73.7%, 84.9%)] all treatment patients were healed and this also 48 months."</seg>
<seg id="2228">"the effectiveness of Imiquimod is a two-week application in one or two treatment of 4 weeks, in two double blind, treatment-free time, was examined in two double blind, placebokontein clinical studies."</seg>
<seg id="2229">"patients had a typical typical, visible, discrete, not hyperkeratotic, non-tropical and non-tropical AK- Läsions within one set of 25 cm2 big treatment."</seg>
<seg id="2230">The year-year data from two combined period studies show that patients with clinically disappointment after one or two treatment of a Rezidivrate of 27% (35 / 128 patients).</seg>
<seg id="2231">The approved indications of aquatosis, acoustical Keratosis and Superfizial Basal cell carcinom is usually not found on paediatric patients. "</seg>
<seg id="2232">"Aldara cream was examined in four randomised, double blind the placebo controlled trials of children in the age of 2 to 15 years with Molluscum Contagiosum (Imiquimod n = 313)."</seg>
<seg id="2233">The effectiveness of Imiquimod could not be shown (3x / week for a period of ≤ 16 weeks).</seg>
<seg id="2234">A minimizing systemic recording of 5% pure Imiquimodine cream through the skin of 58 patients with acute keratosis was observed during 16 weeks.</seg>
<seg id="2235">"the highest drug concentration in serum at the end of the week 16 were observed between 9 and 12 hours and bets 0.1, 0.2 and 1.6 ng / ml at the face of the face (12.5 mg, 1 bag) and on the hands / arms (75 mg, 6 bags)."</seg>
<seg id="2236">"the calculated open-time period was about 10times higher than the 2stalled half-time period after the subcutaneous use in a former study, which has a extended retention of drug use in the skin."</seg>
<seg id="2237">The data for systemic exposition showed that the Resorption of Imiquimod is low in the age of 6 - 12 years low was low and comparable with healthy adults and adults with a healthy adults and adults with acute Keratosis.</seg>
<seg id="2238">"in a four months study, the resistance of resistance to 0,5 and 2.5 mg / kg KG is significantly reduced to significantly reduced body weight and increased Milz-Weight; one also has four months long, for the application of the mouse no similar effects."</seg>
<seg id="2239">"a two-year study for carcinogenesis on the carcinogenesis on three days per week induce, no tumors on the application area."</seg>
<seg id="2240">The corresponding mechanism is not known but as Imiquimod is only a low-systemic absorption of the human skin. it is a risk for people due to the systemic exposition as very low.</seg>
<seg id="2241">"the tumors are treated in the group of mite, which was treated with the real-free cream, before and in a greater number in the control group with a low UVR."</seg>
<seg id="2242">"if you do not need other people, even if you have the same symptoms as you did. if you are aware of the side effects you can select, please inform your doctor or pharmacist."</seg>
<seg id="2243">● Feigners (Condylomata acuminata) that has been formed on the skin in the field of genitals (sexual organic) and the Anus (After) made ● Construction Basal cell carcinom The is a common sense that growing the skin of the skin with very low probability of the body on other parts of the body.</seg>
<seg id="2244">Treatment: heat treated clarity: very distinct inclusions 1 piece</seg>
<seg id="2245">Acoustical Keratinate are harsh areas of the skin that occur in humans during their previous life much of the solar radiation.</seg>
<seg id="2246">"Aldara should only be applied in flat major trout in the face and on the head of patients with a healthy immune system where your doctor, that Aldara for you are the best suitable treatment."</seg>
<seg id="2247">Aldara cream supports your body's own immune system in the production of natural substances which help your body to fight the surface area of Basal cell carcinoma.</seg>
<seg id="2248">"if you have any problems with your immune system, please inform your doctor if you have problems with your immune system, please inform your doctor if you have problems with your immune system. o avoid the contact with your immune system. o avoid the contact with eyes, lips and nose."</seg>
<seg id="2249">"you don't have more cream than your doctor's cream. o check the cream after cleaning up with water. o check the cream after cleaning up to Aldara cream, you have to prepare the cream with a milder soap and water."</seg>
<seg id="2250">"as soon as the reactions are used, you can get your doctor if they have no normal blood image."</seg>
<seg id="2251">"if this daily cleaning is not carried out under the precinction, it can be carried out with increased intraocular surface, fertilisation of the skin or difficulties during the precinction."</seg>
<seg id="2252">Contact Aldara cream not in the Urethra (urinary).</seg>
<seg id="2253">"taking another medicines with your immune system, you should not use this medication for no longer than a treatment cycle."</seg>
<seg id="2254">If you have access during the infection with feigners in the genital area sexual intercourse is the treatment with Aldara cream after sexual intercourse (not before).</seg>
<seg id="2255">Please inform your doctor or pharmacist if you have used other medicines or before use other drugs, even if it is not possible to do. "</seg>
<seg id="2256">"it is not known as Imiquimod in the mother's milk."</seg>
<seg id="2257">The frequency and duration of the treatment are different at Feigwarzen, Basal cell carcinoma and acute keratosis (see specific instructions for each application area). "</seg>
<seg id="2258">Wear a thin layer Aldara cream on the clean and dry skin with the feigns on and off the cream on the skin, until the cream is fully assembled. "</seg>
<seg id="2259">"men with Feigners have to take care of each day and wash the skin area, including the section 2" "What do you have to consider the application of Aldara cream?" ")."</seg>
<seg id="2260">Please contact your doctor or pharmacist if you have the impression that the effect of Aldara is strong or weak.</seg>
<seg id="2261">"6 weeks for 5 days per week, a sufficient amount of Aldara cream to cover the affected area and 1 cm around this area."</seg>
<seg id="2262">Very frequent side effects (with more than 1 of 10 patients) to expect reduction side effects (with less than 1 of 100 patients) to expect significant side effects (with less than 1 of 1,000 patients).</seg>
<seg id="2263">Find your doctor / your doctor or pharmacist / your pharmacist immediately when you feel during the application of Aldara cream.</seg>
<seg id="2264">"if your skin has to be strong on the treatment with Aldara cream, you should not use the cream area with water and a mild organic soap and your doctor or pharmacist."</seg>
<seg id="2265">A erlow number of blood cells can make it possible for infections; it can cause you faster a blessness.</seg>
<seg id="2266">Inform your doctor or pharmacist when one of the side effects you can be examined or avoid side effects that are not found in this use.</seg>
<seg id="2267">"in addition, you can find Juckreiz (32% of patients), Bring (26% of patients) or pain in the areas that you find Aldara cream (8% of patients)."</seg>
<seg id="2268">"as a result, more than 2 weeks after removal of treatment."</seg>
<seg id="2269">"occasionally some patients changes to the application place (Wundmont, inflammation, swelling, skin, Dermatitis) or Reizability, nausea, dry mouth, grievesimilar symptoms and tiredness."</seg>
<seg id="2270">"occasionally some patients under alteration of the applicant (Bluffs, inflammation, sensitivity, heat and disabilities), inflammation of eye, grievous, capillation, capillation, capillation, capillings, fever, diarrhoes, fever, diarrhoes, fever, diarrhoes, fever, or shame."</seg>
<seg id="2271">Aldurazy is used for enzymes in patients with secured diagnosis of a Mukopolysacchariola I (MPS I; α -L-Iduronidase-lack) to treat the non-neurological manifestations of the disease (the symptoms which are not with brain or nerves in connection).</seg>
<seg id="2272">"this means that certain substances (glycosaminoglykane, Gags) are not dismantled and therefore, therefore, in most organs in the body."</seg>
<seg id="2273">"the following non-neurological symptoms of MPS I can occur: enlarged liver, stiff joints, the movements, reduction of lung volume, heart and eye diseases."</seg>
<seg id="2274">Treatment with Aldurazol should be monitored by a doctor, the experience in the treatment of patients with MPS I or other erary metabolic diseases. "</seg>
<seg id="2275">Provisions of Telecommunications Act on storage and use of telecommunications data unconstitutional in part</seg>
<seg id="2276">Deprecated: function ereg _ replace () is deprecated in / www / htdocs / w00cec0c / webEdition / we / include / we _ modules / object / we _ listview _ multiobject.class.php on line 296</seg>
<seg id="2277">"in the study, the safety of the drug has been examined, however, even its effectiveness (by its effect in relation to reduction of GAG concentrations in the urine and in relation to the liver was examined)."</seg>
<seg id="2278">"for children under five years, Aldurazi, GAG concentrations in the urine around 60%, and half of the treated children, at the end of the study, a normal liver."</seg>
<seg id="2279">"the most common side effects of Aldurazy in patients in age of over five years (observed for more than 1 of 10 patients), headaches, abdominal pain, abdominal pain, abdominal pain, abdominal pain, pain in the Gliedoms (in hands and feet), heat, fever, and reactions to the Infusion."</seg>
<seg id="2280">"very frequent side effects of patients under five years, increased blood pressure, reduced oxygen saturation (a measuring size of the lung function), speedykarst (spigte heart rate), fever, and reproach."</seg>
<seg id="2281">"Aldura (allergic) is not applied to Laronidase or one of the other components (anodical reaction), not applied."</seg>
<seg id="2282">"the European drug agency (EMEA) will receive all new information which may be known, check and this summary required."</seg>
<seg id="2283">"on the other hand, the manufacturer of Aldurazole will receive patients who observe Aldurazy, to observe the reactions to the infusion and the development of antibodies."</seg>
<seg id="2284">"in June 2003, the European Commission of the company Genzyme Europe B.V. are a permit for the Invoice of Aldura in the whole European Union."</seg>
<seg id="2285">"Laronidase is a recombinant form of the humanist α -L-Iduronidase, and is produced by recombinable DNA technology using Cho-acid cell nuclei and is produced by recombinable DNA technology."</seg>
<seg id="2286">Aldurazy is for long-term enzymes for patients with secured diagnosis of a Mukopolysacchariola I (MPS I, α -L-Iduronidase-deficiency) in order to treat the non-neurological manifestations of the disease (see section 5.1). "</seg>
<seg id="2287">Treatment with algae in treating patients with MPS I or other erary metabolic diseases.</seg>
<seg id="2288">"the initial infusion rate of 2 E / kg / h may be increased, all 15 minutes in individual steps are increased to a maximum dose of 43 E / kg / h."</seg>
<seg id="2289">"safety and effectiveness of aldurazem for adults over 65 years, and for these patients can be recommended."</seg>
<seg id="2290">"the safety and effectiveness of aldurum in patients with kidney or liver diseases was not determined, and for these patients can be recommended."</seg>
<seg id="2291">"with Aldura, patients can develop infusion-related reactions which are defined as each in connection effect, while the infusion or until the end of the infusion day (see section 4.8)."</seg>
<seg id="2292">"for this reason, these patients also continue to be monitored, and the infusion of Aldurazes should be available in a reasonable clinical environment, which are available in a reasonable clinical environment."</seg>
<seg id="2293">"due to the clinical phase 3 study, almost all patients IgG-siRNA against Laronidase, usually within 3 months after treatment."</seg>
<seg id="2294">"patients, antibodies or symptoms of an infusion-related reaction, must be treated in application of Aldurazem with caution (see Sections 4.3 and 4.8)."</seg>
<seg id="2295">"as little experience in the recovery of treatment after a longer interrupting treatment, due to the theoretically increased risk of a oversensitive action after a interoperability of treatment."</seg>
<seg id="2296">60 minutes before the beginning of Infusion with medicines (antihistaminika and / or antipyretika) to minimise the potential occurrence to minimise reactions.</seg>
<seg id="2297">"in case of light or medium-serious reaction, the treatment with antihistaminica and parliamol / Ibuprofen shall be carried out and / or a reduction of infusion rate on half of the Infusion rate."</seg>
<seg id="2298">"in case of a single, heavy-fugal reaction has to be brought to the fall, until the symptoms are brought to the fall, a treatment with antihistopathic and perfume oil."</seg>
<seg id="2299">The Infusion cannot be added with a reduction of infusion rate to 1 / 2 - 1 / 4 of the infusion rate when the reaction has been added to the reaction.</seg>
<seg id="2300">"3 are (Antihistaminika and parliamol / Ibuprofen and / or Corticosteroids), as well as reduction of the infusion rate on 1 / 2 - 1 / 4 of the Infusion rate, when the pre-balanced reaction."</seg>
<seg id="2301">"Aldurazaar should not be applied at the same time with chloroquin or Procain, because a potential risk of the intraocular pressure of Laronidase."</seg>
<seg id="2302">"animal experimental studies are not on direct or indirect impact on the pregnancy, the embryonic / oale development, birth and postnatal development (see section 5.3)."</seg>
<seg id="2303">"there are no data on Neurology that were compared to Laronidase about the Mother's milk, it is recommended, during the treatment with Aldurazaar."</seg>
<seg id="2304">The effects in clinical trials were mainly used as infusion-related reactions in the phase-3 study (treatment of up to 4 years) and at 35% of patients in the study period under 5 years (treatment time up to 1 year).</seg>
<seg id="2305">Unwanted drug effects in connection with Aldurazy that were observed in the following methods: very often (≥ 1 / 10); frequently (≥ 1 / 10); frequently (≥ 1 / 10 to &lt; 1 / 10).</seg>
<seg id="2306">"in some patients with severe MPS-I-related participation of the upper breathing, and in the history of history, including bronchoselmus, respiration and facial surgery (see section 4.4)."</seg>
<seg id="2307">The analysis particularly focusses on the heterogeneity of regional dynamics and the spatially structured interdependency between locations. IAB-Bibliothek 354 Archive</seg>
<seg id="2308">"intravenously once per week (recommended dose), 200 E / kg of intravenously once per week, 200 E / kg intravenously once 2 weeks or 300 E / kg intravenous all 2 weeks."</seg>
<seg id="2309">"in most patients the treatment came within 3 months after the treatment of a serokonversion, with the patients in age under 5 years after a serokonversion (average after 26 days over 45 days in age of 5 years and older)."</seg>
<seg id="2310">"in addition to the end of phase 3 study (or until the end of phase-3 study), in 13 / 45 patients have no endable antibiotics (RIP) Assay, including 3 patients who never come to Serokonversion."</seg>
<seg id="2311">Patients with a gap between the GAG-Spiegels is a robust reduction of GAG-Spiegels in Harn during patients with high antibodies and a variable reduction by GAG in Harn.</seg>
<seg id="2312">Four patients (three in phase 3 study and one in phase-3 study) showed a marginale to low neutralises in vitro which the clinical effectiveness and / or reduction of GAG in Harn.</seg>
<seg id="2313">"the presence of antibodies could not stand in connection with the indifference of unwanted drug actions, even if the occurrence of unwanted drug actions are typically associated with the education of IgG-antibodies, along with the education of IgG-antibodies, along with the education of IgG-antibodies, along with the education of IgG-antibodies."</seg>
<seg id="2314">The reason for the enzymatic therapy is divided into one for the Hydrolyse of the akeculizing substrats and the reduction of a further accumulation of the enzyme.</seg>
<seg id="2315">"after intravenous infusion, Laronidase is rapidly away from the circulation and from cells into the Lysosomes, at the most likely about Manny-6-phosphate - recipes."</seg>
<seg id="2316">"the safety and effectiveness of Aldurazy were examined in a randomised, double blind, placebokontein phase-3 study on 45 patients in age from 6 to 43 years."</seg>
<seg id="2317">"on the contrary to the study, the majority of patients suffered from the middle part, was the majority of patients from the middle of the middle part and only one patient had been the heavy duty."</seg>
<seg id="2318">Patients were erved if they had an isolated expirator volume (FEV) of less than 80% of the expected value and they had to go into the situation in 6 minutes and 5 meters.</seg>
<seg id="2319">"the primary endpoints for the effectiveness of the effectiveness of the effectiveness of the consequences of the cycle, FEV and the absolute distance of the 6-minute walk."</seg>
<seg id="2320">All patients were then evaluated for an open-label extension study where they received additional 3.5 years (182 weeks) each week 100 E / kg Aldura.</seg>
<seg id="2321">After 26 weeks therapy a improvement of lung function and the ability to improve the lung function and the obedience to the following table is shown in the following table.</seg>
<seg id="2322">"in the open extension study, a improvement and / or maintaining the effects of up to 208 weeks in derb / Aldurazem group and from 182 weeks in the placebo / Aldura group, as from the following table."</seg>
<seg id="2323">"the removal of the imbalance, FEV is not significantly significantly and the absolute infectant is increased to the body size of the children."</seg>
<seg id="2324">"of the 26 patients with a hepatitis before treatment, 22 (85%) up to the end of the study, a normal liver size."</seg>
<seg id="2325">"within the first 4 weeks, the GAG-mirror is found in Harn (µg / mg Kreatinin), which remained constant until the study concluded."</seg>
<seg id="2326">"in addition to the heterogeneous disease of the patient, the clinical trial was taken into consideration for five patients (58%), no change in 10 patients (58%), no change in 10 patients (22%), no change in 10 patients (20%) and a reduction of 9 patients (20%)."</seg>
<seg id="2327">"it was performed a year-year-old phase-2 study, mainly the safety and respiration of Aldural models of 20 patients were examined, which was carried out at the time of their record in the study under 5 years (16 patients with the heavy duty form and 4 with the medium compression shape)."</seg>
<seg id="2328">"in four patients, the dosage is increased due to increased tissue - mirror in the Harn in week 22 in the last 26 weeks on 200 E / kg."</seg>
<seg id="2329">"in several patients, a size growth (n = 7) and a weight gain (n = 7) and a weight gain (n = 3) after the Z-Score (n = 3) after the Z-Score (n = 3) after the Z-Score (n = 3)."</seg>
<seg id="2330">"in a phase-4 study, pharmacology is performed in a phase-4 study, tests on the GAG mirror in Harn, the liver volume and the 6-minute test test."</seg>
<seg id="2331">"intravenously once per week (recommended dose), 200 E / kg of intravenously once per week, 200 E / kg intravenously once 2 weeks or 300 E / kg intravenous all 2 weeks."</seg>
<seg id="2332">"the dosing scheme with 200 E / kg of intravenously all 2 weeks, however, however, the long-term clinical effectiveness of these two Dodge schemata is equal."</seg>
<seg id="2333">"the European Medicines Agency (EMEA) will be available to all new information, which will be available annually, and if necessary, the summary of the features of the drug is updated."</seg>
<seg id="2334">"in the age of 5 years, there was similar to patients in age under 5 years, similar to older and less strong patients."</seg>
<seg id="2335">"based on conventional studies on the conventional studies of the safety spharmakology, toxicity with repeated gift and reproductive use, allow the preclinical data no special dangers for humans."</seg>
<seg id="2336">"however, this drug should not be carried out with other medicines, except with the under 6.6."</seg>
<seg id="2337">"if the used machine will not be used immediately, it is not longer than 24 hours at 2 ° C - 8º C - 8º C."</seg>
<seg id="2338">5 ml of concentrates on the production of a solution in penetration bottle (type - I-glass) with Stoppers (polypropylene) and sealing (polypropylene).</seg>
<seg id="2339">"10 preparation of the Aldurazem Infusion (using aseptic technology) • Je to body weight of the individual patients, first to determine the number of thin penetration bottles."</seg>
<seg id="2340">The owner of the permission of the permission has to be complete within the given period the following study programme is to complete the basis for the annual evaluation report for the benefit risk.</seg>
<seg id="2341">This register will provide a longer-term safety and security information to patients who were treated with Aldura disease as well as data to the natural propulous disease in patients without these treatment.</seg>
<seg id="2342">"in patients who suffer from MPS I suffer, a enzyme called α -L-Iduronidase, the specific substances in the body (glycosaminoglykane), which is missing in a small amount of or this enzyme."</seg>
<seg id="2343">"if you allergies allergic (oversensitive) compared to one of the components of Alduracc, or if you have a severe allergic reaction to laronidase."</seg>
<seg id="2344">A infusion reaction is any side effect that is possible during the infusion or until the end of the infusion day (see section 4 "Which side effects are possible).</seg>
<seg id="2345">"in application of Aldurazy with other medicines, please inform your doctor if you take medicine, the chloroquin or Procain, because there is a risk of harmful effects of aldurazes."</seg>
<seg id="2346">"please inform your doctor or pharmacist if you have to take other medicines or before recently, including non-special drug use."</seg>
<seg id="2347">"notes for handling - thinner and application The concentrates for the production of an infusion solution has to be carried out before the application, and is used for intravenous application (see information for physicians or medical professionals)."</seg>
<seg id="2348">"the initial infusion rate of 2 E / kg / h may be increased when the patient's patient, all 15 minutes are increased to a maximum dose of 43 E / kg / h."</seg>
<seg id="2349">"in some patients with severe MPS-I- uncompromising participation of the upper breathing, and in the history of the history, but heavy reactions to, including bronchoselmus, respiration and face."</seg>
<seg id="2350">"a very often (occurrence at more than 1 of 10 patients): • headaches • exercise • abdominal pain • abdominal pain • abdominal pain • abdominal pain • abdominal pain, pain, pain, pain, pain, pain, pain, pain, pain in poor and legs."</seg>
<seg id="2351">"the European drug agency (EMEA) will be updated every new information that will be available annually, and if necessary, the packaged goods will be updated."</seg>
<seg id="2352">"if the used machine will not be used immediately, it is not longer than 24 hours at 2 ° C - 8º C - 8º C."</seg>
<seg id="2353">"sorry, there is no translation for this news-article."</seg>
<seg id="2354">"Alimta is used together with Cisplatin (one other medicines against cancer), if the cancer has not been removed during cancer. • advanced or metastatic" "lung cancer, which can not be used on other parts of the body. • advanced or metastatic" "lung cancer, which are not the plate epithelial cells."</seg>
<seg id="2355">Alimta is used in patients who were not treated in combination with Cisplatin and in patients who have been used to have other chemotherapies than a few therapy.</seg>
<seg id="2356">"in order to reduce side effects, patients should take care during treatment with Alimta and Corticosteroid as well as folkic acid (a vitamin), and injections of vitamin B12."</seg>
<seg id="2357">"if Alimta together with cisplatin, or after the gift of Cisplatin also a" Antiemetics "(drugs against hepatic) and liquids (for a fluid deficiency)."</seg>
<seg id="2358">"in patients, their blood flow can be changed, or in which certain other side effects should occur, the treatment should be removed or the dose."</seg>
<seg id="2359">"on the other hand, the active form of picklaters are slowed down the formation of DNA and RNA and prevents the cells."</seg>
<seg id="2360">"the transformation of Pemreacts in its active form is lighter than in healthy cells, which leads to higher concentrations of the active form of drug and a longer active time in cancer cells."</seg>
<seg id="2361">"for the treatment of the malaria of Pleurine, Alimta was examined in a main study of 456 patients that had no chemotherapy against their disease."</seg>
<seg id="2362">"in the treatment of non-single lung cancer, the effects of Alimta in a study of 571 patients were treated with local advanced or metastatic illness that had been compared with a chemotherapy, with the effects of Docetaxel (one other medicines against cancer) compared with the effects of Docetaxel (one other medicines against cancer)."</seg>
<seg id="2363">Alimta was compared with Gemcitabin (another medicine against cancer) and both in combination with Cisplatin in a study of 1 725 patients who had no chemotherapy for lung cancer.</seg>
<seg id="2364">"patients who were treated with Alimta and Cisplatin were treated in average 12,1 months, compared with 9,3 months, compared with 9,3 months."</seg>
<seg id="2365">"in patients who had already had a chemotherapy, the average overlife time with Alimta 8,3 months compared with 7,9 months of Docetaxel."</seg>
<seg id="2366">"in both studies, patients, in which the cancer does not have the plate epithelial cells, which are used by Alimta longer life-life times than with the comparison of the comparison."</seg>
<seg id="2367">"in September 2004, the European Commission of Eli Lilly Nederland B.V. are a permit for the incoming of Alimta in the whole European Union."</seg>
<seg id="2368">"any penetration bottle must be used with 4,2 ml 0.9% of sodium chloride solution (9 mg / ml), which gives a solution of 25 mg / ml."</seg>
<seg id="2369">"the corresponding volume of the needed - sis is removed from the water bottle (9 mg / ml) on 100 ml. (see section 6.6)."</seg>
<seg id="2370">ALIMTA is in combination with Cisplatin on the first line therapy of patients with locally advanced or metastasitic bronchialkarma (see section 5.1).</seg>
<seg id="2371">ALIMTA in Monotherapy is displayed at the treatment in two tlinical therapy of patients with lo- kal advanced or metastasilithographic bronchialkarma (see section 5.1).</seg>
<seg id="2372">The recommended dose of ALIMTA 500 mg / m ² body surface area (KOF) is considered as intravenous infusion via a period of 10 minutes on the first day of every 21-day treatment.</seg>
<seg id="2373">The recommended dose of Cisplatin is 75 mg / m ² KOF as infusion over a period of 2 hours about 30 minutes after the Pemrexed- Infusion at the first day of every 21-day treatment.</seg>
<seg id="2374">The recommended dose of ALIMTA 500 mg / m ² KOF has been used as intravenous infusion via a period of 10 minutes on the first day of every 21-day treatment.</seg>
<seg id="2375">"for reduction of the frequency and reproducible of the skin must be given on day before and on day of the day of the Packs, as well as on the day of the day."</seg>
<seg id="2376">During the seven days before the first dose Pemreser must be taken at least 5 cans follids and taking the taking during the whole therapeutic dosage and for further 21 days after the last Pemrexed- dose.</seg>
<seg id="2377">Patients must also have a intramuscular injections vitamin B12 (1000 micrometres) in the week before the first Pemresistor dose.</seg>
<seg id="2378">"in patients, the Pemreser should be obtained before each gift, a fully independent blood image, including a differential price of the Leukozych and a Thrombov."</seg>
<seg id="2379">"the alkaline phosphatase (AP), Amenat-Transaminase (ALL or SGOT) and Alanin-Transaminase (ALT or SGPT) should amount to ≤ 3 times of the upper limit."</seg>
<seg id="2380">"at the beginning of a new treatment cycle, the Nadis has to take place at the beginning of a new treatment."</seg>
<seg id="2381">"after the recovery, patients must be treated according to the information in the tables 1, 2 and 3 further, which are used for ALIMTA as Monotherapy or in combination with Cisplatin."</seg>
<seg id="2382">These criteria correspond to the definition of the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) ≥ CTC degrees 2 blood.</seg>
<seg id="2383">Patients should not be able to develop patients with ALIMTA (excluding neurotoxizations) must be reduced to treatment with ALIMTA.</seg>
<seg id="2384">The treatment with ALIMTA needs to be broken when patients after 2 Dosismatic disease or non-recurmatological toxicological degree or non-recurrent degrees of degree 3 or 4 neurotoxizations.</seg>
<seg id="2385">Clinical studies have no indication that in the age of 65 percent - or compared to patients in age under 65 years.</seg>
<seg id="2386">ALIMTA is not recommended for use in children under 18 years due to not sufficient data for uncertainty and effectiveness.</seg>
<seg id="2387">Clinical trials were necessary in clinical studies in clinical trials with a Kreatinin-Clearance of ≥ 45 ml / min no socket adaption necessary for all patients recommended the recommended dose.</seg>
<seg id="2388">The data situation in patients with a Kreatinin-Clearance of under 45 ml / min was not sufficient; therefore the application is not recommended (see section 4.4).</seg>
<seg id="2389">"however, patients with a liver function returns &gt; &gt; 1.5% of the upper Bilirubin- limit value and / or Transactions of the upper limit (at risk of liver metastases) or &gt; 5.0-fold of the upper limit (at pre-presence of liver metastases) or &gt; 5.0-fold of the upper limit (at pre-presence of liver metastases) or &gt; 5.0-fold of the upper limit (at pre-presence of liver metastases) or &gt; 5.0-fold of the upper limit (at pre-presence of liver metastases) or &gt; 5.0-fold of the upper limit (at pre-presence of liver metastases) or &gt; 5.0-fold of the upper limit (at pre-presence of liver metastases) or &gt; 5.0-fold of the upper limit (at pre-presence of liver metastases) or &gt; 5.0-fold of the upper limit (at pre-presence of liver metastases) or &gt; 5.0-fold of the upper limit (at pre-presence of liver metastases) or &gt; 5.0-fold of the upper limit (at pre-presence of liver metastases) or &gt; 5.0-fold of the upper limit (at pre-presence of liver met</seg>
<seg id="2390">Patients need to be monitored in terms of the cemeteries in terms of a value of ≥ 1500 cells / mm ³ and the Thrombo- cytense has a value of ≥ 100,000 cells / mm ³. "</seg>
<seg id="2391">"a dose reduction for further cycles is based on the Nativity of absolute neutrality number, Thrombozytense and maximum non-flammable toxicity, such as they were observed in previous treatment plants (see section 4.2)."</seg>
<seg id="2392">A lower toxicity and reduction of degree 3 / 4 Volmatological and nichthämatological toxicity as Neutropenie, febrile Neutropenie and infection with degrees 3 / 4 Neutropenie was used when a pretreatment with folliic acid and vitamin B12. "</seg>
<seg id="2393">"therefore, all of the treatment of patients and vitamin B12 as a prophetic measure to the reduction of toxicity tests (see section 4.2)."</seg>
<seg id="2394">Patients with lighter to medium kidney cancer (Kreatinin-Clearance 45 to 79 ml / min) must be the equivalent to a minimum 2 days prior to therapy (see section 4.5).</seg>
<seg id="2395">"all patients, for a therapy with Pemreation is provided, the taking of NSAIDs with long half-time period for at least 5 days before the therapy, the day of therapy and at least 2 days after therapy with Pemreacts (see section 4.5)."</seg>
<seg id="2396">Many patients suffering from which these events were gathered for the occurrence of renal events, including Dehessation, pre-hand of blood pressure or diabetes. "</seg>
<seg id="2397">"at the same time, patients with clinically significant liquid - Angle in transatlantic space, a Drawing of the Ergonomic treatment in the transatlantic treatment."</seg>
<seg id="2398">"5 serious cardiovascular events, including Myokardinfotainment, including Myokardinfotainment, and Zerebrovascular events were used in clinical trials with a other cytotoxical function."</seg>
<seg id="2399">"for this reason, the current application of attendees is not recommended (unless section 4.3 and 4.5) are not recommended (see section 4.3 and 4.5)."</seg>
<seg id="2400">"as the possibility of a missibility of misdiments, men should be able to be able to get in the treatment of treatment - ginn."</seg>
<seg id="2401">In patients with normal kidney function (Kreatinin-Clearance (80 ml / min) can lead to low dose non-astal antiphlogistika (NSAIDs) and acetylsalicylacid in high dosage (≥ 1,3 g daily).</seg>
<seg id="2402">"therefore, if in patients with normal kidney function (Kreatinin-Clearance (80 ml / min) high cans of NSAIDs or acetylsalicylacid in high dosage."</seg>
<seg id="2403">"Ibuprofen) or Acetylsalicylate acid in high dosage for at least 2 days before the therapy, the day of therapy and mindes-, 2 days after therapy with Pemreser (see section 4.4)."</seg>
<seg id="2404">"there are no data concerning the intercom as with NSAIDs with long-time time as Piro- xicam or Rofecoxib, the same application has to be avoided at least 5 days before the therapy, on day of therapy and at least 2 days after therapy."</seg>
<seg id="2405">The large intra-individual variability of the space status during the disease and the possibility of exchange between orological antioagulthood and antineoplastic chemotherapy requires a higher monitoring frequency of the INR (International standards) when the decision was held to treat the patient with oral antioagulthood.</seg>
<seg id="2406">"there are no data for the use of Pailreators in pregnancy, but as with a loss of infestation in pregnancy, as for the use of pregnancy."</seg>
<seg id="2407">Pemreditation may not be applied during pregnancy except if necessary and after careful consideration of the use for the mother and risk of use for the chötus (see section 4.4).</seg>
<seg id="2408">"as the possibility of a miserection of the remuneration of the reproductive ability, should be taken to be taken on the treatment of the treatment of health care."</seg>
<seg id="2409">"it is not well known, whether it is not well known to the mother's milk and unwanted effects when they cannot be excluded."</seg>
<seg id="2410">The following table shows the frequency and severely undesirable effects that were reported in &gt; 5% of 168 patients with Meslyniom and the randomised Cisplatin and Pembians and the randomised Cisplatin as a monotherapy.</seg>
<seg id="2411">Side effects associated: very frequently (≥ 1 / 10 and &lt; 1 / 10), occasionally (≥ 1 / 1,000 and &lt; 1 / 100), rare (≥ 1 / 1,000 and &lt; 1 / 1,000), rare (&lt; 1 / 10.000 and &lt; 1 / 1,000), rare (&lt; 1 / 10.000 and &lt; 1 / 1,000). "</seg>
<seg id="2412">"* * * In National Cancer Institute CTC version 2 for any toxicology, the event" Kreatinin-Clearance "" * * * which was derived from the term "Kreatinin-Clearance" "* * which was derived from the term" Kreatinin-Clearance "" * * which was derived from the term "Kreatinin-Clearance" "* *"</seg>
<seg id="2413">"for this table, a threshold of 5% for this table was set up by 5% for the recording of all events in which the disposition of all events in which the disposition of all events that were possible with Pemretion and Cisplatin for this table."</seg>
<seg id="2414">"the relevant CTC toxicity analysis, which were killed in &lt; 1% (occasionally) of patients reported, the randomised Cisplatin and Pemreases, were randomised Arrhythmic and motorised Neuropathy."</seg>
<seg id="2415">The following table shows the frequency and severely undesirable effects that were randomised with 5% of 265 patients who were randomised and vitamin B12 and 276 patients who were randomised wetaxel as a monotherapy.</seg>
<seg id="2416">* Use on National Cancer Institute CTC version 2 for any toxicological aspects. * * related to National Cancer Institute CTC (v2.0; NCI 1998) should be just as degrees 1 or 2 reports.</seg>
<seg id="2417">"for this table, a threshold of 5% for this table was set up by 5% for the recording of all events in which the disposition of all events in which the disposition of all events were possible."</seg>
<seg id="2418">"the patient's relevant CTC toxicity, which were killed in &lt; 1% (occasionally) of patients reported, the randomised Pemreates were randomised."</seg>
<seg id="2419">"at the same time, the previous relevant laboratory techniques 3 and 4 was compared with the following results of three different types of target groups (12.8% compared with 5.9%) and an increase of Alaninopathy (15,2% compared with 1,9%)."</seg>
<seg id="2420">"these sub-differences are likely to lead to differences in the patient's patient, as the Pha- se 2 studies both chemonaive and / or abytes."</seg>
<seg id="2421">"the following table shows the frequency and severely undesirable effects that could be avoided in connection with the degree of study; they were held at &gt; 5% of 839 Pati- Enten with NSCLC, the randomised Cisplatin and Gemcitabin."</seg>
<seg id="2422">"* * In National Cancer Institute CTC (v2.0; NCI 1998) for every toxicological test. * * * Print on National Cancer Institute CTC (v2.0; NCI 1998), flavours and hair loss is only as degrees 1 or 2."</seg>
<seg id="2423">"for this table, for the recording of all events in which the disposition of all events in which the disposition of all events in which of all events were specified with Pemreation and Cisplatin for possible, a threshold of 5%."</seg>
<seg id="2424">"the patients reported that patients were killed in ≥ 1% and ≤ 5% (often) of patients reported, the randomised Cisplatin and Pemreators were included:"</seg>
<seg id="2425">"at &lt; 1% (occasionally) of patients reported in &lt; 1% (occasionally) of patients reported the ran- dominion of Cisplatin and Pemrety,"</seg>
<seg id="2426">"including Myokardinfulators, including Myokardinfarina, Angina pectoris, cerebrovascular diseases were used in combination with a other cytotoxical function."</seg>
<seg id="2427">"clinical trials have been reported in clinical trials of clinical studies in clinical trials of coli- tis (including scleral and rektal blood cells, sometimes deadly perfo- ration, antioxidinale (rose and Typhlitis)."</seg>
<seg id="2428">Clinical trials have been reported in clinical trials of clinical studies in patients with Pemreation treatment occasionally from sometimes fatal interstitieller pneumonitis with respiratory Insuffix.</seg>
<seg id="2429">It was taken over cases of akutem kidney stones or in combination with other chemotherapeutic agents (see section 4.4).</seg>
<seg id="2430">"there were cases of radiation-pneumonitis in patients reported that during or after their Packs, therapy (see section 4.4)."</seg>
<seg id="2431">ALIMTA (Pemplate) is a antineoplastic anti-anti-anti-anti-acid processes that are necessary for cell replication.</seg>
<seg id="2432">"in vitro studies, the Pemreates as a anti-attack with multiple scleral points (TS), Dihydrofolatrease (TS), Dihydrocannabisidribonucleottofor- myltransferase (GARFT) and Glycinamidribonucleopardiuclease (TS), the follicate key channels of the de novo Biosynthesis of thyme and Purikucleans."</seg>
<seg id="2433">"in EMPHACIS, a multifunctional, randomised, simply-blind, 3 study of ALIMTA plus Cisplatin in chemonaided patients with maligamesthetic disease."</seg>
<seg id="2434">The primary analysis of these study was performed in the population of all patients who were treated in the treatment of the test regulation (randomised and treated).</seg>
<seg id="2435">A statistical significant improvement of the clinical trials (pain and musspnoe) in connection with the malaria Pleuramesareiom has been shown in the context of the Lunar disease in the ALIMTA / Cisplatin arm (212 patients).</seg>
<seg id="2436">The differences between the two treatment parameters caused by a improvement of the lung function in the ALIMTA / Cisplatin arm and a reduction of the lung function in the context of the context.</seg>
<seg id="2437">"a multifunctional, randomised, open Phase III study with ALIMTA-based NSCLC after previous chemotherapy (Intent to treat population n = 283) and from 7,9 months with Docetaxel treatments (ITT n = 288)."</seg>
<seg id="2438">"for patients with NSCMTA in patients with NSCMTA in patients with NSCMTA in patients with NSCMTA in patients with NSCMTA in patients with NSCMTA, p = 0,61-1,00, p = 0,047, p = 1,08-2,26, p = 0,018)."</seg>
<seg id="2439">"limited to a separately randomized, controlled phase 3 study that show that local data (survival and progression-free survival) is similar to Pemreation between patients with (n = 41) and without (n = 540) and without (n = 540) treatment by Docetaxel."</seg>
<seg id="2440">The Effectiveness analysis of the PQ population are compliant with the analysis of ITT population and support the non-underline of ALIMTA Cisplatin combination against the Gemcitric combination.</seg>
<seg id="2441">"medium PFS was 4,8 months for the combination of ALIMTA Cisplatin compared to the combination of ALIMTA Cisplatin compared to 28,6% (95% CI = 25,0 - 31.8) for the combination of ALIMTA Cisplatin compared to 28,2% (95% CI = 25,0 - 31.4) for the combination of citric in Cisplatin (95% CI = 25,0 - 31.8)."</seg>
<seg id="2442">The analysis of the influences of the NSCLC histology on the survival of the survival of the histology, see below below the table. "</seg>
<seg id="2443">CI = Konfidenzinterval; ITT = Intent-to-treat; N = size of the total population of the team of Significant for HR (= Hazard) is clearly identified under the non-subleaks limit of 1,17645 (p &lt; 0.001). "</seg>
<seg id="2444">"patients who were treated with ALIMTA and Cisplatin were treated, required fewer transmissions (16.4% versus 3,9%, p &lt; 0.001) and Thrombozytfusions (1.8% versus 4.5%, p = 0,002)."</seg>
<seg id="2445">"in addition, the patient's gift of Erythropotin / Darbopoetin (10.4% versus 18.1%, p = 0,004), p = 0,004), and iron preparations (4.3% versus 7,0%, p = 0,021)."</seg>
<seg id="2446">The Brazilian properties of Pemreacts as a monotherapists have been examined with various solids with various solids in cans of 0.2 to 838 mg / m ² in Infusi- ons over a period of 10 minutes.</seg>
<seg id="2447">"from 24 hours to 90% of the final dose will be found within 24 hours after the application, in order to be found in Urdu."</seg>
<seg id="2448">Pemretion has a total capacity of 91.8 ml / min and the semi-value time in plasma is 3.5 hours in patients with normal kidney disease (Kreatinin-Clearance 90 ml / min).</seg>
<seg id="2449">"in a study with Reflectioner, which were observed for 9 months of intravenous Bolus injections, were observed contracted."</seg>
<seg id="2450">"if not unprocessed, the storage times and conditions are not exceed 24 hours at 2 to 8 ° C not exceed 24 hours at 2 to 8 ° C not exceed 24 hours at 2 to 8 ° C."</seg>
<seg id="2451">"solve the content of 100 mg / ml bottles with 4,2 ml 0.9% of sodium chloride solution (9 mg / ml) without preservatives (9 mg / ml) without preservatives, resulting in a solution with a concentration of about 25 mg / ml."</seg>
<seg id="2452">The excellent solution is clear and the colouring ranges from colourless to yellow or green yellow without that the product quality is impaired.</seg>
<seg id="2453">"any penetration bottle must be used with 20 ml 0.9% of sodium chloride solution (9 mg / ml), which gives a solution of 25 mg / ml."</seg>
<seg id="2454">"23 serious cardiovascular events, including Myokardinfotainment, including Myokardinfotainment, and Zerebrovascular events were used in clinical trials with a other cytotoxical function."</seg>
<seg id="2455">"* * * In National Cancer Institute CTC version 2 for any toxicology, the event" Kreatinin-Clearance "" * * * which was derived from the term "Kreatinin-Clearance" "* * which was derived from the term" Kreatinin-Clearance "" * * "</seg>
<seg id="2456">"for this table - de a threshold of 5% in the recording of all events, in which the difference - a connection with Pemrewinder and Cisplatin for this table."</seg>
<seg id="2457">* Use on National Cancer Institute CTC version 2 for any toxicological aspects. * * related to National Cancer Institute CTC (v2.0; NCI 1998) should be just as degrees 1 or 2 reports.</seg>
<seg id="2458">"* * In National Cancer Institute CTC (v2.0; NCI 1998) for every toxicological test. * * * Print on National Cancer Institute CTC (v2.0; NCI 1998), flavours and hair - fall only as degrees 1 or 2."</seg>
<seg id="2459">"at &lt; 1% (occasionally) of patients reported in &lt; 1% (occasionally) of patients reported the ran- dominion of Cisplatin and Pemrety,"</seg>
<seg id="2460">"for patients with NSCMTA in patients with NSCMTA in patients with NSCMTA in patients with NSCMTA in patients with NSCMTA, p = 0,61-1,00, p = 0,047, p = 1,08-2,26, p = 0,98-2,26, p = 0,018)."</seg>
<seg id="2461">Dissolve the content of 500 mg / ml) without preservatives (9 mg / ml) without preservatives (9 mg / ml) without preservatives (9 mg / ml) without preservatives.</seg>
<seg id="2462">The excellent solution is clear and the colouring is sufficient by color from yellow to yellow or green yellow without that the product quality is impaired.</seg>
<seg id="2463">"Pharmacovigilance-system The owner of the permission of the permission to provide you to carry out the pharmaceutical - kovigilance-system, as described in Version 2.0."</seg>
<seg id="2464">Risk Management Board The owner of the permission of the permission for the Insolvency Administration (RMP) are placed in the version 1.2 of Risk Management Plan (RMP).</seg>
<seg id="2465">"according to" CHMP Guideline on Risk Management Systems for human use "needs a updated RMP time with the next" Periodic Safety Update Report "(PSUR)."</seg>
<seg id="2466">"in addition, a updated RMP will be submitted in an updated RMP • If new information contained on the current safety - specifications, the pharmaceutical convigilance or risk of an important part of an important (pharmaceutical-vigilance or risk-risk). • On request by the EMEA"</seg>
<seg id="2467">ALIMTA 100 mg powder for the production of a production process for the production of an infusion process - ALIMTA 500 mg of powder for the production of an infusion process.</seg>
<seg id="2468">ALIMTA is used in patients who have no previous chemotherapy in combination with Cisplatin and other medicines for treating cancer.</seg>
<seg id="2469">"if you have a kidney, or earlier, please discuss this with your doctor or hospital, as you may not receive ALIMTA."</seg>
<seg id="2470">"if your kidney and liver function is checked, whether your kidney and liver function is checked and whether you have enough aperture to obtain ALIMTA."</seg>
<seg id="2471">"your doctor may change the dose or treatment, unless it requires your general condition and when your blood pressure is low."</seg>
<seg id="2472">"if you receive Cisplatin, your doctor will ensure that your body is sufficient water, and you will receive the necessary medication to avoid the exhaustion before and after the Cisplatin."</seg>
<seg id="2473">"if you have a liquid collection to remove the lungs, your doctor may be decisive - to remove these fluid before you get ALIMTA."</seg>
<seg id="2474">"if you want to cancel during treatment or in the first 6 months after treatment, please contact your doctor or pharmacist."</seg>
<seg id="2475">"as such medicines, medicines may be used against pain or infections (swellun-), such as drugs, the" non-metabolic antiphlogistika "(NSAIDs), including drugs, the non-metabolic antiphlogistika" (NSAIDs). "</seg>
<seg id="2476">"depending on the planned age of your ALIMTA infusion and / or the extent of your kidney function, your doctor will tell you what other medicines you can take, and when."</seg>
<seg id="2477">Please inform your doctor or pharmacist if you have to take other medicines or before going to be used if it is not possible to do with it.</seg>
<seg id="2478">"a hospital, the nursing staff or a doctor will be applied to the ALIMTA powder with sterile 0,9% of sodium chloride solution (9 mg / ml)."</seg>
<seg id="2479">Your doctor will send you Cortison tablets (according to 4 mg × Keramethma son two times daily) that you have to take on day during day and day after the application of ALIMTA.</seg>
<seg id="2480">"your doctor will have to take care of your doctor (a vitamin) to take or multivitamine, the folliic acid (350 to 1000 micrometres), write which you have to take during the application of ALIMTA in the application of ALIMTA."</seg>
<seg id="2481">"in the week before application of ALIMTA, and about all 9 weeks (according to 3 cycles of the treatment with ALIMTA) you will receive a injections of Vi- tamin B12 (1000 micrometres)."</seg>
<seg id="2482">"in this use, this information is described as" very often "described, this means that it was reported from at least 1 of 10 patients."</seg>
<seg id="2483">"a side effect has been described as" frequently "described, this means that it was reported from at least 1 of 100 patients, but less than 1 of 10 patients reported."</seg>
<seg id="2484">"a side effect was described as" occasionally "described as" occasionally "described by at least 1 of 1,000 but less than 1 of 100 patients reported that they were killed by at least 1 of 10,000 but less than 1 of 1,000 patients reported."</seg>
<seg id="2485">Fever or infection (frequently): if you have a body temperature of 38 ° C or any other signs of infection (because you may possibly have less white blood cells as normal what is common).</seg>
<seg id="2486">"if you feel tired or weak, quickly in breathing or bust (because you may possibly have less hemmoglobin as normal, what is very common)."</seg>
<seg id="2487">"if you don't find a circle of teeth, nose or mouth of your mouth or another bloodshed, or a reddish or rosafes."</seg>
<seg id="2488">"occasionally (at least 1 of 1,000 patients) increased Pulsrate Colitis (inflammation of the inner layer of the intestine, which can be linked with blood vessels in the intestines and end m) interstitielle pneumonitis (discharge of water into the body, that leads to swellations)."</seg>
<seg id="2489">"rarely (for more than 1 of 10,000 patients, but less than 1 of 1,000 patients)"</seg>
<seg id="2490">"occasionally, patients, ALIMTA, usually in combination with other Krebtransmitter - taps, received a headcase or perceiver."</seg>
<seg id="2491">"in patients who were before, during or after their ALIMTA treatment can occur in radiation therapy, a radiation therapy of the lung tissue, which can occur with radiation therapy in connection."</seg>
<seg id="2492">"52 Informed your doctor or pharmacist, when one of the side effects are significant, or if you are aware of the side effects that are not allowed in this package."</seg>
<seg id="2493">"as well prepared, the chemical and physical stability of the thinner and the infusion solution for storage in refrigerator or at 25 ° C for a period of 24 hours."</seg>
<seg id="2494">"sorry, there is no translation for this news-article."</seg>
<seg id="2495">You need to be registered and logged in to view the full-length program. register Login Format: 1 × 50 ′)</seg>
<seg id="2496">Tel: + 34-91-623-01 France Lilly France SAS 18l: + 33- (0) 1 55 49 34 34 Ireland Eli Lilly and Company (Ireland) Limited Phone: + 353- (0) 1 661 4377 Ísland Icepharma hf.</seg>
<seg id="2497">Tel: + 39- 055 42571 Lyly Holdings Limited: + 371 67364000 Lietuva Eli Lilly Holdings Limited</seg>
<seg id="2498">Tel: + 48 (0) 22 440 33 00 Portugal Lilly Portugal - Produtos Farmacêuticos, LDA Tel: + 351-21-4126600 România Eli Lilly România S.r.l. "</seg>
<seg id="2499">Tel: + 421 220 663 111 Suomi / Senior Oy Eli Lilly and Company Limited: + 46- (0) 8 7378800 United Kingdom Eli Lilly and Company Limited Tel: + 44- (0) 1256 315999</seg>
<seg id="2500">Solve the content of 100 mg / ml bottles with 4.6 ml 0.9% of sodium chloride solution (9 mg / ml) without preservatives.</seg>
<seg id="2501">Dissolve the content of 500 mg / ml) without preservatives (9 mg / ml) without preservatives (9 mg / ml) without preservatives.</seg>
<seg id="2502">The solution is clear and the colouring ranges from colourless to yellow or green yellow without that the Pro- inductive quality is impaired.</seg>
<seg id="2503">"it will be applied in the important adults with a body massacre (Body Mass Index - BMI) of ≥ 28 kg per square metres in connection with a kalorific, low-reduced diet."</seg>
<seg id="2504">"patients, the Alli, and after 12 weeks no weight, should be carried out to their doctor or pharmacist."</seg>
<seg id="2505">"these enzymes, these enzymes, they are not able to build some fats in the food, which is dominated by a quarter of the food prepared by the food intake of the intestine."</seg>
<seg id="2506">"in a third study, Alli was compared to all patients with a BMI between 25 and 28 kg / m2 with Placebo."</seg>
<seg id="2507">"in the two studies in patients with a BMI of ≥ 28 kg / m2, patients who had a average weight loss of 4.7 kg, compared to 2.3 kg in the taking of Placebo."</seg>
<seg id="2508">In the study with Alli in patients with a BMI between 25 and 28 kg / m2 cannot be observed for patients relevant weight loss.</seg>
<seg id="2509">"the most common side effects of Alli (observed in more than 1 of 10 patients) are sliced Flaps on After, Flatus (Winde), walk-off (Fäzes), Flatulence (Fäzes), Flatulence (winde), flatulence (winch) and soft chairs."</seg>
<seg id="2510">It may not be applied to patients who are treated with Ciclossum (to prevent the Organizing of transplantation) or with medicines such as warfarin to prevent blood sugar.</seg>
<seg id="2511">"it may not be applied to patients who suffer from a long-term colation, or to Cholestase (a liver disease) or to Cholestase (a liver disease) or solestase (a liver disease)."</seg>
<seg id="2512">"in July 2007, the European Commission will bring the European Commission to the company of Glaxo Group Limited in the entire European Union."</seg>
<seg id="2513">Alli is a weight reduction of adults with overweight (body-mass-index BMI ≥ 28 kg / m2) indices and should be applied in connection with a slightly hypokaline, fat reduction. "</seg>
<seg id="2514">Alli may not be applied to children and adolescents under 18. it does not have enough data to effectiveness and security.</seg>
<seg id="2515">"since Orlists are only minimal resorated, it is necessary at the elders and in patients with limited liver and / or kidney function no adaptation of the dosage."</seg>
<seg id="2516">• Oversensitivity to the active substance or one of the rest of the equals • Cholestase • pregnancy (see section 4.6) • Violation (see section 4.6) • Violation (see section 4.6) • Enhance (see section 4.6) • equality treatment with Warfarin or other oral antioagulthood (see section 4.6 and 4.8).</seg>
<seg id="2517">The likelihood of the preretgastrointestinal symptoms (see section 4.8) can be added if alli along with a fermentation of single maize or oversal diet.</seg>
<seg id="2518">"as the weight reduction in diabetes with a improved metabolic control, patients suffering a medicine with alli a doctor or pharmacist, because the dosage of the antibiotics must be adapted."</seg>
<seg id="2519">"patients, alli as well as medicines against blood pressure or increased cholesterol levels, your doctor or pharmacist, whether the dosage of these drugs has to be adapted."</seg>
<seg id="2520">It is recommended to meet extra pregnant measures to meet in the event of severe diarrative measures (see section 4.5).</seg>
<seg id="2521">"in a study, drug use is observed as well as in several cases with simultaneous application of Orlists and Ciclosporin was observed."</seg>
<seg id="2522">"in combination with the application of Warfarin or other orological antioagularities in combination with Ornament, the Quick-values could be influenced by the Quick-values (see section 4.8)."</seg>
<seg id="2523">"in most patients who were treated in clinical trials up to 4 full years, the concentrations of vitamins A, D, E and K as well as the beta carotins in the standard."</seg>
<seg id="2524">"however, patients are recommended to take the patient before the sleeping area will be able to ensure adequate vitamins intake (see section 4.4)."</seg>
<seg id="2525">"after the gift of a double room Amiodaron was observed in a limited number of volunteers, the at the same time at the same time at the same time, a minor reduction of the Amiodara plasma concentration."</seg>
<seg id="2526">"animal experimental studies have no direct or indirect impact on pregnancy, embryonic / oale development, birth or postnatal development (see section 5.3)."</seg>
<seg id="2527">"the side effects of Orlists are mainly gastrointestinal tract of the drug, which prevents the absorption of one fat."</seg>
<seg id="2528">The gastrointestinal side effects were made from clinical trials with Orlists at 60 mg of a duration of 18 months to 2 years and were used in general and temporarily.</seg>
<seg id="2529">"the results are defined as follows: very frequently (≥ 1 / 10, &lt; 1 / 10), occasionally (≥ 1 / 1,000, &lt; 1 / 100), rare (≥ 1 / 1,000, &lt; 1 / 100), rare (&lt; 1 / 1,000), not known (frequency on the available dates are not abable)."</seg>
<seg id="2530">"the frequency of the known side of which side effects, which was established after the market launch of Orlists, is not known, as these events were forced by a population."</seg>
<seg id="2531">"at the same time, the treatment can cause treatment with alli to conversion in terms of possible or actual gastrointestinal side effects."</seg>
<seg id="2532">Single doses of 800 mg / lists and multi-segments of up to 400 mg three times a period of 15 days have been taken over a period of 15 days to normalto and overweight subjects.</seg>
<seg id="2533">"at the majority of the launch of Orlists cases, however, no side effects or similar side effects are reported at the recommended dose of Orlists."</seg>
<seg id="2534">"based on investigations on human and animal can be attributed by a quick backpacket system, which are made available to the liding properties of Orlists."</seg>
<seg id="2535">The therapeutic effect sets in the lumbar of the magnets and the upper thin slices on the active serine rest of the gastran and pankreefs.</seg>
<seg id="2536">"from clinical trials was derived that 60 mg of Orlists, three times a day, absorption by about 25% of the food block."</seg>
<seg id="2537">"two double blind, randomised, placebo-controlled studies on adults with a BMI ≥ 28 kg / m2, the effectiveness of 60 mg / m2, the effectiveness of 60 mg / m2, the effectiveness of 60 mg / m2, the effectiveness of 60 mg / m2, which was taken three times daily in combination with a hypokaline, fat reduction."</seg>
<seg id="2538">"the primary parameters, the change of body weight compared to the output (at the time of the sea level), as follows: as a change of the body weight (table 1) and as a percentage of those who lost the more than 5% or more than 10% of its output weight (table 2)."</seg>
<seg id="2539">"although in both studies the weight reduction over 12 months, the biggest weight loss in the first 6 months."</seg>
<seg id="2540">The average change in the total amount of 60 mg -2.4% (output value 0.26 mmol / l) and with Placebo + 2.8% (output value 5.26 mmol / l).</seg>
<seg id="2541">The average change of the LDL cholesterol to 60 mg -3.5% (output value 3.3 mmol / l) and with Placebo + 3.8% (output value 3.41 mmol / l).</seg>
<seg id="2542">"at the same time, the average modification -4.5 cm with Orlists at 60 mg (output level 103,7 cm) and with Placebo -3.6 cm (output value 103,5 cm)."</seg>
<seg id="2543">The plasma concentration of non-metabolized Orlists were 8 hours after the oral gift of 360 mg (&lt; 5 ng / ml).</seg>
<seg id="2544">7 In generally the therapeutic dosage of therapeutic dosage is not metabolized organs in plasma only sporadically and in extremely low concentrations (&lt; 10 ng / ml or 0.02 µMol) and no signs of Kumulation.</seg>
<seg id="2545">"in a study with adipous patients who have been tested in a study with adipous patients, one has been identified two main metabolite, namely M1 (in position 4 hydrolysian Lactonring) and M3 (M1 (in position of the N-Formyl-Leuven group)."</seg>
<seg id="2546">"based on conventional studies on safety spharmakology, toxicity of repeated gift, erogenome potential and reproductive processes, the preclinical data is no particular danger for humans."</seg>
<seg id="2547">"Pharmacvigilance system The owner of the permission to ensure that the pharmaceutical convigilance system, depending on the version of July 2007, as in module 1.8.1st of the registration deadline is available before and while the product is available on the market."</seg>
<seg id="2548">"as a result of the agreement on the risk of the risk management system (RMP) from October 2008 to keep the agreement on the risk of risk management (RMP) of October 2008, as well as all other updates of the Russ that will be agreed with the Committee on Humanitarian Law (CHMP)."</seg>
<seg id="2549">"according to the CHMP guidelines for humanity, the updated RMP concept must be submitted by the following PSUR at the following PSUR (Periodic Safety Update report)."</seg>
<seg id="2550">"* Understand the competitive environment, the market's major players and leading brands; * Use five-year forecasts to assess how the market is predicted to develop."</seg>
<seg id="2551">"12 PSURs is the owner of the permission for the Invoice, in the first year after the order of the approval to the alli 60 mg of hard disks PSURs all 6 months, then for two years and after all three years."</seg>
<seg id="2552">"if you are pregnant at 18, • If you are pregnant or breeder, • If you are pregnant or have a rest of the liver, if you are pregnant or other blood cells (disease of the liver, when you have problems with the food intake, if you have problems with the food intake, if you have problems with the food intake, if you have problems with the food intake, if you have problems with the food intake (chronic malnutrition)."</seg>
<seg id="2553">"• take three times per day with every main purpose, the fat contains a capsule with water. • do not take any day before the sleeping, a multivitamintablette (with vitamins A, D, E and K)."</seg>
<seg id="2554">"application: • take three times each day with every main body time, the fat contains a capsule with water. • do not take any day before the sleep, a multivitamintablette (with vitamins A, D, E and K)."</seg>
<seg id="2555">"if you want to read the doctor or pharmacist, if you need further information or advice. • If you have a doctor or pharmacist to help us a doctor or pharmacist."</seg>
<seg id="2556">"• If one of the side effects you can choose from alli. • If one of the side effects you can select, please inform your doctor or pharmacist."</seg>
<seg id="2557">• alli may not be applied to use of alli. • alli may not be applied to use of alli by alli with other medicines. • In case of alli together with food and drinks.</seg>
<seg id="2558">How is alli to take your weight? • How can you take your weight reduction? O adults from 18 years o how long should I take you? O adults from 18 years o how long should I take you? O If you take alli in great quantities? O If you have alli in great quantities you have forgotten your weight.</seg>
<seg id="2559">What side effects are possible? • serious side effects • Very frequent side effects • Complementing side effects • effects on blood circulation • How can you control nutritional differences?</seg>
<seg id="2560">"for more information, please visit our homepage: http: / / www.w3.org / 1999 / xhtml"</seg>
<seg id="2561">Alli serves weight reduction and will be applied for 18 years with a Body Mass Index (BMI) of 28 or about anendetet. alli should be applied in connection with a fat and kalorially reduced diet.</seg>
<seg id="2562">The BMI helps you to determine whether you have a normal weight or overweight.</seg>
<seg id="2563">"even if these diseases are not necessary, you should feel uncomfortable, you should ask your doctor to ask your doctor to ask your doctor to ask your doctor."</seg>
<seg id="2564">"for each 2 kg body weight, which you can lose in the frame of a diet, you can lose your help from alli an additional kilograms."</seg>
<seg id="2565">Please inform your doctor or pharmacist if you have any other medicines or if you do not have any other medicines, even if it is not necessary. "</seg>
<seg id="2566">"Ciclosporin will be used after surgery, in severe rheumatoid arthritis and certain heavy metals patients. • Warfarin or other medicines which have a blood circulation."</seg>
<seg id="2567">"* * * * Sorry, this property owner doesn't provide a description in english..."</seg>
<seg id="2568">Please contact your doctor or pharmacist if you are: • Amiodaron for treatment of cardiovascular diseases. • Acarbose for treatment of diabetes.</seg>
<seg id="2569">Ask your doctor or pharmacist if you take alli and • if you take a medicine against blood pressure because the dosage must be adjusted for a high cholesterol levels.</seg>
<seg id="2570">See more helpful information on the blue sides in section 6.</seg>
<seg id="2571">If you leave a meal or a meal no fat contains no capsule that contains no capsule. alli can only affect the food fat.</seg>
<seg id="2572">"if you take the capsule in connection with a meal, which contains much fat contains nutritional supplements (see section 4)."</seg>
<seg id="2573">"in order to enjoy your body to the new dining table, you start already before the first capsule with a kalorific and low cost reduction."</seg>
<seg id="2574">"eating establishments can be effective because you can feel at any time, what you eat, how much you eat, and it will probably be easier to change your nutritional habits."</seg>
<seg id="2575">"in order to achieve your target balance, you should specify two daily goals: one for the calories and one for fat."</seg>
<seg id="2576">• Check out to be reduced to reduce the likelihood for nutritional purposes (see section 4).</seg>
<seg id="2577">"remember in your doctor if you need physical activity. • lead you during taking medicine, even after taking the taking of alli body."</seg>
<seg id="2578">"• alli may be taken longer than 6 months. • If you can find a reduction of your weight, please ask your doctor or pharmacist to advice."</seg>
<seg id="2579">"under circumstances, you have to finish the removal of alli. • In a successful weight, it is not about to return the diet and then go back to the old habits."</seg>
<seg id="2580">"• When fewer than one hour since the last meal, you get taking the capsule. • If more than one hour since the last meal, you don't take any capsule."</seg>
<seg id="2581">(see section 1).</seg>
<seg id="2582">"allergic reactions: heavy breathing, weld reactions to the following changes: heavy breathing, welds, skin, cheeses, cheeses in the face, heart rasen, cycles."</seg>
<seg id="2583">"29 Very frequent side effects This can take advantage of more than 1 of 10 people, which occur at more than 1 of 10 people, which occur. • Blessing chair, take your doctor or pharmacist, if one of these side effects will be strengthened or you substantially."</seg>
<seg id="2584">"• Magical (abdominal) pain: • Magical (abdominal) pain, • Incontinence (chair) • Suitsriger / liquid chair"</seg>
<seg id="2585">• Increases of certain liver diseases - effects on blood pressure in patients who take warfarin or other blood cells.</seg>
<seg id="2586">"please inform your doctor or pharmacist, if one of the side effects you can choose from either side effects or side effects that are not found in this use."</seg>
<seg id="2587">"the most common side effects are set with the function of the capsules and arise, that contains fat from the body."</seg>
<seg id="2588">These side effects are usually reduced within the first weeks after treatment in the first weeks after treatment.</seg>
<seg id="2589">"with the following basic rules, you can learn more about the usual fat content or better a week, before the first taking the capsules with a low reduced diet."</seg>
<seg id="2590">"if you want to know exactly how much you eat, the likelihood that you are out of your fat limit."</seg>
<seg id="2591">"the amount of calories and fat, which have done per meal, not to take part in order to control them in form of a natural line of main activities, such as you may have to control it with the time by adaptation of their diet."</seg>
<seg id="2592">• Available for children unaccessible. • You may not be able to protect the content before humidity. • The bottle contains two white diamonds with Silicagel who serve to keep the capsules dry.</seg>
<seg id="2593">"you can use your daily dose alli in the blue transport box (shuttle), which is provided by this pack."</seg>
<seg id="2594">"Famar, 190 11 Avlona, Greece Catalent UK Packaging Limited, Sedge Close, Headway, Great Britain, Corby, Northamptonshire NN18 8HS, United Kingdom"</seg>
<seg id="2595">• diabetes • heart disease • diabetes • heart disease • diabetes • heart disease • Identification of cancer diseases • Osteoarthritis Make up with your doctor about your risk for these diseases.</seg>
<seg id="2596">"a permanent weight of weight, for example through the improvement of nutrition and more movement, it can cause severe diseases and has a positive influence on your health."</seg>
<seg id="2597">"choose meals, which contain a wide range of nutrients, and learn to care for healthy health."</seg>
<seg id="2598">"energy is also measured in kilojoules, which can be found in kilojoules. • The recommended caloriension can be found on how many calories you should take a maximum per day."</seg>
<seg id="2599">"please note the below below in this section of the tables. • The recommended dose of fat is the maximum amount of fat that you should take with each meal."</seg>
<seg id="2600">"the amount of application is suitable for you, see the number of calories which is suitable for you."</seg>
<seg id="2601">"if you are the same amount of fat, as previously, this mean that your body can't work this amount of fat."</seg>
<seg id="2602">"with compliance with the recommended fatty acids you can maximize weight, maximize the probability for nutritional purposes."</seg>
<seg id="2603">34 These reduced calorization should allow you to lose weight and continuously around 0.5 kg per week at weight, without fruit and disappointment. "</seg>
<seg id="2604">"•" "physical activity" "means that you are only little or not go, stairs, in the garden, or other physical activities. •" "Low physical activity" "means that you are only little or not go, stairs, in the garden, or other physical activities."</seg>
<seg id="2605">"• For a durable weight, it is necessary to add realistic calories and fat content of your meals. • For you to move more to move, before you start using alli."</seg>
<seg id="2606">"the alli program for the support of weight increases the capsules with a nutrient plan and a large number of other information materials that can help you, calorient and low cost reduction."</seg>
<seg id="2607">"in combination with one on your type, the support of the weight can help you to develop a healthy lifestyle and your destination."</seg>
<seg id="2608">"Aloxi is applied in chemotherapies, the strong influence of nausea and vomiting (such as Cisplatin), as well as chemotherapeutic, Doxorubicin or Carboplatin)."</seg>
<seg id="2609">The effectiveness of Aloxi can be used by the additional gift of a Corticosteroids (a medicine that can be used as antiemetics).</seg>
<seg id="2610">The use of patients under 18 years is not recommended because it is not recommended for the effects in this age group not enough information.</seg>
<seg id="2611">"this means that the active substance of a chemical substance in the body, 5-hydroxytryptamin (5HT, also known as Serotonin), which prevents the receptors in the intestines."</seg>
<seg id="2612">"Aloxi was examined in three main studies at 1 842 adults, the chemotherapies, which have a strong or moderate stamina."</seg>
<seg id="2613">"in chemotherapies, the strong influence of nausea and vomiting, 59% of patients who were treated with Aloxi (132 of 223), compared to 57% of the patient treatment patients (126 of 221)."</seg>
<seg id="2614">"in chemotherapies that were treated with Aloxi, 81% of patients who were treated with Aloxi (153 of 189), compared to 69% of the chemotherapy (153 of 189)."</seg>
<seg id="2615">"compared with Dolasetron, these values at 63% for Aloxi (119 of 189 patients) and 53% for Dolasetron (101 of 191 patients)."</seg>
<seg id="2616">"in March 2005, the European Commission publishes the European Commission to Helsinki Switzerland, a permit for the insolvency of Aloxi in the whole European Union."</seg>
<seg id="2617">"Alois is indivisible: the prevention of acute bronchitis, and the prevention of harmful chemotherapy due to a cancer treatment and prevention of nausea chemotherapy due to a Kremserous chemotherapy due to a Kremserous chemotherapy."</seg>
<seg id="2618">"the effectiveness of Aloxi for prevention of nausea and vomiting, which is amplified by a strong chemotherapy, can be amplified by adding one of the chemotherapy to the Corticosteroids."</seg>
<seg id="2619">"since Palonosetron the large intestine can extend, patients with anamestial Obstipation or signs of subacute Ileus to the injection moulding."</seg>
<seg id="2620">"as with other 5HT3 Antennas, however, the QT interval is extended by the same gift of Palonosetron with drug use, which is extended by QT intervall, or in which the QT- Intervall is extended or are extended to such extension."</seg>
<seg id="2621">"except in connection with a further chemotherapeutics, Aloxi in days after chemotherapy neither shall be used for prevention of nausea and vomiting."</seg>
<seg id="2622">"in the clinical trials of the Palonosetron against tumors of the tumors of the tumors of the five, chemotherapist, Cypricein, Doxorubicin and Mitomycin C)."</seg>
<seg id="2623">"in a clinical study, no significant improvement in clinical study showed no significant improvement between a unique intravenous dose of Palonosetron and a Steady's concentration of metoclopramous, a CYP2D6-Inhibitors."</seg>
<seg id="2624">"in one of a population based on a population based on the population of the CYP2D6 Inhibitors (Amiodaron, Celecoxib, Charidin, dioxetin, dioxetin, seronavir, Sertrine and Terbinafin), as well as from CYP2D6-Inhibitors (Amiodaron, seronavir, Sertrine and Terbinafin), no significant increase in the Clearance of Palonosetron."</seg>
<seg id="2625">"experience in the application of Palonosetron, therefore, Palonosetron was not applied, therefore, Palonosetron was not applied in pregnancy, unless it is necessary to be taken from the treated doctor as necessary."</seg>
<seg id="2626">Clinical trials were most frequently used in clinical trials (total 633 patients) who were at least possibly with Aloxi in connection, headaches (9%) and Obstipation (5%). "</seg>
<seg id="2627">"(users Viewing this Forum: 0) 1,506 194 Tauchschein?"</seg>
<seg id="2628">"in the group with the highest dosage, similar to the figs of unwanted events like in the other Dodge groups; there were no dose effects of active relationships."</seg>
<seg id="2629">"however, there were no evidence of dialysis studies, because of the large amounts of distribution is a dialysis."</seg>
<seg id="2630">"in two randomised weldable studies have been compared to 1,132 patients who were compared with ≤ 50 mg / m2 Doxorubicin and 250 micrometer (half-time period 7,3 hours) or 100 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Doxorubicin and 250 mg / m2 Dox</seg>
<seg id="2631">"in a randomized case study, a total of 667 patients, which compared to 667 patients, which compared to a strong chemotherapy with ≥ 60 mg / m2 of the Palonosetron, which were compared to the 32 mg Ondanerron, which were compared to the day 1 intravenous chemotherapy."</seg>
<seg id="2632">Results of studies with high-chemotherapy chemotherapy and the study with strong chemotherapy chemotherapy are summarized in the following tables.</seg>
<seg id="2633">"in clinical trials to indications of chemotherapy therapy, the effects of palonosetron on blood pressure, heart rate and EKG parameters including the Qtc intervalls with the corresponding effects of Ondangerron and Dolasetron."</seg>
<seg id="2634">"after the pre-clinical studies, Palonosetron the ability to block the ventures of the ventures and repolarisation of the Ionisation channels, and the duration of the sharepochs."</seg>
<seg id="2635">The study of the EKG's objective was the evaluation of the EKG effects of i.v. Bismarck in single doses of 0.25, 0,75 and 2,25 mg. "</seg>
<seg id="2636">Resorption of intravenous art follows the initiation of the plasma precipation. a slow Elimination of the body with an average capacity of approximately 40 hours.</seg>
<seg id="2637">The average maximum plasma concentration (Cmax) and the surface under the concentrations of time-curve (AUC0- ∞) are generally generally employed in the whole dose range of 0,3- 90 m / kg at the same time and cancatization.</seg>
<seg id="2638">Intravenosetron 0.25 mg each second day for a total 3 cans of the palm oil per day (± SD) increase in the palonosetron plasma concentration in 42 ± 34%.</seg>
<seg id="2639">Due to the intravenocinetic simulation of 0.25 mg of Palonosetron is comparable in the following days (AUC0- ∞) with the following exposition (AUC0- ∞) with the following exposition (AUC0- ∞) was comparable to the total exposition of 0.75 mg higher.</seg>
<seg id="2640">About 40% are converted into two primary metabolites that have less than 1% of the antagonistic effect on 5HT3 receptor.</seg>
<seg id="2641">In-vitro studies on metrics have shown that CYP2D6 and the Isoenzyme CYP3A4 and CYP1A2 on Metabolism are involved.</seg>
<seg id="2642">"Elimination of a intravenous single dose of 10 micrometer / kg [14C] -Palonosetron have been found approximately 80% of the dose within 144 hours in the urine, Palonosetron as an unparalleled function of approximately 40% of the given dose."</seg>
<seg id="2643">"after a unique intravenous Bolestion, the total body of 173 ± 73 ml / min and renal Clearance 53 ± 29 ml / min."</seg>
<seg id="2644">"although patients with severe liver function returns the terminale Eliminationshakers and the average systemic exposition with Palonosetron, a reduction of the dose is however non-justified."</seg>
<seg id="2645">"in pre-clinical studies, effects were observed, only after expositions were observed, which is sufficient to be measured as sufficient for clinical use in clinical use."</seg>
<seg id="2646">"10. in the clinical trials, the Palonosetron is only in very high concentrations of Ionisation channels, which can reduce the ventures of the ventures and repolarisation."</seg>
<seg id="2647">"high cans Palonosetron (each dose is given in about the 30cm of the therapeutic exposition at the day), the day of liver tumors, endocrene nelasms (in thyroid, hypophyse, Pankreas, outweirons) and skin tumors, but not at mighs."</seg>
<seg id="2648">"the underlying mechanisms are not fully known, but due to the use of high dosing and da Aloxi in the most common application, the results of this results as for the people."</seg>
<seg id="2649">"the owner of this document has to bring the European Commission to inform the European Commission on the plans for the incoming of these decision to inform the plans of this decision."</seg>
<seg id="2650">"• When one of the side effects you can differ considerably or you are able to notice or side effects, please inform your doctor."</seg>
<seg id="2651">"Aloxi is a clear, colourless injure solution for injections in a Vene. • This can cause the effect of one as a serotonin the chemical substance, which occur in connection with a chemotherapy that occur in connection with a chemotherapy because of cancer."</seg>
<seg id="2652">21 In application of Aloxi with other medicines please inform your doctor if you have used other medicines / or before going to be used if it is not needed.</seg>
<seg id="2653">"pregnancy If you are pregnant or believe, your doctor will not give your doctor for Aloxi, unless it is clear."</seg>
<seg id="2654">Ask your doctor or pharmacist to advice if you are pregnant or believe are pregnant.</seg>
<seg id="2655">In some very rare cases it came to allergic reactions to Aloxi or to Bring or pain at the insertion.</seg>
<seg id="2656">"it is a clear, colourless solution and is a clear, colourless solution and is available in a pack with 1 stamping bottle made of glass, which contains 5 ml of the solution."</seg>
<seg id="2657">"for the first time, in the first half of this year, the owner of the Confirmation of the Human Rights Watch."</seg>
<seg id="2658">"Latvija Pharmaceutical Swiss Latvia Sia 54-5" ertrillion of Street Riga, Europa-1011 Tel: + 37167502185 Lietuva UAB Pharmaceutical Swiss Life. "</seg>
<seg id="2659">United Kingdom United States Ltd Ltd Office Village Chester Business Park Chester CH4 9QZ - UK Tel: + 44 1244 625 152</seg>
<seg id="2660">"in June 2006, the Committee for Humanarzs (CHMP), a negative report, in which the provision of the approval for the treatment of hepatitis 6 million IE is recommended."</seg>
<seg id="2661">"this means that the alphabet is a biological medicine called Roferon-A with the same medical-effective component, which is already in the EU."</seg>
<seg id="2662">Alphabet should be used for treatment of adult patients with chronic diseases (long-halotherapy) hepatitis C (one by a virus infection).</seg>
<seg id="2663">"in a microsimulation of the liver tissue, the liver tissue damage on, also the values of the liver tissue is increased by the liver tissue (ALT) in blood."</seg>
<seg id="2664">It is produced by a yeast in which a gene (DNA) was brought to the formation of the active ingredients.</seg>
<seg id="2665">"the manufacturer of Alpheon laid data before the comparison of Alpheon with Roferon-A, (active structure, composition and purity of the drug, certainty, security and effectiveness of hepatitis C)."</seg>
<seg id="2666">"in the study of patients with hepatitis C, the effectiveness of the Alpheon was compared with the effectiveness of reference."</seg>
<seg id="2667">"in the study, the study was measured as many patients to 12 of 48 treatment weeks as well as 6 months after setting the treatment to the medication (i.e. no signs of virus in blood)."</seg>
<seg id="2668">"(44-20) 74 18 84 00 fax: mail @ emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int.</seg>
<seg id="2669">"furthermore, concerns have concerns that data for the stability of the active ingredients and the market is not sufficient."</seg>
<seg id="2670">The number of patients with hepatitis C based on treatment with Alpheon and Roferon-A calls was similar to clinical study.</seg>
<seg id="2671">"after setting the treatment with the alphabet, the disease in more patients come back to the reference specs; in addition, Alpheon more side effects."</seg>
<seg id="2672">"apart from the study of the question of the question, how eweit the medication is a immune system (i.e. the body forms antibodies - special proteins - against the medicines), not sufficient."</seg>
<seg id="2673">"it can be applied to the treatment of Impeer (one with a patient treatment), and small indoors (Riss- or cutting), abdiced and grids."</seg>
<seg id="2674">"Altargo shall not be used for treating infections, the white or probably caused by methicilline resistance hylococcus aureus (MRSA) because Alargo against this kind of infections may not be."</seg>
<seg id="2675">"Altargo can be applied in patients from the age of nine months, but in patients under 18 years the treatment of the skin is no longer than 2% of the body surface."</seg>
<seg id="2676">"if the patient's patient after two to three days, the doctor should pay attention to patients again and alternative treatments."</seg>
<seg id="2677">The bacteria of bacteria that can be produced by bacterial infections (the parts of the bacteria where proteins are produced) and inhibiting the growth of bacteria.</seg>
<seg id="2678">"in all five studies of the percentage of patients, their infection after the end of the treatment was used."</seg>
<seg id="2679">119 (85.6%) of 139 patients under Altargo and 37 (52.1%) of the 71 patients under the treatment of Placebo.</seg>
<seg id="2680">"at the same time, Altargo and Cefalliin similar contact rates: if the results of both studies have been overcome during the treatment of both groups."</seg>
<seg id="2681">"in these two studies, Altargo has been found that Altargo at the treatment of cancerths (eiterfilled-filled joints in body tissue) or infections, the white or probably by MRSA, not effective enough."</seg>
<seg id="2682">The most common-effect effect with Altargo (which was observed in 1 to 10 of 100 patients) is a friction at the contractor.</seg>
<seg id="2683">"the Committee on Humanist agents (CHMP) to the end, that the benefits of Altargo at the short-surface treatment of the following surface treatment: • Impez, • infected small Lazerations, Abbreviations or implants."</seg>
<seg id="2684">"in May 2007, the European Commission will bring the European Commission to meet Altargo in the entire European Union."</seg>
<seg id="2685">Patients suffering from two to three days are not allowed to be examined and an alternative therapy in account (see section 4.4).</seg>
<seg id="2686">"in case of sensitivity, or severe local Irritation by the application of Retapamulin salbe shall be covered by the treatment of retapamulin salbe, and an appropriate alternative treatment of infection."</seg>
<seg id="2687">Retapamulin should not be applied to treatment of infections in which MRSA as a pathogens (see section 5.1).</seg>
<seg id="2688">"in clinical trials, the effectiveness of Retapamulin in patients with infections that were caused by a methicillin-resistant hylococcus aureus (MRSA)."</seg>
<seg id="2689">An alternative therapy should be taken into account when after a 2-3 days or two-day treatment.</seg>
<seg id="2690">The effect of the affected application of Retapamulin and other topical means at the same skin is not examined and the current application of other topical drugs is not recommended.</seg>
<seg id="2691">Due to the small plasticides in humans according to topical use on the sensitive skin or intractable wines) is a clinically relevant Hemisphere in vivo (see section 5.2).</seg>
<seg id="2692">"3 After two-times daily 200 mg cetoconazol increased the medium Retapamless Auc (0-24) and Cmax in topical application of 1% retapamulin salbe on the diced skin of healthy adult men around 81%."</seg>
<seg id="2693">"due to the low-systemic exposition after topical application in patients the dose is not required for required, if topical Retapamulin during a systemic treatment with CYP3A4 Inhibitors."</seg>
<seg id="2694">Animal studies have shown a reproductive medicine to oregovina and are insufficient in relation to a statement on the birth and the fötale / postnatal development (see section 5.3).</seg>
<seg id="2695">Retapamulin Salbe should be applied during pregnancy during pregnancy if a topical antibacterial therapy is clear and the application of Retapamulin in the gift of a systemic antibiotics.</seg>
<seg id="2696">"in the decision, whether it should be finished / expired or the therapy with Altargo, is between the benefits of the food and the benefit of the Altargo therapy for the woman."</seg>
<seg id="2697">"in clinical trials at 2150 patients with a surface area of skin infections, the Altargo was used, was the most common interest of Irritation, which was about 1% of the patients."</seg>
<seg id="2698">"active Retapamulin is a semi-synthetic derivatives of Pleuromutilin, a substance that is characterized by fermentation of Clitopilus, in a substance that is isolated by fermentation of Clitopilus."</seg>
<seg id="2699">The active mechanism of Retapamulin is based on the selected hemisphere of bacterial protein molecules by interaction on a specific binding area of the bacterial riches of the bacteria of other ripenal interagulation of the bacterial infections.</seg>
<seg id="2700">Data indicate that the Bindentation of ripenal protein L3 are involved in the region of ripenal P-bending station and the PeptidyltransferaseCentre.</seg>
<seg id="2701">"due to Binding at this bending point, Pleuromutiline the Peptidyltransfer, block partially p-Bindlertiline interactions and prevent the normal education of the active self-elite unit units."</seg>
<seg id="2702">"should be the reason for local prevalence of the resistance of Retapamulin in at least some of infection forms, should have a advice through experts."</seg>
<seg id="2703">"there were no differences in the In-vitro activity of Retapamulin compared to S.aureus, regardless of whether the insulation is sensitive or reticated to methicillin."</seg>
<seg id="2704">"in case of non-loving treatment at S.aureus, the presence of tribes with additional Virulenzfactors (such as PVL = Panton-Valentine Leucocidin) in the case."</seg>
<seg id="2705">Resorption In a study with healthy adults was 1% retapamulin salbe daily under occlusion for up to 7 days.</seg>
<seg id="2706">"from 516 patients (adults and children), 1% retapamulin salbe twice daily for 5 days to the topical treatment of secondary glaucoma."</seg>
<seg id="2707">The sample was carried out at the days 3 or 4 in the adult patients prior to the meditative and in the children between 0-12 hours after the last application.</seg>
<seg id="2708">"however, the maximum individual systemic recording on humans according to topical use of 1% Salbe on 200 cm2 (Cmax = 22 ng / ml; Auc (0-24) = 238 + h / ml) 660-mal lower than the Retapamulin IC50 for the PGP-Heming."</seg>
<seg id="2709">Metabolism (in vitro oxidative Metabolism) in human liver microsoms was used primarily due to CYP3C8 and CYP2D6 (see section 4.5).</seg>
<seg id="2710">"in studies at the orchard of toxicity (50, 150 or 450 mg / kg) that were carried over 14 days, there were signs of adaptive liver and thyroid."</seg>
<seg id="2711">In-vitro verification on Genetic and / or chromosomal effects in the mouse-Lymphoma test or in cultures of human peripheral blood lymphoo.es as well as in the Rarities microphone test for in-vivo examination of chromosomal effects.</seg>
<seg id="2712">"there were neither in male nor with female Rites signs of restricted fidations of 50, 150 or 450 mg / kg / day, making a up to 5 times higher exposition in humans (topical application to 200 cm2)"</seg>
<seg id="2713">In a embryotoxological study of ≥ 150 mg / kg / day (according to the ≥ 3 times the estimated human exposition (see above)), development stoxizations (reduced body weight of fötus and delay Ossification) and maternal toxicity. "</seg>
<seg id="2714">"the owner of the permission of the permission to ensure that a pharmaceutical convigilance system, as in the module 1.8.1 of the certifications (version 6.2) is present and works before the product is applied and as long as the market is applied."</seg>
<seg id="2715">"the owner of the permission of the permission to provide detailed studies and additional pharmaceuticals plan (RMP) was accepted and in the module 1.8.2 of certifications, as well as all additional updates of the RMP which are agreed with the CHMP."</seg>
<seg id="2716">"as in the CHMP" Guideline on Risk Management Systems for preuse "described, the updated RMP will be submitted by the next Periodic Safety Update Report."</seg>
<seg id="2717">Friction or other signs and symptoms associated to the treated place you should speak the application of Altargo and with your doctor.</seg>
<seg id="2718">"no other Salinas, Creole or Lotions on the area that has been treated with Altargo, if it was not expressly agreed by your doctor."</seg>
<seg id="2719">"it may not be used in the eyes, at the mouth or on the lips, in the nose or female genital area."</seg>
<seg id="2720">"if the salbe made from worship on one of these surfaces, wash the place with water and ask your doctor to advice if symptoms occur."</seg>
<seg id="2721">"according to the end of the salbe, you can cover the surface area with a sterilen association or a Gaza band, unless your doctor has not been able to cover the surface area."</seg>
<seg id="2722">"it is offered in a aluminium tube with a plastic cap, which contains 5, 10 or 15 grams of salbe, or in a aluminium bag that contains 0.5 g salbe."</seg>
<seg id="2723">To protect against hepatitis A and hepatitis B (diseases which affect the liver) in children aged between a and 15 years old against these two diseases.</seg>
<seg id="2724">"in the framework of a two-existing vaccine, a protection against hepatitis B may be achieved only after the second dose."</seg>
<seg id="2725">This reason may only be used if the immune system is a low risk of hepatitis C infection.</seg>
<seg id="2726">"if a total dose of hepatitis A or B, you can be given an amrix or another hepatitis B or B vaccine."</seg>
<seg id="2727">Vaccines affect the immune system (the natural decontamination of the body).</seg>
<seg id="2728">"after a child has received the vaccine, the immune system the viruses and surface antigens as" foreign-" and generates antibodies. "</seg>
<seg id="2729">The inactive vaccine contains the same components such as the 1996-approved vaccine TwinÂ adults and since 1997.</seg>
<seg id="2730">"the three vaccines are used to protect the protection against the same diseases, however, TwinÂ adults and TwinÂ children in the frame of three cans."</seg>
<seg id="2731">The use of Twinrix adults also contain some of the data that use the use of Twinrix adults also available as a cover for the application of amrix.</seg>
<seg id="2732">The main indices for the effectiveness was the proportion of the well-known children who had a month after the last injections.</seg>
<seg id="2733">"in an additional study with 208 children, the effectiveness of the vaccine has been compared with a six-month distance between the two injections."</seg>
<seg id="2734">One month after the last injuncing children had a month after the last injections on the development of the development of antibiotics against hepatitis A and B.</seg>
<seg id="2735">The additional study showed that the degree of protection is similar to an sewage and a 12-month distance between the injections.</seg>
<seg id="2736">"the most common side effects of amrix (observed in more than 1 of 10 vaccine), headache, appetite, pain in the injections, Roman, maternity) and friction."</seg>
<seg id="2737">"if you have any queries, please log in using your e-mail address and your password.:"</seg>
<seg id="2738">"in August 2002, the European Commission of GlaxoSmithKline Biologyls.as a permit for the execution of amrix in the entire entire world."</seg>
<seg id="2739">"the standardization plan for biodiversity is composed of two vaccines, with the first dose of the choice and the second dose of the choice between six and twelve months after the first dose."</seg>
<seg id="2740">"as a result of hepatitis A as well for hepatitis B, it can be used with the corresponding monovalysts."</seg>
<seg id="2741">Anti-hepatitis A anti-hepatitis A virus (anti-HBsAg) - and anti-hepatitis A-virus (anti-HBsAg) - and anti-hepatitis A-virus (anti-HAV) and anti-hepatitis A-virus (anti-HAV).</seg>
<seg id="2742">"it is not completely independent, whether immunity people who need to have a hepatitis-A- impregnation, because they need to be protected by the immunological memory may be protected by the immunological memory."</seg>
<seg id="2743">"3 How can be used for the rare case of medical treatment for the rare case of the vaccine, appropriate ways of medical treatment and monitoring may be available immediately."</seg>
<seg id="2744">"if a fast protection against hepatitis B is required, the standardization scheme is recommended, the 360 ELISA-units formalincompatible hepatitis-A-virus and 10 µg recombinant hepatitis B surface."</seg>
<seg id="2745">"in case of hemalalysis and people with disorders of the immune system, no adequate anti-HAV- and anti-HBS-antibodies are necessary, so that in these cases the gift of other vaccines may be necessary."</seg>
<seg id="2746">"since a intraocular injection molding or intramustice can lead to a suboptimal impairment, this injections are avoided."</seg>
<seg id="2747">"in case of Thrombozytopenie or blood cells can be subdivided into injections, as it may occur in these cases after intramuscular gift."</seg>
<seg id="2748">"in the second life of the second life year in the form of a separate injections, Tetanuse-, Tetellulärem pertussing -, insolvency poliomyelitis- and Haemophilus-vaccine, the immune system was sufficient for all anti-vaccine (see section 5.1)."</seg>
<seg id="2749">Patients under immunological therapy or in patients with immune defect must be achieved.</seg>
<seg id="2750">"in a clinical study, which was observed with 3 vaccines, was the frequency of pain, Roman, swellaritis, headaches and fever."</seg>
<seg id="2751">"in clinical trials, 2029 vaccines were killed in a total of 1027 vaccines in age of 1 to 15 years."</seg>
<seg id="2752">"in a study with 300 participants in the age of 12, including 15 years, the compatibility of the Ambient is compared with the 3-cans combination."</seg>
<seg id="2753">Only exceptions were the higher frequency of pain and maternity on a calculation based on a calculation based on a calculation based on a calculation of a calculation based on a calculation based on a calculation basis per person.</seg>
<seg id="2754">"pain was observed after the gift of amrix at 50.7% of subjects, compared with 39,1% of subjects."</seg>
<seg id="2755">"according to the complete vaccine, 66.4% of subjects that had been received over 63,8% of subjects that were treated with the 3-string combination."</seg>
<seg id="2756">"however, the frequency of Matters was comparable to the entire vaccine of 39,6% of the subjects who were compared with 36,2% of subjects, which were compared with the 3-cans."</seg>
<seg id="2757">"the frequency of severe pain and maternity was low, and comparable to the combination of the combination with the 3-cans vaccines."</seg>
<seg id="2758">"in a comparison study, 1 to 11-year old vaccinations was comparable with 360 ELISA units in the amrixgroup with 360 ELISA units and 10 µg recombinant hepatitis C-virus and 10 µg recombinant hepatitis B surface."</seg>
<seg id="2759">"• This report provides you with valuable data on the actual market situation, trends and future outlook of the market for different product segments, 2008-2019 (US dollars)"</seg>
<seg id="2760">The share of vaccinations that reported about heavy side effects during the 2 cans vaccines with 360 ELISA- units formalincompatible hepatitis A-virus and 10 µg recombinant hepatitis A-virus and 10 µg recombinant hepatitis A-virus and 10 µg recombinant hepatitis A-virus and 10 µg recombinant hepatitis A-virus and 10 µg recombinant hepatitis A-virus.</seg>
<seg id="2761">"in clinical trials, the SeroConverter were performed for Anti-HAV 99.1% a month after the first dose and 100% one month after the second part of the month."</seg>
<seg id="2762">"the Seroconverter rates for anti-HBS were 74,2% one month after the first dose and 100% one month after the second, for the month 6 months."</seg>
<seg id="2763">"Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems."</seg>
<seg id="2764">"in the 289 persons, the immune system was significantly higher than hepatitis B (SP in the table below) against hepatitis B in the month 2 and 6."</seg>
<seg id="2765">"* Understand the competitive environment, the market's major players and leading brands; * Use five-year forecasts to assess how the market is predicted to develop."</seg>
<seg id="2766">"in both studies, the vaccines are either a 2-cans vaccines with the amrix or a 3-cans with 360 ELISA units, with a combination of 360 ELISA units and 10µg recombinant hepatitis B surface surface."</seg>
<seg id="2767">"for persons, at the time of the Grundimmerisation between 12 and 15 years old, the persistence of anti-HAV- and anti-HBS-antibodies have been identified at least 24 months after the immune system in 0-6 months."</seg>
<seg id="2768">"in this study, the immune system is comparable to both anti-virus anti-virus anti-virus and 10 µg recombinant hepatitis- A-virus and 10 µg recombinant hepatitis B surface surface of 0.5 ml."</seg>
<seg id="2769">"in a clinical study at 12 to including 15-year-old, the persistence of anti-HAV- and anti-HBS-antibodies are comparable to the 0-6 months in the 0-12 months."</seg>
<seg id="2770">"when the first dose is based on a combined diphtherie-, Tetanuse-, Tetellulärem pertussing, Tetanusophilus fenzae type b-vaccines (DTPa-IPV / hib) or with the first dose of a combined masks (DTPa-IPV / hib) or with the first dose of a combined masks (DTPa-IPV / hib) or with the first dose of a combined masks (DTPa-IPV / hib) or with the first dose of a combined masks (DTPa-IPV / hib) or with the first dose of a combined masks (DTPa-IPV / hib) or with the first dose of a combined masks."</seg>
<seg id="2771">"a clinical study that was carried out with 3 cans of the current formulation in adults, showed for the present formulation of seroprotectile and seroconverter, as for the earlier formulation."</seg>
<seg id="2772">"the vaccine is both before and after the Resustice, as well as after the Resustice in eye and / or physikalisch visible changes."</seg>
<seg id="2773">"in accordance with Article 114 of the Directive 2001 / 83 / EC on the state of state, state of state or one of this purpose."</seg>
<seg id="2774">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="2775">Main page "Catalogue" Aquaristics, Nano-Aquariums, Filters, Pumps, Aquarium Lighting, Filter Media "</seg>
<seg id="2776">EU / 1 / 02 / 224 / 001 1-injection packers with needle-EU / 1 / 02 / 224 / 004 1-injection packers with Nadeln EU / 1 / 02 / 224 / 005 50 finished parts without needles</seg>
<seg id="2777">"the hepatitis A virus is typically used by virushalal foods and drinks, but can be transferred by other ways, as well as through the water purification of water."</seg>
<seg id="2778">"you can feel very tired, have a dark urine, a bladder, yellow, and / or eyes (yellow.) and other symptoms which may possibly make a stationary treatment."</seg>
<seg id="2779">"as in all vaccines, amrix is not fully connected to infection with hepatitis A or hepatitis B virus, even if the complete vaccine series has been completed."</seg>
<seg id="2780">"if you are working on your child before the delay of both vaccines are already infected with hepatitis A or hepatitis B virus (although you don't feel like your child will not be uncomfortable or sick / feel) may not prevent it."</seg>
<seg id="2781">A protection against other infections that cause the liver or symptoms associated with hepatitis C or hepatitis B infection.</seg>
<seg id="2782">"• If you already have an allergic reaction to amrix or any part of this vaccine, including Neomycin (an antibiotics)."</seg>
<seg id="2783">"if you have a allergic reaction to hepatitis A or hepatitis C or hepatitis B, if you have any allergic reaction to hepatitis A or hepatitis B."</seg>
<seg id="2784">"• If you would like to have a protection against hepatitis B, i.e. between 6 months and before the usually exceeded the second vaccine dose)."</seg>
<seg id="2785">In a possible risk of infection with hepatitis B between the first and second image is the doctor for your child by an imacuation.</seg>
<seg id="2786">"instead, he will advise you / your child 3 injections of a combined hepatitis C / hepatitis B vaccine with a reduced thickness of hepatitis A-virus and 10 micrometres of a recombinant hepatitis C-virus and 10 micrometres of a recombinant hepatitis-B surface treatment)."</seg>
<seg id="2787">"the second vaccine of this vaccine with reduced prices of effective stock, usually a month after the first dose."</seg>
<seg id="2788">"if you are suffering from a disease or treatment in your body, it is a disease or treatment in your body because of a disease or treatment in your body."</seg>
<seg id="2789">"in these cases, the immune system cannot be sufficient, but the immune system is necessary to see that a blood test can be necessary to see how much the reaction to the Impress is."</seg>
<seg id="2790">21 Sages you will take your doctor if you are able to take a more medicines (including those that you can get any other medicines) or if you are used without having to drink / or the child from the future? or if you are in a near future or this is planned for the future.</seg>
<seg id="2791">"it may be that in this case the immune system is not sufficient, and the person can be protected against one or both hepatitis A and B virus."</seg>
<seg id="2792">"when a other vaccine can be given at the same time, the ambition should be given to separate places and as possible as possible as possible as possible as possible."</seg>
<seg id="2793">"it is probably that the reaction to the vaccine is not sufficient, it is probably that the reaction to the vaccine would be sufficient."</seg>
<seg id="2794">"in the case of hepatitis B, there is no need for hepatitis C as well as hepatitis B as well as hepatitis B and hepatitis B."</seg>
<seg id="2795">"important information on certain other components of amrix, inform your doctor if you already have an allergic reaction to Neomycin (antibiotics)."</seg>
<seg id="2796">"if you don't miss the agreed date for the second session, speak with your doctor and agree to a new appointment as soon as possible."</seg>
<seg id="2797">♦ Executive Summary • Enhance your understanding of the consequences of the market. • pain or complaints regarding the insertion of the insertion or tubes • water pain • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • appetite • Appetit</seg>
<seg id="2798">♦ Superior (up to 1 case per 10 deimed cans): • swelling on the injector • fever (over 38 ° C) • Benommenities • stomach-intestines</seg>
<seg id="2799">Another side effects that day or weeks after the impregnation or single iments against hepatitis A and hepatitis B very rare (less than 1 case per 10,000 verimed cans) are:</seg>
<seg id="2800">"these include individual or extended information, which can be seen or blessings, swelling of the eye, and facial tongues, sudden facial blood pressure, and consciousness."</seg>
<seg id="2801">"Grips-similar complaints, including Schütsch, muscle and joint pain Krampurry, Schwindel, misunderstandings such as cribling and" Ameiotic "," multiple sclerosis, disorders of the tendons, strong headaches and stiffness of the neck, interruption of normal brain functions "</seg>
<seg id="2802">"symptoms of blood vessels, symptoms of blood vessels or disease, appetite and abdominal pain, appetite and abdominal pain, appetite and abdominal pain, appetite and abdominal pain, appetite and abdominal pain (blue spots), caused by separation of blood planting."</seg>
<seg id="2803">"23 Informed your doctor or pharmacist, when one of the side effects of side effects, you can change or avoid side effects that are not permitted in this package."</seg>
<seg id="2804">Amrix is available in packages to 1 and 10 with or without needles to 50 without needles.</seg>
<seg id="2805">"on the basis of the data, which has become known for the first permission of the Instructor, the CHMP the view that the benefit risk ratio for amrix is positive."</seg>
<seg id="2806">"however, however, however, only in a membership state (in the Netherlands since 2003), the available safety data for this drug has been limited."</seg>
<seg id="2807">Ammonia can also be used in the age of over a month with incomplete Enzymity or with a complete endocrystopathy in the history of the history.</seg>
<seg id="2808">"ammonite is divided into several types of meals - split, under the food, or via a Gastrostomos (through the abdominal belt in the stomach of the stomach) or a noensonde (through the nose into the stomach of the stomach) or a noensonde (through the nose into the stomach of the stomach)."</seg>
<seg id="2809">"this is not a comparable study, because of ammonia cannot be compared with another treatment or with Placebo (a headquarter, i.e. without any active substances)."</seg>
<seg id="2810">"it can also be used for appetite loss, a abruptive acid content in the blood, deportation, headache, abdominal or taste, abdominal pain, irritation, irritation, abdominal, unpleasant body, unpleasant body, unpleasant body, unpleasant body weight."</seg>
<seg id="2811">The Committee on Humanist agents (CHMP) lead to the end that ammonite patients with disorders of the urinary cycle comes to high ammonia values.</seg>
<seg id="2812">"ammonite was admitted under" extraordinary circumstances "because due to the seldom of the disease at the time of the approval only limited information about this medicine models."</seg>
<seg id="2813">"the use is in all patients with all patients, where a complete Enzymity had already manifested in the New Apostolic Church (within the first 28 liver age)."</seg>
<seg id="2814">"in patients with a delay of delayed form (incomplete Enzymity, which is manifest after the first life of manifesting), then a indications for use when in the Anamnesis is a hyperopia."</seg>
<seg id="2815">"for acid, for children who don't work in the location, tablets, or for patients with luckdysfunction is AMMONAPS also available in granulatform."</seg>
<seg id="2816">The daily dose is suitable for the protein tolerances and the growth and the development of the daily protein intake of patients.</seg>
<seg id="2817">"according to the previous clinical experience, the normal day of sodium phenylesbutyrat: • 450 - 600 mg / kg / day in children with a body weight of less than 20 kg • 9,9 - 13,0 g / m ² / day with children with a body weight of 20 kg and with Hermigua and adults."</seg>
<seg id="2818">"in patients who suffer from a early composition of Carbamylate synthetase or Ornithinkoarbamylase, is the subsistence of Citrullin or arginine in a dosage of 0,17 g / kg / day or 3,8 g / m ² / day."</seg>
<seg id="2819">Patients with a argininosuccinatsynthetase lack of arginine in a dosage of 0.4 - 0.7 g / kg / day or 8,8 - 15,4 g / m ² / day. "</seg>
<seg id="2820">AMMONAPS tablets may not be accepted as a risk for the origin of Ösophagusulzera, when the tablets did not take immediately in the stomach. "</seg>
<seg id="2821">"any tablet AMMONAPS contains 62 mg (2,7 mmol) sodium, according to 2.5 g (108 mmol) sodium per 20 g sodium phenylphenyrat, which corresponds to maximum daily dose."</seg>
<seg id="2822">AMMONAPS should therefore be applied to patients with condensation agent or severe kidney cancer.</seg>
<seg id="2823">"as Metabolism and elimination of sodium phenylesbutyCouncil on the liver and the kidneys, AMMONAPS in patients with liver or kidney disease can only be applied only with extreme control."</seg>
<seg id="2824">"the importance of these results in relation to sangere women is not known; the use of AMMONAPS during pregnancy is therefore intoxicated (see 4.3)."</seg>
<seg id="2825">Phenylonate (190 - 474 mg / kg) came to a slower loss of neurons.</seg>
<seg id="2826">"it also found a delay of cerebral Synapsen, and a reduced number of functional nerve damage in the brain and therefore a disability of the brain growth."</seg>
<seg id="2827">"it could not be noted if phenyl acetate for humans in the mother's milk, and from this reason is the use of AMMONAPS during the standpoint, (see 4.3)."</seg>
<seg id="2828">"in clinical trials with AMMONAPS, at 56% of patients at least a undesirable event (AE) and at 78% of these unwanted events were done that they were not with AMMONAPS."</seg>
<seg id="2829">"the frequency is defined as follows: very frequently (≥ 1 / 10), frequently (≥ 1 / 100, &lt; 1 / 10) and occasionally (≥ 1 / 1,000, &lt; 1 / 100)."</seg>
<seg id="2830">"a likely toxic reaction to AMMONAPS (450 mg / kg / day) was reported by a 18 years old collection, a metabolic endocrystie in combination with Lakshazionale, heavy hypokalemia, peripheral and pankreditation."</seg>
<seg id="2831">"a case of overdosages, in a 5 months old small child, with a minor portion of 10 g (1370 mg / kg)."</seg>
<seg id="2832">This symptoms can be taken with the accumulation of phenyl acetate from cans to 400 mg / kg / day a dosed limiting neurotoxic.</seg>
<seg id="2833">"phenyl acetate is a metabolic connection, which is transferred by Acetyelling with glutamine to phenyl acetylglutamine, which is generated by the nuts."</seg>
<seg id="2834">Phenyl acetylglutamine (both connections contain 2 nitrogen oxide); phenyl acetylglutamine (both connections contain 2 nitrogen oxide).</seg>
<seg id="2835">5 patients with disorders of the urinary cycle can be assumed that for each grams of sodium phenylene particles between 0.05 and 0.15 g phenylene particles are produced.</seg>
<seg id="2836">It is important to improve the diagnosis and treatment immediately started to improve the survival of living and the clinical result.</seg>
<seg id="2837">"the result of the early manifested form of the disease was almost always inferior, and the disease was almost always inferior to treatment with peritoneal dialysis and essential amino acids or with their stickfree analog signals within the first life of life."</seg>
<seg id="2838">"sodium benzoate, sodium benzoate, sodium benzoate, sodium benzoate, sodium benzoate, sodium benzoate and sodium phenylene, was possible to increase the survival rate of neupartal (but within the first life months) diagnosed diseases on 80%."</seg>
<seg id="2839">"in patients, their disease was diagnosed in the course of pregnancy, the survival rate 100%, but even in these patients came to spiritual disabilities or other neurological Defizites."</seg>
<seg id="2840">"in patients with a delayed form of the disease (including risk patients with the heterozygary form of the Ornithinkeratoplasty, which were treated with sodium phenylesbutyrat, and a proteinated reduction, was the survival rate 98%."</seg>
<seg id="2841">"in case of existing neurological Defizite, the treatment of neurological Defizite are hardly able to occur in treating patients with some patients."</seg>
<seg id="2842">"phenyl acetylate acid is known to phenyl acetate oxidized, which is in liver and kidney cancer with glutamine, with phenyl acetylglutamine."</seg>
<seg id="2843">The concentrations of phenylesyrat and its metabolites in plasma and urine were obtained after the gift of a single dose of 5 g diumphenylene in plasma and in patients with disorders of urinary cans by up to 20 g / day (not controlled trials).</seg>
<seg id="2844">The behavior of phenylesyrat and its metabolites was also examined by Krediphenylesbutyrat (up to 2 g / m ²) or phenyl acetate.</seg>
<seg id="2845">"according to an oral single dose of 5 g sodium phenylesbutyrat in tablet form, 15 minutes after taking the removal of phenylesyrat."</seg>
<seg id="2846">"during the majority of patients with urecyclerosis disorders, or hemmogloomy (300-650 mg / kg / day up to 20 g / day) at the next morning after the following morning, no phenyl acetate in plasma."</seg>
<seg id="2847">"in three of six patients with liver tissues, which were treated with sodium phenylesbutyrat (20 g / day oral in three single beds), the middle phenylene particles of the third day five times higher than after the first place."</seg>
<seg id="2848">This medication is made within 24 hours of up to 80 - 100% in the form of condensate product phenylonglutamine.</seg>
<seg id="2849">"according to the results of the Micronucleus tests, sodium phenylesbutyrat in with toxic and non-toxic substances (examination 24 and 48 h) to orangling effects (examination 24 and 48 h) to org. a single dose of 878 to 2800 mg / kg)."</seg>
<seg id="2850">AMMONAPS Granulate will be taken either in oral (acid and children who do not have any tablets) or patient with a Gastrostomy or a noensonde.</seg>
<seg id="2851">"according to the previous clinical experience, the normal daily dose of sodium phenylesbutyrat: • 450 - 600 mg / kg / day with a body weight of less than 20 kg • 9,9 - 13,0 g / m ² / day in children with a body weight of 20 kg."</seg>
<seg id="2852">"the concentration of ammonia, arginine, essential amino acids (especially algable amino acids), carnitin and serum prototyping a plasma should be held within the normal range."</seg>
<seg id="2853">"in patients who suffer from a early composition of Carbamylate synthetase or Ornithinkoarbamylase, is the subsistence of Citrullin or arginine in a dosage of 0,17 g / kg / day or 3,8 g / m ² / day."</seg>
<seg id="2854">AMMONAPS Granulat contains 124 mg (5.4 mmol) sodium per gram sodium hydrostatic butyrat, according to 2.5 g (108 mmol) sodium per 20 g diumphenylesbutyrat. "</seg>
<seg id="2855">"when Rattenfaves in the birth of phenyl acetate (active metabolic of phenylesyrat), came to the pyramids in the pyramid cells of the brain cells."</seg>
<seg id="2856">"a likely toxic reaction to AMMONAPS (450 mg / kg / day) was reported by a 18 years old collection, a metabolic endocrystie in combination with Lakshazionale, heavy hypokalemia, peripheral and pankreditation."</seg>
<seg id="2857">Phenyl acetylglutamine (both connections contain 2 nitrogen oxide); phenyl acetylglutamine (both connections contain 2 nitrogen oxide).</seg>
<seg id="2858">Phenyl acetylglutamine in patients with disorders of uryl acetylglutamine in patients with disorders of uryl acetylglutamine between 0.12 and 0.15 g phenylene particles are produced.</seg>
<seg id="2859">"in addition, existing neurological Defizite are hardly retained in treating diseases, and in some patients can occur in some patients."</seg>
<seg id="2860">"according to an oral single dose of 5 g sodium phenylesbutyrat in granulatform, 15 minutes after taking the removal of phenylesyrat."</seg>
<seg id="2861">"during the duration of durability, the patient can store the finished product chain for a period of 3 months in a temperature of not over 25 ° C."</seg>
<seg id="2862">"in this procedure, the small measuring spoon 0,95 g, the medium measurement spoons 2,9 g and the large measurement spoons 8,6 g sodium phenylphenyrat."</seg>
<seg id="2863">"if a patient does not receive medication over a probe, AMMONAPS can also be used in water (the solvent of sodium phenylesbutyrat is up to 5 g in 10 ml water)."</seg>
<seg id="2864">"in patients with these rare diseases are missing certain liver diseases, so that it is the stickable waste of waste products that can be stored in the body."</seg>
<seg id="2865">"when using you laboratory tests, you need to take the doctor that you have AMMONAPS, as sodium phenylesbutyrat the results of certain laboratory tests."</seg>
<seg id="2866">"in case of AMMONAPS with other medicines, please inform your doctor or pharmacist if you do other medicines or pharmacist if you do not have any other medicines, even if it is not necessary."</seg>
<seg id="2867">"during the standtime you may not take AMMONAPS, because the medicines in the mother's milk and your baby."</seg>
<seg id="2868">"in rare cases, confusion, headache, headaches, flavors, cause of the obedience, diarrative, memory dysfunction and a reduction of existing neurological conditions."</seg>
<seg id="2869">If you find one of these symptoms you will find immediately with your doctor or with the emergency service of your hospital.</seg>
<seg id="2870">"if you have forgotten the dose of AMMONAPS you have forgotten the appropriate dose as as possible, as possible with the next meal."</seg>
<seg id="2871">"symptoms of blood cells (red blood cells, white blood cells), chronic pain, abdominal pain, abdominal pain, abdominal pain, irritation, irritation, uncomfortable skin care, weight gain and anomal laboratory values."</seg>
<seg id="2872">"please inform your doctor or pharmacist, if one of the side effects you can choose from either side effects or side effects that are not found in this use."</seg>
<seg id="2873">You may not use AMMONAPS according to the box and the container.</seg>
<seg id="2874">"as AMMONAPS and contents of the pack AMMONAPS tablets are available from white colour and oval shape, and they are with the embossing" UCY 500. "</seg>
<seg id="2875">"30 When using you laboratory tests, you need to take the doctor, that you have AMMONAPS, as sodium phenylesbutyrat the results of certain laboratory tests."</seg>
<seg id="2876">"in case of AMMONAPS with other medicines, please inform your doctor or pharmacist if you do other medicines or pharmacist if you do not have any other medicines, even if it is not necessary."</seg>
<seg id="2877">"you should use AMMONAPS distributed on the same single dull oral, or via a magnets (hose, the abdominal wall directly into the stomach) or a noensonde (hose that is carried through the nose into the stomach)."</seg>
<seg id="2878">"• If you take a straight edge of the tank, e.g. a knife back on the upper edge of the measurement of the measurement of the measurement. • The recommended number of measurement spoon granulate from the container."</seg>
<seg id="2879">"at the same time, Angiox is applied to the treatment with" acute Koronarsyndromes "(ACS, reduced blood sugar), for example, instabiler Angina (a form of pain in breast girdle with different thickness) or myokardinfarina (a anomal measurement)."</seg>
<seg id="2880">"at the same time, Angiox is used to prevent blood sugar in patients who used a higher dose and the Infusion can be used up to four hours after the procedure."</seg>
<seg id="2881">This can increase the blood flow of the blood flow to the heart and to increase the effectiveness of a PCI.</seg>
<seg id="2882">"almost 14 000 patients took part of the main study on the treatment of ACS parts, which was compared with a glykoprotein-IIb / IIIa-Inhibitor (GPI, another antioagulans) and a GPI."</seg>
<seg id="2883">"while the PCI has been used to prevent a stent (a short distance), which is used in the Arterie to prevent one lock, and they received other medicines to prevent blood flow, such as Abciximab and Aspirin."</seg>
<seg id="2884">"during the treatment of ACS, Angiox - with or without gift of GPI - at the reduction of new events (deaths, heart rate or Revaskforce) after 30 days or a year, as well as the conventional treatment."</seg>
<seg id="2885">"in patients suffering from a PCI, Angiox was in relation to all indications such as hepatic, except in severe blood, in which it was significantly more effective than hepatic."</seg>
<seg id="2886">Angiox cannot be applied to patients which may possibly be oversensitive (allergic) against bivalirudin, other shudine or one of the other components are used. "</seg>
<seg id="2887">"it may also be applied to patients who had recently had a blood, as well as people with strong blood pressure or heavy kidney problems or a heart infection."</seg>
<seg id="2888">"the Committee for Humanist agents (CHMP) to the end, that Angiox at the end, that Angiox at the end of the treatment of ACS and during a PCI is a annelling replacement for hepatic."</seg>
<seg id="2889">"in September 2004, the European Commission to company The Medicines Company UK Ltd. a permit for Ingiox of Angiox in the whole European Union."</seg>
<seg id="2890">Treatment of adult patients with acute coronaract (instabile Angina / non-ST-Hebrews (IA / NSTEMI)) with an emergency handle or if a early intervention is scheduled.</seg>
<seg id="2891">The recommended initialdose of Angiox at patients with ACS is a intravenous Bolusb of 0.1 mg / kg / h.</seg>
<seg id="2892">"if the patient is carried out a PCI, a additional Bolus of 0.5 mg / kg and the infusion for the duration of the surgery on 1,75 mg / kg / h / h."</seg>
<seg id="2893">After the PCI can be added to clinical requirements again the reduced weight dose of 0.25 mg / kg / h for 4 to 12 hours.</seg>
<seg id="2894">"immediately before the procedure, a bolt securing of 0.5 mg / kg, followed by an infusion of 1,75 mg / kg / h for the duration of the surgery."</seg>
<seg id="2895">The recommended dosage of Angiox at patients with a PCI is made of a initial intravenous Bolustice of 0.75 mg / kg body weight and one of the subsequent intravenous infusion with a dose of 1,75 mg / kg body weight / h at least for the duration of the surgery.</seg>
<seg id="2896">"the security and effectiveness of a allway Bolus gift of Angiox was not examined and is not recommended, even if a short PCI procedure is planned."</seg>
<seg id="2897">"this value (ACT after 5 minutes) on 225 seconds, a second bolt securing of 0.3 mg / kg / body weight."</seg>
<seg id="2898">"in order to reduce the possibility of low ACT values, it should be carefully mixed and tested medication before the application carefully mixed and the bolusdose of intravenous medication."</seg>
<seg id="2899">"as soon as the ACT value more than 225 seconds, a further monitoring is necessary, the 1,75 mg / kg infusion dose is correct."</seg>
<seg id="2900">"in patients with medium-hard kidney compounds (GFR 30-59 ml / min), which can be treated with bivalirudin (whether with bivalirudin) should be used to be treated with bivalirudin (whether with bivalirudin) should be used for a lower risk rate of 1.4 mg / kg / h."</seg>
<seg id="2901">The ACT-value of 225 seconds is a second bolusdose of 0.3 mg / kg and the ACT 5 minutes after the second bolusdose.</seg>
<seg id="2902">"in patients with medium kidney cancer, which were included in the phase III- PCI study (WIP-2), which were included in the phase 5 minutes after the gift of the Bivalirudin-Bolus without delay in the average 366 ± 89 seconds."</seg>
<seg id="2903">3 In patients with severe kidney cancer (GFR &lt; 30 ml / min) and also in dialysis patients is Angiox patient (see under section 4.3).</seg>
<seg id="2904">"the treatment with Angiox can be used 30 minutes after the intravenous gift of unfussed hepatic or 8 hours after the subcutaneous use of a molecular hepatitis."</seg>
<seg id="2905">"• detergents against the active compounds or any other substances or against shudine • active blood vessels or disinfectomy (GFR &lt; 30 ml / min) and for dialysis, patients with dialysis."</seg>
<seg id="2906">Patients are carefully observed in terms of symptoms and signs of a blood flow. especially if bivalirudin in combination with another antioagulans (see section 4.5).</seg>
<seg id="2907">"even if the PCI patients can occur in bivalirudin the most blood vessels of arteries, can occur in patients who occur with a permetic Koronaral (PCI) during treatment, during the treatment."</seg>
<seg id="2908">"in patients, the warfarin take-up and with bivalirudin should be treated to ensure that the value of treatment with bivalirudin could be reached before the treatment."</seg>
<seg id="2909">"from the knowledge about the active mechanism of antioagulthood (hepatic, Warfarin, Thrombolytic or Thrombozytention) can be used to increase the blood circulation."</seg>
<seg id="2910">"during the combination of Bivalirudin, the clinical and biological hemoagulation are the clinical and biological hemmostaseparrays in any case."</seg>
<seg id="2911">The experimental investigations are in relation to the effects on the pregnancy that embryonic / oale development that empiries or the postnatal development of insufficient (see under section 5.3).</seg>
<seg id="2912">4612 were randomised to bivalirudin plus GPIIb / IIIa Inhibitor and 4603 were randomised to either unfussed hepatic or Enoxaparin plus GPIIb / IIIa Inhibitor.</seg>
<seg id="2913">Both in the Bivalirudin group as well as in patients with hepatic treatment of women as well as patients over 65 years and patients over 65 years are more unwanted events than in male or younger patients.</seg>
<seg id="2914">Heavy blood vessels were defined according to ACUITY and TIMI measures for heavy blood vessels as in the footnotes of table 2.</seg>
<seg id="2915">Both light as well as heavy blood cells were significantly less frequent than in groups with hepatic plus GPIIb / IIIa-Inhibitor and bieldrudin plus GPIIb / III- Inhibitor (see table 2).</seg>
<seg id="2916">"a ACUITY has been defined as one of the following events: intracranial, retroperitoneal, intraocular or surgical intervention caused by ≥ 4 g / dl without weakened blood circulation, reduction of the hemorgloomy, reduction of blood pressure, use of blood products."</seg>
<seg id="2917">"other, less often observed blood vessels that were more than 0.1% (occasionally), retroperitoneal, Gastroast, ear, nose or neck."</seg>
<seg id="2918">The following information on side effects are based on the data of a clinical study with bivalirudin at 6000 patients who underwent to the PCI.</seg>
<seg id="2919">Both in the Bivalirudin group as well as in patients with hepatic treatment of women as well as patients over 65 years and patients over 65 years are more unwanted events than in male or younger patients.</seg>
<seg id="2920">Both light and heavy blood cells were significantly less frequent than in the comparison of hepatic plus GPIIb / IIIa-Inhibitor.</seg>
<seg id="2921">"the following side effects that are not listed above, after extensive application in practice reports and are based on system of classes in the table 6."</seg>
<seg id="2922">In case of overdosed treatment is the treatment with bivalirudin and the patient's patient with regard to signs of blood.</seg>
<seg id="2923">"Angiox contains Bivalirudin, a direct and specific Thrombine, both on the katalytic centre of Thrombin binds, regardless of whether Thrombin is bound in the liquid phase or in the liquid phase."</seg>
<seg id="2924">"the Binding of Bivalirudin at Thrombin, and thus the effect of bivalirudin-Arg3-Pro4 slowly turns out the function of the active centre of Thrombin."</seg>
<seg id="2925">"in addition, bivalirudin have come with serum of patients, where it was in the past of heparininseparable Thrombotic Syndrome (HIT / HITTS), no Thrombotic units."</seg>
<seg id="2926">"in case of healthy subjects and in patients with Bivalirudin, Bivalirudin have a dose and concentration dependent effect that is characterized by the extension of ACT, aPTT, PT, INR and TT."</seg>
<seg id="2927">"if the patient had been carried out a PCI, a additional Bolus of 0.5mg / kg Bivalirudin and the infusion for the duration of the surgery on 1.75mg / kg / h."</seg>
<seg id="2928">"in the arm of the ACUITY study, unfussed hepatic or Enoxaparin in accordance with the relevant guidelines for the treatment of akutem Corina / non-ST-Hebrews (IA / NSTEMI)."</seg>
<seg id="2929">Patients in arm A and B were randomised to receive a GPIIb / IIIa Inhibitor either at the beginning of the sea (at the time of the sea) or at the PCI.</seg>
<seg id="2930">"in the ACUITY study, the characterisation of high-risopatization, which is distributed within 72 hours, evenly distributed over the 3 treatment."</seg>
<seg id="2931">"about 77% of patients had a recursive ischemia, 70%, dynamic EKG- changes or increased kardiale biomass, 28% diabetes and about 99% of all patients underwent within 72 hours of an Angiography."</seg>
<seg id="2932">"the primary analysis and results from the ACUITY study for the 30-day and the 1st annual point for the total population (ITT), and for the patient, the Aspirin and Clopidoggy or protocol (before the Angiography or before the PCI), are shown in tables 7 and 8."</seg>
<seg id="2933">ACUITY study; 30-days and 1 year risk differences in the combined end point and its components for patients who received Aspirin and Clopidogrel according to protocol *</seg>
<seg id="2934">Patients who received Aspirin and Clopidogrel according to the arm of the arm A arm B UFH / Enox Bival B- A C + GPIIb / IIIa risk Diff.</seg>
<seg id="2935">"the frequency of blood vessels both in the ACUITY- as well as in TIMI, as well as in TIMI, as well as in TIMI, as well as in TIMI, as well as in the TIMI."</seg>
<seg id="2936">Share this: print & PDF Email Facebook Twitter Tumblr More Google LinkedIn Pinterest Pocket</seg>
<seg id="2937">"* Clopidogrel before Angiography or before PCI 1 A ACUITY has been defined as one of the following events: inextraction or surgical intervention, hemoito-neal, captivation of hemodical or surgical intervention, shortening of the hemodical or surgical intervention."</seg>
<seg id="2938">"the 30-days results, based on four-points and three-ply points of a randomized double blind study with over 60,000 patients with over 60,000 patients with over 60,000 patients."</seg>
<seg id="2939">Clinical trials with a small number of patients received limited information about the application of Angiox in patients with HIT / HITTS.</seg>
<seg id="2940">The most important characteristics of bivalirudin were found in patients with patients suffering from a permetic Koronaral (PCI) as well as in patients with ACS.</seg>
<seg id="2941">"it is expected to be expected that Bivalirudin as Peptid is a catabolism in its amino acids, with subsequent recitation of amino acids in the body-pool."</seg>
<seg id="2942">The primary metabolism of the Arg3 Pro4 Binding of the Arg3-Binding of the N-terminale sequence by Thrombin results is not effective because the loss of its Affective Centre of Thrombin cannot be effective.</seg>
<seg id="2943">The Elimination is performed in patients with normal kidney function after a process first order of 25 ± 12 minutes.</seg>
<seg id="2944">"based on conventional studies on the conventional studies on the safety spharmakology, toxicity of repeated gift, genotoxity or reproductive data, the preclinical data is no special dangers for humans."</seg>
<seg id="2945">The toxicity of animals with repeated or continuous exposition (1 day to 4 weeks) with a exposition up to 10-fold of the clinical Steady-state-Plasmakerage (1 day to 4 weeks).</seg>
<seg id="2946">Side effects due to a long-term physiological load as a reaction to a non-homeostatic coagulation were comparable to the clinical application that were observed in very much higher dosage.</seg>
<seg id="2947">"for the production of the used solution 17 not under controlled and validated aseptic conditions, it is not longer than 24 hours at 2 ° C up to 8 ° C."</seg>
<seg id="2948">Angiox is a freezer of dried powder in a single dose-stantibody bottles made of type-1-glass to 10 ml.</seg>
<seg id="2949">5 ml sterile water for injection purposes will be given into a filter bottle of Angiox and easily raised up until everything is clear and the solution is clear.</seg>
<seg id="2950">"sodium chloride (0,9%) sodium chloride solution for injections, or with 9 mg / ml (0.9%) sodium chloride solution for injections in a total volume of 50 ml to receive a final cleaning of 20 / ml Bivalirudin."</seg>
<seg id="2951">"the owner of the permission of the permission of the Instructional plan is to be agreed, as in version 4 of the risk management plan (RMP) agreed and in the module 1.8.2 of the risk management plan (RMP), as well as in the module of the RMP, which was created by CHMP."</seg>
<seg id="2952">"according to the CHMP Guideline to risk management systems for humanity, the reworked RMP at the next Periodic Safety Update Report (PSUR)."</seg>
<seg id="2953">• patients with breast cancer due to a heart disease (acute coronaral infections (ACS) • patients who are used for treatment of closures in the blood vessels (Angioplasties and / or permetic Koronaral infections (PCI).</seg>
<seg id="2954">"if you are pregnant or make you pregnant with you, you will be able to become pregnant."</seg>
<seg id="2955">"there were no investigations of the impact on the transport and the ability to serve machines, but one knows that the effects of this drug can be achieved by only in short term."</seg>
<seg id="2956">"during the beginning of the injection or infusion, you will inform your doctor about the possible sign of a allergic reaction."</seg>
<seg id="2957">"• A particularly careful monitoring is carried out in less than 1 of 1000 treated patients. • The dose you will receive a radiation therapy for the vessels that you receive the heart with blood, which you will receive from your body weight and of the type of therapy."</seg>
<seg id="2958">"• 0.1 mg / kg body weight as injections followed by an infusion (Tropical solution) with 0.25 mg / kg body weight per hour (0.1 mg / kg body weight per hour (0.1 mg / kg body weight per hour (0.1 mg / kg body weight per hour."</seg>
<seg id="2959">"likely, when Angiox in combination with other geration or antibiotics may be accepted (see section 2" "in application of Angiox with other medicines."</seg>
<seg id="2960">"• Thrombose (blood pressure), which could lead to serious complications such as a heart attack."</seg>
<seg id="2961">"this is a significant impact (with less than 1 of 100 treated patients). • pain, blood, and Blueberry at the point of point (after a PCI Treatment)."</seg>
<seg id="2962">"please inform your doctor if one of the side effects you can choose from either side effects or side effects, which are not in the use of this information."</seg>
<seg id="2963">Angiox may be applied to the label on the label and the box on the "" specified date "" date. "</seg>
<seg id="2964">Polska The Medicines Company UK Ltd Ltd Ltd.: + 800 843 633 26 Lub + 41 61 564 1320 Per person: + 30 210 5281700 E-mail:</seg>
<seg id="2965">Apidra will be used for treatment of adults, adolescents and children from six years with diabetes. "</seg>
<seg id="2966">Apidra is subcutaneous (under the skin) into the abdominal wall.</seg>
<seg id="2967">Diabetes is a disease in which the body is not sufficient insulated in the control of the Glucosespiegels (sugar) in blood or the insect in not effective.</seg>
<seg id="2968">ISO-8859-1 (Western Europe) iso-8859-2 (Central Europe) iso-8859-2 (Central Europe)</seg>
<seg id="2969">"Apidra was examined in combination with a long-effective cleaning in patients with type-1 diabetes, in two studies with a total of 1 549 adults and in a study with 572 children aged between four and 17 years."</seg>
<seg id="2970">"in one study, Apidra can be examined in a study with 878 adults."</seg>
<seg id="2971">"the main indices for the effectiveness was the change of the substance glycosyliosis hemmoglobin (HbA1c) in blood, which shows how well the blood sugar is set."</seg>
<seg id="2972">"Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems."</seg>
<seg id="2973">"in adults with Type-2 diabetes, the lowering of HbA1c concentration 0.46% after six months with Apidra compared to 30% of humaninsulin."</seg>
<seg id="2974">Apidra may not be applied to patients who could possibly be oversensitive (allergic) against dosinglulisin or one of the rest of substances or in patients who already suffer from a hypoglycemia.</seg>
<seg id="2975">The cans of Apidra must be adapted when it comes together with a number of other medicines which can affect the blood vessels.</seg>
<seg id="2976">"in September 2004, the European Commission of Sanofi-Aventis Germany GmbH is a permission for the incoming of Apidra in the entire European Union."</seg>
<seg id="2977">Apidra is known as subcutaneous injections either in the area of the abdomen, the upper body or the chtamuskels or subcutaneous through continuous infusion in the area of the abdominal cord. "</seg>
<seg id="2978">"due to the reduced gluten capacity, the insulated capacitor of the insulin can be reduced in patients with a limitation of the liver function."</seg>
<seg id="2979">"each change of the active thickness, the brand (herds), the insintyps (normal, NPH, zinkable, etc.), the type of the insins (animal Insulin) and / or the manufacturing method can go to a change of the insulin requirements."</seg>
<seg id="2980">"3 A insufficient dosage or provisions of a treatment, particularly in patients with a insulinous diabetes, can lead to a hyperglycemia and a diabetic Ketoazio."</seg>
<seg id="2981">The conversion of a patients on a other insinteger type or a Insulin a other manufacturer should be required to take a change of the dosage.</seg>
<seg id="2982">The time of the buretariat of a hypoglycemia is based on the active profile of the used amino acid and can therefore be change on the treatment of treatment.</seg>
<seg id="2983">"the substances that increase the blood circulation of the blood circulation, the circulation of antibacterial infections, promethyl-oxidase inhibitors, propoxyloid, propoxygeny, propoxyloid, Salizylate and Sulphylamide antibiotics."</seg>
<seg id="2984">"in addition, the effect of symptoms of symptoms such as Betablockers, Clonidine, Guanethinn, and reserve the symptoms of adrenering the symptoms of the adreneration."</seg>
<seg id="2985">"some differences between Insu- linglulisin and humaninsulin in relation to the pregnancy, the embryonic / oale development, the birth or the postnatal development (see section 5.3)."</seg>
<seg id="2986">"it is not well known, whether insult lulisin into the human mother's milk, but in general it is neither in the mother's milk, nor will it be given after the mother's milk."</seg>
<seg id="2987">"the following are the clinical trials known to those suffering from clinical trials (very frequently: ≥ 1 / 10, &lt; 1 / 10; rare: ≥ 1 / 100, &lt; 1 / 10; rare: ≥ 1 / 1,000, &lt; 1 / 1,000; very rare: &lt; 1 / 10.000, &lt; 1 / 1,000; very rare: &lt; 1 / 10.000, &lt; 1 / 1,000; very rare: &lt; 1 / 10.000, &lt; 1 / 1,000; very rare: &lt; 1 / 10.000, &lt; 1 / 1,000; very rare: &lt; 1 / 10.000, &lt; 1 / 1,000; very rare: &lt; 1 / 10.000, &lt; 1 / 1,000; very rare: &lt; 1 / 10,000, &lt; 1 / 1,000; very rare: &lt; 1 / 10,000, &lt; 1 / 1,000; very rare: &lt; 1 / 10,000, &lt; 1 / 1,000; very rare: &lt; 1 / 10,000, &lt; 1 / 1,000; very rare: &lt; 1 / 10,000, &lt; 1 / 1,000; very rare: &lt; 1 / 10,000, &lt; 1 / 1,000; very rare: &lt; 1 / 10,000, &lt; 1 / 1,000; very rare: &lt; 1 / 10,000, &lt; 1 / 1,000; very rare: &lt; 1 / 10,000, &lt; 1 / 1,000; very rare: &lt; 1 / 10,000, &lt; 1 / 1,000; very rare: &lt; 1 / 10,000, &lt; 1 / 1,000; very rare: &lt; 1 / 10,000, &lt; 1 / 1,000; very rare: &lt; 1 / 10,000, &lt; 1 / 1,000; very rare: &lt; 1 / 10,000, &lt; 1 / 1,000; very rare: &lt; 1 / 10,000, &lt; 1 / 1,000; very rare: &lt; 1 / 10,000, &lt; 1 /</seg>
<seg id="2988">"cold - welds, cool and bacon skin, fatigue, nervous skin or stairway, anxiety, concentrating, concentrating dysfunction, Benommenities, excessive Hun- ger, changes of the tendon, headaches, nausea and heart."</seg>
<seg id="2989">Lidauystrophies is able to change the injections within the injector area can occur in the result of a Lidauystrophies.</seg>
<seg id="2990">"heavy hypoglycereal with consciousness can be treated by a intramuscular or subcutaneous injections of Glukagon (0,5 to 1 mg) which will be treated by a corresponding person, or by intravenous gift of Glucose by a doctor."</seg>
<seg id="2991">"after a Glukagonist, the patient should be monitored for the heavy hypoglycemia to prevent the heavy hypoglycemia."</seg>
<seg id="2992">Insulin reduces blood sugar levels (especially by skeletal musculature and fat) as well as the Hemisphere of Glucosity production in the liver.</seg>
<seg id="2993">Clinical trials with healthy volunteers and patients with diabetes have shown that with subcutaneous Ga- be faster and the active duration of shorter is considered as a hu- manem normal insulin.</seg>
<seg id="2994">"in a study with 18 male persons in the age of 21 to 50 years with type-1-diabetes melli- tus, insemlulisin the therapeutic dosage range of 0,075 to 0,15 E / kg."</seg>
<seg id="2995">ISO-8859-1 (Western Europe) iso-8859-2 (Central Europe) iso-8859-2 (Central Europe)</seg>
<seg id="2996">"in 2 minutes ago, a comparable postoperative postoperative control is reached in 2 minutes before the meal was given a comparable postoperative postoperative control of 30 minutes before the meal."</seg>
<seg id="2997">"insect lulisin 2 minutes before the meal, was given a better postoperative control as with humaninsulin, the 2 minutes before the meal was given."</seg>
<seg id="2998">"insect lulisin 15 minutes after the beginning of the meal, a similar glacial control like in humaninsulin, the 2 Mids before the meal will be given (see figure 1)."</seg>
<seg id="2999">ISO-8859-1 (Western Europe) iso-8859-2 (Western Europe) iso-8859-2 (Central Europe)</seg>
<seg id="3000">Insulin lulisin at a gift of 15 minutes (GLULISIN - later) after the beginning of the meal in comparison to humanem Nor- malinsulin that was 2 minutes (NORMAL - before the meal) before the meal (Figure 1C) was given before the meal.</seg>
</doc>
</tstset>
